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Abstract 
Janis Jaunzems 
Solid-Phase Assisted Synthesis of Glycoconjugates, and Synthesis of 15N-
labelled Aminoglycosides 
Key words: glycoconjugates – glycosidation – polymer-assisted synthesis – olefin 
metathesis macrocyclisation – aminoglycosides  
 
During the first part of this Ph. D. work, studies on the polymer-assisted synthesis of 
deoxyoligosaccharides and glycoconjugates were carried out. Here, their preparation on a 
polymer-support in direct comparison with solution-phase glycosidation using polymer-
bound catalysts and reagents were carried out. In the second part of this work, synthetic 
approaches towards new artificial macrocyclic aminoglycosides with nucleic acid binding 
properties were developed. Particular focus was put on the synthesis of their 15N-labelled 
analogues. Various 2-deoxyglycoconjugates were prepared on a new polystyrene resin 
which contains a silyl linker system. Glycals were employed as glycoside donors. This 
polymer showed excellent properties for non-destructive reaction monitoring using the gel-
13C-NMR technique. In a comparative study 2-deoxy glycoconjugates were prepared in 
excellent yields in solution using polymer-supported catalysts. The common Ferrier type 
side reactions were suppressed to a minimum which allowed to apply this approach for 
automated parallel glycoconjugate and oligosaccharide synthesis.  Using 2-
deoxythioglycosides as valuable glycosyl donors, two rapid and highly efficient 
glycosidation methods in solution were developed, utilizing new polymer-bound 
iodo(l)bistrifluoracetate and selectfluor as thiophilic promoters. Diphenyl disulphide 
liberated during the glycosidation process can quantitatively be removed by the first 
scavenging protocol for this purpose using polymer-supported borohydride in iso-propanol. 
Employing the elaborated orthogonal glycosidation strategy, a small library of various 2-
deoxyoligosaccharides and glycoconjugates was synthesized with potential biological 
properties. 
In the synthesis of new macrocyclic aminodeoxysaccharides allyl glycosides were 
employed in the olefin metathesis homodimerisation reaction. The amine function was 
introduced with high degree of stereo-selectivity by carrying out reductive amination on 
uloside using benzyl amine or ammonium acetate as nitrogen source. Olefin metathesis 
macrocyclisation proceeded in a highly diluted solution to avoid unfavored 
polymerizations. 15N-labelled ammonium acetate was utilized in a elaborated reductive 
amination procedure to introduce 15N into homodimeric uloside. The 14N- and 15N-labelled 
macrocyclic aminodeoxysaccharides obtained form tight complexes with TAR-RNA (HIV-
1) and are therefore good tools for the evaluation of these complexes using NMR 
spectroscopy. 
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Zusammenfassung 
Janis Jaunzems 
Festphasen unterstützte Synthese von Glycoconjugaten und Synthese von 
15N-markierten Aminoglycosiden 
Stichwörter: Glycokonjugate – Glycosidierung – Polymerunterstützte Synthese – 
Olefinmetathese – Makrocyclisierung – Aminoglycoside 
 
Im ersten Teil der vorliegenden Dissertation wurden Untersuchungen zur 
polymerunterstützten Synthese von Desoxyoligosacchariden und Glycokonjugaten 
durchgeführt. Die Darstellung an der festen Phase wurde hierbei der Glycosidierung in 
Lösung unter Verwendung von polymergebundenen Katalysatoren und Reagenzien 
gegenübergestellt. Der zweite Teil dieser Arbeit richtete sich an die Synthese von neuen 
künstlichen makrocyclischen Aminoglycosiden, welche Nukleinsäure-Bindungsaffinitäten 
aufweisen. Besonderes Interesse wurde auf die Darstellung der 15N-markierten Analoga 
gesetzt. Verschiedene 2-Desoxyglycokonjugate wurden auf einem neuen Polystyrolharz 
mit Silyl-Linkersystem hergestellt, wobei Glycale als Glycosiddonoren eingesetzt wurden. 
Dieses Polymer eignet sich hervorragend für die nichtzerstörende Reaktionskontrolle 
mittels Gel-13C-NMR-Technik. In einer vergleichenden Studie wurden 2-
Desoxyglycokonjugate in exzellenter Ausbeute unter Verwendung von 
polymerunterstützten Katalysatoren hergestellt. Die herkömmlichen Nebenreaktionen vom 
Ferriertyp wurden auf ein Minimum reduziert, so daß dieser Ansatz die automatisierte 
Parallelsynthese von Glycokonjugaten und Oligosacchariden erlaubte. Unter Verwendung 
von 2-Desoxythioglycosiden als nützliche Glycosyldonoren wurden zwei schnelle und 
hocheffiziente Glycosidierungsmethoden in Lösung entwickelt, welche das neue 
polymergebundene Iod-(I)-bistrifluoracetat und Selectfluor™ als thiophile Reagenzien 
benutzen. Das während der Glycosidierung freigesetzte Diphenyldisulfid kann quantitativ 
beseitigt werden durch das erste Abfangprotokoll für diesen Zweck, in welchem 
polymergebundenes Borhydrid in iso-Propanol eingesetzt wird. Durch Einsatz dieser 
ausgearbeiteten orthogonalen Glycosidierungsstrategie wurde eine kleine Bibliothek von 
verschiedenen 2-Desoxyoligosachariden mit möglicher biologischer Aktivität synthetisiert.  
Bei der Synthese von neuen makrocyclischen Aminodesoxysacchariden wurden 
Allylglycoside für die Homodimerisierung durch Olefinmetathese eingesetzt. Die 
Aminofunktion wurde mit hoher Stereoselektivität durch reduktive Aminierung an Ulosid 
mit Benzylamin oder Ammoniumacetat als Stickstoffquelle eingeführt. Die 
Olefinmetathesen zur Makrocyclisierung wurde in einer hochverdünnten Lösung 
durchgeführt, um unerwünschte Polymerisationsprodukte zu vermeiden. 15N-markiertes 
Ammoniumacetat wurde in dem ausgearbeiteten reduktiven Aminierungsprotokoll 
verwendet, um 15N in homodimeres Ulosid einzuführen. Die erhaltenen 14N- und 15N-
markierten makrocyclischen Aminodesoxysaccharide bilden starke Komplexe mit TAR-
RNA (HIV-1) und sind aus diesem Grunde nützliche Werkzeuge für die Untersuchung 
dieser Komplexe mittels NMR-Spektroskopie. 
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Abbreviations 
abs.  absolute 
Ac  acetyl 
Bn  benzyl 
Bu  butyl 
Bz  benzoyl 
Bn  benzyl 
CSA  DL-camphersulfonic acid 
CAN  ceric ammonium nitrate 
CM  cross metathesis 
CoA  coenzyme A 
COSY  correlation spectroscopy 
Cy  cyclohexyl 
d  day(s) 
DEPT distortionless 
enhancement by 
polarization transfer 
DIBAL diisobutylaluminium 
hydride 
DMAP 4-N,N-
dimethylaminopyridine 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DMTST dimethyl(methylthio) 
sulfoniumtrifluoromethane
sulfonate 
eq.  equivalent 
DNA  desoxyribonucleic acid 
Et  ethyl 
GC  gas chromatography 
h  hour(s) 
HIV  human immunodeficiency 
HMQC heteronuclear multiple 
quantum coherence 
HPLC high pressure liquid 
chromatography 
IDCP iodoniumdi-
collidinperchlorat 
IR  infrared spectroscopy 
L  ligand 
LiHMDS  lithium hexametyldisilazan 
M  molecular ion 
Me  methyl 
Min  minute(s) 
Ms  methanesulfonyl 
MS mass spectrometry or 
molecular sieves 
NBS  N-bromsuccinimide 
NIS  N-iodsuccinimide 
NMR nuclear magnetic 
resonance 
NOE nuclear overhauser 
enhancement 
PE  petrol ether 
Ph  phenyl 
Piv  pivaloyl 
Pr  propyl 
Py  pyridine 
RCM  ring closing metathesis 
Rf  retention factor 
RT  room temperature 
TAR RNA trans-activation response 
region 
TASF tris-(dimethylamino)-sulfur-
(trimethylsilyl)-difluoride 
TBAF tetrabutylammonium 
floride 
TBDPS  tert-butyldiphenylsilyl 
TBS  tert-butyldimethylsilyl 
t-Bu  tert-butyl 
TES  triethylsilyl 
Tf  trifluoromethylsulfonyl 
Tfa  trifluoroacetyl 
THF  tetrahydrofurane 
THP  tetrahydropyrane 
t.l.c.  thin layer chromatography 
TMS  tetramethylsilyl 
TMSOTf trimethylsilyl 
trifluoromethanesulfonate 
TOCSY total correlation 
spectroscopy 
Ts  toluol-4-sulfonyl 
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1. Introduction 
1.1. Natural products and their role in human history and today 
 
The first records on the use of natural products in form of plants to treat diseases 
can be dated back as early as 2700 B.C. in China, in the time of the Emperor 
Shennung. The Ebers papyrus describes a variety of plants used in the Egyptian 
medicine at about 1550 B.C. But plants were not only used as curatives. On 
Sumerian tablets that can be dated back to 3500 B.C. narcotic activity of Papaver 
somniferum was noted, making the Opium alkaloids to one of the oldest known 
drugs. Seminal from Cannabis were used during Skytten’s steam-bath rituals as 
narcotic; the poisoning effect of deadly nightshade and henbane was well known. 
All kinds of biological effects were regarded as spiritual and attributed to divinity, 
and frequently some or other “magical recipes” were ascribed together with a 
certain folk. The first scientific classification of plants is dated back to 370-285 B.C. 
by Theophrastus, and three hundred years later Dioscorides in “de materia 
medica” (77 AD) described the use of more than 600 plants in medical and other 
use. Around this time and later chemistry or “Alchemy” was mostly based on 
chaotic experiments with common substances by means of distillations and 
sublimations. The alchemists efforts were directed to obtain the elixir of life or gold 
from lead. For more than 500 years much of the medicinal knowledge in Europe 
was centered in the Church, and only after the invention of the printing press 
(1500’s AD) , herbal medicine became commonly available to the common people. 
Only in the 19th century prompted partly by Friedrich Wöhler's synthesis of urea 
(1828), organic chemistry gained its rapid growth. Urea synthesis overturned the 
belief that only living organisms could produce organic molecules. Robert Koch 
discovered microorganisms and disclosed (1876) some microorganism ability to 
cause infectious diseases. One year later Louis Pasteur reported that the bacterial 
disease anthrax, which can cause respiratory failure, could be overcome harmless 
in animals with the injection of soil bacteria. While at the end of the 19th century 
some antibiotics were known, they were not being developed into an effective drug 
until the British scientist Alexander Flemings discovered in 1928 another 
antibacterial agent. Fleming observed bacterial cell lysis occurring in an area 
adjacent to a contaminant Penicillium mold growing on the plate. In fact he 
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rediscovered Penicillin, since more than thirty years earlier a French student 
Ernest Duchesne observed antibiotic properties of Penicillium, but was not able to 
resolve the connection between the fungus and the active substance. 1939 
Howard Florey, Ernst Chain, and Norman Heatley obtained the Penicillium fungus 
from Fleming and were able to isolate Penicillin G in pure form. By 1946, Penicillin 
became widely distributed in clinics. Penicillin bioactivity is based on the beta-
lactam ring opening followed by the irreversible covalent binding on the active site 
of the enzyme transpeptidase, which cross connects polysaccharide chains 
forming the bacterial cell walls. Thereby bacterial cell walls get structurally weak 
causing cell lysis. Fleming’s invention was the first step in the beginning of the 
antibiotic era. 
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Figure 1 
Many natural products that show medicinal properties or biological activity fall in 
the general class of terpenes. These compounds are made up from five-carbon 
(isoprene) units, put together in a regular pattern and often joined in a head-to-tail 
manner in terpenes up to 25 carbons. Head-to-head dimers are also common 
consisting from 30 and more carbons. Today one of the best known terpenoid with 
anticancer activity is Taxol, first isolated from the bark of the Pacific yew Taxus 
brevifolia in the early 1960's. Taxol stabilizes the mitotic apparatus in cells that 
suppresses rapid proliferation causing them to act as normal cells. Steroids, an 
another class of terpenes, are modified triterpenes that are one of the important 
natural products in human life. They are often familiar as androgens (testosterone) 
and estrogens (progesterone) due to their role as hormones. Steroid hormones are 
formed in the testicle, adrenal cortex and ovary; their main role in the organism is 
development of the sexual character, reproduction and metabolism. Another group 
of steroidal terpenes are cardiac glycosides that were firstly isolated from Nerium 
Oleander and different types of digitalis-foxglove plants. They exert a positive 
inotropic effect (increase myocardial contractility), negative chronotropic effect 
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(heart rate lowering), negative dromotropic effect (impede stimulus conduction), 
and positive bathmotropic effect (promote myocardial excitability). One of the best 
known cardiac glycoside is Digitoxin 2 which demonstrates also cytotoxic effect on 
some human tumor cells. It blocks cell proliferation and can introduce apoptosis in 
several malignant cell lines.  
A great part of diseases is caused by insufficiency or excess of some specific 
metabolites in a living organism. These biologically active substances can originate 
from bacteria or viruses, or can be produced by organisms itself in some 
anomalous metabolism pathways. Enzymes are complex organic molecules that 
catalyses almost all synthetic and regulatory processes in living organisms. The 
enzyme activities can be suppressed or inhibited by specific metabolites or drugs. 
In case of malignant bacteria, viruses or cancer cells some essential enzyme 
inhibition can cause the termination of important metabolic processes leading to 
growth or replication slowdown or stop. Inhibition of bacterial Alanin-Racemase, 
which catalyzes the biosynthesis of specific peptidosaccharides, leads to the 
inhibition of bacterial cell wall synthesis. This is one example of many how humans 
fight with various diseases.1e-s  
 
1.2. Antibiotic resistance 
 
Already in the year 1945, Fleming reported about possible formation of resistant 
forms of bacteria in case of misuse of Penicillin. But not earlier than 1970s 
antibiotic resistance was considered to be a real threat, when cases of deaths from 
strains of bacteria that cause meningitis and gonorrhea were registered after 30 
years of successful treatment of these infections. Bacteria can acquire resistance 
on specific or classes of antibiotics through random bacterial DNA mutations that 
can result in the formation of new resistance strains. These mutations are then 
inherited to all of the bacterial progeny resulting from the mutated cells. Among this 
vertical evolution, bacteria frequently undergo horizontal evolution where nearby 
bacteria cells can process gene exchange by transduction, transformation and 
conjugation mechanisms. Thus transferred genes can be incorporated into the 
bacterial genome forming new genotypes by a process known as genetic 
recombination. Resistance genes protect bacteria against the inhibitory effects of 
antibiotics by producing enzymes degrading antibiotics, by altering common 
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antibiotic binding sites on the bacteria cell or in other ways avoiding antibiotics to 
affect normal bacteria’s metabolism. The fight between medicinal chemistry and 
bacteria still continues today: scientists develop new antibiotics or modify natural 
antibiotics that can be inert against bacteria defense; at the same time bacteria 
demonstrate constantly growing resistance against various antibiotics even against 
whole antibiotic classes. Many antibiotics that are widely used for a half of a 
century are now inactive against the designated bacterial infections leaving 
humanity with few still effective medicines. For how long more this will be the case 
is still unclear.1e-s 
 
1.3. Carbohydrates and their role in biological processes 
 
Already for more than a century carbohydrates and their chemistry have engaged 
the minds and hearts of many scientists and persist to be both dynamic and 
challenging. Carbohydrates can be found as monomers (glucose, fructose), 
oligomers, or polymers (starch, cellulose), or as components of biopolymers (RNA, 
DNA) and other naturally occurring substances. Prior to the recognition of the role 
of carbohydrate in biological processes, it seems that most oligomeric and 
polymeric carbohydrates rather play roles as structural and food storage elements, 
whereas the other main polymeric natural compounds, such as RNA, DNA and 
proteins, were left to control the complex functioning of organisms. Increased 
awareness of the vital biological roles exerted by oligosaccharides has led to an 
expanding interest and appreciation for those structures. These complex 
biomolecules, in the form of glycoprotein and glycolipid conjugates, carry detailed 
structural information and serve as mediators in a variety of biological events 
including imflammation,1a-d immunological response,2 metastasis,3 fertilization,4 
and many other biologically important processes.5 Some cell surface 
carbohydrates are specific markers for certain types of tumors6 while others 
function as binding sites for other substances, including bacterial and viral 
patogens.7  
Deoxysugars are widely distributed in plant and animal species either as single 
structural elements or as components of oligosaccharides in antibiotic and 
anticancer agents such as erythromycin A 1 and altromycin B 3, cardiac glycosides 
such as digitoxin 2 and others. (Figure 2) Kennedy and White8a listed more than a 
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hundred various naturally occurring deoxymonosaccharides. In glycoconjugate 
based natural products the deoxysugar moiety can be O- or C- glycosidically 
attached to the aglycone. Among the great diversity of glycoconjugates different 
macrolactones, peptides, steroids or oligoaromatic moieties can be found as 
aglycon parts. In many cases, the deoxysugar fragment in the glycoconjugate is 
vital for the bioactivity. Therefore, varying the sugar portion of the glycoconjugate 
or constructing fully new artificial fragments, may lead to new or improved 
bioactivity in various therapeutic areas8b.     
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Figure 2 Structures of some glycoconjugate-based natural products 
 
2. Polymer-supported synthesis of oligosaccharides 
 
The preparation of biologically important oligosaccharides and glycoconjugates 
typically requires multistep transformations involving iterative protection-
glycosidation-deprotection steps with chromatographic purification of intermediates 
at each stage of the synthesis. Such preparations could greatly benefit from 
developments in polymer-supported oligosaccharide synthesis. (Scheme 2) 
 
A
Linker
A B A B A B 
Scheme 2 Polymer-bound synthesis 
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Seven years after the development of Merrifield’s peptide synthesis9 on solid 
support, Frechet, Schuerch,10 and other scientists undertook pioneering efforts to 
investigate possibilities of polymer-supported oligosaccharide synthesis. Their 
attempts were impeded by lack of the suitable glycosylating activators that would 
be compatible with the special demands of solid-phase synthesis. Twenty years 
later, after substantial methodological progress in the solution-phase field was 
achieved which provided commodious choice of various protecting group 
strategies11 and powerful glycosylation agents12a, the interest in this field was 
reborn.12b,c,d,e In spite of many different polymer and linker systems developed so 
far a lot of challenges remained finding an ideal method of polymer-supported 
oligosaccharide synthesis. Such reactions require good swelling of the polymer by 
the solvent for achieving an efficient reaction. However, not all solvents that have 
good swelling properties are acceptable or compatible with the required 
glycosylation conditions. Furthermore, the problem to control the glycosidic bond 
geometry is still present due to limitations of solvent, glycosylating agent, and 
condition choice. Recently, controlled-pore glass (CPG)13, commonly used for 
automated DNA synthesis, has been proposed as alternative to common polymers, 
because no pre-swelling is required. This removed the restrictions in the choice of 
solvents, however low loadings and incompatibility with silyl protecting groups 
widely used in sugar chemistry greatly reduces the applicability of such a method 
in the solid-phase synthesis area. Alternatively, various soluble polyethylene glycol 
(PEG)14 resins were applied in the field of carbohydrates as polymeric carriers, but 
other difficulties, such as loss of material during the precipitation step after each 
stage of synthesis hampered further progress in this area. Nevertheless, progress 
in polymer-supported synthesis of oligosaccharides in the past decade is self-
evident, and it is conceivable that the synthesis of simple oligosaccharide 
sequences may soon be automated in the similar fashion as oligonucleotides and 
oligopeptides. 
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2.1. Analytical techniques 
 
The modern organic chemist is commonly dependent on a dozen analytical 
techniques such as NMR spectroscopy that allow rapid analysis of the reaction 
process. Though, a major limitation in solid-supported oligosaccharide synthesis is 
associated with the difficulty in analyzing the reaction intermediates bound to the 
polymer. Normally, a small amount of polymer-bound intermediate or product is 
cleaved from the resin and analyzed using classical techniques that generally lead 
to product losses and require additional manipulations. Search for non-destructive 
and rapid analytical methods is essential for the success of solid-phase synthesis 
of oligosaccharides. While 13C-NMR-gel spectroscopy is known in polymer-bound 
peptide chemistry for more than a decade15, only recently this technique was 
adapted to solid-phase oligosaccharide synthesis.16 In 1971 Sternlicht and co-
workers17 were the first to publish the application of 13C-NMR for studying solvent 
swollen cross-linked polymers. In the field of solid phase peptide synthesis, Manatt 
and co-workers15b used 13C-NMR spectroscopy to determine chlormetylation levels 
in cross-linked polystyrenes and investigated the application of 19F-NMR to monitor 
peptide synthesis on a cross-linked polystyrene resin, employing fluorinated 
protecting groups.15c Epton and co-workers15d have employed gel-phase 13C-NMR 
to characterize intermediates in peptide synthesis on a phenolic cross-linked 
poly(acryloylmorpholine) resin. Recently, the Magic Angle Spinning technique (HR-
MAS) using high resolution probes proved to be extremely useful for the analysis 
of polymer-bound oligosaccharides.18 Detailed 1H-, 13C and HMQC spectra could 
be obtained for polymer-bound intermediates. Danishefsky and co-workers used 
this technique to analyze a polymer-bound trisaccharide on Merrifield resin.18b 
However, HR-MAS technique requires special equipment which reduces broader 
application, therefore gel-13C-NMR spectroscopy remains with its advantages and 
drawbacks to be the most widely used analytical tool for many chemists. 
 
3. Polymer-assisted solution-phase synthesis  
  
For more than thirty years polymer-supported synthesis pioneered by Merrifield 
dominated in polypeptide, polynucleotide and to a smaller extent also in 
oligosaccharide chemistry. In the shadow of solid-phase chemistry functionalized 
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polymer techniques have developed quite slowly.19 Recently, more and more 
scientific groups have recognized the value of this technique for classic solution-
phase synthesis.20 During this process the substrate remains in the solution during 
the whole reaction and various polymer-bound reagents or catalysts promote 
chemical transformations. After each step, polymer-supported reagents or 
catalysts were separated and only the product which could be directly used in the 
next step without additional purification remains in solution (Scheme 3). In fact, this 
approach is similar to the classical synthesis in solution and reactions can be 
monitored using common methods like the well known thin layer chromatography 
technique. The polymer-bound reagents and catalysts can be regenerated and 
reused again. In spite of growing interest for polymer-supported reagents, their 
application in sugar and oligosaccharide chemistry is scarce.20b,21  
 
A
D
B
E
C
or
A + B
D
A B
E + C A B C 
 
Scheme 3 Polymer-supported synthesis in solution 
 
4. Objective  
 
Polymer-supported deoxyoligosaccharide and deoxyglycoconjugate synthesis was 
studied in this work using a newly developed butyl diethylsilane polystyrene resin 
from Argonaut Technologies.22 This resin evokes interest in several aspects: 
attaching of the first sugar moiety proceeds similar to classical silyl protection of 
alcohols; resin swelling capabilities in solvents such as dichloromethane or 
tetrahydrofuran is impressive (>8 ml/g); the resin contains a quite long linker which 
can greatly improves the option of carrying out gel-13C-NMR spectroscopy. In a 
comparative study new polymer-supported reagents and catalysts were used to 
synthesize deoxyoligosaccharides and deoxyglycoconjugates in solution.  
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5. Polymer-supported 2-deoxyoligosaccharide and 2-
deoxyglycoconjugate synthesis using PS-DES resin 
 
Glycals can be used as classic glycosyl donors for the construction of complex 
glycosides and 2-deoxyglycosides. The possibility of utilizing them as glycosyl 
donors in 2-deoxyoligosaccharide synthesis has been demonstrated in the 
pioneering works of Lemieux and Thiem23 through halonium-mediated 
glycosylation of the suitable acceptors. This strategy was successfully applied in 2-
deoxyoligosaccharide and glycoconjugate synthesis by many other scientists.24 
Generally, I (IDCP, NIS, PhIOAc2, PhI(OCOCF3)2), Br (NBS, PhBrOAc2), SePh 
(PhSeCl) can serve as electrophiles (Scheme 4). The 2-deoxy-2-haloglycosides 6 
formed can subsequently be reduced with various reducing agents (H2/Pd, 
Bu4SnH, AIBN).  
 
O
OR
RO
RO
E+ O
OR
RO
RO
E+
O
OR'
E
OR
RO
RO
R'OH
reductive
removal of E O
OR'
OR
RO
RO
4 5 6 7
 
Scheme 4 Haloglycosidation 
 
The stereochemistry of glycosidations is generally controlled by trans-diaxial 
addition usually yielding the α-linked glycoside.  
Earlier, Hadfield and Sartorelli reported on treatment of glucal tribenzoate 8 in 
refluxing methanol and the presence of cation exchange resin AG 50W-X8. They 
afforded an anomeric mixture of methyl 2-deoxy-3,4,6-tri-O-benzoyl-D-arabino-
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hexopyranoside 9 in 38% yield (Scheme 5). Along with the product significant 
amounts of the Ferrier rearranged product 10 was isolated.25b As a result this direct 
method for preparing 2-deoxyglycosides remained synthetically unattractive. 
 
O
OBz
BzO
BzO
AG 50W-X8
Methanol
O
OBz
BzO
BzO OMe
+ O
OBz
BzO OMe
O
OBz
BzO
BzO
H+
O
OBz
BzO
BzO
+
H
HO-Me
O
OBz
BzO
BzO
H
+
O
OBz
BzO
BzO
H+
HO-Me
Ferrier rearrangement path
proton-induced glycosidation path
8 9 10
 
Scheme 5 First glycosidation of methanol with glycal using acid catalysis.25a Mechanisms of proton-
induced glycosidation and Ferrier rearrangement.  
 
Later a similar strategy was used by Wakamatsu26a and Tatsuta26b groups in the 
synthesis of glycosylated macrocyclic antibiotics like elaiophylin 12 and 
oleandomycin 11 (Figure 3). They used campforsulfonic acid in dichloromethane to 
promote glycosidation. Sabesan and co-workers further developed Satorelli’s idea 
in using polymer-bound sulfonic acid such as Dowex 50x8.27a,c To suppress the 
tendency of protonating the C-3 oxygen which usually leads to Ferrier 
rearrangement, aprotic solvents with low polarity ought to be used together with a 
“nonhydrated” proton source. Catalytic amounts of soluble bromide ions (LiBr, n-
Bu4N+Br-) have a great impact on the reaction speed, eventually due to traces of 
liberated HBr. Falck et al. reported a successful preparation of 2-
deoxyglycopyranosides by using the triphenylphosphonium bromide catalyzed 
addition of alcohol to glycal triacetates.27b This work proves directly the necessity of 
a mild proton source as complexed HBr to avoid the unfavorable Ferrier 
rearrangement.  
 18
OO
O O
O
O
O
O
O
O
OH
OH
HO
OH
OH
OH OH
OH
O
OH
O
O
O
O
O
O
HO
N
O
OMe
OH
Oleandomycin Elaiophylin11 12  
Figure 3 macrocyclic antibiotics 
 
5.1. Synthesis of carbohydrate monomers and test samples 
5.1.1. Synthesis of glycals 
 
In 1944 Reichstein and co-workers published a three step transformation of 
unprotected sugars to glycals28a. In the first step carbohydrate 13 was 
peracetylated using acetic anhydride, and then anomeric acetate 14 was replaced 
by halogen. Halide 15 obtained was involved in a Reformatsky-type28b,c reaction 
with zinc and the intermediate organozinc glycoside was directly subjected to β-
elimination affording glycal 16 with low to moderate yields. Later Koreeda and co-
workers offered an improved one-pot procedure for the same sequence29 (Scheme 
7). After the pearcetylation process without use of any base, HBr in acetic acid was 
directly added to the reaction mixture to furnish haloglycoside 15. Excess of HBr 
was neutralized with sodium acetate and the mixture was poured into a suspension 
of zinc in water/acetic acid buffered by sodium acetate. No intermediate had to be 
isolated and after workup crude peracetylated glycal 16 was obtained. In case of 
3,4-di-O-acetyl-L-rhamnal and -L-fucal subsequent kugelrohr-destillation under 
reduced pressure is sufficient to afford pure compounds, otherwise purification by 
column chromatography is necessary. 
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O
AcO
a
b
c
13 14
1516  
Scheme 7 Reagents and conditions: (a) Ac2O, HBr cat.; (b) HBr/AcOH, 12h; (c) Zn, CuSO4*5H2O, 
NaOAc, AcOH/H2O, moderate cooling, 3h. 
 
Using this methodology 3,4-bis-O-acetyl-L-rhamnal and -L-fucal were synthesized 
from the corresponding free sugars with 75% and 37% overall yields, respectively. 
Additional protecting group manipulations were performed if necessary. 
3,4,6-Tri-O-acetyl-D-allal 115 was taken as a staring material to synthesize 6-
deoxy-D-allal 118. After full deacetylation the hydroxyl group at C-6 was selectively 
tosylated in pyridine with subsequent addition of acetic anhydride. The tosylate 117 
obtained was subjected to nucleophilic substitution with sodium iodide in acetone 
to yield 6-iodo-6-deoxy glycal. After reduction with lithium aluminiumhydride fully 
deprotected 6-deoxy-D-allal was silylated using TESCl to afford glycal 118 in 
excellent yields (Scheme 7a). 
O
a
b,c
d,e,f
115 116
117118
AcO
OAc
AcO
O
HO
OH
HO
O
AcO
OAc
TsO
O
TESO
OTES
 
Scheme 7a Reagents and conditions: (a) Amberlyst A-26 –OH form, MeOH, 99%; (b) TsCl, Py, RT; 
(c) Ac2O, 90% for two steps; (d) NaI, Acetone, reflux, 12h, 97%; (e) LiAlH4, THF, 2h, 90%; (f) 
TESCl, imidazole, DMAP, DMF, 92%.  
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5.1.2. Synthesis of 2-deoxyphenylthioglycosides 
 
Thiophenol can be used as an acceptor in glycosylation reactions with glycals if 
induced by a mild proton source. Using the strategy of Bolitt as mentioned above 
3,4-di-O-acetyl-L-rhamnal 17 was subjected in a glycosidation reaction to 
thiophenol and PPh3*HBr. Anomeric product mixture was obtained with an α/β-
ratio of 3.3:1 (59% yield). Both anomers can be separated using column 
chromatography to furnish α-glycoside 18 and β-glycoside 19 (Scheme 8). When 
camphorsulfonic acid was used as an alternative proton source, Ferrier 
rearrangement took place in considerable amounts. Using the same approach, 
glycal 20 was involved in glycosidation with thiophenol to yield an anomeric 
mixture 21 with an α/β ratio of 1:1. 
 
O
OAc
AcO
O
OAc
AcO
SPh
O
OAc
AcO
O
OAc
AcO
SPh
AcO AcO
a
b
O
OAc
AcO
SPh
17 18 19
20 21
+
 
Scheme 8 Reagents and conditions: (a) PhSH, PPh3*HBr 1 eq, CH2Cl2, RT, 24h; (b) PhSH, 
PPH3*HBr 0.6 eq, CH2Cl2, RT, 24h. 
 
Thioglycosides obtained can directly be used as donors in glycosidation reactions 
or subjected to protecting group manipulations and used as glycosyl acceptors. 
 
5.1.3. Synthesis of test samples 
 
It is well known that solid-phase reactions can not be rapidly monitored by thin 
layer chromatography or gas chromatography. Therefore, all necessary 
optimizations and, if possible, also product analysis should be performed in 
solution prior to the solid-phase experiment. 
Bis-O-TES-L-fucal 22 and testosterone 23 was chosen as a test system for 
optimizing the reaction conditions. Fucal 22 is best suited for reaction optimization 
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because it exclusively forms α-configured glycosides due to ribo-configured 
hydroxyl functions at C-3 and C-4, and actually it is one of the most reactive 
glycosyl donors in its class.32c These features ease reaction monitoring and 
subsequent analysis of products. After exhaustive optimization suitable reaction 
conditions were achieved using 5 to 10 mol% PPh3*HBr as activator in 
dichloromethane. The glycosidation was completed within 30 minutes. The amount 
of the activator used depends on the donor activity and the nature of protection 
groups employed. For example, when silyl protection such as the triethylsilyl group 
is used, less catalyst is needed to initiate glycosidation which is in contradiction to 
benzoyl or pivaloyl groups.34 It is worth to notice that PPh3*HBr is able to cleave 
silyl ethers at higher concentrations. Generally 1 - 2 mg of activator per 5 ml 
dichloromethane is best for achieving initiation without side reactions. 
Glycosidation reactions of some steroids and sugars with L-fucal 22 are 
summarized in Table 1.  
 
Donor Acceptor Product 
O
H
HH
HO
23  
O
H
HH
OO
OR
RO
24 (90%), R=TES
TBAF 35 (91%), R=H
 
O
O
OH
HO
H
H
25
H
 
O
O
OH
O
H
H
O
OR
RO 26 (85%), R=TESTBAF 36 (97%), R=H
H
 
 
O
OH
HO
SPh
27  
O
O
HO
SPh
O
OTES
TESO
28 (72%)
 
O
OTES
TESO
22
 22
OO
HO
SPh
O
OTES
TESO
29
 
O
O
O
SPh
O
OTESTESO
O
TESO
TESO
30 (87%)
 
O
OR
HO
R = Bz, Piv
31, 32  
O
OTES
TESO
O
OR
O
R = Bz, Piv
33, 34 (85%)  
 
Table 1 Glycosidation of some alcohols 
 
Among the commonly used leaving groups, thioglycoside 27 was chosen as a 
universal building block. It is well known that thioglycosides are stable under most 
reaction conditions frequently used in sugar chemistry, though they can be easily 
activated by various promoters such as NIS-TfOH, MeOTf, DMTST, IDCP, 
selectfluor, and others.30 These facts allow for the development of an orthogonal 
glycosidation strategy using thioglycoside 27 which can serve both as a donor or 
acceptor. 
More than a decade ago, Fraser-Reid firstly reported on the concept of “armed” 
and “disarmed” glycosyl donors while investigating the chemistry of n-pentenyl 
glycosides.31 Since then the laboratories of Danishefsky,32a van Boom,30b,f 
Mereyala, 32b and others have extended this phenomenon to the various other 
glycosyl donors. A great contribution in field of thioglycosides was made by the 
Wong group who quantified reactivities of various glycosyl donors.32c Generally, 
glycosyl donors with ester protection groups undergo glycosylation reactions much 
more slowly than the corresponding donors with ether protection. The reason for 
this phenomenon is the electron withdrawing character of the ester group 
destabilizing the possible cationic transition state en route to glycoside formation.33 
The same strategy also works well with glycals as can be seen from experiments 
with glycals 31 and 32. Bissilylated fucal 22 acts in this case as a donor while 3-O-
benzylated rhamnal 31 is not activated under the given conditions and acts as a 
simple alcohol. 
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5.1.4. Selective decarestrictine D protecting methods 
 
Decarestrictine D or Tuckolide 35 is a 10-membered lactone isolated from 
Penicillum corylophilum, simplicissimum35a and in an independent research from 
the Canadian Tuckahoe fungi Polyporus tuberaster.35b It potently inhibits liver cell 
HEP-G2 cholesterol biosynthesis (IC50 of 100 nm), but has no significant activity in 
antibacterial, antifungal, antiprotozoal, or antiviral area.  
 
35
O
Me
HO
OH
OH
O
1
2
3
45
6
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9
10
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HO
Me
O
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Scheme 9 Decarestrictine D 
 
First glycosidation of decarestrictine D 35 was performed in the Kirschning group 
for investigating potential antibiotic activity.24d The different reactivities of the 
decarestrictine D hydroxyl groups have been investigated earlier.36 The hydroxyl 
group at C-3 forms a hydrogen-bond with the ester carbonyl oxygen which reduces 
its reactivity. The most active hydroxyl group is the equatorially oriented one at C-7 
while the axial oriented hydroxyl group at C-4 is somewhat less reactive. This 
observation allows to selectively protect the hydroxyl function at C-7. If 
decarestrictine 35 is fully silylated and then subjected to mild acidic silyl group 
cleavage with PPh3*HBr in dichloromethane, clean deprotection of the hydroxyl 
function at C-3 takes place. The possible decarestrictine D protecting routes for 
affording various protecting group combinations are summarized in Scheme 10. 
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Scheme 10 Reagents and conditions: (a) TESCl or TBSCl 1.5 eq, DCM, imidazole, - 30o C, 1h; (b) 
Py, Ac2O 4 eq, 50o C, 5 – 7h; (c) TBAF, AcOH ph 7, RT, 5d; (d) TBSCl 3.5 eq, imidazole, DMAP, 
DMF, 50o C, 2h; (e) PPh3*HBr 5 mol%, DCM, RT, 6h; (f) TBSCl 2 eq, imidazole, DMAP, DMF, -30o 
C 1h, then → RT + 0.25 eq TBSCl, 1h.  
 
5.2. Activation of PS-DES resin and attaching the first carbohydrate 
 
Commercially available silyl resin 44 has a silane (Si-H) moiety which offers a 
number of unique advantages: it is stable to moisture; alcohols, carbonyl, aromatic, 
or unsaturated derivatives can be attached directly using TBAF, rhodium-based or 
Wilkinson catalysts.37 It also can be easily transformed into a reactive silyl chloride 
derivative, which can be used immediately in a classical sense (e.g TESCl). The 
silyl resin 44 was treated with 1,3-dichloro-5,5-dimethylhydantoin in 
dichloromethane according to the Yonhang Hu22 protocol (Scheme 11). The resin 
45 obtained was gently washed with abs. dichloromethane and THF several times.  
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Scheme 11 Chlorination of PS-DES resin 
 
3-O-TES-L-fucal 46 and –rhamnal 47 were used as glycal moieties which contain a 
free hydroxyl group at C-4. Both sugars were attached to the resin with excellent 
results using the above mentioned protocol (Scheme 12).  
 
Si Cl Si O
O
OTES
O
OTES
R'
R
45
imidazole, CH2Cl2, 
4h, RT
46: R'=OH, R=H
47: R'=H, R=OH
48: ribo (83%)
49: arabino (83%)
Loading ~ 1.0 mmol/g  
 
Scheme 12 Attaching glycals to the PS-DES resin 
 
The loading of the polymer can be monitored by weight difference or by gel-13C-
NMR spectroscopy according to the relative signal strength. Identically calculated 
loadings using gravimetry of both glycals indicate the actual resin loading 
capability. This was lower than certified by the manufacturer. In the IR spectra no 
Si-H bond absorption were detected at 2100 cm-1, which clearly points to full 
possible resin loading. Nevertheless, this polymer showed excellent loading yields 
compared to the commercially available PSAMCOOH-resin which was involved in 
the same glycal attaching procedure before.38  
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Figure 4 Representative Gel-13C-NMR spectra from polymer-bound glycal 49 
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5.3. Glycosidation of some aglycons and sugars using polymer-bound 
glycals 48 and 49 
 
In the first solid-phase experiment polymer-bound fucal 48 was treated with 
testosterone as acceptor by adopting those reaction conditions which were 
optimized for solution chemistry. Only partial glycosidation was observed as judged 
by gel-13C-NMR spectroscopy. The characteristic glycal signals (C-1’ and C-2’ at 
143.1 and 102.7 ppm, respectively) did not fully disappear although signals from 
the product were clearly recognizable (C-3 at 199.2 from testosterone carbonyl, C-
4 at 123.8 from testosterone olefinic double bond and C-1’ at 98.8 for anomeric 
center). The data acquired indicate a reduced kinetics on the polymer compared to 
solution-phase synthesis. Further optimizations indicated that four hours are 
sufficient to drive the reaction to completion. Various natural products and some 
sugars were successfully glycosidated using polymer-bound fucal 48 and rhamnal 
49 (Table 2 and Table 3). 
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 Polymer-bound fucal 48, loading 1.07 mmol/g 
Si O
O
OTES
 
Acceptor Polymer-bound product Cleaved product 
O
H
HH
HO
23  O
O
OTES
O
H
HH
O
52 (78%)
0.63 mmol/g
 
HO
O
OH
O
H
HH
O
53 (78%)
 
O
O
OH
HO
H
H
25
H
 O
O
OTES
O
O
OH
O
H
H
54 (75%)
0.62 mmol/g
H
 
HO
O
OH
O
O
OH
O
H
H
55 (74%)
H
 
O
HO
OAc
OAc
O
40  O
O
OTES
O
O
OAc
OAc
O
56  
HO
O
OH
O
O
OAc
OAc
O
57 (45% for two steps)
 
O
OH
HO
SPh
27  O
O
OTES
O
O
HO
SPh
58 (70%)
0.62 mmol/g  
not subjected to cleavage 
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OOR
HO
R = Bz, Piv
31, 32  
O
O
OTES
O
OR
O
R = Bz 59 (70%, 0.60 mmol/g)
      Piv 60 (76%, 0.69 mmol/g)  
HO
O
OH
O
OBz
O
61 (70%)  
O
OBz
HO
50  
O
O
OTES
O
OBz
O
62 (64%)
0.55 mmol/g  
not subjected to cleavage 
O
BzO
HO SPh
51
O
 
decomposition _ 
Table 2 Glycosidation conditions with polymer-bound fucal 48: PPh3*HBr 1 mg in 2.5 ml CH2Cl2, 
acceptor 3 eq, 4h, RT. 
 
Yields on solid phase are generally slightly lower in comparison with previous tests 
in solution. The polymer-bound glycoconjugates and disaccharides can be easily 
analyzed using gel-13C-NMR spectroscopy, but signals are significantly weaker in 
comparison to polymer-bound glycal spectra. It is already known12b that large 
molecules gave very poor gel-NMR spectra.  
Figure 5 Representative Gel-13C-NMR spectra from polymer-bound glycoconjugate 63 
20
0.
46
45
17
2.
19
13
12
4.
78
04
99
.1
14
3
88
.4
62
2
80
.0
63
3
71
.5
19
9
69
.7
50
6
69
.0
86
2
54
.8
44
9
54
.3
61
0
51
.0
89
5
43
.7
52
2
40
.6
83
0
39
.5
85
3
38
.0
61
5
36
.6
60
5
36
.4
00
5
34
.8
98
3
33
.7
50
1
32
.4
79
1
29
.4
96
5
24
.3
76
2
21
.5
52
5
19
.2
84
9
19
.0
39
3
18
.3
46
1
12
.6
12
0
7.
97
56
6.
32
90
(ppm)
020406080100120140160180200220
16 
7 
6 
2 
8 
1 12 
10 
2` 
13 
18 
19 
6` 
11 
15 
TES
TES 
9
143`
5`4`171`45 3 
O
O
OTES
1'
2'
3'4'
5'
6'
O
H
HH
O
 29
Polymer-bound rhamnal 49, loading 0.99 mmol/g 
Si O
O
OTES
 
Acceptor Polymer-bound product Cleaved product 
O
H
HH
HO
23  O
O
OTES
O
H
HH
O
63 (77%)
0.62 mmol/g  
HO
O
OH
O
H
HH
O
64 (48%)
α/β = 8:1
 
O
O
OH
HO
H
H
25
H
 O
O
OTES
O
O
OH
O
H
H
65 (67%)
0.53 mmol/g
H
  
O
HO
OAc
OAc
O
40  
O
O
OTES
O
O
OAc
OAc
O
67 (62%)
0.57 mmol/g  
not subjected to cleavage  
O
OH
HO
SPh
27  O
O
OTES
O
O
HO
SPh
68 (80%)
0.66 mmol/g 
 
HO
O
OH
O
O
OH
O
H
H
66 (71%)
α/β = 2:1
H
HO
O
OH
O
O
HO
SP
HO
O
OH
O
OHO
SPh
69 (19.1%)
70 (α - 47%)
71 (β - 33%)
Table 3 Glycosidation conditions with polymer-bound rhamnal 49: PPh3*HBr 1 mg in 2.5 ml CH2Cl2, 
acceptor 3 eq, 4h, RT. 
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The lower yield in experiment 62 compared with other trials (Table 2) could be 
explained with reduced reactivity of fucal 50 axial oriented hydroxyl function at C-4. 
Polymer-bound disaccharides with thiophenyl or glycal moiety such as 58 and 59 
could be involved in further glycosidation reactions to build trisaccharides or 
glycoconjugates with two or more carbohydrate skeletons. Preliminary tests in 
solution to build similar substances gave good to excellent results which are 
summarized in Table 4. 
 
Donor Acceptor Product(conditions) 
O
O
HO
SPh
O
OTES
TESO
28
  
O
H
HH
O
O
O
HO
O
RO
RO R=TES 72b (38%, only α)
R=H 73 (77%)
TBAF
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O
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30
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H
HH
HO
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O
H
HH
OO
O
O
O
ORRO
O
OR
RO
R=TES 75b (12%,β)
R=H 77 (95%)
TBAF
R=TES 74b (67%, α)
R=H 76 (89%)
TBAF
 
O
OBz
HO
31  
 
O
H
HH
OO
OBz
HO
78a (65%, only α)  
O
H
HH
HO
23
O
H
HH
HO
23
Table 4 Reagents and conditions: (a) 31 and 23 0.1 mmol, PPh3*HBr 8 mg in 5 ml CH2Cl2, RT, 5h; 
(b) Donor and acceptor 0.1 mmol, selectfluor™ 1 eq, acetonitrile 5 ml, 0o C, 15 min. 
 
Moderate yield in experiment 72 was caused by self-glycosidation at the free 
hydroxyl group in the disaccharide. This can not be considered in polymer-
supported synthesis due to negligible self-interacting possibilities on solid support. 
Experiment 78 demonstrated the excellent selectivity of a reaction with two 
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possible acceptors: testosterone and glycal itself. Sterically hindered C-4 hydroxyl 
in benzoylated glycal 31 reacts significantly slower than the testosterone alcohol 
function. This approach could be employed to build glycoconjugate libraries using 
orthogonal synthesis strategy with possible automatization. 
 
5.4. Attempts to attach a third component on solid-support and astounding 
results 
 
Polymer-bound disaccharide 58 was subjected to the identical glycosidation 
reaction conditions as was described in experiment 72 but after the reaction no 
weight difference of polymer was observed and gel-NMR showed intact 
thioglycoside on polymer. No polymer swelling in the acetonitrile was observed 
which could be the main reason for this negative result. On the other hand, 
acetonitrile was essential for the thioglycoside activation with selectfluor™ 
therefore different solvent mixtures were tested. A 1:1-mixture of 
dichloromethane/acetonitrile was optimal in the means of polymer swelling and 
selectfluor™ solubility. This approach was tested with little success; only 17% of 
the product was isolated after cleavage from the resin. The remaining thioglycoside 
seemed to have been decomposed because no traces of it were detected in the 
cleaved mixture (Table 5). 
 
Donor Acceptor Product 
O
O
OTES
O
O
HO
SPh
58
0.62 mmol/g
 
O
H
HH
HO
23  R1O
O
OR2
O
O
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O
H
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O
R1=PS,R2=TES: 79a
R1=R2=H: 80 (17% for two steps)
TBAF
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OOTES
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O
HO
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58
0.62 mmol/g
 
R1O
O
OR2
O
O
O
O
R2O
R2O
R1=PS,R2=TES: 81b(76%)
R1=R2=H: 82 (63%)
SPh
TBAF
 
O
O
OTES
O
O
O
SPh
O
TESO
TESO
81 0.36 mmol/g  
O
H
HH
HO
23  
R1O
O
OR2
O
O
O
O
R2O
R2O
O
H
HH
O
R1=PS,R2=TES: 83a
R1=R2=H: 84 (15% for two steps)
TBAF
Table 5 Reagents and conditions: (a) Donor and acceptor 0.1 mmol, selectfluor™ 1 eq, acetonitrile 
5 ml, RT, 4h; (b) PPh3*HBr 1 mg in 2.5 ml CH2Cl2, acceptor 3 eq, 4h, RT. 
 
Any attempt to modify glycosidation conditions or use other electrophilic promoters 
(PhI(OAc)2 (5 eq), Et4NI (5.5 eq) , CH2Cl2 , RT. overnight; NIS (1.6 eq), TMSOTf 
(cat.), CH2Cl2, -50oC → -20oC 3h) gave no better results. If more aggressive 
thiophilic promoters and conditions were used, immediate cleavage of the 
glycoside from the polymer support was observed. Any attempt to introduce other 
donors on solid support (2-deoxysulfoxides and -fluorides) failed due to high 
instability. For example, it was observed that PPh3*HBr also activate sulfoxide 51 
usually employed for glycal activation. This unusual activity compared to non 2-
deoxysulfoxides can only be explained by the absence of the C-2 hydroxyl or other 
function with free electron pairs that could stabilize sulfoxides. There are also no 
literature evidences of applying 2-deoxysulfoxyglycosides in oligosaccharide 
synthesis. 
Previously obtained polymer-bound disaccharides with glycal moiety can also 
serve as glycosyl donors in glycosidation reaction. Polymer-bound disaccharides 
59, 60, and 62 were involved in glycosidation reactions with some steroids and 
sugars using a well optimized method for glycoconjugate synthesis on polymer-
support (see Table 2). Surprisingly, no traces of the products were detected also 
after the resin was processed with TBAF solution to  cleave the product. After 
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cleavage always two products were obtained which originated from glycosidation 
of each individual sugar unit (Table 6). 
 
Polymer-bound donor Acceptor Products 
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Table 6 Reagents and conditions: PPh3*HBr 1 mg in 2.5 ml CH2Cl2, acceptor 3 eq, 6h, RT. 
 
At first it seems that glycosidation conditions are too aggressive, therefore the 
glycosidic bond is cleaved. However, after careful analysis of the reaction pathway 
together with in situ monitoring, facts force to consider different reasons of failure. 
The glycosidated testosterones 78, 87, and 88 appears within minutes after the 
catalyst is added. If the catalyst concentration is lowered, no reaction takes place. 
Also, without an acceptor no cleavages were observed. These facts push to 
consider a “conjugate” glycosidation-cleavage mechanism (Scheme 13). Formation 
of the polymer-bound glycoconjugate 52 indicates that a fucal intermediate was 
present on the resin which subsequently is activated by the catalyst and reacts 
with the hydroxyl function of the aglycon.  
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Scheme 13 Proposed mechanism of “conjugated” glycosidation-cleavage on solid support 
 
After protonation of the polymer-bound glycal, nucleophilic attack of an alcohol 
forms an oxonium ion 90. Subsequently the released proton migrates to the 
neighboring glycosidic bond protonating the anomeric oxygen (90 - 91) which leads 
to the “retro glycosidation” reaction with glycosidic bond cleavage. If the glycosidic 
bond had been protonated and cleaved prior to the glycosidation, formation of free 
glycal 31 would have been observed in solution along with glycoconjugate 92.  
Recently, Kirschning and co-workers described the synthesis of 2-deoxyglycosides 
using the acetate glycosidation approach employing glycals in iodacetylation to 
yield desired donors.39a The corresponding 2-iodo-2-deoxyglycosyl acetates can 
be activated using silyl triflates that have proven to be powerful activating agents in 
solution.39b,c,d Iodoacetylation on polymer support was performed using hypervalent 
iodine - PhI(OAc)2 in dichloromethane with excellent yields (Scheme 14). Further 
attempts to glycosidate testosterone with polymer-bound disaccharide 93 using 
TMSOTf as an activator39a failed. The glycoconjugate 53 was detected in the 
reaction solution that can originate from polymer-bound disaccharide “retro 
glycosidation”→glycosidation under acidic conditions.  
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Scheme 14 Reagents and conditions: (a) PhI(OAc)2 10 eq, Et4N+I- 11eq, CH2Cl2, RT, 12; (b) 23, 
TMSOTf 3 eq, CH2Cl2, -70o C → -30o C, 4h; (c) TBAF, THF, RT, 12h, 82%, manno/gluco = 2.3:1. 
 
6. Polymer-assisted glycosidation of glycals and thioglycosides 
6.1.1. Polymer assisted glycosidation of glycals using new polymer-bound 
triphenylphosphonium bromide 
 
The idea of automation of oligosaccharide and glycoconjugate synthesis is one of 
the greatest challenges in carbohydrate chemistry. One approach is the use of 
reagents or catalysts on solid-support which can be removed by simple filtration 
after the reaction yielding, in the best case, the pure product in solution. The 
preparation of glycoside 78 offers further synthetic options. It can directly be 
transformed into disaccharide 96 by adding a glycosyl donor, namely glycal 22 to 
the same reaction mixture which created glycoside 78. By this “one pot” procedure 
very rapid access to complex glycoconjugates becomes frasable. This approach 
was first tested in solution using classic reagents (Scheme 15). 
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Scheme 15 Reagents and conditions: (a) 23 and 31 1 eq, CSA cat., LiBr, CH2Cl2/CH3CN – (1:1), 
RT, 4h; (b) 22 1.1 eq, +CH2Cl2, RT, 6h. 
 
The glycoconjugate 96 was obtained in good yield and only a final purification was 
necessary. In order to make the first glycosidation more efficient the remaining free 
hydroxyl group in glycal 31 C-4 should be protected with an easy removable 
protective group. Triethylsilyl or t-butyl-dimethylsilyl ethers can be used in this 
case, which can be later cleaved under mild acidic conditions or by using some 
fluoride source. Preliminary tests with the silylated glycal 97 gave better yields in 
comparison with the unprotected glycal 31. The silyl group was removed using the 
same proton source, which was employed to initiate the glycosidation, at slightly 
elevated concentration with prolonged reaction time (Scheme 16). 
O
OBz
TBSO
O
H
HH
HO
23
O
H
HH
OO
OBz
HO
78 (81%)
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+ Dowex-50x8, LiBr
CH3CN/CH2Cl2
 
Scheme 16 Glycosidation using fully protected glycal  
 
Both silyl ethers showed equal improvement as far as the yield of the glycosidation 
is concerned, though the TES ether was much easier cleaved under mild acidic 
conditions. However, further experiments employing polymer-bound catalysts gave 
no improvements in comparison to the model experiment (see Scheme 15) using 
non-polymer-bound catalysts (Scheme 17). 
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Scheme 17 Reagents and conditions: (a) PS-PPh2*HBr cat., LiBr, CH2Cl2, RT, 4h, then Dowex 
50x8 cat., +CH3CN, 10h, RT; (b) 22 1.1 eq, +CH2Cl2, RT, 5h. 
 
Diluting the reaction mixture by adding dichloromethane or acetonitrile can allow to 
change catalyst concentration thus initiating or suppressing silyl group cleavage. 
The greatest benefit in all polymer-assisted experiments was an anomerically pure 
glycosidic bond formation generating exclusively α-glycosides. This phenomenon 
could be explained with the heterogeneous nature of the glycosidation reactions, 
as the glycal may form π-stack with polystyrene and is activated by proton on the 
surface of the polymer in a more favored manner. The oxonium ion intermediate 
then may be stabilized by free electron pair on phosphor forming tight sandwich-
type complex. This complex hampers any nucleophilic attack from the bottom side; 
thereby an acceptor approaches oxonium species from the opposite side yielding 
exclusively α-configured glycoside (Scheme 18).  
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Scheme 18 Glycosidation with polymer-bound PPh3*HBr catalysts 
 
Utilizing the same mild acidic conditions that cleave silyl groups from the 
glycoconjugate 100 proved to be not successful since the glycosidic bond oxygen 
was protonated and the glycosidic bond was hydrolyzed faster than the silyl ethers. 
Any attempts to optimize proton-induced deprotection of the glycoconjugates 100 
and 96 failed (Scheme 19). Reactions mainly yielded glycoconjugates 99 or 78 
respectively. The glycoconjugate 78, for example, could be glycosidated once 
more with fucal 22 to afford disaccharide 96 again. 
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Scheme 19 Reagents and conditions: (a) Dowex 50x8 1-5 mol%, CH2Cl2/acetonitrile; (b) PS-
PPh2*HBr cat., CH2Cl2, 22, RT, 4h, 55% for two steps. 
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Additional experiments with the mono-substituted fucal 46 revealed excellent 
yields. At first, testosterone was glycosylated using glycal 46 as glycosyl donor. 
After the acceptor was completely consumed a second portion of glycal 22 was 
added. The axially oriented C-4 hydroxyl function in fucals is very unreactive 
compared to the aglycon alcohol. Therefore the oxonium ion species is attacked 
exclusively by the aglycon alcohol under kinetic control. The glycoconjugate 
formed can then slowly be glycosylated at the C-4 hydroxyl group. This “one-pot” 
system allows the easy production of various glycoconjugates in excellent yields 
without intermediate purification (Table 7).  
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Table 7 Reagents and conditions: (a) PS-PPh2*HBr cat., LiBr, CH2Cl2, RT, 2h; (b) +22 1.2 eq, + 
CH2Cl2, RT, 4h; (c) instead of glycal 22, allal 118 was used in the step b, reaction time 24h. Allal 
118 has demonstrated unusual low reactivity in the experiment 5.  
6.1.2. Towards the development of new polymer-bound fluorides for the 
deprotection of silylated alcohols 
 
O-Silylation of alcohols was first introduced in the late fifties but silyl ethers were 
not widely appreciated as protecting groups in organic synthesis until the early 
seventies. Now silyl protecting groups play a major role in modern organic 
synthesis. They are readily formed and cleaved under mild conditions. Varying the 
substituents on silicon allows to finely tune their relative stability. The triethylsilyl 
group, for example, is more stable than trimethylsilyl but can be easier cleaved 
than the t-butyldimetylsilyl group. Not only the bulkiness of substituents affects silyl 
group stability but also their electronic nature. Thus, electron withdrawing groups, 
such as aryl substituents, enhance the stability under acidic conditions whereas 
the opposite effect can be noticed under basic conditions. Silicon has a high affinity 
for fluorine due to the greater strength of the silicon-fluorine bond (142 kcal/mol) 
compared to the silicon-oxygen bond (112 kcal/mol). Therefore, fluoride ions can 
be used to cleave silyl ethers under mild and highly specific conditions.  
Nowadays, many methods have been developed to cleave silyl ethers in solution, 
but polymer-supported variants can rarely be found in the literature. The Colonna 
group in 1979 firstly reported the use of basic ion exchange resin to attach naked 
fluoride ions. They used it in various SN2 fluorinations of steroids and sugars.40a 
Later Huang and co-workers used this resin to cleave various TMS-ethers.40b 
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Montmorillonite K-10 was used as acidic catalyst to cleave various silyl ethers.40c,d 
Masaki et al. offered polymer-bound π-acid dicyanoketene acetal catalyst for this 
purpose.40e Recently, DeShong and co-workers elaborated a new fluoride salt 
which is stable and compatible with most organic solvents.41 They allowed 
triphenyl-silylfluoride to react with TBAF to form tetrabutylammonium (triphenyl-
silyl)difluorosilicate (TBAT). It is not only a milder and non-basic fluorinating agent 
compared to TBAF but is also more stable and does not contain any molecular 
water. We used polymer-supported fluoride (Amberlyst A-26 F- form) instead of 
TBAF, the silicate is formed directly on the polymer-bound amine. 
Ph3SiF
TBAF Bu4N
+Ph3SiF2
- (TBAT)
A-26 -F
Me3N
+ Si
F
F
Ph
Ph
Ph
-
 
Scheme 20 Synthesis of TBAT and its polymer-bound version 
 
In such a way, a new polymer-bound TBAT was obtained and employed in some 
silyl ether deprotecting reactions to evaluate its capabilities in this area (Scheme 
21). This new polymer is neutral to light acidic, and prior to reaction it should be 
gently washed with acetonitrile to remove any traces of free HF. 
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Scheme 21 Deprotection of silylated alcohols with polymer-bound TBAT 
 
The resin developed only showed moderate results because significant extent (10-
20%) of glycosidic bond cleavage was observed. However, in the same case, 
TBAF in tetrahydrofuran gave excellent yields without side reactions. The 
glycoconjugate 108 obtained was purified by short silica gel column filtration to 
eliminate unpolar triethylsilyl fluoride and employed in a glycosidation reaction with 
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glycal 22 to afford two major products. Kinetically both C-3 hydroxyl groups in both 
fucals have similar activity but a hydroxyl function in the center of the 
glycoconjugate is slightly more hindered than on the terminal pyranose. This can 
also be observed in the current experiment (Scheme 22). The linear product 109 
prevails over the branched trisaccharide 110. The linear glycoconjugate was 
deprotected using TBAF solution in THF buffered with acetic acid to afford almost 
quantitative deprotection. 
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Scheme 22 Reagents and conditions: (a) 22, PS-PPh2*HBr cat. CH2Cl2, RT, 24h; (b) TBAF, THF, 
RT, 12h. 
 
To evaluate the reactivity of Amberlyst A-26 (fluoride form) towards silyl ethers, the 
persilylated glycoconjugate 26 was chosen for a deprotection reaction using 
methanol as a solvent. No reaction was observed at room temperature for 10 
hours. After elevating the temperature to 50o C cleavage of the triethylsilyl groups 
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started. However, the glycosidic bond was also not stable under these conditions. 
Almost fifty percent of the starting material was deprotected within 20 hours. The 
second fraction isolated was free digitoxigenin (Scheme 23). The results observed 
allow to conclude that traces of acid in the polymer are capable to cleave the 
sensitive 2-deoxysugar glycosidic bond. The mixture of free digitoxigenin and 
glycoconjugate 36 was subjected to further glycosidation reaction without 
purification. Mono-protected fucal 46 was added together with polymer-bound 
PPh3*HBr to the above afforded mixture in dichloromethane. When both starting 
materials 25 and 36 were fully consumed, glycal 22 was added to the reaction 
mixture. After 5 hours the reaction was quenched by addition of Amberlite A-21 
and the resulting product mixture was purified by column chromatography. The 
disaccharide 105 originates from the free digitoxigenin which was formed in the 
first deprotection reaction. The other isolated trisaccharides 113 and 114 originate 
from glycoconjugate 36. 
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Scheme 23 Reagents and conditions; (a) Amberlyst A-26 F-, MeOH, 50o C, 20h; (b) 46 1.2 eq, PS-
PPh2*HBr, CH2Cl2, RT, 4h; (c) +22 1.2 eq, RT, 5h, yields are calculated from free digitoxigenin. 
 
Summary 
In order to secure excellent deprotection of 2-deoxyoligosaccharide and –
glycoconjugate silyl ethers without undesirable side reactions, a polymer-bound 
reagent with the following qualities is necessary: 
• it should be slightly basic 
• it should contain fluoride ions with similar activity and substrate 
accessibility as in TBAF 
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• it should be compatible with various organic solvents (such as 
methanol, acetonitrile or CH2Cl2). 
 
6.1.3. 3-Deoxy-3-azido-glycals as potential glycosyl donors 
 
The reaction of L-rhamnal 17 with sodium azide in the presence of boron trifluoride 
which yields a mixture of α- and β-L-erythro-hex-2-enopyranosyl azides 120a and 
120b is well documented.41 The Ferrier products are in reversible equilibrium with 
the corresponding glycal-type azides 121a and 121b by means of a [3,3]-
sigmatropic rearrangement (Scheme 24). It needs to be pointed out that these 
azidoglycals have not been regarded as proton-induced glycosyl donors in 
literature. 
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Scheme 24 Synthesis of 3-deoxy-3-azidoglycals 
 
 In the first minutes after the reaction is completed only Ferrier products 120a and 
b were observed in the 1H-NMR spectrum of the crude product in a about 1.2:1 
ratio. Within 48 hours these eno-pyranosides rearrange to the corresponding 
azidoglycal 121a, b which results in a mixture of regio- and stereoisomers in an 
approximate 60/40 ratio. Consequently, if these azidoglycals have similar donor 
capabilities as classic glycals, they could be activated with a proton source and 
can be utilized in glycosidation reactions in the presence of alcohols. This may 
lead to various azido-glycoconjugates. The [3,3]-sigmatropic rearrangement 
equilibrium could be then inclined in glycal direction, and in the best case the sugar 
could be fully consumed in the glycosidation reaction. 
Thus, glycal mixture was employed in the glycosidation reaction with allyl alcohol 
catalyzed by the polymer-bound PPh3*HBr (Scheme 25). Generally, this reaction 
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was significantly slower than the corresponding glycosidation with rhamnal 17. 
Nevertheless, the overall yield was high enough to apply such a strategy in 2,3-
deoxy-3-azido(amino)glycoconjugate synthesis. 
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Scheme 25 Glycosidation of allyl alcohol with 3-deoxy-3-azidoglycals 
 
The isolated allyl glycoside 126 was deacetylated under basic conditions and 
subjected once more in the proton-induced glycosidation with the azidoglycal 
mixture. After 48 hours the reaction was terminated and the product mixture was 
purified by column chromatography. Ribo-configured C-4 hydroxyl group in 
allylglycoside 126a is sterically hindered, which hampers the accessibility of the 
substantially deactivated oxonium ion. Therefore, the two disaccharides 127 and 
128 were isolated only in low yields together with the starting material (Scheme 
26). 
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Scheme 26 Glycosidation of allylglycoside with 3-deoxy-3-azidoglycals 
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The scope and limitations of using this strategy in the synthesis of some amino-
glycoconjugates is shown in Schemes 26 and 26a. Testosterone 23 was 
glycosidated with glycal mixture 121a, b in moderate yields using the above 
mentioned reactions conditions. It is worth to notice a high kinetic selectivity of the 
given reaction, because only ribo-configured azidoglycal 121a reacted within 24 
hours yielding an anomeric mixture of glycoconjugates in excellent yields (about 
80% when calculating only ribo-configured glycal). The arabino-configured 
azidoglycal 121b remained unreacted and could be reisolated . 
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Scheme 26a Representative synthesis of glycoconjugates 133 and 134; Reagents and conditions: 
(a) PS-PPh2*HBr cat., CH2Cl2, RT, 24h; (b) Amberlyst A-26 (OH- form), MeOH; (c) 22 1 eq, PS-
PPh2*HBr cat., CH2Cl2, RT, 24h; (d) TBAF, THF, RT, 4h; (e) + PS-PPh2, RT, 24h. 
 
Both glycoconjugates were deacetylated and separated by column 
chromatography. Further glycosidation with fucal 22 afforded disaccharides 131 
and 132. After removing the TES groups with TBAF and subsequent Staudinger 
azide reduction with polymer-bound triphenylphosphine glycoconjugates 133 and 
134 were obtained in excellent yields.  
 
6.1.4. Polymer-bound triphenylphosphonium bromide as effective promoter 
for alcohol protection/deprotection with the tetrahydropyranyl (THP) group 
 
Tetrahydropyranyl ethers, introduced as a protecting group for alcohols in 1948, 
are still widely used in modern chemistry.42 They can both be formed under mild 
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acid-catalyzed conditions in CH2Cl2, and cleaved under similar conditions using 
other solvents such as methanol or a mixture of THF-water.43 As substrate 
dihydropyran (DHP) is commonly used, which is protonated to build up an oxonium 
ion similar to glycals. This oxonium ion is attacked in the following by a nucleophilic 
alcohol. The similarities in the activation-addition mechanisms suggested to 
evaluate polymer-bound PPh3*HBr as a potential reagent to introduce the THP 
group under very mild conditions. As test substances, some complex alcohols 
were employed and protected by proton-catalyzed addition to DHP. In a second 
set of experiments the THP-ethers were successfully deprotected using polymer-
bound PPh3*HBr as a mild proton source in methanol  as a solvent (Table 8). 
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Table 8 Reagents and conditions: (a) PS-PPh2*HBr cat. DCM, RT, 3h; (b) PS-PPh2*HBr cat., 
methanol, RT, 12h. 
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The mildness of the procedure is demonstrated for digitoxigenin 25 and the allyl 
alcohol 138 which easily can undergo retro-aldol reactions. In all cases, addition of 
alcohol to DHP proceeded almost quantitatively, and the following deprotection 
yielded chromatographically pure starting alcohol. Consequently, this reagent 
turned out to be a very powerful tool for the protection/deprotection of alcohols as 
the corresponding THP-ethers. 
 
6.2. Polymer-assisted glycosidation of thioglycosides 
6.2.1. Polymer-bound iodo(I)bis(trifluoroacetate), a versatile electrophilic 
promoter for the glycosidation of thioglycosides 
 
Thioglycosides are widely utilized glycoside donors in carbohydrate chemistry. 
Ferrier et al. introduced the use of mercuric salts for the activation of thioglycosides 
due to high sulfur affinity to mercury.44a In the early eighties Nicolaou and co-
workers offered the first thioglycoside-based glycosidation method using the 
halogen (I) based electrophilic reagent NBS.44b Later many other groups evaluated 
and further developed thioglycosides in electrophilic glycosidations by employing 
such electrophile catalysts as DMTST44c, IDCP44d, and NIS/TfOH44e.  
Recently, new halogenate (I)-complexes on solid support were developed in the 
Kirschning group.45 One of these reagents, polymer-bound 
iodo(I)bis(trifluoroacetate), could be a very potent electrophilic activator of 
thioglycosides.  
The first experiments were conducted by employing some simple alcohols as test 
systems in order to evaluate polymer capabilities for the activation of thioglycoside 
(Scheme 27). 
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Scheme 27 Glycosidation of some alcohols using polymer-bound iodo(I)bis(trifluoroacetate) 
 
In both experiments glycosidation proceeded very rapidly, but formation of minor 
decomposition products were observed. In the second experiment, rhamnal 143 
was also isolated as a by-product, which originated from the possible of a proton at 
C-2 when the oxonium cation is generated. A lower reaction temperature led to 
elongated reaction times without any improvements concerning the purity of the 
reaction products. In addition, liberated iodine and trifluoroacetic acid catalyzed 
silyl group cleavage which could be one of the reasons of the detected impurities.  
To improve the yields, reaction conditions had to be thoroughly optimized. As an 
optimal reaction medium a bipolar aprotic solvent system (THF/CH3CN 1:2) was 
chosen in which important reaction intermediates can be stabilized to avoid 
unfavorable side reactions. In the given conditions the reaction rate accelerated 
drastically, which meant lower reaction temperature (Table 9). 
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Table 9 Glycosidation using polymer-bound iodo(I)bis(trifluoroacetate) 
 
All reactions were carried out at lower temperature in a 1:2 mixture of THF/CH3CN 
using one equivalent of donor, acceptor, and polymer-bound activator. Isolated 
yields highly depend on the nature of glycosyl acceptors. Sterically inconveniently 
placed hydroxyl groups can be made responsible for reduced yields or may cause 
formation of other products. For example, the effort to glycosylate 
diacetonfructopyranose 144 led to the formation of pyranose 146 as a by-product. 
If diacetonglucofuranose is employed as an acceptor, this side reaction proceeds 
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exclusively leading to pyranose 146 in 85% isolated yield and none of the desired 
disaccharide 148 was formed. The extremely low reactivity of a hydroxyl group at 
C-3 is well documented, therefore this carbohydrate is well suited for determining 
the activity of different promoters. The trifluoroacetic acid liberated in the reaction 
medium after thioglycoside activation could be a reason for the formation of 
pyranose 146. This acid can act as a weak nucleophilic acceptor, and if another 
nucleophile is not present in the reaction medium or is sterically inaccessible the 
intermediated anomeric, trifluoroacetate is formed (Scheme 28). In the following 
and upon work-up this ester easily hydrolyses to form free pyranose 146.  
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Scheme 28 Mechanism of formation of monosaccharide 146 
 
These test reactions clearly demonstrate the applicability of the new polymer-
attached activator in glycosidations of non-hindered alcohols. Indeed, polymer-
bound iodo(I)bis(trifluoroacetate) showed excellent thiophylicity towards 
thioglycosides. The use of other more stable protecting groups could allow 
elevated reaction temperatures. Thereby, the trifluoroacetate intermediate, for 
which we collected evidence in some experiments (pyranose 146 were 
occasionally isolated), can itself be activated, thus driving the glycosidation to 
completion.  
 
6.2.2. Polymeric scavenger reagent for diphenyl disulphide 
 
Several reviews about polymer-supported scavenger reagents were recently 
published.46 The clear advantage of this technology lies in the area of purification – 
simple addition of a polymeric scavengers to the reaction mixture with subsequent 
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filtration leads to the required target molecule in high purity. These functionalized 
polymers can be used to remove an excess of reactant or equally well liberated by-
products. In addition to the known applications of solid-supported reagents this 
purification technique can also be applied in traditional solution-phase synthesis.  
In all thioglycosidation reactions diphenyl disulphide is formed as a by-product. 
Commonly, it can be separated during the purification process by column 
chromatography. In the automated solution-phase synthesis such additional 
operations are not always feasible. Therefore, polymer-assisted purification 
techniques can help avoiding these additional procedures. Up to date no polymeric 
scavengers for disulphides are reported. Disulphides, if not removed, can slow 
down the oxidation and reduction processes and contaminate different transition-
metal catalyzed reactions which are planned to be conducted in the next steps. 
In this work a new method is disclosed which allows complete scavenging of 
diphenyl disulphide which is liberated during the thioglycosidation process 
(Scheme 29). Polymer-bound borohydride is used as a reagent of choice in 
isopropanol: borohydride resin reacts only sluggishly with isopropanol. Upon 
reaction thiophenol is formed and is attached to the polymer as thioboric acid 
ester. As an alternative polymer-bound 2-amino-1-thioethanol in CH2Cl2 could be 
used. In this case thiophenol, reduced by borohidride resin, forms disulphide with 
polymer-attached thiol in the presence of air. Both procedures allow quantitative 
removing of the diphenyl disulphide from the reaction medium, though, in second 
procedure employed polymer-bound thiol is fairly expensive that limits its 
application.  
NMe3
+BH4
- + Ph-SS-Ph
NMe3
+BH4-n(SPh)n
-
isop
rop
ano
l
1. MeOH
HN NH
S
2.
S
HS
CH
2 Cl2
 
Scheme 29 Polymer-supported borhydride and 2-amino-1-thioethanol as a scavengers for 
disulphides. 
 
In a typical procedure after workup of the thioglycosidation reaction, the crude 
product (0.1 mmol) containing diphenyl disulphide is dissolved in a 3 ml of 
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isopropyl alcohol. Subsequently 100 mg of polymer-supported borhydride is added. 
The resulting suspension is then allowed to shake for 12 hours whereupon 
disulphide is fully scavenged. This procedure can be repeated if the next step of 
synthesis is very sensible to sulfur traces such as catalytic debenzylation of benzyl 
ethers using hydrogen over Pd or Pt catalysts.  
 
6.2.3. Selectfluor as powerful thiophilic activator for 2-deoxythioglycosides 
 
In the last decade 1-chlormethyl-4-fluoro-1,4-diazonia-bicyclo[2.2.2]octane 
bis(tetrafluoroborate) (selectfluor) was introduced as mild fluorinating agent.47 Its 
application in sugar chemistry - especially in addition to glycals was extensively 
studied in the Dax and Wong laboratories.48 Wong and co-workers were also the 
first to report on the ability of selectfluor to activate thioglycosides in the 
presence of boron trifluoride-etherate complex. No additional aspects more in the 
thioglycoside area were reported since then. Wong also proposed a mechanism for 
the activation of thioglycosides using selectfluor (Scheme 30).  
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Scheme 30 Thioglycoside activation mechanism by Wong48d 
 
Wong proposed a fluorosulfonium ion as an intermediate, which later decomposes 
to glycosyl fluoride or can be activated with boron trifluoride-etherate complex for 
further glycosidations with alcohols.  
This activation method has briefly been evaluated on 2-deoxythioglycosides which 
allowed to prepare glycoconjugates 72 and 74 in excellent yields (See Table 4 in 
chapter 5.3). In the case of 2-deoxythioglycosides boron trifluoride is not necessary 
for glycosyl activation in conjunction with selectfluor. As a test system for 
determining the stereospecificity of these glycosidations α- and β-configured 
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thioglycoside donors 18 and 19, respectively, were chosen in the glycosidation with 
testosterone (Scheme 31). 
O
AcO
AcO
SPh
O
AcO
AcO SPh
O
H
HH
HO
O
AcO
AcO
O
H
HH
O
O
AcO
AcO
O
H
HH
O
18
19
23
SelectfluorTM
150 (97%, α/β - 2:1)
+
 
Scheme 31 Reagents and conditions: 18 or 19 1 eq, 23 1 eq, Selectfluor 1 eq, CH3CN, MS 4Ǻ, 0o 
C, 20 min. 
 
Surprisingly, both anomers yielded the same α/β-ratio of glycosidation products. 
These observations point to an identical intermediate which in fact originates from 
different thioglycosides. Such an intermediate could be the oxonium ion that is a 
common species in glycosidation processes. Therefore, the fluorosulfonium ion 
(Scheme 30) decomposes before a nucleophile attacks the anomeric center with 
activated phenylthio group. The phenylfluorosulfide later forms diphenyldisulfide in 
a still obscure fashion. After diphenyldisulfid is removed by the scavenging protocol 
described above the products could be obtained in high yields and with excellent 
purity without necessity of additional purification. This strategy was tested on 
various aglyca and sugars (Table 10). 
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Table 10 Glycosidation of thioglycosides with Selectfluor as an electrophilic activator (I)  
 
Thioglycoside 21 was used as an anomeric mixture (α/β - 1:1) because the 
stereochemistry at the anomeric center was irrelevant for the stereochemical 
outcome of the glycosidation. It is obvious that the efficiency of the glycosidations 
conducted is hardly influenced by steric factors. Even diacetonglucofuranose can 
be glycosylated with excellent results which is in sharp contrast to the efforts using 
the polymer-attached iodate(I) complex mentioned above. This approach has clear 
advantages over the thioglycosidation procedures developed by Nicolaou44b and 
van Boom44e, who employed NBS, NIS and combinations, where the liberated 
succinimide competes with the acceptor. Surprisingly, this method can also be 
employed using glycals despite the fact that selectfluor has been utilized as 
fluorinating agent for glycals48. These results testify a much greater affinity of 
selectfluor for sulfur than for the enolether double bond of glycals. One 
equivalent of boron trifluoride is liberated during the reaction, therefore basic 
molecular sieves are essential to buffer the reaction medium thus avoiding 
possible side reactions catalyzed by Lewis acids. After thioglycoside activation 
selectfluor is transformed into a salt with low solubility in most of organic solvents 
so that it can be separated by simple filtration through a pad of basic alumina. The 
remaining diphenyldisulphide is scavenged using the protocol mentioned above to 
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yield a pure product which can be used in the next step without additional 
purification. The anomeric mixture obtained can be separated chromatographically 
if pure anomers are needed. The given method was further evaluated for the 2-
deoxy-L-rhamnoside thioglycoside with silyl protection in order to evaluate silyl 
group stability (Table 11). 
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Table 11 Glycosidation of thioglycosides with Selectfluor as an electrophilic activator (II) 
 
The overall yields are slightly lower compared to fully acetylated phenylthiodonor, 
but the general trend remains. Less hindered alcohols still gave almost quantitative 
yields and chromatographically pure products. With more hindered acceptors the 
yields slightly decrease.  
An often employed protecting group in natural product synthesis is the benzyl ether 
which needs to be cleaved in the final step using H2/Pd or H2/Pt.49 This 
hydrogenation may be hampered or completely suppressed if thioglycosidation is 
involved in the previous steps liberating thio impurities. To prove the quality and 
versatility of diphenyldisulphide scavenging an additional experiment was 
conducted with fully O-benzylated thioglycoside donor 167 (Scheme 32). The 
thioglycoside 167 was involved in a glycosidation reaction with cyclohexanol as 
acceptor with a subsequent scavenging procedure. The following palladium-
catalyzed hydrogenation of the benzyl ethers was performed to determine whether 
the remaining sulfur traces (if such exist) were large enough to contaminate the 
catalyst. 
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Scheme 32 Reagents and conditions: (a) Selectfluor, CH3CN, 0o C, 15 min; (b) polymer-bound-
NMe3 BH4, i-PrOH, 12h, and repeat, 98%; (c) Pd/C-10%, H2, 20 bar, 2h, 99%. 
 61
The standard scavenging procedure with a minimal amount of scavenger had to be 
be repeated because the traces of thiophenol, remaining after the first treatment 
with borhydride resin, deactivated the palladium catalyst. However, after the 
second scavenging step de-O-benzylation was achieved with large efficiency to 
yield glycoside 169.  
 
7. Orthogonal oligosaccharide and glycoconjugate synthesis 
employing polymer bound triphenylphosphonium bromide and 
selectfluor as activators for glycosidation 
 
The thioglycosidation strategy which utilized glycals can be applied to an 
orthogonal oligosaccharide and glycoconjugate synthesis. The previously prepared 
disaccharide 159 which contains a glycal moiety may be directly activated for the 
next glycosidation step. In this work a new approach of obtaining oligosaccharides 
and glycoconjugates through polymer-assisted synthesis in solution is 
demonstrated. Disaccharides 170 and 171 are initally obtained using selectfluor 
thioglycoside activation (Scheme 33). 
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Scheme 33 Reagents and conditions: (a) Selectfluor, CH3CN, 0o C, 15 min; (b) PS-PPh3*HBr cat, 
23, CH3CN, RT, 24h; (c) Amberlyst A-26 OH- , MeOH, RT, 12h. 
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In both disaccharides the glycosidic bond was established as pure α-epimers 
although in the first procedure α-thioglycoside 18 and in the second example the β-
configured thioglycoside 19 was used. This proves once again that the proposed 
mechanism occurs through an identical intermediate in both cases. The 
disaccharides obtained were separately utilized in further glycosidation steps in 
which one of them acts as a donor and the other is applied as an acceptor after a 
deacetylation procedure. The products 172 and 173 were obtained in good yields 
without further optimizations which probably could improve the final outcome.  
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8. Conclusions and outlook 
 
In this work polymer-bound 2-deoxyoligosaccharide and –glycoconjugate synthesis 
on PS-DES resin was compared with related polymer-assisted solution-phase 
synthesis using polymer-bound reagents and catalysts. The new polymer, 
developed by Argonaut technologies, demonstrated good to excellent results in 
disaccharide and small glycoconjugate synthesis on polymer-support. Attaching 
the first sugar onto the polymer proceeded with excellent yields and loading was 
much better (up to 1.1 mmol/g) compared with the other widely used polymers in 
solid-phase carbohydrate chemistry (0.1 – 0.65 mmol/g).12d Glycosidation of the 
second carbohydrate or the aglycon with the polymer-bound glycal gave good 
yields, though it was impossible to drive the glycosidation to completion in spite of 
3-fold excess of the acceptor. In this way, glycoconjugates such as 52 and 54 were 
synthesized in 78 and 75% yields, respectively, and disaccharides, like 58, 60 and 
68, were obtained in 70, 76, and 80% yield, respectively. Further attempts to attach 
a third acceptor onto the polymer-support were unsuccessful or gave low yields. 
The main problem was the elevated instability of the 2-deoxysugar glycosidic bond 
in the presence of a mild proton source in comparison to experiments in solution, 
where no decomposition was observed under identical conditions. The glycal 
activation on the polymer-supported disaccharide always led to the 
retroglycosidation. Further attempts to utilize the thioglycosidation strategy on 
polymer-support disclosed low reactivity of thioglycoside donors due to the 
restricted amount of thioglycoside activators, that may be compatible with the labile 
linker system used, and the limited choice of reaction conditions in which no 
decomposition of polymer-bound disaccharide was observed. Nevertheless, this 
polymer can be involved as a polymeric carrier in small disaccharide and 
glycoconjugate library synthesis with an acceptable outcome. This polymer has 
demonstrated excellent swelling capabilities in dichloromethane and chloroform 
that eases polymer-bound intermediate characterization using gel-13C-NMR 
techniques. Both, polymer-bound disaccharides and glycoconjugates, could be 
easily monitored and characterized without cleavage from the polymeric carrier. 
Measuring the signal strength in gel-NMR spectra, it was possible to determine 
relative polymer loading and the glycosidation progress as the starting material 
 64
signals slowly disappeared a companied by the appearance of the successive 
product signals.  
The first selective protecting strategy for decarestrictine-D was developed and the 
different reactivity of all the three hydroxyl functions was further24d evaluated. 
Partially protected decarestrictine 40 was successfully involved in glycosidation 
reactions on solid support and in solution using polymer-assisted techniques. 
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Figure 6 Selected substances from the polymer-bound synthesis chapter 
 
The newly developed polymer-bound triphenylphosphonium bromide (P-TPHB) 
was involved in several glycosidation reactions as a mild proton source for glycal 
activation. Using an “armed-disarmed” donor technique a new one-pot 
glycoconjugate and oligosaccharide-synthesis method was developed based on 
different reactivities of the glycal and carbohydrate hydroxyl groups. Using this 
strategy, a small glycoconjugate library was synthesized with good to excellent 
yields (96, 100, 103, 104, 105, 106, 107, 109, 110, 112, 113, 114 and 119). This 
method can be automated if a proper and efficient polymer-bound reagent for the 
silyl ether cleavage is applied. The developed polymer-bound triphenyl 
difluorosilicate presented moderate affinity for silyl ethers. Traces of HF present in 
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polymer cavities frequently catalyzed side reactions which paralleled silyl ether 
cleavage.  
Further P-TPHB was evaluated on 3-azidoglycals which could possibly undergo 
glycosidation reactions by protonation. Azidoglycals 121 showed acceptable 
activity as glycosidic donors in reactions with non-hindered alcohol acceptors. 
Applying this method several 2-deoxy-3-azidodisaccharides and 2-deoxy-3-
aminoglycoconjugates were synthesized in good yields (127, 128, 133 and 134).  
Dihydropyran is commonly used to introduce a tetrahydropyranyl protective group 
for alcohols under mild acidic conditions. This protecting group can be cleaved 
using slightly more acidic conditions in a protic solvent system. Polymer-bound 
triphenylphosphonium bromide was successfully tested for the introduction and 
cleavage of THP protecting groups. Several alcohols were quantitatively protected 
and deprotected with high purity of the final product.  
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Figure 7 Selected substances from the polymer-assisted synthesis chapter (I) 
 
Polymer-bound iodo(I)bis(trifluoroacetate)45 was involved in electrophilic 
thioglycoside activations. Polymer-bound iodo(I) complex showed excellent affinity 
for sulfur. However, side-reactions, caused by the release of iodine and 
trifluoroacetic acid, hampered the use of the reagent with hindered alcohol 
acceptors, where liberated trifluoroacetic acid competes with the acceptor resulting 
in instable glycosyltrifluoroacetates.  
A method using selectfluor as electrophilic thioglycoside activator, developed by 
the Wong group, was further developed in the 2-deoxythioglycoside area.30g This 
protocol showed excellent results: most of the reactions proceeded almost 
quantitatively and with superior product purity. Employing hindered acceptors such 
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as diacetonglycofuranose or 2,3,6-trideoxy-3-azido-α-L-allylglycoside in 
thioglycosidations was also successful. Thioglycosidations activated by 
selectfluor were compatible with silylated carbohydrates as well as disarmed 
glycals. Using the developed method, a small library of various disaccharides and 
glycoconjugates (150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 
163, 164, 165, 166 and 168) was synthesized. Furthermore, employing the above 
elaborated glycal glycosidation protocol together with the selectfluor technique, 
some oligosaccharides and glycoconjugates were synthesized through an 
orthogonal synthesis strategy (170, 171, 172 and 173). The electrophilic 
thioglycoside activation with selectfluor always leads to the same intermediate 
regardless of the starting conformation of the anomeric center: α, β, or mixture of 
both. Stereocontrol during glycosidic bond formation depends exclusively on the 
solvent employed and the configuration of the acceptor. In all thioglycosidations 
diphenyldisulphide (or R-SS-R) is liberated as a by-product which can hamper or 
inhibit further transformations. Therefore a careful purification step is often a must. 
In this work a new and simple protocol using a polymer-bound scavenger 
technique to remove liberated diphenyldisulphide by simple filtration is presented. 
Polymer-bound borohydride is used to reduce disulphide to thiophenol, which is 
later attached to the polymer as phenylthioborate. Isopropanol is essential as a 
solvent for successful disulphide scavenging without undesired side reactions such 
as reduction of carbonyl functions or transesterifications. The quality of the given 
disulphide scavenging protocol is sufficient to allow sulfur sensitive reactions, such 
as palladium-catalyzed hydrogenations, without further purification. 
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Figure 8 Selected substances from the polymer-assisted synthesis chapter (II) 
 
Polymer-assisted solution-phase oligosaccharide synthesis showed several 
advantages over polymer-bound synthesis. The yields are generally higher with 
excellent product purity in most cases. There is no need of donor or acceptor 
excess – each of them is used equimolar which may save costs of complex 
saccharide building blocks. A standard sequence for a trisaccharide synthesis can 
be achieved in much shorter time as on a polymer-support. Elaborated polymer-
assisted solution phase techniques for 2-deoxyoligosaccharide and glycoconjugate 
synthesis can be automated for parallel synthesis. In the nearest future this would 
allow to produce small glycoconjugate libraries in a short time using the recently 
developed PASSflow technique.20a 
 69
9. New 15N-labelled neo-aminodeoxysaccharides  
9.1. Introduction 
 
Carbohydrates, in particular protonable polyamines are fundamentally involved in 
many important biological processes. Their ability to specifically bind to 
polinucleotides could induce RNA conformation alterations and inhibit DNA or RNA 
synthesis.38 Aminodeoxysugars are widely distributed in natural products as 
structural components of glycoconjugate and aminoglycoside antibiotics such as 
daunomycin 174 or kanamycin A 175. (Figure 9). 
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These structures are well suited to form complexes with oligonucleotides, as the 
rigid feature of the sugar ring along with the flexibility of the glycosidic linkage gives 
them the ability of preorganization. Tor et al. showed that a spacer-linked dimer 
derived from 175 also recognizes RNA with enhanced binding properties in 
contradistinction to natural kanamycin. 87b Nicolaou and co-workers presented a 
similar example where the head-to-head and head-to-tail 1,4-butanediol linked 
dimers of the oligosaccharide portion of calichamicin γ1Ι showed 1000 times higher 
affinity than the monomeric calichamicin γ1Ι 176 oligosaccharide by selectively 
binding to the TCCT-rich areas in DNA.87f,g In order to magnify the ability of 
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preorganization which could improve the binding capabilities Kirschning and co-
workers recently initiated a project on the preparation of new 1,4-butanediol-linked 
oligomeric and macrocyclic aminodeoxysugars in order to search for specific 
oligonucleotide binders with therapeutic potentials.83c,d,e 
 
9.2. Objective 
 
Based on the initial research by Dr. G.-W. Chen, who was involved in the 
development of the first spacer linked linear and cyclic aminoglycosides58,79,85, the 
preparation of correspondent 15N-labelled analogues was envisaged. Some 
spacer-linked neooligosaccharides with TAR-RNA especially tetramer 215 (see 
Scheme 55) clearly indicated the strong formation of RNA/aminoglycoside complex 
in presence of Tat-protein. The HIV TAR-RNA was chosen as the target since the 
binding to the Tat-protein is well characterized and the known interactions between 
the RNA and the protein could therefore be used in competitive binding studies.50 
In order to evaluate the RNA-binding properties and thoroughly explore the actual 
binding between the RNA and macrocyclic oligoaminodeoxysaccharides, NMR 
studies of labelled TAR-RNA, macrocyclic oligoaminodeoxyglycosides and the 
complexes of both should be carried out. For this purpose the novel non-labelled 
macrocycles 215, 216 and fully 15N-labelled macrocycles 220 and 221 should be 
synthesized on a “large scale”. 
 
9.3. Strategy  
 
In the earlier developed synthetic strategy for the preparation of macrocycles 215 
and 216 the amino function has been introduced at an early stage of 
monosaccharide construction through the azide functionality. Such a way is not 
acceptable for the preparation of a 15N-labelled macrocyclus assembly due to low 
overall yield of the macrocycle synthesis. High costs of 15N3- and the fact that only 
one third of nitrogen isotope is used for introducing the amino function forced us to 
develop a truly new synthetic strategy towards 15N-labelled macrocyclic 
oligoaminodeoxysaccharides. The key points of the new strategy should comprise 
following priorities: 
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• Introduction of nitrogen isotope into sugar molecule should 
occur as late as possible in order to reduce the nitrogen losses 
during the synthesis 
• Cheap nitrogen source is desirable  
• All nitrogen atoms should be involved for the introduction of the 
amino function (azide is not favorable).  
 
After a careful study of possible synthetic routes the following strategy was 
proposed: (Scheme 34) 
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As a key building block in the given strategy, spacer-linked bisallylated homodimer 
196 with a free alcohol functionality at C-3 was chosen, which could be derived 
from well accessible L-rhamnal. This opens up various pathways to introduce the 
desirable 15N-labelled amino functionality in the given molecule and at the same 
time furnishing ribo-configuration at the hexose moiety. 
One approach could be activation of hydroxyl function by various means (such as 
triflate or Mitsunobu reaction) followed by nucleophilic attack of the eligible nitrogen 
nucleophile. (Figure 10) 
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Figure 10 
 
The other possibility could start with the corresponding ulose, which undergoes 
reductive amination using an appropriate amine. An impending sterical outcome 
should also lead predominantly to the ribo-configured 3-amino glycoside due to 
more favorable hydride attack from the bottom side of the imine. 
 
9.4. Preparation of spacer-linked head to head dimer 196: the key building 
block in the synthesis of 15N-labelled cyclic 
neooligoaminodeoxysaccharides.  
 
Glycal 17 served as the starting carbohydrate-based building block for the 
synthesis of the spacer-linked diol 196. Allyl rhamnosides 178 and 179 were 
prepared by treatment of L-rhamnal 17 with allyl alcohol using polymer-bound 
triphenylphosphonium bromide as a mild acidic promoter. The role of polymer-
bound PPh3*HBr as mild glycosidation promoter of glycals has been studied in the 
previous chapter. The isolated yield of both epimers was 72.6 % (α/β = 1.3:1). The 
required α-epimer 179 was easily separated after column chromatography. As 
byproducts the Ferrier rearranged glycosides F were formed.51 (Scheme 37) 
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Prior to metathesis dimerisation, the protecting groups in glycoside 179 should be 
manipulated in the advisable way for further allylation at C-4.  
The obtained allyl rhamnoside 179 was deacetylated in methanol using Amberlyst 
A-26 in OH- form as basic transesterification catalyst. Then the hydroxyl group at 
position C-3 of the protected diol 180 was protected as TBS ether in a well 
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established way.52 Allyl glycoside 180 was subjected to the olefin metathesis 
reaction using Grubbs-1 catalyst, however the desired product 181 was not 
detected. A possible reason could be the free alcohol function at C-4. Therefore, 
an additional protection group was needed, which was introduced as an acetate 
using acetanhydride in pyridine to afford glycoside 182 in almost quantitative yield 
(Scheme 38). 
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Scheme 38 Reagents and conditions: a) Amberlyst A-26 (OH- form), methanol, RT, 12h, 98%; b) 
TBSCl, imidazole, DMF, 0o C, 89%; c) Grubbs 1 (10 mol%), benzene, RT; d) Ac2O, pyridine, RT, 
99%, 12h; e) Grubbs 1 (10 mol%), benzene, RT, 48h, 72%; f) PtO2/H2, 99%; g) Amberlyst A-26 
(OH- form), methanol, RT, 12h. 
 
Further dimerisation metathesis and successive hydrogenation of the double bond 
delivered 183 in good yields (72% for two steps). Nevertheless, glycoside 183 
could not be deprotected in the usual manner without migration or cleavage of the 
silyl protecting groups. This failure led to the use of a slightly different approach 
towards target compound 184. The new strategy avoids differentiation of the 
hydroxyl groups prior to dimerisation. The differentiation will be carried out on the 
level of homodimer, instead. Allyl rhamnoside 179 could also undergo olefin 
metathesis dimerisation to yield desired dimer 184 after hydrogenation, 
deprotection and 3-O-silylation (Scheme 39). 
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Scheme 39 Reagents and conditions: a) Grubbs 1 (10 mol%), RT, 48h; b) PtO2/H2; c) Amberlyst A-
26 (OH- form), methanol, RT, 12h; d) TBSCl, imidazole, DMF, 0o C. 
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Allylation of the remaining hydroxyl groups in 184 was performed in various ways. 
The classical protocol using allyl bromide and sodium hydride showed an 
unspecific reaction due to pronounced silyl group (3→4) migration and 
deprotection at C-3.53 Formation of the desired bisallylated glycoside was not 
observed. A milder method using freshly prepared, dried silver oxide and allyl 
iodide54 gave no reaction. This result could be due to sterical hindrance by the 
bulky TBS group at C-3. Wong et al. described a modified procedure for the 
allylation of neamine at the sterically hindered C-5 alcohol of the cyclohexane ring 
system55 where lithium hexamethyldisilazan was used as a deprotonating base 
together with tetrabutylammonium iodide as activator of allyl bromide. This 
approach gave no better results, either; the migration of silyl groups was still 
dominant (Scheme 40). In order to avoid this effect, a different protection group at 
the C-3 alcohol should be used with limited or no migration qualities under basic 
conditions. Such decent protecting group could be the pivaloyl- or TBDPS-group, 
which meet the desired requirements in compliance with early published data.88   
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For affording the 3-O-pivaloyl glycoside 189, alcohol 188 was treated with pivaloyl 
chloride in pyridine. The reaction predominantly gave 3-O-pivaloylation which is in 
accordance with the different reactivity of both hydroxyl groups in the rhamnose 
ring system. Compound 189 was subjected to the allylation reaction using Wong’s 
approach to afford bis-allyl glycoside in 35% yield (Scheme 8). 
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Scheme 41 Reagents and conditions: a) PivCl, pyridine, 0o C, 5h, 85%, b) allyl bromide, LiHMDS, 
TBAI, DMSO, RT. 
 
However, again substantial migrations of the pivaloyl groups were observed which 
leads to highly reduced yields for the desired dimer 190. Later, experiments with 
TBDPS protected dimer 193 gave decent results yielding almost 50% of expected 
bis-allylated glycoside 194 and 45% of mono-allylated glycoside 195. No 
byproducts originating from silyl group migration were observed. It is worth to 
notice that the yield only 50% of bis-allylated glycoside 194, although a high 
excess of reagents was used and the reaction conditions have thoroughly been 
optimized. Anyway, the monoallylated byproduct 195 can be recycled which 
increases the total yield to 85% (Scheme 42). 
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Scheme 42 Reagents and conditions: a) TBDPSCl, imidazole, DMF, 0o C, 12h, 85%; b) allyl 
bromide, LiHMDS, DMSO/THF = 1:1, 0o C, 5 min, 50% for 194, 45% for 195; c) TBAF, THF, RT, 
20h, 85%. 
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 Treatment of allylated dimer 194 with tetrabuthylammonium fluoride in 
tetrahydrofuran gave the title compound 196 in 85% yields. 
 
9.5. 15N-labelling of spacer linked head to head dimer 196 
9.5.1. Activation of alcohol function 
 
One of the oldest and simplest ways to convert an alcohol into an amino group is 
the activation of the hydroxyl group by sulphonating followed by displacement with 
azide in a SN2 reaction. For this purpose Guthrie and Richardson56 used the 
mesylate as a leaving group. On the other hand, the conversion of an alcohol to a 
mesylate followed by elimination under basic conditions is also a well known 
method to build up olefinic double bonds.57 Under SN2 conditions elimination 
frequently occurs when the nucleophilic attack lead to a strained transition state or 
an unfavorable geometry. Therefore, in this case the use of such an activating 
group can lead to undesired elimination products. An alternative could be the 
activation as the trifluormethylsulfonyl ester which shows a low elimination 
tendency. Reckendorf and later Kirschning and co-workers58 used this approach to 
introduce azide in sugar molecules. Nicolau et al.59 applied a similar strategy to 
introduce an amino functionality during the total synthesis of amphotericin B.  
Alcohol 196 was successfully triflated with Tf2O in dichloromethane and pyridine as 
a base in 96% yield. The colorless material 197 obtained is fairly unstable and 
must be used immediately in the next reaction step.68 As an azide source, 
tetrabutylammonium azide in benzene was used, which can be prepared from 
sodium azide by a modified Brändstrom procedure.86 The advantage of n-Bu4NN3 
over sodium azide is based on its high solubility in organic solvents which allows 
more options to chose different solvents and conditions.60 Unfortunately, this 
method gave only a moderate yield of product 198 (Scheme 43). 
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Scheme 43 Reagents and conditions: a) Tf2O, pyridine, CH2Cl2, - 15o C, 96%; b) n-Bu4NN3, 
benzene, 70o C, 10 min, 36%. 
 
Such low yields in conjunction with the fact that azide was used as a nitrogen 
source were not acceptable for a 15N-labelling strategy. The azide function can be 
reduced in various ways, such as: lithium aluminium hydride in THF, or following 
Staudinger’s protocol with triphenyl phosphine62 and its modifications.63 In our case 
the reduction of azide 198 using LiAlH4 or Staudinger protocol gave only moderate 
yields (Scheme 44). 
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Scheme 44 Reagents and conditions: a) LiAlH4, THF, RT or PPh3, THF/H2O; b) TFAA, 
triethylamine, CH2Cl2, - 30o C, 1h, 60% from 198.  
 
The conversion of alcohols or alkenes to amides by the reaction with nitriles in the 
presence of sulfuric acid is named the Ritter reaction.64 While the successful 
course of the reaction certainly depends on the reactivity of the nitrile, a major 
factor is the stability and reactivity of the carbocationic intermediates. Tertiary 
alcohols generally give good yields, secondary and primary alcohols give only 
mediocre results due to the instability of the primary and secondary carbenium ions 
in the common organic medium.65 More than a decade ago Jaouen and co-
workers66 have published a modified approach of the Ritter reaction. They showed 
that this important limitation can sometimes be overcome using chromium 
tricarbonyl complex which directly influences the stability of the carbenium ions. 
However this method was limited to the conversion of benzyl alcohols. Martinez 
and Hanack67 found an alternate strategy to stabilize the carbocationic 
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intermediate. They used alkyl triflates as masked carbocations which easily 
extends the scope of the reaction to secondary and primary aliphatic alcohols. For 
example n-butanol can be aminated with acetonitrile in the presence of 1 eq of 
Tf2O in a 90% yield. (Scheme 45) 
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Scheme 45 
 
Glycoside 197 was involved in this modified Ritter reaction, but only formation of 
decomposition products was observed. This could be explained in terms of the 
high instability of triflate 197 under acidic conditions where decomposition took 
place within minutes. 
To our surprise, triflated alcohol 197 showed extraordinarily stability under basic 
conditions: heating in DMF in the presence of benzyl amine or refluxing in 
methanol with ammonia for several hours indicated no reaction or decomposition 
of the starting material.  
Barton et al.69 published different conditions for Ritter-type reactions. They used a 
stable chlorodiphenylmethyl hexachloroantimonate70 as a free carbocation source 
to induce the activation of alcohols. This carbocation reacts with alcohols and yield 
an oxonium-type intermediate which is attacked by a free electron pair of the nitril. 
This intermediate is almost identical to the Hanack strategy (Scheme 45). 
Superficially the reaction seems to be a non-protic analogue of the Ritter reaction 
(Scheme 46). 
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Alcohol 196 was subjected to the same procedure as menthol in the Scheme 46, 
though again only decomposition of the starting material was observed. 
 
9.5.2. Reductive amination 
 
A standard protocol for the preparation of amines is the reduction of oximes and 
their O-alkyl or –acyl derivatives by hydrogenation or the use of reagents such as 
lithium aluminium hydride, borane or a zinc-copper couple in acetic acid. Since the 
reductions can be highly stereoselective, this has become a very useful method for 
preparing amino sugar derivatives from oximes. The stereochemical outcome can 
depend upon the reducing conditions or disposition of substituents adjacent to the 
reaction center.71 As shown in Scheme 47 catalytic hydrogenation of the β-methyl 
glycoside oxime gives exclusively the β-glycoside of mannosamine with an axial 
amino group at C-2. On the other hand, the α-anomer which has an axial methoxy 
group at C-1 gives predominantly the glucosamine derivative.71b 
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Scheme 47 Reagents and conditions: a) H2, Pd/C; b) LiAlH4, THF, RT; c) BH3*THF, RT. 
 
Alcohol 196 was easily oxidized with Dess-Martin periodinane to the corresponding 
ulose derivative 201 which was subsequently transformed to the oxime using well 
established techniques89 (Scheme 48). 
OMeO
HO
O
OMeO
HO
O
196
OMeO
O
O
OMeO
O
Oa
OMeO
N
O
OMeO
N
Ob
HO
HO
201 202  
Scheme 48 Reagents and conditions: a) Dess-Martin periodinane, CH2Cl2, RT, 2h, 99%; b) 
hydroxylamine hydrochloride, sodium acetate, MeOH, RT, 3h, 96%. 
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 Due to the allylic domain in 202 the correct reducing agent has to be well chosen. 
Ipaktschi has demonstrated an improved reduction method of oximes using sodium 
borohydride in the presence of transition metal compounds.72 The combination of 
NaBH4 with NiCl2 * 6H2O converted the unsaturated oximes through exhaustive 
reduction into saturated amines. If the reduction is carried out in the presence of 
MoO3 olefinic double bonds were not attacked. Later on Bandgar and co-workers 
evaluated this strategy on polymer-support.73 Lithium triethylborohydride and 
sodium cyanoborohydride do not react at all or the reduction is not complete.74 
Borane in THF or DIBALH are also not acceptable due to a possible attack of the 
allylic double bond or the induction of a Beckmann rearrangement.75 Lithium 
aluminium hydride could be a suitable reductive agent for oximes.76 However any 
attempts to reduce the oximine 202 failed in this case (Scheme 49). 
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Scheme 49 Reagents and conditions: a) NaBH4, MoO3, MeOH, RT (decomposition); or b) LiAlH4, 
THF, RT (decomposition); or c) Zn, AcOH, RT, 24h. (no reaction) 
 
Another strategy for reductive amination of ketones could be the use of primary 
amines (such as benzyl amine) or ammonia salts. Borch and co-workers 
demonstrated a wide applicability of this method subjecting different primary and 
secondary amines (also ammonium salts) in the condensation with different 
aldehydes and ketones followed by in situ reduction using sodium 
cyanoborohydride.74b The reduction of aldehydes and ketones with sodium 
cyanoborohydride is pH- dependent. Under neutral conditions in water or methanol 
negligible reduction of aldehydes and ketones occur. As the pH is lowered the 
reduction becomes progressively more rapid. Therefore ideal conditions for the 
reductive amination should be at pH 6-7. To maintain the given pH level sodium 
acetate is used as a buffer. 
Diketone 201 reacted with benzyl amine acetate in methanol, and sodium 
cyanoborohydride was added. After four hours, the diketone was fully consumed 
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and t.l.c. indicated that only one product was established. NMR-spectroscopy and 
mass spectrometry surely yielded expected benzyl amine 203 with the desired 
ribo-configuration at C-3 and no arabino-configured amine would be detected. 
Such a high stereoselectivity has already been explained above (see scheme 35). 
Amine 203 was subjected to the ring closing olefin metathesis with Grubbs 1 
catalyst without success. This is in compliance with prior investigations from the 
Fürstner group77 (Scheme 50). 
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Scheme 50 Reagents and conditions: a) benzylamine, AcOH, NaOAc, NaCNBH3, MeOH, 90%; b) 
Grubbs 1, benzene, 50o C; or Grubbs 2, benzene, RT. 
 
In the total synthesis of Anatoxin Danheiser and co-workers employed a reductive 
amination step using ammonium acetate as a nitrogen source.78 This procedure 
was adopted for the uloside system and finally the desired aminoglycoside 204 
was synthesized in moderate yields. The diamine obtained was directly 
trifluoroacetylated using ethyl trifluoroacetate as mild acylating agent. As minor 
byproducts diastereomeric aminoglycosides 205 were isolated (Scheme 51). 
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Scheme 51 Reagents and conditions: a) ammonium acetate, NaCNBH3, MeOH, RT, 24h; b) 
CF3COOEt, NEt3, MeOH, RT, 12h. 
 
In spite of moderate yields for the reductive amination step this strategy could be 
ideal for the 15N-labelling of uloside 201. The 15N-labelled ammonium acetate is 
relatively cheap comparatively to other 15N-nitrogen sources and yielded 
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aminoglycoside 204 is identical to the non-labelled macrocycle prepared before by 
an alternate route.79 This can facilitate further steps such as ring closing olefin 
metathesis which leads to 15N-labelled macrocyclic spacer linked 
oligoaminodeoxysaccharides.  
Uloside 201 was subjected to the reductive amination reaction employing 15N-
labelled ammonium acetate using the protocol described above. Along with the 
main product 206 two minor byproducts were isolated: one was the previously 
described diastereomeric aminoglycoside 207 (here 15N-labelled) and the second 
one was the cyclic aminoglycoside 208 (Scheme 52).  
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Scheme 52 Reagents and conditions: a) 15N-ammonium acetate, NaCNBH3, MeOH, RT, 24h; b) 
CF3COOEt, NEt3, MeOH, RT, 12h. 
 
The structure and stereochemistry of cyclic aminoglycoside 208 was proven using 
NMR spectroscopy (1H-NMR, 13C-NMR, 1H-1H- and 1H-13C-COSY, NOE and 
TOCSY), mass spectrometry (ESI) and IR-absorption spectra to indicate CN 
moiety. 1H-NMR-spectra clearly indicated two different allyl moieties, two different 
carbohydrate skeletons and one 15NH with coupling constant 81.5 Hz at 4.7 ppm. 
In 13C-NMR-spectra along with two different allylic fragments and pyranoses were 
detected two quaternary carbons: at 122 ppm, and 57.5 ppm with small coupling 
constant. Further 1H-1H- and 1H-13C-COSY-spectra allowed to characterize all 
signals indicating that C-3 from second carbohydrate skeleton now is quaternary 
and bound directly to 15NH. C-3 from first sugar also is bound to 15NH generating 
macrocyclic structure. Electro spray mass spectrometry data gave single molecular 
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ion [M+] with mass 438.26. Acquired data pointed to one substituent at C-3’’ with 
relative mass 26. Careful analysis of possible reaction routes and eventual product 
structures lead to consider the cyano group with the mass 26. Measured infrared 
spectra clearly detected a strong signal at 2279 cm-1 that could originate from the 
cyanide moiety. Prior observed quaternary carbon signal at 122 ppm in 13C-NMR-
spectra also is in accordance with the usually observed nitrile 13C- shift.  Molecular 
modeling calculations were made yielding a 3D-structure which meets the NOE-
data. 
15N
H
C
N
NOE for 208
 
The formation of cyclic aminoglycoside 208 could be explained according to the 
following mechanism (Scheme 53).  
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Scheme 53 Proposed mechanism for the formation of cyclic aminoglycoside 208 
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Initially, only one keto function undergoes reductive amination. The amine attacks 
the second uloside yielding a Schiff-base. Subsequently cyanide anion originated 
from NaCNBH3 attacks the intermediate cyclic imine carbon from the less hindered 
side to form the final cyclic cyanoamine 208. Further reduction of this imine could 
be hampered by the actual cyclic disaccharide conformation which does not allow 
sodium cyanoborohydride to approach and form a complex with the imine double 
bond essential for hydride transfer.  
 
9.6. Synthesis of macrocyclic spacer-linked oligoaminodeoxysaccharides 
9.6.1. Olefin metathesis reaction 
 
Olefin metathesis which is catalyzed by transition metal complexes has been 
widely employed for the extension of carbon skeletons and various cyclisations in 
synthetic organic chemistry80 since the introduction of highly active Schrock’s81 
molybdenum catalyst 209 and particularly after the acquirement of the air and 
moisture stable ruthenium benzylidene catalyst 210 by the Grubbs group.82 
Recently more and more applications of olefin metathesis can be found in 
carbohydrate chemistry.34   
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More than thirty years ago Herrison and Chauvin proposed a hypothetical 
mechanism of olefin metathesis reaction. A metallocyclobutane complex was 
proposed as the key intermediate in metathesis olefinations. Recently, Grubbs and 
co-workers provided substantial evidences for the existence of the key 
metallocyclobutane intermediate.84 The catalytic cycle starts when the catalyst 
precursor transforms into the active methylidene form A. After the first alkene 
molecule is coordinated to the catalyst, one of the phosphine ligands dissociates 
during the formation of the metallocyclobutane B. With the release of ethylene, 
another alkene molecule coordinates to the catalytic center C. Subsequent 
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cycloaddition forms the second metallocyclobutane complex D which transfers 
again to catalyst A after cycloreversion, and liberates olefinic product (Scheme 54).  
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Scheme 54 
R1 = R2 (ring-closing metathesis, self-metathesis) 
R1 ≠ R2 (ring-closing metathesis, cross-coupling metathesis) 
 
9.6.2. Olefin metathesis macrocyclisation of dimer aminoglycosides 204 and 
206  
 
Previously obtained spacer linked dimer 204 was subjected to the olefin 
metathesis dimerisation with subsequent ring-closing metathesis macrocyclisation 
in the presence of Grubbs ruthenium benzylidene complex 210. In order to avoid 
polymerization of the starting material, a diluted solution of glycoside 208 in DCM 
was used.61 After 7 days of reaction at room temperature the desired tetracyclus 
211 and small amount of hexacyclus 212 along with 30% of starting material was 
isolated. At elevated temperatures the yield of the desired macrocycle improves 
minimally, however, side reactions such as allylic double bond isomerisation 
prevail. No ring-closing metathesis product 217 was detected. This observation 
can be explained with the axial orientation of protected amino groups at C-3 that 
do not allow the molecule to take the right preorganization for smooth self-
cyclisation. Instead, dimerisation and trimerization to linear tetra- and 
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hexasaccharides occurs prior to macrocyclisation. On the other hand, if L-
acosamine-based dimer with equatorial oriented protected amino groups at C-3 
was allowed to macrocyclise under the same conditions, self-cyclisation was 
observed predominantly.83e 
Spacer linked macrocycles 211 and 212 were hydrogenated over platinum oxide in 
ethyl acetate to afford 213 and 214, and subsequent removal of the trifluoroacetyl 
groups in 1M NaOH-water/THF/methanol mixture led to the target cyclic tetramer 
215 and hexamer 216 in almost quantitative yields (Scheme 55). 
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Scheme 55 Reagents and conditions: a) Grubbs 210, CH2Cl2, RT, 7 days, 44% for 211, 4.5% for 
212; b) PtO2/H2, ethyl acetate, RT, 12h, 99%; c) 1M NaOH/THF/MeOH = 3:1:2, RT, 24h, 95% for 
215, 99% for 216. 
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After the successful preparation of the macrocyclic spacer-linked 
oligoaminosaccharides 215 and 216 the main efforts were directed towards the 
analogous synthesis of 15N-labelled macrocyclic oligoaminosaccharides. 
Previously prepared 15N-labelled dimer 206 was subjected to the olefin metathesis 
macrocyclisation conditions according to the previous protocol using non-labelled 
aminoglycoside 204. The macrocycles 218 and 219 generated were hydrogenated 
and deprotected respectively to yield the target molecules 220 and 221 with similar 
yields as described above. (Scheme 56) 
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Scheme 56 Reagents and conditions: a) Grubbs 210, CH2Cl2, RT, 7 days, 45% for 218, 5% for 
219; b) PtO2/H2, ethyl acetate, RT, 12h, 99%; c) 1M NaOH/THF/MeOH = 3:1:2, RT, 24h, 99%. 
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10. Conclusions and outlook 
 
The objective of the second part of this work was to develop a synthetic route for 
15N-labelled macrocyclic neooligoaminodeoxysaccharides, and synthesize the non-
labelled and nitrogen 15N-labeled macrocyclic spacer-linked 
oligoaminosaccharides on a “large scale” for NMR and biological evaluations with 
TAR-RNA.  Uloside 201 was chosen as the key building block en route to the 15N-
labelled macrocycles. The intermediate satisfied the following parameters: it is 
easyly synthesized on a gram scale; it has proven to be an ideal structure for 
introducing a 15N-label in a desirable axial configuration using readily available and 
cheap 15N-labelled ammonium acetate; labeling leads to a well known structure 
which was previously prepared by Dr. G.-W. Chen 83e,85 for non-labelled linear and 
macrocyclic oligoamino-deoxysaccharide synthesis. By employing this well worked 
out strategy the following macrocyclic spacer-linked oligoaminodeoxysaccharides 
were prepared: (Figure 11) 
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Figure 11 
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Along with the target aminoglycosides, also cyclic cyanamin 208 was isolated from 
this reductive amination process.  
Further investigations in olefin metathesis process with homodimer 203 could open 
a new route in high-yielding macrocycle synthesis due to the perfect stereo control 
in the reduction process and excellent overall yields. The fluctuant yields in the 
reductive amination process with ammonium acetate points to still undiscovered 
influence of some reaction conditions, therefore the field of optimizations and 
hence improved yields is not yet exhausted. Preliminary affinity studies of spacer-
linked neooligosaccharide 215 have been accomplished with TAR-RNA, the 
important m-RNA domain of HIV-1 virus.85 An extraordinary binding property 
between TAR-RNA and 215 was observed, leading to formation of the 
aminoglycoside-RNA complex. Such complexation could force the TAR-RNA to 
adopt an alternative conformation. Further in-depth studies of TAR-
RNA/aminoglycoside complex with contribution of 1H-, 13C-, and 15N-NMR 
spectroscopy are in progress under guidance of Dr. T. Carlomagno in department 
of NMR-based structural biology (Prof. C. Griesinger) of Max-Planck-Institute for 
biophysical chemistry, Göttingen. 
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11. Experimental part 
11.1. General methods: 
 
Melting Points: All melting points were determined in glass capillaries on a Büchi 
or Gallenkamp apparatus and are uncorrected. 
 
Polarimeter: Optical rotations were measured with a Perkin-Elmer model 243B 
polarimeter at the sodium line and given in deg per dm with the expression of 
concentration in g per 100 mL. 
 
IR-Spectroscopy: IR spectra were recorded on a Bruker FT-IR aparatus Vector 
22. The liquid substances spectra were recorded using NaCl plates or ATR unit, 
solid substances were pressed together with KBr. 
 
1H-NMR-Spectra: 1H-NMR spectra were recorded on a Bruker DPX 200-NMR, 
Bruker ARX 400-NMR and Bruker AM 500-NMR spectrometer. Chemical shifts are 
reported in ppm (parts per million) relative to internal tetramethylsilane (δ = 0.00), 
chloroform (δ = 7.26), methanol (δ = 3.31), benzene (δ = 7.16), pyridine (δ = 8.71). 
Coupling constants J are given in Hertz (Hz). Multiplicities are described by using 
the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, b = broad.  
 
15N-NMR-Spectra: 15N-NMR spectra were recorded on a Bruker AM 500-NMR 
spectrometer. Chemical shifts are reported in ppm (parts per million) relative to 
internal nitromethane (δ = 0.00), Coupling constants J are given in Hertz (Hz). 
Multiplicities are described by using the following abbreviations: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, b = broad. 
 
13C-NMR-Spectra: 13C-NMR spectra were recorded on a Bruker DPX 200-NMR 
(50 MHz), Bruker ARX 400-NMR (100 MHz) and Bruker AM 500-NMR (125 MHz) 
spectrometer. Chemical shifts are reported in ppm (parts per millions) relative to 
internal standards such as chloroform (δ = 77.0), methanol (δ = 49.0), benzene (δ 
= 128.06), pyridine (δ = 149.5). Multiplicities refer to the resonance in the off-
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resonance spectra and were elucidated using the distortionless enhancement by 
polarization transfer (DEPT) spectral editing technique, with secondary pulses at 
90° and 135°. 1JCH Coupling are described by using the following abbreviations: s = 
singlet (due to quaternary carbon), d (+) = doublet (methine), t (-) = triplet 
(methylene), q (+) = quartet (methyl).  
Complete assignments of complex structures were performed employing a 
combination of homo- and heteronulear correlation experiments (1H, 1H-COSY and 
13C, 1H-COSY), NOE, 1D-NOESY, ROSY, TOCSY and HMQC. 
 
MS-Spectra: Mass spectra were obtained on Micromass LCT with Lock-Spray 
using electrospray ionization (ESI) mode. Ion mass (m/z) signals are reported as 
values in atomic mass units followed, in parentheses, by peak intensities relative to 
the base peak (100 %). 
 
Chromatography: Elution of all reactions were monitored by analytical thin layer 
chromatography (t.l.c.) using silica gel 60 F254 precoated plates (E. Merck, 
Darmstadt) and spots were detected either by UV-absorption or by charring with 
H2SO4/4-methoxybenzaldehyde in methanol. Rf´s are given under these conditions 
too. Flash column chromatography were performed using E. Merck silica gel 60 of 
230-400 meshes and normal column chromatography were done on E. Merck 
silica gel 60 of 35-70 meshes. The solvents for chromatography were freshly 
distilled before use. 
 
Reagents and solvents: All commercial available chemicals were used without 
further purification unless otherwise stated, but some reagents were dried under 
vacuum before use.  
All reactions involving air- or/and moisture-sensitive reagents were conducted 
under nitrogen or argon (high purity and dried over NaH, Firma Linde) atmosphere 
with dry, freshly distilled solvents using standard syringe-cannula/septa 
techniques. All solvents were dried by usual methods and stored under nitrogen 
atmosphere in the dark in well-stoppered bottles. 
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11.2. Typical protocols: 
General procedure for the glycosidation with SelectfluorTM. TP1 
To a stirred solution of thioglycoside (0.1 mmol) and acceptor (0.1 mmol) in 
acetonitrile (5 ml), powdered molecular sieves 4A (50 mg) was added. The 
suspension was cooled to 0oC and selectfluor (0.105 mmol) was added. The 
reaction mixture was shaken for 20 min (t.l.c.: ethyl acetate / petroleum ether 1:1) 
and the reaction was terminated by addition of dry Amberlite A-21. The resulting 
suspension was filtered through a pad of Al2O3. The solvent was evaporated under 
reduced pressure and the residue was redissolved in isopropanol (5 ml). After 
addition of polymer-supported borohydride (100 mg) the mixture was shaken 
overnight in order to remove thio-derived impurities. The suspension was filtered 
and concentrated under reduced pressure. The purity of the crude products as well 
as the α/β-ratios were determined at this stage by NMR-spectroscopy. Separation 
of the anomers was achieved by column chromatography (silica gel; petroleum 
ether / ethyl acetate).  
 
General procedure for the glycosidation with SelectfluorTM. TP2 
TP2 is identical to TP1 except for that the scale was downsized to 0.05 mmol.    
 
General procedure for the metathesis olefinations. TP3 
The sugar (1 mmol) was dissolved in 1 ml of benzene and Grubs 1 catalyst 
[17222-30-9] (1 mol%) was added under argon. The reaction mixture was stirred 
for 6 h, then a second portion of the catalyst (1 mol%) was added and the mixture 
was stirred for additional 12 h. 
Then, the reaction temperature was elevated to 40oC and an additional portion of 
the catalyst was added (2 mol% in 24 h in 2 portions). The solvent was evaporated 
under reduced pressure and the residue was purified by column chromatography 
(silica gel; petroleum ether / ethyl acetate) to yield main products and unreacted 
starting material. The isolated products were hydrogenated without further 
analysis.  
 
General procedure for catalytic hydrogenation. TP4 
The sugar (1 mmol) was dissolved in a mixture of solvents (ethyl acetate 
/CH2Cl2/MeOH 16:8:1) 10 ml and PtO2 (7 mol%) was added. The suspension was 
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stirred for 5 h under positive H2 pressure. The reaction mixture was filtered and 
concentrated under reduced pressure to give the product in almost quantitative 
yield.  
 
General procedure for allylation. TP5 
To a vigorously stirred solution of homodimeric diol (0.1 mmol) and allyl bromide 
(20 eq) in DMSO (0.5 ml) was added LiN(SiMe3)2 as solution in THF (200 µl) (7 eq)  
at 0°C. After 5 min the reaction was diluted with ethyl acetate and water. The 
organic layer was washed with water until neutral pH. The organic phase was dried 
(MgSO4), filtered and concentrated in vacuum. The crude oil was purified by 
column chromatography (ethyl acetate / petroleum ether 1:10) to yield bisallylated 
homodimer, along with monoallylated product: yield 50-55% bisallylated 
homodimer, 40-45% monoallylated product. The latter can be used for another 
allylation step according to the procedure described above. 
 
General procedure for introducing THP ethers. TP6 
The chirale alcohol (0.033 mmol) was dissolved in CH2Cl2 abs. (3 ml). DHP 2.8 mg 
(3.3 µl, 1 eq) and polymer bound PPH3HBr (cat.) were added, and the suspension 
was vigorously shaken for 3 h at room temperature. The reaction mixture was 
filtered through a pad of Celite and concentrated under reduced pressure.  
 
General procedure for cleaving THP-ethers. TP7  
To a stirred solution of THP protected alcohol (0.033 mmol) in methanol (5 ml) at 
room temperature was added polymer bound PPH3HBr (2 mg). The mixture was 
stirred at room temperature for 12 h. The reaction mixture was filtered through a 
pad of Celite and concentrated under reduced pressure.  
 
General procedure for deacetylation of alcohols. TP8 
To a stirred solution of sugar (10.0 mmol) in methanol (50 ml) was added Amberlite 
A-26(OH- form) (1 g). After 24h the reaction mixture was filtered and the solvent 
was removed under reduced pressure. The product was dried under reduced 
pressure for 4h and could directly be used for the next step. 
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11.3. Preparation of general reagents:  
TBAF buffered solution (pH – 7) for mild silyl ether cleavage. 
(TBAF /AcOH/THF – 266 mg/0.151 ml/8.4 ml). 
 
Polymer-bound Iodo-bis-trifluoroacetate 
 
NMe3
+ I-(OCOCF3)2  
To a suspension of polymer-bound iodide A-26+I- (5 g, 2.9mmol/g) in CH2Cl2 (30 
ml) 11.22 g (26 mmol) PhI(OCOCF3)2 was added. The mixture was shaken for 2 h, 
polymer was filtered off, washed with CH2Cl2 (20 x 20 ml) and dried in high 
vacuum.  
 
Polymer-bound triphenylphosphonium bromide 
P
H
+
Br-
 
The suspension of polymer-bound triphenylphosphine (0.5g, 1.12 mmol/g) in 
HBr/AcOH (33%) 5ml was shaken for 24 h. The slurry washed with CH2Cl2 20x5ml 
and dried under reduced pressure to afford dark yellow polymer. 
 
Polymer-bound tetramethylammonium triphenyldifluorosilicate TBAT  
Ph3SiOH
HF/H2O
MeOH
Ph3SiF
 
Triphenylsilanol was recrystallised from petroleum ether / ethyl acetate prior to use. 
A solution of triphenylsilanol (25 g, 90.4 mmol) in methanol (90 ml) in a 
polyethylene bottle was prepared and cooled to 5oC. Aqueous HF (13 ml, 49%, 
360 mmol) was slowly added and the resulting reaction mixture was allowed to 
warm to room temperature, followed by stirring for additional 30 min. Distilled water 
(50 ml) was added to induce further product precipitation. The resulting slurry was 
filtered in vacuum and washed with water. The crude product was recrystallised 
from solvent mixture (MeOH/water - 15:1) and dried under vacuum.  
Yield: 23.9g (86 mmol, 95%). 
 
NMe3+ F2SiPh3 
-Ph3SiFNMe3+F
- +
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Polymer-supported fluoride was washed with acetonitrile / ethyl acetate prior to 
use. A mixture of 2 g fluoride resin and triphenylsilylfluoride (3.3 g, 2 eq, 12 mmol) 
in CH2Cl2 (100 ml) was shaken for 30 min and the solvent was slowly evaporated 
under reduced pressure. The resulting polymer diluted with ethyl acetate (50 ml) 
and once more evaporated. This procedure was repeated more 3 times, and then 
resulted polymer-bound TBAT was filtered, washed with ethyl acetate and dried 
under high vacuum. 
  
11.4.1. Experiments to the chapter 5.1. 
 
3-O-TES-L-rhamnal (47) 
To a solution of L-rhamnal (130 mg, 1 mmol), DMAP (24.9 mg, 0.2 mmol) and 
imidazole (102 mg, 1.5 mmol) in 10 ml of DMF was dropwise added TESCl (158 
mg, 1.05 mmol) at - 50° C in 30 min. After all TESCl was added, the reaction 
mixture was stirred another 1 h at - 50° C. The resulting mixture was allowed to 
warm to RT and DMF was removed by filtration column (silica gel, petroleum ether 
/ ethyl acetate 5:1). The crude product was purified by column chromatography 
over silica gel (petroleum ether / ethyl acetate 10:1, Rf- 0.26) 
 
 Yield: 170 mg (0.70 mmol, 70%), colorless oil. 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 6.15 (dd, J = 6.2, 1.7 Hz, 1H, 1-
H), 4.55 (dd, J = 6.2, 2.0 Hz, 1H, 2-H), 4.19 (ddd, J = 6.7, 2.0, 1.7 Hz, 1H, 3-H), 
3.90(dq, J = 9.2, 6.3 Hz, 1H, 5-H), 3.45 (ddd, J = 9.2, 6.7, 3.8 Hz, 1H, 4-H), 2.18 
(d, J = 3.8 Hz, 1H, OH), 1.37 (d, J = 6.3 Hz, 3H, 6-H), 0.90 (t, J = 8.0 Hz, 9H, 
SiCH2CH3), 0.57 (q, J = 8.0 Hz, 6H, SiCH2CH3).  
 
13C-NMR (50 MHz, CDCl3, CDCl3=77 ppm) δ:143.6 (+, C-1), 103.4 (+, C-2), 74.8 
(+, C-4), 74.3 (+, C-5), 70.5 (+, C-3), 17.2 (+, C-6), 7.1 (+, SiCH2CH3), 5.3 (-, 
SiCH2CH3). 
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3-O-TES-L-Fucal (46) 
To a solution of L-fucal (2 g, 15.4 mmol), DMAP (0.35 g, 0.2 eq, cat.) and 
imidazole (1.5 g, 1.5 eq, 23.1 mmol) in DMF (20 ml) at - 60° C TESCl (2.3 g, 15.4 
mmol) was added dropwise. The reaction mixture was stirred for 1 h at the same 
temperature and then allowed to warm up to RT. The DMF was removed by 
filtration column (silica gel, petroleum ether / ethyl acetate 5:1) and crude product 
was purified by column chromatography over silica gel (petroleum ether / ethyl 
acetate 10:1, Rf- 0.26) 
 
Yield: 3 g (12.3, 80%), colorless oil. 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 6.30 (d, J = 5.8 Hz, 1H, 1-H), 
4.45 (ddd, J = 5.8, 2.0, 1.4 Hz, 1H, 2-H), 4.41 (dd, J = 3.6, 2.0 Hz, 1H, 3-H), 3.92 
(bq, J = 6.8, 1H, 5-H), 3.57 (ddd, J = 3.6, 2.0, 1.4 Hz, 1H, 4-H), 2.75 (dd, J = 1.4, 
1.4 Hz, 1H, OH) 1.35 (d, J = 6.8 Hz, 3H, 6-H), 0.94 (t, J = 7.6 Hz, 9H, 
Si(CH2CH3)3), 0.6 (q, J = 7.6 Hz, 6H, Si(CH2CH3)3). 
 
13C-NMR (50 MHz, CDCl3, CDCl3 = 77 ppm) δ: 144.5 (+, C-1), 101.6 (+, C-2), 72.4, 
68.0, 65.0 (3+, C-4, C-5, C-3), 16.7 (+, C-6), 6.5 (+, Si(CH2CH3)3), 5.3 (-, 
Si(CH2CH3)3). 
 
Phenyl [3,4-di-O-acetyl-2,6-dideoxy]-1-thio-α(β)-L-glycopyranosides (18, 19) 
O
OAc
AcO
SPh O
OAc
AcO
SPh
18 19
+
 
3,4-Bis-O-acetyl-rhamnal (200 mg, 0.93 mmol) was added to a solution of 
thiophenol (0.10 g, 1.0 mmol) in dry CH2Cl2 (5 ml). Triphenylphosphine 
hydrobromid (343 mg, 1.0 mmol) was added and the solution was stirred for 24 h. 
The reaction mixture was evaporated in a nitrogen flow and the residue was 
purified by column chromatography over silica gel (petroleum ether / ethyl acetate 
10/1, Rf- 0.32). 
 
Yield:  fraction-α: 18 118 mg (0.364 mmol, 39%), colorless crystals. 
 fraction-β: 19 36 mg (0.110 mmol, 12%), colorless crystals. 
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 mix fraction (α/β) 24 mg (0.074 mmol, 8%), light yellow syrup. 
 
fraction-α 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 7.46 (m, 2H, Ph), 7.3 (m, 3H, 
Ph), 5.62 (d, J = 5.6 Hz, 1H, 1-H), 5.28 (ddd, J = 11.7, 9.5, 5.6 Hz, 1H, 3-H), 4.80 
(dd, J = 9.5, 9.5 Hz, 1H, 4-H), 4.39 (dq, J = 9.5, 6.2 Hz, 1H, 5-H), 2.46 (ddd, J = 
13.3, 5.6, 1.1 Hz, 1H, 2-Hax), 2.22 (ddd, J = 13.3, 11.7, 5.6 Hz, 1H, 2-Heq), 2.01, 
2.00 (2s, 6H, 2COCH3), 1.21 (d, J = 6.2 Hz, 3H, 6-H) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 170.2, 170.1 (2s, 2 x COCH3), 
134.5, 131.2, 129.0, 127.3 (s, 3d, Ph), 83.0 (d, C-1), 74.8, 69.3, 66.8 (3d, C-3, 4, 
5), 35.9 (t, C-2), 21.0, 20.8 (2q, 2 x COCH3), 17.4 (q, C-6) 
 
fraction-β 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 7.50 (m, 2H, Ph), 7.32 ( m, 3H, 
Ph), 5.00 (ddd, J = 11.8, 9.5, 5.3 Hz, 1H, 3-H), 4.81 (dd, J = 11.8, 2.0 Hz, 1H, 1-H), 
4.76 (dd, J = 9.5, 9.5 Hz, 1H, 4-H), 3.53 (dq, J = 9.5, 6.2 Hz, 1H, 5-H), 2.45 (ddd, J 
= 12.7, 5.3, 1.9 Hz, 1H, 2-Hax), 2.06, 2.03 (2s, 6H, 2 x COCH3), 1.84 (ddd, J = 
12.7, 11.8, 11.8 Hz, 1H, 2-Heq), 1.27 (d, J = 6.2 Hz, 3H, 6-H) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 170.3, 170.0 (2s, 2 x COCH3), 
132.9, 132.2, 128.9, 127.8 (s, 3d, Ph), 81.5 (d, C-1), 74.3, 73.7, 71.7 (3d, C-3, 4, 
5), 36.5 (t, C-2), 20.9, 20.8 (2q, 2 x COCH3), 17.9 (q, C-6) 
 
Phenyl [3,4,6-tri-O-acetyl-2-deoxy]-1-thio-α(β)-D-glycopyranoside (21) 
3,4,6-Tri-O-acetyl-glucal (15 g, 0.055 mol) was added to a solution of thiophenol 
(6.1 g, 0.055 mol) in dry CH2Cl2 (150 ml). Triphenylphosphine hydrobromid (10 g, 
60 mol%) was added and solution was stirred for 24 h. The reaction mixture was 
evaporated in a nitrogen flow and the residue was purified by column 
chromatography over silica gel (petroleum ether / ethyl acetate 10/1, Rf- 0.30). 
 
Yield: 13 g (0.034 mol, 62%, α/β - 1:1), light yellow crystals. 
 
 99
α-anomer 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.38 (m, 2H, Ph-o), 7.21 (m, 3H, 
Ph-m, p), 5.68 (d, J = 5.5 Hz, H1, 1-H), 5.30 (ddd, J = 11.5, 9.5, 5.5 Hz, 1H, 3-H), 
5.02 (dd, J = 9.5, 9.5 Hz, 1H, 4-H), 4.55 (ddd, J = 9.5, 5.5, 2.0 Hz, 1H, 5-H), 4.30 
(dd, J = 12.0, 5.0 Hz, 1H, 6-H), 4.01 (dd, J = 12.5, 2.0 Hz, 1H, 6-H), 2.48 (ddd, J = 
13.5, 5.5, 1.5 Hz, 1H, 2-Hax), 2.22 (ddd, J = 13.5, 11,5 5.5 Hz, 1H, 2-Heq), 2.03 (s, 
3H, CH3CO), 2.01 (2s, 6H, 2 x CH3CO). 
 
13C-NMR (50 MHz, CDCl3, CDCl3 = 77 ppm) δ: 171.58, 170.41 (3 x COCH3), 
134.21 (Ph-1), 131.73 (+, Ph-o), 129.75 (+, Ph-m), 128.01 (+, Ph-p), 83.62 (+, C-
1), 69.88 (+, C-4), 69.71 (+, C-3), 69.11 (+, C-5), 62.73 (-, C-6), 35.51 (-, C-2), 
21.35, 21.12 (3+, 3 x CH3CO). 
 
Phenyl (2,6-dideoxy)-1-thio-α-L-glycopyranoside (27) 
To a solution of thioglycoside 18 (0.93 g, 2.87 mmol) in 50 ml of methanol 5 g of 
Amberlite A-26 (OH- form) was added. The suspension was shaken overnight and 
then filtered from the polymer and evaporated under reduced pressure. The 
residue crystallizes as a colorless powder. 
 
Yield: 630 mg (2.61 mmol, 91%). 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.38 (m, 2H, Ph-o), 7.21 (m, 3H, 
Ph-m, p), 5.58 (d, J = 5.5 Hz, 1H, 1-H), 4.17 (dq, J = 9.1, 6.2 Hz, 1H, 5-H), 3.95 
(ddd, J = 11.8, 9.1, 5.0 Hz, 1H, 3-H), 3.16 (dd, J = 9.1, 9.1 Hz, 1H, 4-H), 2.72 (bs, 
2H, 2 x OH), 2.37 (ddd, J = 13.0, 5.0, 1.0 Hz, 1H, 2-Heq), 2.12 (ddd, J = 13.0, 11.8, 
5.0 Hz, 1H, 2-Hax), 1.31 (d, J = 6.2 Hz, 3H, 6-H). 
 
13C-NMR (50 MHz, CDCl3, CDCl3=77 ppm) 135.0 (P1-H), 131.1 (2x+, P2-H, 6), 
128.9 (2x+, P3-H, 5), 127.1 (+, P4-H), 83.9 (+, C-1), 78.3 (+, C-3), 69.8 (+, C-4), 
68.5 (+, C-5), 38.5 (-, C-2), 17.5 (+, C-6). 
 
Phenyl (3-O-TES-2,6-dideoxy)-1-thio-α-L-glycopyranoside 
To a solution of thioglycoside 27 (630 mg, 2.62 mmol), DMAP (64 mg, 0.2 eq, cat.) 
and imidazole (267 mg, 3.93 mmol) in DMF (10 ml) at - 60° C TESCl (0.396 g, 2.63 
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mmol) dropwise was added. The reaction mixture was stirred for 1 h at the same 
temperature then allowed to warm up to RT. DMF was removed by filtration 
through a short column (silica gel, petroleum ether / ethyl acetate 5:1). The crude 
product was purified by column chromatography over silica gel (petroleum ether / 
ethyl acetate 10:1, Rf- 0.24).  
 
Yield: 0.8 g (2.26 mmol, 86%), colorless crystals. 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.38 (m, 2H, Ph-o), 7.21 (m, 3H, 
Ph-m, p), 5.56 (dd, J = 5.0, 1.0 Hz, 1H, 1-H), 4.18 (dq, J = 9.4, 6.2 Hz, 1H, 5-H), 
3.9 (ddd, J = 11.3, 8.6, 5.4 Hz, 1H, 3-H), 3.14 (ddd, J = 9.4, 8.6,1.9 Hz, 1H, 4-H), 
2.34 (d, J = 2.2 Hz, 1H, OH), 2.25 (ddd, J = 13.3, 5.4, 1.3 Hz, 1H, 2-Heq), 2.10 
(ddd, J = 13.3, 11.3, 5.4 Hz, 1H, 2-Hax), 1.30 (d, J = 6.2 Hz, 3H, 6-H), 0.99 (t, J = 
7.7 Hz, 9H, 3 x CH3CH2Si), 0.66 (q, J = 7.7 Hz, 6H, 3 x CH2Si). 
 
13C-NMR (50 MHz, CDCl3, CDCl3 = 77 ppm) 135.0 (Ph-1), 131.1 (2+, Ph-o), 128.9 
(2+, Ph-m), 127.1 (+, Ph-p), 83.9 (+, C-1), 78.1 (+, C-3), 70.9 (+, C-4), 68.5 (+, C-
5), 39.5 (-, C-2), 17.7 (+, C-6), 6.8 (+, Si(CH2CH3)3), 5.0 (-, Si(CH2CH3)3). 
 
D-Allal (116) 
10 g (0.0367mol) of Tri-O-acetylallal 115 was dissolved in 100 ml of methanol and 
Amberlite A-26 (OH- form, 5 g) was added. The mixture was shaken overnight. The 
reaction mixture was filtered and the solvent was evaporated to give a white 
crystalline substance. 
 
Yield: 5.3g (0.0366 mmol, 99%). 
 
3,4-Di-O-acetyl-6-tosyl-D-allal (117) 
O
AcO
OAc
TsO
 
To a solution of allal 116 (4 g, 0.027 mol) in 30 ml of pyridine was added 
toluolsulfonyl chloride (5.22 g, 0.027 mmol). The mixture was stirred until no 
starting material was observed (t.l.c. ethyl acetate / petroleum ether – 1:2). Then 
acetanhydride (6 ml, 0.06 mmol) was added and the solution was allowed to stir for 
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12h more. The solvent was evaporated under reduced pressure and the crude 
product was purified by column chromatography over silica gel (ethyl acetate / 
petroleum ether - 2:2). 
 
Yield: 9.4g (0.0245 mmol, 90%, Rf-0.5) 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.82 (bd, J = 8.1 Hz, 2H, Ph), 
7.39 (bd, J = 8.1 Hz, 2H, Ph), 6.45 (d, J = 6.0 Hz, 1H, 1-H), 5.47 (dd, J = 6.0, 3.7 
Hz, 1H, 3-H), 5.08 (ddd, J = 12.4, 6.0, 2.3 Hz, 1H, 5-H), 4.93 (bdd, J = 6.0, 6.0 Hz, 
1H, 2-H), 4.1-4.4 (m, 3H, 4-H, 6-H), 2.50 (s, 3H, CH3-Ph), 2.10 (s, 3H, Ac), 2.00 (s, 
3H, Ac). 
 
3,4,-Di-O-acetyl-6-iodo-6-deoxy-D-allal 
O
AcO
OAc
I
 
The sugar 117 (5 g, 0.013 mol) was dissolved in 100 ml of acetone and NaI (3.9 g, 
0.026 mol) was added successively. The solution was refluxed for 12 h, 
whereupon t.l.c. (ethyl acetate / petroleum ether – 1:4) indicated the completion of 
the substitution. Solvent was evaporated under reduced pressure and the crude 
product was purified by column chromatography over silica gel (ethyl acetate / 
petroleum ether - 1:4). 
 
Yield: 4.3g (0.0127 mmol, 97%, Rf-0.53) 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 6.56 (d, J = 5.8 Hz, 1H, 1-H), 
5.47 (dd, J = 5.8, 3.8 Hz, 1H, 3-H), 4.99 (dd, J = 10.4, 3.8, 1H, 4-H), 4.95 (dd, J = 
5.8, 5.8 Hz, 1H, 2-H), 3.92 (ddd, J = 10.4, 5.7, 2.8 Hz, 1H, 5-H), 3.48 (dd, J = 11.0, 
2.8 Hz, 1H, 6-H), 3.35 (dd, J = 11.0, 5.7 Hz, 1H, 6-H’) 2.10 (s, 3H, Ac), 2.07 (s, 3H, 
Ac). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 170.21 (s, CO), 169.13 (s, CO), 
147.66 (d, C1), 97.80 (d, C2), 70.77, 70.74 (2d, C4, C3), 62.56 (d, C5), 20.98, 
20.58 (2q, 2 x COCH3), 4.53 (t, -CH2-I). 
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6-Deoxy-D-allal 
O
HO
OH  
A solution of 3,4-di-O-acetyl-6-iodo-6-deoxy-D-allal (3.1 g, 9.1 mmol) in 10 ml of 
THF was added to a suspension of LiAlH4 in THF (1.897g, 50 mmol, 5.5 eq in 50 
ml). After 2 h the reaction mixture was treated with NaF (23.76 g) and water 10 ml 
in 32.7 ml of THF at 0oC. The resulting suspension was stirred for 1 h and filtered 
through a pad of celite, solids were washed with THF and the solvent was 
evaporated to afford a white solid. The crude product was siliylated without further 
purification. 
 
Yield: 1.05 g (8 mol, 88%). 
 
6-Deoxy-3,4-diO-TES-D-allal (118) 
O
TESO
OTES 
A solution of 6-deoxy-D-allal (1.1 g, 8 mmol), DMAP (50 mg, cat.) and imidazole 
(1.8 g, 24 mmol) in 20 ml of DMF was stirred, and dropwise TESCl (3.0 g, 20 
mmol) was added. After all TESCl was added, the reaction mixture was stirred for 
another 5 h at RT. DMF was removed by filtration through a short silica gel column 
(petroleum ether / ethyl acetate - 5:1). The crude product was purified by column 
chromatography over silica gel (petroleum ether / ethyl acetate 10:1) to afford a 
colourless oil. 
 
Yield: 2.6 g (7.2 mmol, 91%, Rf- 0.26) 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 6.33 (d, J = 5.8 Hz, 1H, 1-H), 
4.82 (dd, J = 5.8, 5.7 Hz, 1H, 2-H), 4.16 (dq, J = 9.5, 6.3, 1H, 5-H), 4.05 (dd, J = 
5.7, 3.3 Hz, 1H, 3-H), 3.55 (dd, J = 9.5, 3.3, 1H, 4-H), 1.33 (d, J = 6.3 Hz, 3H, 6-H), 
1.00 (m, 18 H, TES), 0.65 (m, 12H, TES). 
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17-O-[3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl]-testosterone (24) 
O
H
HH
OO
OTES
TESO
 
To a solution of testosterone (50 mg, 0.173 mmol), and 3,4-bis-O-TES-L-fucal 22 
(0.312g, 4 eq, 0.692 mmol) in 3 ml of CH2Cl2 PPh3HBr (3.7 mg, 5mol %) was 
added. The solution was stirred for 30 min then the reaction was terminated by 
addition of Amberlite A-21 and stirred for 10 min more. Polymer was filtered off, 
washed with ethyl acetate and the filtrate was evaporated under reduced pressure. 
Residue was purified by column chromatography (silica gel, petroleum ether / ethyl 
acetate -3:1, Rf-0.32). 
 
Yield: 101 mg (0.156 mmol, 90%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.68 (s, 1H, 4-H), 4.85 (d, J = 2.8 
Hz, 1H, 1-H’), 3.99 (ddd, J = 11.5, 4.4, 2.4 Hz, 1H, 3-H’), 3.79 (bq, J = 6.7 Hz, 1H, 
5-H’), 3.55 (bd, J = 2.4 Hz, 1H, 4-H’), 3.42 (t, J = 8.3 Hz, 1H, 17-H), 2.7 – 0.5 (m).  
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.5 (C-3), 171.2 (C-5), 123.8 (+, 
C-4), 98.7 (+, C-1’),87.1 (+, C-17), 73.6 (+, C-4’), 67.6, 67.5 (2+, C-3’, C-5’), 53.8 
(+, C-9), 50.1 (+, C-14), 42.7 (C-13), 38.5 (C-10), 37.0 (-, C-12), 35.6 (-, C-1), 35.4 
(+, C-8), 33.9 (-, C-2), 33.4 (-, C-2’), 32.7 (-, C-6), 31.4 (-, C-7), 28.5 (-, C-16), 23.3 
(-, C-15), 20.5 (-, C-11), 17.3 (+, C-19), 17.2 (+, C-6’), 11.5 (+, C-18), 7.0, 6.8 (2+, 
2 x SiCH2CH3), 5.1, 4.8 (2-, 2 x SiCH2CH3). 
 
[α]D23 = -14.76 ° (c=1.26, CHCl3) 
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3-O-[3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl]-digitoxigenin (26) 
O
O
OH
O
H
H
O
OTES
TESO
H
 
To a solution of digitoxigenin (100 mg, 0.266 mmol) and 3,4-bis-O-TES-L-fucal 22  
(0.3g, 3 eq, 0.8 mmol) in 5 ml of CH2Cl2 was added PPh3HBr (10 mg, 10 mol %). 
The solution was stirred for 30 min then the reaction was terminated by addition of 
Amberlite A-21 and stirred for another 10 min. Polymer was filtered off, washed 
with ethyl acetate and the filtrate was evaporated under reduced pressure. 
Residue was purified by column chromatography (silica gel, petroleum ether / ethyl 
acetate -3:1, Rf-0.19). Treating with acetonitrile causes spontaneous 
crystallization.  
 
Yield: 165 mg (0.225 mmol, 85%).  
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.84 (s, 1H, 22-H), 4.98 (dd, J = 
18.1, 1.6 Hz, 1H, 21-H), 4.92 (d, J = 2.7 Hz, 1H, 1-H’), 4.78 (dd, J = 18.1, 1.6 Hz, 
1H, 21-H), 4.05 (ddd, J = 11.9, 4.3, 2.7 Hz, 1H, 3-H’), 3.85 (bs, 1H, 14-H), 3.80 
(bq, J = 6.7 Hz, 1H, 5-H’), 3.56 (bs, 1H, 4-H’), 2.75 (m, 1H, 3-H), 2.20 – 0.5 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  174.6 (s, C-20), 174.5 (s, C-23), 
117.6 (d, C-22), 95.8 (d, C-1’), 85.6 (s, C-14), 73.8 (d, C-4’), 73.4 (t, C-21), 70.8 (d, 
C-3), 67.8 (d, C-3’), 67.6 (d, C-5’), 50.9 (d, C-17), 49.6 (s, C-13), 41.9 (d, C-8), 
40.0 (t, C-12), 36.5 (d, C-5), 35.6 (d, C-9), 35.2 (s, C-10), 33.7 (t, C-2’), 33.2 (t, C-
4), 30.4 (t, C-15), 29.9 (t, C-1), 26.8 (t, C-2), 26.7 (t, C-6), 26.6 (t, C-16), 23.8 (q, C-
19), 21.4 (t, C-7), 21.2 (t, C-11), 17.3 (q, C-6’), 15.7 (q, C-18), 7.0, 6.9 (2q, 2 x 
SiCH2CH3), 5.2, 4.9 (2t, 2 x SiCH2CH3). 
 
[α]D23 = - 44.84 ° (c=1.22, CHCl3) 
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17-O-[2,6-dideoxy-α-L-galactopyranosyl]-testosterone (35) 
O
H
HH
OO
OH
HO
 
A solution of glycoside 24 (230 mg, 0.35 mmol) in “TBAF mixture” (10 ml) was 
stirred for 4 days. The resulted solution was evaporated and the crude product was 
purified by column chromatography over silica gel (ethyl acetate, Rf- 0.31) 
 
Yield: 132.7 mg (0.318 mmol, 91%), crystalline powder. 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 4.92 (d, J = 3.5 
Hz, 1-H’), 3.99 (m, 1H, 3-H’), 3.94 (bq, J = 6.7 Hz, 1H, 5-H’), 3.60 (bs, 1H, 4-H), 
3.49 (t, J = 8.8 Hz, 1H, 17-H), 2.5 – 0.7 (m).  
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.6 (C-3), 171.2 (C-5), 123.9 (+, 
C-4), 98.2 (+, C-1’), 87.1 (+, C-17), 71.4 (+, C-4’), 66.0 (+, C-3’), 65.6 (+, C-5’), 
53.9 (+, C-9), 50.2 (+, C-14), 42,8 (C-13), 38.6 (C-10), 37.1 (-, C-12), 35.7 (-, C-1), 
35.4 (+, C-8), 33.9 (-, C-2), 33.3 (-, C-2’), 32.8 (-, C-6), 31.5 (-, C-7), 28.4 (-, C-16), 
23.3 (-, C-15), 20.6 (-, C-11), 17.4 (+, C-6’), 16.7 (+, C-19), 11.6 (+, C-18). 
 
LC-MS (ESI) (-c): m/z (%): 417.24 (100) [M – H]-; HR-MS C25H37O5: calc. 
417.2641, found 417.2646  
 
[α]D23  = -13 ° (c=1.0, CHCl3) 
 
3-O-[2’,6’-dideoxy-α-L-galactopyranosyl]-digitoxigenin (36) 
O
O
OH
O
H
H
O
OH
HO
H
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A solution of 26 (127 mg, 0.18 mmol) in “TBAF mixture” (20 ml) was stirred for 4 
days. The resulted solution was evaporated and the crude product was purified by 
column chromatography over silica gel (ethyl acetate, Rf- 0.37). 
 
Yield: 90 mg (0.179 mmol, 97%), crystalline powder. 
 
1H-NMR (400 MHz, CD3OD, CD3OD = 3.31 ppm) δ: 5.84 (s, 1H, 22-H), 4.98 (dd, J 
= 18.1, 1.6 Hz, 1H, 21-H), 4.92 (d, J = 2.7 Hz, 1H, 1-H’), 4.78 (dd, J = 18.1, 1.6 Hz, 
1H, 21-H), 4.0 -3.85 (m, 3H, 14-H, 3-H’, 5-H’), 3.54 (bd, J = 2.7 Hz, 1H, 4-H’), 2.84 
(bdd, J = 9., 5.4 Hz, 1H, 3-H), 2.25 – 0.85 (m).    
 
13C-NMR (100 MHz, CD3OD, CD3OD =50.2 ppm) δ:  179.6 (C-20), 178.4 (C-23), 
119.0 (+, C-22), 98.3 (+, C-1’), 87.6 (C-14), 76.5 (+, C-4’), 74.2 (-, C-21), 73.6 (+, 
C-3), 68.9 (+, C-3’), 68.3 (+, C-5’), 53.3 (+, C-17), 52.3 (C-13), 43.9 (+, C-8), 42.1 
(-, C-12), 39.3 (+, C-5), 38.0 (+, C-9), 37.6 (C-10), 35.1 (-, C-2’), 34.6 (-, C-4), 32.9 
(-, C-15), 32.2 (-, C-1), 29.2 (-, C-2), 29.1 (-, C-6), 28.7 (-, C-16), 25.6 (+, C-19), 
23.8 (-, C-7), 23.8 (-, C-11), 18.4 (+, C-6’), 17.6 (+, C-18). 
 
LC-MS (ESI) (-c): m/z (%): 503.29 (100) [M – H]-; HR-MS C29H43O7: calc. 
503.3009, found 503.3009  
 
[α]D23  = - 53.2 ° (c=0.5, MeOH) 
 
Phenyl [3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl]-(1→3)-2,6-dideoxy-1-
thio-α-L-glycopyranoside (28) 
O
O
HO SPh
O
TESO
TESO
 
To a solution of 3,4-bis-O-TES-L-fucal 22 (50 mg, 0.139 mmol) and thioglycoside 
27 (40 mg, 0.166 mmol) in CH2Cl2 (2 ml) was added PPh3*HBr (1 mg, cat.). After 
15 min reaction was terminated by addition of Amberlite A-21 and stirred for 
another 10 min. The polymer was filtered off, washed with ethyl acetate and the 
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filtrate was evaporated under reduced pressure. The residue was purified by 
column chromatography on silica gel (petroleum ether / ethyl acetate 6:1, Rf- 0.25). 
 
Yield: 60 mg (0.1 mmol, 72%).   
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm)  δ: 7.38 (m, 2H, Ph-o), 7.21 (m, 3H, 
Ph-m, p), 5.54 (d, J = 5.3 Hz, 1H, 1-H), 5.11 (d, J = 3.2 Hz, 1H, 1-H’), 4.19 (dq, J = 
9.1, 6.1 Hz, 1H, 5-H),  3.94 (ddd, J = 11.8, 4.9, 2.5 Hz, 1H, 3-H’), 3.81 (ddd, J = 
11.4, 9.1, 4.8 Hz, 1H, 3-H), 3.79 (bq, J = 6.4 Hz, 1H, 5-H’), 3.57 (bdd, J = 2,5, 0.5 
Hz, 1H, 4-H’), 3.21 (ddd, J = 9.1, 9.1, 2.1 Hz, 1H, 4-H), 2.48 (ddd, J = 13.2, 4.8, 0.9 
Hz, 1H, 2-H), 2.31 (d, J = 2.5 Hz, 1H, OH), 2.08 (ddd, J = 12.0, 11.8, 3.2 Hz, 1H, 2-
H’), 2.06 (ddd, J = 13.2, 5.3, 4.8 Hz, 1H, 2-H), 1.59 (ddd, J = 11.8, 4.9, 1.3 Hz, 1H, 
2-H’), 1.28 (d, J = 6.1 Hz, 3H, 6-H), 1.15 (d, J = 6.4 Hz, 3H, 6-H’), 0.95 (t, 18H, 2 x 
(CH3CH2)3Si ), 0.62 (2q, 12H,  2 x (CH3CH2)3Si ). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) 135.2 (s, Ph-1), 131.2 (2d, Ph-o), 
128.9 (2d, Ph-m), 127.0 (d, Ph-p), 100.02 (d, C-1’ ), 83.8 (d, C-1 ), 78.0 (d, C-3 ), 
76.4 (d, C-4 ), 73.4 (d, C-4’ ), 68.5 (d, C-5 ), 68.0 (d, C-5’ ), 67.4 (d, C-3’ ), 37.4 (t, 
C-2 ), 33.5 (t, C-2’ ), 17.8 (q, C-6 ), 17.3 (q, C-6’ ), 7.0, 6.8 (2q, 2 x (CH3CH2)3Si ), 
5.2, 4.8 (2t, 2 x (CH3CH2)3Si ). 
 
Phenyl {di-[3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl]-(1→3),(1→4)}-2,6-
dideoxy-1-thio-α-L-glycopyranoside (30)  
O
O
O
SPh
O
OTESTESO
O
TESO
TESO
 
To a solution of 3,4-di-O-TES-L-fucal 22 (300 mg, 0.84 mmol) and thioglycoside 27 
(58 mg, 0.241 mmol) in CH2Cl2 (6 ml) was added PPh3*HBr (1 mg, cat.). After 15 
min, the disaccharides 29 (3-O, TLC: petroleum ether / ethyl acetate 3:1, Rf- 0.59) 
and regioisomer (4-O, Rf- 0.35) were fully formed (relationship ~6:1). The desired 
trisaccharide 30 has Rf- 0.76 (petroleum ether / ethyl acetate 3:1). The reaction 
mixture was stirred for another 5 h, and treated with saturated NaHCO3 solution 
and 30 ml of ethyl acetate. The phases were separated and the aqueous phase 
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was extracted 3 times with ethyl acetate. The combined organic layers were dried 
over Na2SO4 and concentrated under reduced pressure. Residue was purified by 
column chromatography over silica gel (petroleum ether / ethyl acetate 10:1, Rf- 
0.25) 
 
Yield: 200 mg (0.21 mmol, 87%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3=7.26 ppm) δ: 7.43 (m, 2H, Ph), 7.24 (m, 3H, 
Ph), 5.52 (d, J = 5.0 Hz, 1H, 1-H), 5.18, 5.03 (d, d, J = 3.6 Hz, J = 3.4 Hz, 2H, 1-H’, 
1-H’’), 4.15 (dq, J = 9.3, 6.1 Hz, 1H, 5-H), 3.84 (m, 5H), 3.56 (dd, J = 9.4, 1.6 Hz, 
2H, 4-H’,4-H’’), 3.20 (t, J =  9.3 Hz, 1H, 4-H), 2.43 (dd, J = 13.9, 4.5 Hz, 1H), 2.05 
(m, 3H), 1.55 (m, 2H), 1.24 (d, J = 6.1 Hz, 3H, 6-H), 1.14 (d, J = 6.4 Hz, 3H, 6-H’), 
1.13 (d, J = 6.4 Hz, 3H, 6-H’’), 0.95(m, 36H, 4 x TES), 0.62(m, 24H, 4 x TES). 
 
13C-NMR (100 MHz, CDCl3, CDCl3=77 ppm): q-135.3, 131.1, 128.9, 126.9 (Ph), 
100.8, 100.5 (2d, C-1’, C-1’’), 83.6 (d, C-1), 83.1 (d, C-4), 79.4 (d, C-3), 73.5, 73.4 
(2d, C-4’, C-4’’), 68.0 (2d, C-5, C-5’’), 67.7 (d, C-5’), 67.4, 67.3 (2d, C-3’, C-3’’), 
38.1 (t, C-2), 33.6 (2t, C-2’, C-2’’), 18.1 (q, C-6), 17.3, 17.2 (2q, C-6’, C-6’’), 7.0, 
6.99, 6.81, 6.77 (4q, 12x CH3-TES), 5.2, 4.8, 4.7 (3t, 12x CH2-TES).  
 
3-O-Pivaloyl-L-rhamnal (32) 
A solution of L-rhamnal (697 mg, 5.36 mmol) in dry pyridine (10 ml) was cooled to -
50°C, and PivCl (646 mg, 1 eq, 5.36 mmol) was dropwise added. The reaction was 
stirred at the same temperature another 2h until full adduct consumption was 
observed (t.l.c., petroleum ether / ethyl acetate 5:1, Rf- 0.42). To the reaction 
mixture 1 ml of methanol was added, and solution was evaporated under reduced 
pressure. The crude product 32 was purified by column chromatography over silica 
gel (petroleum ether / ethyl acetate 5:1, Rf- 0.42). 
 
Yield: 610 mg (2.85 mmol, 53%). 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 6.43 (dd, J = 6.1, 1.3 Hz, 1H, 1-
H), 5.17 (ddd, J = 6.1, 2.6, 1.5 Hz, 1H, 2-H), 4.67 (dd, J = 6.1, 2.6 Hz, 1H, 3-H), 
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3.93 (dq, J = 9.1, 6.3 Hz, 1H, 5-H), 3.59 (dd, J = 9.1, 6.1 Hz, 1H, 4-H), 3.37 (bs, 
1H, OH), 1.40 (d, J = 6.3 Hz, 3H, 6-H), 1.22 (s, 9H, Piv). 
13C-NMR (50 MHz, CDCl3, CDCl3 = 77 ppm) δ: 180.6 (CO-Piv), 146.5 (+, C-1), 98.7 
(+, C-2), 74.5, 73.5, 72.8 (3+, C-3, C-4, C-5), 38.9 (C(CH3)3-Piv), 27.1 (+, C(CH3)3-
Piv), 17.0 (+, C-6).  
 
(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-2,6-dideoxy-L-glycal 
(34) 
O
OTES
TESO
O
OPiv
O
 
To a solution of 3,4-bis-O-TES-L-fucal 22 (33.5 mg, 0.093 mmol) and glycal 32 (20 
mg, 0.093 mmol) in CH2Cl2 (5 ml) was added PPh3*HBr (1 mg, cat.). After 30 min, 
the reaction mixture was treated with saturated NaHCO3 solution, phases were 
separated, and the aqueous phase was extracted 3 times with CH2Cl2. The 
combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure. The crude product 34 was purified by column chromatography over silica 
gel (petroleum ether / ethyl acetate 10:1, Rf- 0.45). 
 
Yield: 45 mg (0.0785 mmol, 85%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 6.36 (dd, J = 6.0, 1.2 Hz, 1H, 1-
H), 5.19 (dddd, J = 6.0, 3.2, 1.2, 0.6 Hz, 1H, 2-H), 5.12 (d, J = 3.2 Hz, 1H, 1-H’), 
4.70 (dd, J = 5.8, 3.2 Hz, 1H, 3-H), 4.06 (dq, J = 7.7, 6.6 Hz, 1H, 5-H), 3.93 (ddd, J 
= 11.8, 4.4, 2.4 Hz, 1H, 3-H’), 3.86 (bq, J = 6.4 Hz, 1H, 5-H’), 3.70 (dd, J = 7.7, 5.8 
Hz, 1H, 4-H), 3.58 (bd, J = 2.4 Hz, 1H, 4-H’), 2.04 (ddd, J = 12.3, 11.8, 3.2 Hz, 1H, 
2-H’), 1.53 (ddd, J = 12.3, 4.4, 0.9 Hz, 1H, 2-H’), 1.36 (d, J = 6.6 Hz, 3H, 6-H), 1.19 
(s, 9H, Piv), 1.16 (d, J = 6.4 Hz, 3H, 6-H’), 0.95, 0.94 (2t, J = 7.8 Hz, 18H, 2 x 
TES), 0.65, 0.64 (2q, J = 7.8 Hz, 12H, 2 x TES). 
 
13C-NMR (100 MHz, CDCl3, CDCl3=77 ppm) δ: 178.0 (CO-Piv), 145.6 (C-1), 99.0, 
98.9 (2+, C-2, C-1’), 76.4, 73.6, 73.5, 70.9, 68.2, 67.3 (6+, C-3, C-4, C-5, C-3’, C-
4’, C-5’), 38.7 (C(CH3)3-Piv), 33.4 (-, C-2’), 27.0 (+, C(CH3)3-Piv), 17.25, 17.20 (2+, 
C-6, C-6’), 7.0, 6.8 (2+, TES), 5.2, 4.8 (2-, TES). 
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 3-O-Benzoyl-L-rhamnal (31) 
A solution of L-rhamnal (3 g, 0.023 mol) in dry pyridine (50 ml) was cooled to -
30°C, and BzCl (3.24 g, 0.023 mol) dropwise was added. The reaction was stirred 
at the same temperature for another 2h until full adduct consumption was detected 
(t.l.c., petroleum ether / ethyl acetate 5:1, Rf- 0.45). To the reaction mixture 1 ml of 
methanol was added, and solution was evaporated under reduced pressure. The 
crude product 31 was purified by column chromatography over silica gel 
(petroleum ether / ethyl acetate 5:1, Rf- 0.45). 
 
Yield: 4.4 g (18.8 mmol, 83%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.65-7.40 (m, 5H, Ph), 6.49 (d, J 
= 6.1 Hz, 1H, 1-H), 5.47 (ddd, J = 6.4, 2.4, 1.5 Hz, 1H, 3-H), 4.83 (dd, J = 6.1, 2.4 
Hz, 1H, 2-H), 4.01 (dq, J = 9.3, 6.4 Hz, 1H, 5-H), 3.78 (dd, J = 9.3, 6.4 Hz, 1H, 4-
H), 1.45 (d, J = 6.4 Hz, 3H, 6-H). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 168.1 (CO-Ph), 146.8 (+, C-1), 
133.4, 129.8, 128.4 (3+, Ph), 98.8 (+, C-2), 74.8, 74.3, 72.7 (3+, C-3, C-4, C-5), 
17.1 (+, C-6). 
 
7-O-TES-Decaristrictine D (36) 
O
Me
TESO
OH
OH
O
1
2
3
45
6
7
8
9
10
 
To a solution of decarestrictine D 35 (10 mg, 0.046 mmol) and imidazole (4.7 mg, 
1.5 eq, 0.069 mmol) in CH2Cl2 (5 ml) at - 30° C dropwise was added TESCl (6.9 
mg, 0.046 mmol). The reaction mixture was stirred another 1 h at the same 
temperature, then allowed to warm to RT and the solvent was evaporated under 
reduced pressure. The crude product 36 was purified by column chromatography 
over silica gel (petroleum ether / ethyl acetate 2:1, Rf- 0.33) 
 
Yield: 12 mg (0.0364, 79%), colorless crystals. 
 
 111
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm)  δ: 5.85 (ddd, J = 15.8, 9.5, 1.2 Hz, 
1H, 6-H), 5.73 (dd, J = 15.8, 2.8 Hz, 1H, 5-H), 5.20 (ddq, J = 10.8, 6.2, 1.8 Hz, 1H, 
9-H), 4.59 (bs, 1H, OH3), 4.40 (bs, 1H, 4-H), 4.12 (ddd, J = 9.5, 9.5, 4.0 Hz, 1H, 7-
H), 4.03 (dd, J = 6.3, 4.2 Hz, 1H, 3-H), 2.60, 2.37 (dd, J = 14.2, 1.8 Hz, 1H, 2-H, 
dd, J = 14.2, 6.3 Hz, 1H, 2-H), 1.88 - 1.79 (m, 2H, CH2-8), 1.73 (bs, 1H, OH4), 1.22 
(d, J = 6.2 Hz, 3H, CH3-10), 0.92 (t, J = 8.0 Hz, 9H, TES), 0.56 (q, J = 8.0 Hz, 6H, 
TES).   
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 174.9 (s, C-1), 134.7 (d, C-6), 
127.8 (d, C-5), 73.8 (d, C-3), 72.9 (d, C-7), 72.2 (d, C-4), 68.3 (d, C-9), 44.4 (t, C-
8), 33.3 (t, C-2), 21.3 (q, C-10), 6.8 (q, TES-CH3), 4.9 (t, TES-CH2). 
 
3,4-Di-O-TBS-7-O-TES-decarestrictine D (41) 
O
TESO
OTBS
OTBS
O
 
To a solution of decarestrictine D 35 (100 mg, 0.46 mmol) and imidazole (138 mg, 
4.5 eq, 2.07 mmol) in CH2Cl2 (30 ml) at - 30° C dropwise was added TESCl (69 
mg, 0.46 mmol). The reaction mixture was stirred for another 1 h at the same 
temperature and then evaporated under nitrogen flow allowing to warm up to RT. 
The resulted cake was dissolved in DMF (5 ml) and TBSCl (207 mg, 3 eq, 1.38 
mmol) was added, and reaction temperature was raised to 50°C. After reaction 
completes (1-2 h), DMF was removed by filtration column (silica gel, petroleum 
ether / ethyl acetate 5:1) and crude product was purified by column 
chromatography over silica gel (petroleum ether / ethyl acetate 10:1, Rf- 0.26). 
 
Yield: 240 mg (0.429 mmol, 93%), colorless oil. 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm)  δ: 5.85 (ddd, J = 15.8, 9.08, 1.2 Hz, 
1H, 6-H), 5.65 (dd, J = 15.8, 2.5 Hz, 1H, 5-H), 5.20 (ddq, J = 11.4, 6.3, 1.7 Hz, 1H, 
9-H), 4.15 (m, 2H, 4-H, 7-H), 3.89 (ddd, J = 8.6, 4.3, 2.0 Hz, 1H, 3-H), 2.55, (dd, J 
= 13.2, 2.0 Hz, 1H, 2-H), 2.15 (dd, J = 13.2, 6.8 Hz, 1H, 2-H), 1.88 - 1.60 (m, 2H, 
CH2-8), 1.18 (d, J = 6.3 Hz, 3H, CH3-10), 0.92 (t, J = 7.9 Hz, 9H, TES), 0.82 (s, 
18H, 2 x TBS),  0.56 (q, J = 7.9 Hz, 6H, TES), 0.1 (2s, 12H, TBS).   
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 13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 170.9 (s, C-1), 136.2 (d, C-6), 
127.5 (d, C-5), 74.2 (d, C-3), 73.1 (d, C-7), 73.0 (d, C-4), 67.3 (d, C-9), 44.0 (t, C-
8), 32.2 (t, C-2), 25.70 (TBS) 21.3 (q, C-10), 18.09 (TBS) 6.8 (q, TES-CH3), 4.9 (t, 
TES-CH2), -4.2, -4.9 (TBS). 
 
4-O-Tbs-7-O-TES-Decarestrictine D (42) 
O
TESO
OTBS
OH
O
 
A solution of decarestrictine 41 (200 mg, 0.36 mmol) in CH2Cl2 (15 ml) was stirred 
with 3 mg of PPh3*HBr at RT. After 6 h, TLC (petroleum ether / ethyl acetate 7:1, 
Rf- 0.39) showed completion of the reaction. The reaction mixture was treated with 
saturated NaHCO3 solution, phases were separated and the aqueous phase was 
extracted 3 times with CH2Cl2. The combined organic layers were dried over 
Na2SO4 and concentrated under reduced pressure. The crude product 42 was 
purified by column chromatography over silica gel (petroleum ether / ethyl acetate 
7:1). 
 
Yield: 134 mg (0.3 mmol, 84%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.85 (ddd, J = 15.5, 9.3, 1.4 Hz, 
1H, 6-H), 5.64 (dd, J = 15.5, 2.7 Hz, 1H, 5-H), 5.20 (ddq, J = 10.9, 6.4, 1.9 Hz, 1H, 
9-H), 4.65 (bs, 1H, OH3), 4.32 (bs, 1H, 4-H), 4.10 (ddd, J = 9.8, 9.3, 3.8 Hz, 1H, 7-
H), 3.9 (bs, 1H, 3-H), 2.60, 2.31 (ddd, J = 14.0, 6.1, 1.7 Hz, 1H, 2-H, ddd, J = 14.1, 
6.3, 3.13 Hz, 1H, 2-H), 1.84- 1.76 (m, 2H, CH2-8), 1.22 (d, J = 6.4 Hz, 3H, CH3-10), 
0.95 (t, J = 7.9 Hz, 9H, TES), 0.85 (s, 9H), 0.56 (q, J = 7.9 Hz, 6H, TES), 0.0 (2s, 
6H, 2 x CH3 –tBuSi). 
 
13C-NMR (100 MHz, CDCl3, CDCl3=77 ppm) δ: 175.3 (C-1), 135.3 (+. C-6), 127.6 
(+, C-5), 74.7 (+, C-3), 73.2 (+, C-7), 72.6 (+, C-4), 68.2 (+, C-9), 44.3 (-, C-8), 32.8 
(-, C-2), 25.7 (3+, 3 x CH3-t-Bu) 21.3 (+, C-10), 18.1 (CCH3 t-Bu) 6.8 (+, TES-CH3), 
4.9 (-, TES-CH2), -4.2, -4-9 (2+, 2 x CH3 t-Bu). 
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4,7-Di-O-TBS-decarestrictine D (42); 3,7-di-O-TBS-decarestrictine D (43)  
O
TBSO
OTBS
OH
O
O
TBSO
OH
OTBS
O
 
To a solution of decarestrictine D 35 (20 mg, 0.093 mmol), DMAP (1 mg, cat.) and 
imidazole (19.2 mg, 0.18 mmol) in DMF (2 ml) at - 30° C was added TBSCl (28 
mg, 0.186 mmol). The reaction mixture was stirred for 1 h at the same 
temperature, then was allowed to warm to RT and more 5 mg (0.033 mmol) TBSCl 
was added. After the reaction was complete (TLC, petroleum ether / ethyl acetate 
7:1, Rf- 0.39), it was quenched by a drop of methanol. DMF was removed by a 
filtration column (silica gel, petroleum ether / ethyl acetate 5:1) and the crude 
product mixture was purified by column chromatography over silica gel (petroleum 
ether / ethyl acetate 10:1, Rf- 0.26) to afford two fractions. 
 
Yield:  1st fraction: 42 (31 mg, 0.070 mmol, 75%) 
2nd fraction: 43 (8 mg, 0.018 mmol, 19.4%). 
 
1st fraction 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.83 (ddd, J = 15.5, 9.6, 1.6 Hz, 
1H, 6-H), 5.64 (dd, J = 15.5, 2.7 Hz, 1H, 5-H), 5.19 (ddq, J = 10.9, 6.4, 1.8 Hz, 1H, 
9-H), 4.69 (bs, 1H, OH3), 4.31 (m, 1H, 4-H), 4.10 (ddd, J = 9.9, 9.6, 3.9 Hz, 1H, 7-
H), 3.87 (bs, 1H, 3-H), 2.58, 2.31 (dd, J = 14.0, 1.7 Hz, 1H, 2-H, dd, J = 14.0, 6.1 
Hz, 1H, 2-H), 1.84-1.76 (m, 2H, CH2-8), 1.22 (d, J = 6.4 Hz, 3H, CH3-10), 0.91, 
0.85 (2s, 18H, 6 x CH3-tBuSi),  0.0 (3s, 12H, 4 x CH3-tBuSi). 
 
[α]D23  = - 49.0° [C1, CHCl3 ] 
 
2nd fraction 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.79 (ddd, J = 16.3, 9.2, 0.8 Hz, 
1H, 6-H), 5.67 (dd, J = 16.3, 4.3 Hz, 1H, 5-H), 5.11 (ddq, J = 10.0, 6.4, 2.8 Hz, 1H, 
9-H),  4.12 (ddd, J = 9.3, 9.2, 4.6 Hz, 1H, 7-H), 3.99, 3.94 (m, 2H, 3-H, 4-H), 2.56, 
2.22 (dd, J = 13.9, 3.5 Hz, 1H, 2-H, dd, J = 13.9, 8.7 Hz, 1H, 2-H), 1.80- 1.70 (m, 
2H, CH2-8), 1.58 (bs, 1H, OH4), 1.20 (d, J = 6.4 Hz, 3H, CH3-10), 0.92, 0.86 (2s, 
18H, 6 x CH3-tBuSi), 0.14, 0.03, 0.02 (3s, 12H, 4 x CH3 -tBuSi). 
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 3,4-Di-O-acetyl-7-O-TBS-decarestrictine D (39) 
O
TBSO
OAc
OAc
O
 
To a solution of decarestrictine D 35 (100 mg, 0.46 mmol) and imidazole (47 mg, 
1.5 eq, 0.69 mmol) in CH2Cl2 (30 ml) at - 30° C was added TBSCl (69 mg, 0.46 
mmol). The reaction mixture was stirred for 1 h at the same temperature, and then 
the solvent was evaporated under nitrogen flow, allowing mixture to warm up to 
RT. Dry pyridine (5 ml) and Ac2O (187 µl, 4 eq) was added and the reaction 
temperature was raised to 50°C. After reaction completion (5-7 h), pyridine was 
evaporated under reduced pressure and the crude product was purified by column 
chromatography over silica gel (petroleum ether / ethyl acetate 2:1, Rf- 0.53). 
 
Yield: 185 mg (0.446, 97%), colorless oil. 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.70 (dd, J = 16.2, 9.2 Hz, 1H, 6-
H), 5.59 (dd, J = 16.2, 3.3 Hz, 1H, 5-H), 5.20, 5.03 (2m, 3H, 9-H, 4-H, 3-H), 4.08 
(ddd, J = 8.5, 8.4, 5.7 Hz, 1H, 7-H), 2.54 (m, 2H, 2-H), 2.06, 2.05 (2s, 6H, 2 x 
CH3CO), 1.73 (m, 2H, 8-H), 1.16 (d, J = 6.4 Hz, 3H, 10-H), 0.79 (s, 9H, t-Bu), -
0.04, -0.08 (2s, 6H, Si(Me)2). 
 
3,4-Di-O-acetyl-decarestrictine D (40)  
O
HO
OAc
OAc
O
 
A solution of decarestrictine 39 (160 mg, 0.38 mmol) in “TBAF mixture” (3 ml) was 
stirred for 5 days. The solution was evaporated and the crude product was purified 
by column chromatography over silica gel (petroleum ether / ethyl acetate 2:1, Rf- 
0.1). 
 
Yield: 109 mg (0.363 mmol, 96%), crystalline powder. 
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1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (dd, J = 16.0, 7.9 Hz, 1H, 6-
H), 5.66 (dd, J = 16.0, 2.6 Hz, 1H, 5-H), 5.22, 5.00 (2ddd, J = 5.2, 2.6, 2.6 Hz, J = 
10.0, 5.2, 2.6 Hz, 2H, 4-H, 3-H), 5.08 (m, 1H, 9-H), 4.12 (ddd, J = 10.6, 7.9, 3.4 Hz, 
1H, 7-H), 2.68 (bs, 1H, OH7), 2.61, 2.52 (2ddd, J = 14.3, 10.0, 2.6 Hz, J = 14.3, 
2.6, 2.6 Hz, 2H, 2-H), 2.08, 2.07(2s, 6H, 2 x CH3CO), 1.83-1.73 (m, 2H, 8-H), 1.18 
(d, J = 6.2 Hz, 3H, 10-H). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.8, 169.4, 169.2 (3s, C-1, 2 x  
CH3CO), 136.9 (d, C-6), 123.4 (d, C-5), 72.1, 70.8 (3d, C-3, C-4, C-7), 68.0 (d, C-
9), 42.3 (t, C-8), 33.7 (t, C-2), 21.2 (q, C-10), 20.9, 20.8 (2q, 2 x CH3CO). 
 
[α]D23  = + 46.4° [C 0.5, CHCl3 ] 
 
11.4.2. Experiments to the chapter 5.2. 
3-O-TES-4-O-(PS-DES)-L-rhamnal (49) 
Si O
O
OTES
 
To a suspension of silane resin 44 (50 mg, 0.079 mmol) in 1 ml of CH2Cl2 was 
added 3 eq. (0.24 mmol, 47 mg) of 1,3-dichloro-5,5-dimethylhydantoine. The 
suspension was shaken for 2 h, and then polymer was filtered off and washed with 
CH2Cl2 (5x3 ml). This polymer bound silylchlorid 45 was used for further 
transformations immediately after washing. Obtained polymer-bound silylchlorid 45 
was suspended in 1 ml of CH2Cl2 and solution of 3-O-TES-L-rhamnal 47 (3eq, 0.24 
mmol, 58 mg) and imidazole (3.5 eq, 19 mg) in 1 ml of CH2Cl2 was added. The 
polymer was allowed to shake overnight, and then suspension was filtered and 
polymer-bound glycal washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried 
in high vacuum for 4 h. The loading of 49 was determined by resin weight 
difference. 
 
Yield: (66 mg, 0.992 mmol/g, 83%). 
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13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  GEL-NMR :143.4 (C-1), 103.1 (C-
2), 75.6 (C-4), 75.3 (C-5), 70.3 (C-3), 17.4 (C-6), 6.9 (SiCH2CH3), 5.6 (SiCH2CH3). 
 
3-O-TES-4-O-(PS-DES)-L-Fucal (48) 
Si O
O
OTES
 
To a suspension of silane resin 44 (1.0 g, 1.58 mmol) in 10 ml of CH2Cl2 was 
added 3 equivalents (4.74 mmol, 934 mg) of 1,3-dichloro-5,5-dimethylhydantoine. 
The suspension was allowed to stir for 2h, and then polymer was filtered off and 
washed with CH2Cl2 (5x10 ml). Polymer-bound silylchlorid 45 was used for further 
transformations immediately after washing. Obtained silyl resin 45 was suspended 
in 5 ml of CH2Cl2 and solution of 3-O-TES-L-fucal 46 (3eq, 1.1 g, 4.74 mmol) and 
imidazole (3.5 eq, 0.38 g, 5 mmol) in 5 ml of CH2Cl2 was added. The polymer was 
allowed to shake overnight, and then suspension was filtered and polymer-bound 
glycal washed with CH2Cl2 (5x10 ml), acetonitrile (5x10 ml) and dried in high 
vacuum for 4 h. The loading of polymer 48 was determined by resin weight 
difference. 
  
Yield: (1.355 g, 1.07 mmol/g, 83%).  
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  GEL-NMR : 143.1 (C-1), 102.7 
(C-2), 73.7 (C-5), 70.3 (C-4), 66.5 (C-3), 16.6 (C-6), 6.9 (SiCH2CH3), 5.3 
(SiCH2CH3). 
 
11.4.3. Experiments to the chapter 5.3. 
17-O-[3-O-TES-4-O-(PS-DES)-2,6-dideoxy-α-L-galactopyranosyl]-testosterone 
(52) 
O
O
OTES
O
H
HH
O
 
To a suspension of polymer-bound glycal 48 (200 mg, 0.214 mmol) in 5 ml of 
CH2Cl2 were added testosterone (0.172 g, 0.642 mmol) and 2 mg (cat.) of 
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PPh3*HBr. The suspension was shaken for 4 h, then polymer filtered off and 
washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high vacuum for 4 
h.  Resin 52 was weighted and loading was determined by weight difference. 
 
Yield:  245 mg (0.625 mmol/g, 78%). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  GEL-NMR :  199.2 (C-3), 171.2 
(C-5), 123.8 (C-4), 98.8 (C-1’), 87.1 (C-17), 73.7 (C-4’), 67.7 (C-3’), 67.5 (C-5’), 
53.8 (C-9), 50.0 (C-14), 42.7 (C-13), 38.6 (C-10), 37.0 (C-12), 35.7 (C-1), 35.4 (C-
8), 33.9 (C-2), 33.4 (C-2’), 32.7 (C-6), 31.5 (C-7), 28.5 (C-16), 23.3 (C-15), 20.5 (C-
11), 17.3 (C-6’, C-19), 11.5 (C-18), 6.9 (SiCH2CH3), 5.2 (SiCH2CH3). 
 
17-O-[2,6-dideoxy-α-L-galactopyranosyl]-testosterone (53) 
HO
O
OH
O
H
HH
O
 
Polymer 52 (240 mg, 0.150 mmol) was suspended in “TBAF mixture” (10 ml). The 
suspension was shaken for 5 days, and then polymer was filtered off and filtrate 
evaporated under reduced pressure. The crude product was purified by column 
chromatography over silica gel (ethyl acetate, Rf- 0.31). 
 
Yield: 49 mg (0.118 mmol, 78%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 4.92 (d, J = 3.5 
Hz, 1-H’), 3.99 (m, 1H, 3-H’), 3.94 (bq, J = 6.7 Hz, 1H, 5-H’), 3.60 (bs, 1H, 4-H), 
3.49 (t, J = 8.8 Hz, 1H, 17-H), 2.5 – 0.7 (m).  
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.6 (C-3), 171.2 (C-5), 123.9 (+, 
C-4), 98.2 (+, C-1’), 87.1 (+, C-17), 71.4 (+, C-4’), 66.0 (+, C-3’), 65.6 (+, C-5’), 
53.9 (+, C-9), 50.2 (+, C-14), 42,8 (C-13), 38.6 (C-10), 37.1 (-, C-12), 35.7 (-, C-1), 
35.4 (+, C-8), 33.9 (-, C-2), 33.3 (-, C-2’), 32.8 (-, C-6), 31.5 (-, C-7), 28.4 (-, C-16), 
23.3 (-, C-15), 20.6 (-, C-11), 17.4 (+, C-6’), 16.7 (+, C-19), 11.6 (+, C-18).     
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 3-O-[3’-O-TES-4’-O-(PS-DES)-2’,6’-dideoxy-α-L-galactopyranosyl]-
digitoxigenin (54) 
O
O
OTES
O
O
OH
O
H
H
H
 
To a suspension of polymer-bound glycal 48 (140 mg, 0.150 mmol) in 5 ml of 
CH2Cl2 were added digitoxigenin (100 mg, 0.3 mmol) and 2 mg (cat.) of PPh3*HBr. 
This suspension was shaken for 4 h, then polymer filtered off and washed with 
CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high vacuum for 4 h. Polymer 54 
was weighted and loading was determined by weight difference. 
 
Yield: 182 mg (0.62 mmol/g, 75%). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) GEL-NMR δ: 174.5 (C-20), 174.5 (C-
23), 117.5 (C-22), 95.8 (C-1’), 85.4 (C-14), 73.8 (C-4’), 73.6 (C-21), 70.8 (C-3), 
67.7 (C-3’), 67.6 (C-5’), 50.9 (C-17), 49.5 (C-13), 41.8 (C-8), 40.0 (C-12), 36.5 (C-
5), 35.6 (C-9), 35.1 (C-10), 33.7 (C-2’), 33.0 (C-4), 30.4 (C-15), 29.8 (C-1), 26.8 (C-
2), 26.7 (C-6), 26.6 (C-16), 23.7 (C-19), 21.4 (C-7), 21.1 (C-11), 17.3 (C-6’), 15.7 
(C-18), 7.0, 6.8 (2 x SiCH2CH3), 5.2, 4.9 (2 x SiCH2CH3). 
 
3-O-[2,6-dideoxy-α-L-galactopyranosyl]-digitoxigenin (55) 
HO
O
OH
O
O
OH
O
H
H
H
 
A suspension of polymer-bound glycoside 54 (162 mg, 0.099 mmol) in “TBAF 
mixture” (10 ml) was stirred for 5 days. The polymer was filtered off and the 
resulted solution was evaporated. The residue was purified by column 
chromatography over silica gel (ethyl acetate, Rf- 0.37) 
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 Yield: 37 mg (0.073 mmol, 74%), crystalline powder. 
 
1H-NMR (400 MHz, CD3OD, CD3OD = 3.31 ppm) δ: 5.84 (s, 1H, 22-H), 4.98 (dd, J 
= 18.1, 1.6 Hz, 1H, 21-H), 4.92 (d, J = 2.7 Hz, 1H, 1-H’), 4.78 (dd, J = 18.1, 1.6 Hz, 
1H, 21-H), 4.0 -3.85 (m, 3H, 14-H, 3-H’, 5-H’), 3.54 (bd, J = 2.7 Hz, 1H, 4-H’), 2.84 
(bdd, J = 9.6, 5.4 Hz, 1H, 3-H), 2.25 – 0.85 (m). 
 
13C-NMR (100 MHz, CD3OD, CD3OD =50.2 ppm) δ:  179.6 (C-20), 178.4 (C-23), 
119.0 (+, C-22), 98.3 (+, C-1’), 87.6 (C-14), 76.5 (+, C-4’), 74.2 (-, C-21), 73.6 (+, 
C-3), 68.9 (+, C-3’), 68.3 (+, C-5’), 53.3 (+, C-17), 52.3 (C-13), 43.9 (+, C-8), 42.1 
(-, C-12), 39.3 (+, C-5), 38.0 (+, C-9), 37.6 (C-10), 35.1 (-, C-2’), 34.6 (-, C-4), 32.9 
(-, C-15), 32.2 (-, C-1), 29.2 (-, C-2), 29.1 (-, C-6), 28.7 (-, C-16), 25.6 (+, C-19), 
23.8 (-, C-7), 23.8 (-, C-11), 18.4 (+, C-6’), 17.6 (+, C-18). 
 
[α]D23  = - 53.2 ° (c=0.5, MeOH) 
 
7-O-[3-O-TES-4-O-(PS-DES)-2,6-dideoxy-α-L-galactopyranosyl]-3,4-di-O-
acetyl-decarestrictine D (56)  
O
O
OTES
O
O
OAc
OAc
O
 
To a suspension of polymer-bound glycal 48 (100 mg, 0.107 mmol) in 5 ml of 
CH2Cl2 was added decarestrictine jj-67 (100 mg, 0.321 mmol) and 1.5 mg (cat.) of 
PPh3*HBr. The suspension was shaken for 4 h, then polymer filtered off and 
washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high vacuum for 4 
h. Loading of polymer 56 was determined after cleaving of glycoconjugate from 
polymer support with “TBAF mixture” 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) GEL-NMR δ: 169.8, 169.4, 168.9 (2 
x CH3CO, C-1), 125.9 (C-5), 93.7 (C-1’), 74.3, 73.6, 71.9, 70.7, 68.3, 67.5 (C-3, C-
4, C-7, C-9, C-3’, C-4’, C-5’), 40.9 (C-8), 33.4, 32.9 (C-2, C-2’), 21.4 (C-10), 20.9 (2 
x CH3CO), 17.4 (C-6’), 6.8, 6.4, 5.2 (TES). 
 120
 7-O-[2,6-dideoxy-α-L-galactopyranosyl]-3,4-di-O-acetyl-decarestrictine D (57) 
HO
O
OH
O
O
OAc
OAc
O
 
Yield: 21 mg (0.048 mmol, 45%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.82 (dd, J = 16.0, 3.3 Hz, 1H, 5-
H), 5.60 (ddd, J = 16.0, 9.6, 1.3 Hz, 1H, 6-H), 5.34 (ddd, J = 5.1, 3.3, 1.2 Hz, 1H, 4-
H), 5.16 (ddq, J = 10.1, 6.4, 2.8 Hz, 1H, 9-H), 5.02 (ddd, J = 7.2, 5.1, 2.3 Hz, 1H, 3-
H), 4.85 (d, J = 3,1 Hz, 1H, 1-H’), 4.08 (ddd, J = 9.6, 9.6, 4.6 Hz, 1H, 7-H), 3.97 
(ddd, J = 11.3, 5.4, 3.1 Hz, 1H, 3-H), 3.87 (bq, J = 6.4 Hz, 1H, 5-H’), 3.60 (bd, J = 
2.9 Hz, 1H, 4-H’), 2.69 (dd, J = 13.9, 7.2 Hz, 1H, 2-H), 2.54 (dd, J =  13.9, 2.3 Hz, 
1H, 2-H), 2.15, 2.13 (2s, 6H, 2 x CH3CO), 1.9-1.7 (m, 4H, 8-H, 2-H’), 1.26, 1.23 
(2d, J = 6.4, 6.4 Hz, 6H, 10-H, 6-H’). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.9, 169.5, 169.1 (2 x COCH3, 
C-1), 133.9 (+, C-6), 126.5 (+, C-5), 93.5 (+, C-1’), 74.8, 71.9, 71.2, 70.8, 68.1, 
65.8, 65.79 (7+, C-3, C-4, C-7, C-9, C-3’, C-4’, C-5’, ), 40.9 (-, C-8), 33.3 (-, C-2), 
32.8 (-, C-2’), 21.4 (+, C-10), 21.0, 20.9 (2+, 2 x COCH3), 16.8 (+, C-6’). 
 
Phenyl [3-O-TES-4-O-(PS-DES)-2,6-dideoxy-α-L-galactopyranosyl]-(1→3)-2,6-
dideoxy-1-thio-α-L-glycopyranoside (58) 
O
O
OTES
O
O
HO SPh
 
To a suspension of polymer-bound glycal 48 (200 mg, 0.214 mmol) in 5 ml of 
CH2Cl2 was added thioglycoside 27 (200 mg, 0.98 mmol) and 2 mg (cat.) of 
PPh3*HBr. The suspension was shaken for 4 h, then polymer filtered off and 
washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high vacuum for 4 
h.  Resin 58 was weighted and loading was determined by weight difference  
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Yield:   236 mg (0.62 mmol/g, 70%). 
 
13C-NMR (100 MHz, CDCl , CDCl = 77 ppm): GEL-NMR: 135.2 (Ph-1), 131.1 (Ph-
o), 128.9 (Ph-m), 127.7 (Ph-p), 99.9 (C-1’), 83.8 (C-1), 77.9 (C-3), 76.4 (C-4), 73.4 
(C-4 ), 68.6 (C-5), 67.9 (C-5’), 67.4 (C-3 ), 37.4 (C-2), 33.5 (C-2 ), 17.8 (C-6), 17.3 
(C-6 ), 6.8 ((CH CH ) Si), 5.3 ((CH CH ) Si). 
3
’ ’
’
3 
3 2 3 3 2 3
’
 
[3-O-TES-4-O-(PS-DES)-2,6-dideoxy-α-L-galactopyranosyl]-(1→4)-3-O-
benzoyl-2,6-dideoxy-L-glycal (59) 
O
O
OTES
O
OBz
O
 
To a suspension of polymer-bound glycal 48 (500 mg, 0.5 mmol) in 10 ml of 
CH2Cl2 was added glycal 31 (351 mg, 1.5 mmol) and 5 mg of PPh3*HBr. The 
suspension was shaken for 4 h, then polymer was filtered off and washed with 
CH2Cl2 (5x5 ml), acetonitrile (5x5 ml) and dried in high vacuum for 4 h. The 
resulted polymer was weighted and loading was determined by weight difference. 
 
Yield: 181 mg (0.60 mmol/g, 70%). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) GEL-NMR δ: 166.1 (PhCO), 145.9 
(C-1), 133.1, 129.6, 128.4 (Ph), 98.8, 98.6(C-2, C-1’), 76.0, 73.7, 73.5, 71.7, 68.2, 
67.3 (C-3, C-4, C-5, C-3’, C-4’, C-5’), 33.4 (C-2’), 17.3 (C-6, C-6’), 6.9, 5.3 (TES). 
 
IR (KBr) 1721.3 cm-1 (PhCO). 
 
[2,6-dideoxy-α-L-galactopyranosyl]-(1→4)-3-O-benzoyl-2,6-dideoxy-L-glycal 
(61) 
HO
O
OH
O
OBz
O
 
A suspension of polymer-bound disaccharide 59 (190 mg, 0.6 mmol/g) in 10 ml of 
mixture (TBAF /AcOH/THF – 266 mg/0.151 ml/8.4 ml) was stirred for 2 days. The 
resulted mixture was filtered, solvent evaporated and flash chromatography over 
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silica gel (ethyl acetate / petroleum ether = 1:1, Rf- 0.14) afforded 61 as a 
crystalline powder. 
 
Yield: 29 mg (0.08 mmol, 70%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.0 (m, 2h, Ph), 7.5 (m, 3H, Ph) 
6.45 (dd, J = 6.0, 1.2 Hz, 1H, 1-H), 5.50 (dd, J = 4.2, 5.4 Hz, 1H, 3-H), 5.26 (d, J = 
3.2 Hz, 1H, 1-H’), 4.88 (dd, J = 6.0. 4.2 Hz, 1H, 2-H), 4.15 (dq, J = 7.1, 6.6 Hz, 1H, 
5-H), 4.00 (bq, J = 6.3 Hz, 1H, 5-H’), 3.92 (dd, J = 7.1, 5.4 Hz, 1H, 4-H), 3.82 (m, 
1H, 3-H’), 3.64 (d, J = 1.5 Hz, 1H, 4-H’), 1.85 (dd, J = 13.2, 5.5 Hz, 1H, 2-H’), 1.71 
(dd, J = 13.2, 3.2 Hz, 1H, 2-H’), 1.43 (d, J = 6.3 Hz, 3H, 6-H’), 1.28 (d, J = 6.6 Hz, 
3H, 6-H). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 166.0 (CO-Ph), 145.9 (C-1), 
133.2, 129.6, 128.5 (Ph), 98.6, 97.5 (2+, C-2, C-1’), 75.4, 73.4, 71.1, 70.6, 66.4, 
65.6 (6+, C-3, C-4, C-5, C-3’, C-4’, C-5’), 32.9 (-, C-2’), 17.2, 16.7 (2+, C-6, C-6’). 
 
[3-O-TES-4-O-(PS-DES)-2,6-dideoxy-α-L-galactopyranosyl]-(1→4)-3-O-
pivaloyl-2,6-dideoxy-L-glycal (60) 
O
O
OTES
O
OPiv
O
 
To a suspension of polymer bound glycal 48 (150 mg, 0.16 mmol) in 2.5 ml of 
CH2Cl2 was added glycal 32 (53 mg, 0.25 mmol) and 1 mg of PPh3*HBr (cat.). The 
suspension was shaken for 6 h, then filtered, washed with CH2Cl2 (5x3 ml), 
acetonitrile (5x3 ml) and dried in high vacuum for 4 h. Polymer bound glycoside 60 
was weighted and loading was determined by weight difference.  
 
Yield: 176 mg (0.69 mmol/g, 76%). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) GEL-NMR δ: 178.1 (PivCO), 145.7 
(C-1), 98.9, 97.6(2x+, C-2, C-1’), 78.6, 76.1, 72.1, 70.9, 70.3, 69.4 (6x+, C-3, C-4, 
C-5, C-3’, C-4’, C-5’), 38.9 (C(CH3)3), 33.5 (-, C-2’), 26.9 (+, C(CH3)3), 17.3 (2x+, 
C-6, C-6’), 6.9, 5.3 (TES). 
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IR (KBr) 1730.9 cm-1 (PivCO). 
 
3-O-Benzoyl-L-fucal (50) 
 A solution of L-fucal (1 g, 7.7 mmol) in dry pyridine (20 ml) was cooled down to -
30°C and benzoyl chloride (1.08 g, 7.7 mmol) was added dropwise. The reaction 
was stirred another 2h until t.l.c. (petroleum ether / ethyl acetate 5:1) showed full 
starting material consumption. The reaction was quenched by addition of methanol 
(1 ml), and the resulted solution was evaporated under reduced pressure. The 
crude product was purified by flash column chromatography over silica gel 
(petroleum ether / ethyl acetate 5:1, Rf- 0.45). 
 
Yield: 1.56 g (6.67 mmol, 87%). 
 
[3-O-TES-4-O-(PS-DES)-2,6-dideoxy-α-L-galactopyranosyl]-(1→4)-3-O-
benzoyl-2,6-dideoxy-L-galactal (62) 
O
O
OTES
O
OBz
O
 
To a suspension of polymer bound glycal 48 (157 mg, 0.55 mmol/g) in 2.5 ml of 
CH2Cl2 was added glycal 50 (150 mg, 2.75 mmol) and 1 mg of PPh3*HBr. The 
suspension was shaken for 4 h, polymer filtered and washed with CH2Cl2 (5x3 ml), 
acetonitrile (5x3 ml) and dried in high vacuum for 4 h. The polymer 62 was 
weighted and loading was determined by weight difference  
 
Yield: 14 mg (0.35 mmol/g, 64%). 
 
1-Fluoro-3,4-di-O-acetyl 2,6-dideoxy-β-L-glucopyranoside 
O
AcO
AcO F
 
To an ice cooled mixture of thioglycoside 18 (0.62 g, 1.9 mmol) and MS 4Α in dry 
acetonitrile was added selectfluor™ (2 g, 5.7 mmol) in 15 min under N2. The 
mixture was stirred for 20 min, and then solid NaHCO3 was added. The 
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suspension was allowed to stir another 5 min., diluted with CH2Cl2 and filtered. The 
filtrate was evaporated and the crude product was purified by column 
chromatography over silica gel (ethyl acetate / petroleum ether=1:5, Rf-0.5). 2-
Deoxy-fluoropyranose is highly unstable and can spontaneously decompose 
followed by intensive blue colour.  
 
Yield: 0.4 g (1.71 mmol, 90%), white crystalline powder. 
 
1H-NMR (400 MHz, CD2Cl2, TMS = 0.00 ppm) δ: 5.69 (d, J = 51.3 Hz, H1, 1-H), 
5.20 (ddd, J = 11.5, 9.6, 5.4 Hz, 1H, 3-H), 4.80 (dd, J = 9.9, 9.6 Hz, 1H, 4-H), 4.03 
(dq, J = 9.9, 6.3 Hz, 1H, 5-H), 2.45 (dddd, J = 13.7, 5.1, 5.0, 1.2 Hz, 1H, 2-Hax), 
2.05 (s, 3H, CH3CO), 2.01 (s, 3H, CH3CO), 1.83 (dddd, J = 38.9, 13.7, 11,5, 2.7 
Hz, 1H, 2-Heq), 1.21 (d, J = 6.3 Hz, 3H, CH3CH). 
 
13C-NMR (100 MHz, CD2Cl2, TMS = 0.00 ppm) δ: 170.7 (2 x COCH3), 107.5, 105.4 
(+, C-1), 73.8 (+, C-4), 68.8, 68.7 (+, C-3), 66.7 (+, C-5), 35.2, 35.0 (-, C-2), 21.0 
(2+, 2 x CH3CO), 17.6 (+, C-6). 
 
3,4-Di-O-acetyl 2,6-dideoxy-α-L-glucopyranosyl-phenylsulfoxide 
O
AcO
AcO SPh
O
 
 To a vigorously stirred mixture of thioglycoside 18 (325 mg, 1.0 mmol), Ac2O (112 
µl, 1.1 mmol) and SiO2 (200 mg) in CH2Cl2 (5 ml) was added H2O2 (30%, 136 µl, 
1.2 mmol). The reaction mixture was allowed to stir overnight, slurry extracted with 
ethyl acetate, organic layers combined and evaporated under reduced pressure. 
No product further purification is required.  
 
Yield: 320mg (0.94 mmol, 94%). 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.67 (m, 2H, Ph-o), 7.56 (m, 3H, 
Ph-m, p), 5.55 (ddd, J = 10.5, 8.7, 5.4 Hz, 1H, 3-H), 4.82 (dd, J = 9.3, 8.7 Hz, 1H, 
4-H), 4.51 (dd, J = 6.0, 2.2 Hz, 1H, 1-H), 4.26 (dq, J = 9.3, 6.1 Hz, 1H, 5-H), 2.86 
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(ddd, J = 14.4, 5.4, 2.2 Hz, 1H, 2-Hax), 2.00 (ddd, J = 14,4, 10,5, 6.0 Hz, 1H, 2-
Heq), 2.13 (s, 3H, CH3CO), 2.05 (s, 3H, CH3CO), 1.24 (d, J = 6.1 Hz, 3H, 6-H). 
 
2,6-Dideoxy-α-L-glucopyranosyl-phenylsulfoxide 
O
HO
HO SPh
O
 
To a solution of 3,4-Di-O-acetyl 2,6-dideoxy-α-L-glucopyranosyl-phenylsulfoxide 
(320 mg, 0.94 mmol) in 10 ml of methanol 1 g of Amberlite A-26 (OH- form) was 
added. The suspension was shaken for 12h and polymer was filtered off, washed 
with methanol and combined filtrates were evaporated under reduced pressure.  
 
Yield: 235 mg (0.92 mmol, 98%), colourless crystalline powder. 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.60 (m, 5H, Ph), 4.53 (d, J = 5.7 
Hz, 1H), 4.20 (m, 1H), 3.98 (dq, J = 9.3, 6.0 Hz, 1H, 5-H), 3.26 (dd, J = 9.3, 9.1 Hz, 
1H, 4-H), 2.85 (dd, J = 14.5, 5.1 Hz, 1H, 2-Hax), 1.98 (ddd, J = 14.5, 11.4, 5.7 Hz, 
1H, 2-Heq), 1.34 (d, J = 6.0 Hz, 3H, 6-H). 
 
3-O-Benzoyl-2,6-dideoxy-α-L-glucopyranosyl-phenylsulfoxide (51) 
O
BzO
HO SPh
O
 
A solution of 2,6-Dideoxy-α-L-glucopyranosyl-phenylsulfoxide (2.6 g, 0.01 mol) in 
dry pyridine (50 ml) was cooled down to -30°C, and benzoyl chloride (1.41 g, 0.01 
mol) dropwise was added. The reaction mixture was allowed to stir another 1h at 
the same temperature, 1 ml of methanol was added to quench the acetylation and 
solution was evaporated under reduced pressure. The crude product was purified 
by column chromatography (petroleum ether / ethyl acetate 2:1, Rf- 0.48). 
 
Yield: 3.2 g (8.9 mmol, 89%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.07 (m, 2H, Ph), 7.56 (m, 8H, 
Ph), 5.63 (ddd, J = 10.8, 9.0, 5.2 Hz, 1H, 3-H), 4.57 (dd, J = 5.8, 1.8 Hz, 1H, 1-H), 
4.14 (dq, J = 9.2, 6.1 Hz, 1H, 5-H), 3.52 (dd, J = 9.2, 9.0 Hz, 1H, 4-H), 3.00 (ddd, J 
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= 14.4, 5.2, 1.8 Hz, 1H, 2-Hax), 2.18 (ddd, J = 14.3, 10.8, 5.8 Hz, 1H, 2-Heq), 1.39 
(d, J = 6.1 Hz, 3H, 6-H). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 170.1 (COPh), 135.4, 133.4 131.8, 
131.7, 131.2, 130.4, 126.4, (Ph), 96.9 (+, C-1), 79.3, 76.9, 74.6 (+,C-3, C-4, C-5), 
30.0 (-, C-2), 19.9 (+, C-6). 
 
17-O-[3-O-TES-4-O-(PS-DES)-2,6-dideoxy-L-glycoopyranosyl]-testosterone 
(63) 
O
O
OTES
O
H
HH
O
 
To a suspension of polymer-bound glycal 49 (200 mg, 0.198 mmol) in 5 ml of 
CH2Cl2 were added testosterone (0.172 g, 3 eq, 0.594 mmol) and 2 mg of 
PPh3*HBr (cat.). The suspension was shaken for 4 h, and then the polymer was 
filtered off and washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high 
vacuum for 4 h. Polymer bound glycoconjugate 63 was weighted and loading was 
determined by weight difference. 
 
Yield: (244 mg, 0.623 mmol/g, 77%). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  GEL-NMR : 199.4 (C-3), 171.2 
(C-5), 123.8 (C-4), 98.1 (C-1’), 87.4 (C-17), 79.0 (C-4’), 70.5 (C-3’), 68.7 (C-5’), 
53.8 (C-9), 50.1 (C-14), 42.7 (C-13), 39.7 (C-2’), 38.6 (C-10), 37.0 (C-12), 35.6 (C-
1), 35.4 (C-8), 33.9 (C-2), 32.7 (C-6), 31.5 (C-7), 28.5 (C-16), 23.4 (C-15), 20.5 (C-
11), 18.3 (C-6’), 17.3 (C-19), 11.6 (C-18), 7.0 (SiCH2CH3), 5.3 (SiCH2CH3). 
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3-O-[3-O-TES-4-O-(PS-DES)-2,6-dideoxy-L-glycoopyranosyl]-digitoxigenin 
(65) 
O
O
OTES
O
O
OH
O
H
H
H
 
To a suspension of polymer-bound glycal 49 (100 mg, 0.099 mmol) in 2.5 ml of 
CH2Cl2 was added digitoxigenin (0.100 g, 3 eq, 0.3 mmol) and 1 mg (cat.) of 
PPh3*HBr. The suspension was shaken for 4 h, then the polymer was filtered off 
and washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high vacuum 
for 4 h. The obtained polymer-supported glycoconjugate 65 was weighted and 
loading was determined by weight difference  
 
Yield: (125 mg, 0.53 mmol/g, 67%). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  GEL-NMR :  174.5 (C-20), 174.4 
(C-23), 117.5 (C-22), 94.6 (C-1’), 85.4 (C-14), 79.1 (C-4’), 73.5 (C-21), 73.4 (C-3’), 
73.3 (C-5’), 70.3 (C-3), 50.9 (C-17), 49.6 (C-13), 41.7 (C-8), 40.2 (C-12), 39.9 (C-
2’), 36.3 (C-5), 35.6 (C-9), 35.1 (C-10), 33.0 (C-4), 30.2 (C-15), 29.5 (C-1), 26.8 (C-
2), 26.6 (C-6, C-16), 23.7 (C-19), 21.3 (C-7), 21.1 (C-11), 18.4 (C-6’), 15.7 (C-18), 
6.9 (SiCH2CH3), 5.3 (SiCH2CH3). 
 
17-O-[2,6-dideoxy-L-glycopyranosyl]-testosterone (64) 
HO
O
OH
O
H
HH
O
 
Polymer bound glycoside 63 (231 mg, 0.150 mmol) was suspended in CH2Cl2 (10 
ml) and TASF (10 eq) was added. The suspension was shaken for 5 days, then 
filtered and the filtrate was evaporated under reduced pressure. The crude product 
was purified by column chromatography (ethyl acetate, Rf- 0.44). Partial cleavage 
was detected by later resin treating by TBAF in THF. 
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Yield: 30 mg (0.072 mmol, 48%), α/β = 8:1 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.71 (s, 1H, 4-H), 4.87 (d, J = 3.2 
Hz, 1H, 1-H’α), 4.44 (dd, J = 9.8, 1.9 Hz, 0.1H, 1-H’β), 4.01 (ddd, J = 11.8, 5.4, 3.4 
Hz, 1H, 3-H’), 3.66 (dq, J = 6.4, 9.3 Hz, 1H, 5-H’), 3.49 (t, J = 8.3 Hz, 1H, 17-H), 
3.09 (t, J = 8.8 Hz, 1H, 3-H’), 2.5 – 0.7 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  199.7 (s, C-3), 171.4 (s, C-5), 
123.8 (d, C-4), 98.0 (d, C-1’), 87.1 (d, C-17), 78.2 (d, C-4’), 69.3 (d, C-5’), 67.6 (d, 
C-3’), 53.8 (d, C-9), 50.2 (d, C-14), 42.8 (s, C-13), 38.6 (s, C-10), 38.0 (t, C-2’), 
37.1 (t, C-12), 35.7 (t, C-1), 35.4 (d, C-8), 33.9 (t, C-2), 32.8 (t, C-6), 31.5 (t, C-7), 
28.5 (t, C-16), 23.3 (t, C-15), 20.6 (t, C-11), 17.6 (q, C-6’), 17.4 (q, C-19), 11.6 (q, 
C-18). 
 
3-O-[2’,6’-dideoxy-L-glycopyranosyl]-digitoxigenin (66) 
HO
O
OH
O
O
OH
O
H
H
H
 
A suspension of polymer-bound glycoside 65 (100 mg, 0.081 mmol) in “TBAF 
mixture” (10 ml) was stirred for 5 days. The polymer was filtered off, resulted 
solution was evaporated and residue was purified by column chromatography over 
silica gel (ethyl acetate, Rf- 0.31). 
 
Yield: 29 mg (0.0575 mmol, 71%), white powder, α/β = 2:1 
 
1H-NMR (400 MHz, CD3OD, CD3OD = 3.31 ppm) δ:  5.90 (s, 1H, 22-H), 5.07 (bd, J 
= 18.0 Hz, 1H, 21-H), 4.93 (bs, 0.7H, 1-H’α), 4.92 (bd, J = 18.0 Hz, 1H, 21-H), 4.59 
(d, J = 9.3 Hz, 1.3H, 1-H’β), 4.03 (bs, 0.3H), 3.90  (bs, 0.7H), 3.82 (m, 0.7H, 3-H’), 
3.67 (dq, J = 8.6, 6.7 Hz, 0.7H, 5-H’), 3.51 (m, 0.3H, 3-H’), 3.22 (dq, J = 8.3, 6.6 
Hz, 0.3H, 5-H’), 2.95 – 2.80 (m, 2H, 4-H’, 3-H), 2.25 – 0.8 (m).  
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 13C-NMR (100 MHz, CD3OD, CD3OD = 50.2 ppm) δ: 179.6 (C-20), 178.4 (C-23), 
119.0 (C-22), 100.1 (C-1’β), 98.0 (C-1’α), 87.6 (C-14), 80.29, 79.73, 76.53, 75.83, 
74.46, 74.33. 73.57, 71.00, 70.61, 62.72, 53.31, 52.25, 43.89, 42.37, 42.15, 40.99, 
39.32, 39.14, 38.01, 37.56, 37.51, 34.58, 34.28, 32.85, 32.40. 32.11, 29.26, 29.10, 
29.02, 28.79, 26.58, 25.57, 25.48, 23.77, 23.67, 23.57, 22.06, 19.46, 19.38, 17.60, 
15.67 
 
7-O-[3-O-TES-4-O-(PS-DES)-2,6-dideoxy-L-glycopyranosyl]-3,4-di-O-acetyl-
decarestrictine D (67) 
O
O
OTES
O
O
OAc
OAc
O
 
To a suspension of polymer-bound glycal 49 (100 mg, 0.107 mmol) in 5 ml of 
CH2Cl2 was added decarestrictine 40 (100 mg, 0.321 mmol) and 1.5 mg (cat.) of 
PPh3*HBr. The suspension was shaken for 4 h, then polymer filtered off and 
washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high vacuum for 4 
h. Loading of polymer-bound glycoside 67 was determined by weight difference. 
 
Yield: 121 mg (0.066 mmol, 62%). 
 
13C-NMR (100 MHz, CDCl3, CDCl3=77 ppm) GEL-NMR δ: 169.8, 169.7, 168.9 (2x 
CH3CO, C-1), 134.4 (C-6), 125.7 (C-5), 93.0 (C-1’), 78.9, 74.2, 72.2, 71.9, 70.8, 
68.0 (C-3, C-4, C-7, C-9, C-3’, C-4’, C-5’), 40.9 (C-8), 37.4 (C-2’), 33.3 (C-2), 21.4 
(C-10), 20.9 (2x CH3CO), 18.2 (C-6’), 6.9, 5.3 (TES). 
 
Phenyl [3-O-TES-4-O-(PS-DES)-2,6-dideoxy-α-L-glucoopyranosyl]-(1→3)-2,6-
dideoxy-1-thio-α-L-glycopyranoside (68) 
O
O
OTES
O
O
HO SPh
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To a suspension of polymer bound glycal 49 (460 mg, 0.456 mmol) in 8 ml of 
CH2Cl2 were added thioglycoside 27 (327 mg, 3 eq, 1.368 mmol) and 4 mg of 
PPh3*HBr. The suspension was shaken for 4 h, then polymer filtered off and 
washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high vacuum for 4 
h.  Polymer-bound disaccharide 68 was weighted and loading was determined by 
weight difference 
 
Yield: 547 mg (0.66 mmol/g, 80%). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm): GEL-NMR: 135.1 (Ph-1), 131.1 (Ph-
o), 128.9 (Ph-m), 127.0 (Ph-p), 99.1 (C-1’), 83.7 (C-1), 78.7 (C-5’), 76.5 (C-4), 75.9 
(C-4’), 72.7 (C-5), 70.4 (C-3), 68.5 (C-3’), 39.4 (C-2), 37.5 (C-2’), 18.2 (C-6), 17.7 
(C-6’), 7.0, 6.9 ((CH3CH2)3Si), 5.7, 5.3 ((CH3CH2)3Si). 
 
Polymer-bound glycoside 68 was treated with ”TBAF mixture” for 3 days to 
determine the regioisomeric disaccharide ratio. The following disaccharides 70, 69, 
71 (relative ratio was analyzed by 1H-NMR spectroscopy: 47%, 19.1%, 33% 
respectively) were isolated. 
 
Phenyl [2,6-dideoxy-α-L-glycopyranosyl]-(1→3)-2,6-dideoxy-1-thio-α-L-
glycopyranoside (70) 
HO
O
OH
O
O
HO SPh
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm)  δ: 7.38 (m, 2H, Ph-o), 7.21 (m, 3H, 
Ph-m, p), 5.54 (d, J = 5.4 Hz, 1H, 1-H), 5.12 (d, J = 3.5 Hz, 1H, 1-H’), 4.17 (dq, J = 
9.1, 6.2 Hz, 1H, 5-H),  3.90 (ddd, J = 11.8, 9.1, 2.5 Hz, 1H, 3-H’), 3.82 (ddd, J = 
11.4, 9.1, 4.8 Hz, 1H, 3-H), 3.68 (dq, J = 9.1, 6.2 Hz, 1H, 5-H’), 3.20 (t, J = 9.1 Hz, 
1H, 4-H), 3.12 (t, J = 9.1, 1H, 4-H’), 2.5 – 1.5 (m, 4H, 2-H, 2-H’), 1.28 (d, J = 6.2 
Hz, 3H, 6-H), 1.26 (d, J = 6.2 Hz, 3H, 6-H’). 
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Phenyl [2,6-dideoxy-α-L-glycopyranosyl]-(1→4)-2,6-dideoxy-1-thio-α-L-
glycopyranoside (69) 
HO
O
HO
O
HO
O SPh
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.38 (m, 2H, Ph-o), 7.21 (m, 3H, 
Ph-m, p), 5.54 (d, J = 5.4 Hz, 1H, 1-H), 5.36 (d, J = 3.5 Hz, 1H, 1-H’), 4.17 (dq, J = 
9.1, 6.2 Hz, 1H, 5-H),  4.03 (ddd, J = 11.6, 8.6, 4.8 Hz, 1H, 3-H’), 3.81 (ddd, J = 
11.4, 9.1, 4.8 Hz, 1H, 3-H), 3.72 (m, 1H, 5-H’), 3.20 (t, J = 9.1 Hz, 1H, 4-H), 3.11 (t, 
J = 9.1, 1H, 4-H’), 2.5 – 1.5 (m, 4H, 2-H, 2-H’), 1.28 (d, J = 6.2 Hz, 3H, 6-H), 1.26 
(d, J = 6.5 Hz, 3H, 6-H’). 
 
Phenyl [2,6-dideoxy-β-L-glycopyranosyl]-(1→3)-2,6-dideoxy-1-thio-α-L-
glycopyranoside (71) 
HO
O
OH
O
O
HO SPh
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.38 (m, 2H, Ph-o), 7.21 (m, 3H, 
Ph-m, p), 5.54 (d, J = 5.4 Hz, 1H, 1-H), 4.62 (dd, J = 9.7, 2.1 Hz, 1H, 1-H’), 4.15 
(dq, J = 9.4, 6.2 Hz, 1H, 5-H),  3.75 (ddd, J = 11.9, 9.4, 5.4 Hz, 1H, 3-H), 3.63 (dd, 
J = 11.6, 5.6 Hz, 1H, 3-H’), 3.42 (q, J = 6.2 Hz, 1H, 5-H’), 3.17, 3.16 (t, J = 9.4 Hz, 
2H, 4-H, 4-H’), 2.27 (m, 2H), 2.19 (dd, J = 11.6, 5.6 Hz, 1H), 1.70 (ddd, J = 12.1, 
9.7, 9.7 Hz, 1H), 1.39 (d, J = 6.2 Hz, 3H, 6-H), 1.26 (d, J = 6.2 Hz, 3H, 6-H’). 
 
17-O-[(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→3)-(2,6-dideoxy-α-
L-glycopyranosyl)]-testosterone (72) 
O
H
HH
O
O
O
HO
O
TESO
TESO
 
To an ice cooled solution of disaccharide 28 (60 mg, 0.1 mmol) and testosterone 
(29 mg, 0.1 mmol) in dry acetonitrile (5 ml) selectfluor™ (35 mg, 0.1 mmol) was 
added. After 15 min, the reaction mixture was treated with saturated NaHCO3 
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solution and 5 ml of ethyl acetate. The phases were separated and the aqueous 
phase was extracted 3 times with ethyl acetate. The combined organic layers were 
dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by column chromatography over silica gel (petroleum ether / ethyl acetate 
3:1, Rf- 0.33) 
 
Yield: 30 mg (0.0386 mmol, 38%), crystalline powder.  
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 5.08 (d, J = 3.1 
Hz, 1H, 1-H’), 4.83 (d, J = 3.1 Hz, 1H, 1-H’’), 3.95 (ddd, J = 11.9, 4.4, 2.2 Hz, 1H, 
3-H’’), 3.81 (m, 2H, 5-H’’, 3-H’), 3.73 (dq, J = 9.5, 6.2 Hz, 1H, 5-H’), 3.57 (bd, J = 
2.2 Hz, 1H, 4-H’’), 3.47 (t, J = 8.6 Hz, 1H, 17-H), 3.16 (dt, J = 9.3, 1.7 Hz, 1H, 4-
H’), 2.5 – 0.5 (m).  
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.5 (C-3), 171.3 (C-5), 123.8 (+, 
C-4), 99.8 (+, C-1’’), 98.1 (+, C-1’), 87.2 (+, C-17), 77.9 (+, C-3’), 76.1 (+, C-4’), 
73.4 (+, C-4’’), 67.7 (+, C-5’’), 67.6 (+, C-5’), 67.4 (+, C-3’’), 53.8 (+, C-9), 50.1 (+, 
C-14), 42.8 (C-13), 38.6 (C-10), 37.1 (-, C-2’), 37.0 (-, C-12), 35.7 (-, C-1), 35.4 (+, 
C-8), 33.9 (-, C-2), 33.5 (-, C-2’’), 32.7 (-, C-6), 31.5 (-, C-7), 28.4 (-, C-16), 23.3 (-, 
C-15), 20.5 (-, C-11), 17.8 (+, C-19), 17.3 (+, C-6’), 17.2 (+, C-6’’), 11.5 (+, C-18), 
7.0, 6.8, 5.1, 4.8 (2 x TES). 
 
[α]D23  = - 36° [C1, CHCl3 ] 
 
17-O-[(2,6-dideoxy-α-L-galactopyranosyl)-(1→3)-(2,6-dideoxy-α-L-
glycopyranosyl)]-testosterone (73) 
O
H
HH
O
O
O
HO
O
HO
HO
 
Glycoconjugate 72 (15 mg, 0.019 mmol) was stirred in “TBAF mixture” (5ml) for 3 
days. The reaction mixture was concentrated under reduced pressure and crude 
product purified by column chromatography over silica gel (ethyl acetate, Rf- 0.22). 
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 Yield: 8 mg (0.015 mmol, 77%). 
 
1H-NMR (400 MHz, CD3OD, CD3OD = 3.31 ppm) δ: 5.71 (s, 1H, 4-H), 5.15 (d, J = 
2.7 Hz, 1H, 1-H’’), 4.92 (1H, 1-H’), 3.92 (m, 2H, 3-H’’, 5-H’’), 3.83 (ddd, J = 11.7, 
9.1, 5.3 Hz, 1H, 3-H’), 3.68 (dq, J = 9.6, 6.1 Hz, 1H, 5-H’), 3.52 (m, 2H, 17-H, 4-
H’’), 3.01 (t, J = 9.4 Hz, 1H, 4-H’), 2.5 – 0.5 (m). 
 
13C-NMR (100 MHz, CD3OD, CD3OD = 50.2 ppm) δ: 203.6 (C-3), 176.4 (C-5), 
125.3 (+, C-4), 102.2 (+, C-1’’), 100.7 (+, C-1’), 89.7 (+, C-17), 79.3 (+, C-3’), 78.1 
(+, C-4’), 73.5 (+, C-4’’), 68.9 (+, C-5’’), 68.8 (+, C-5’), 68.1 (+, C-3’’), 56.7 (+, C-9), 
52.7 (+, C-14), 45.3 (C-13), 41.2 (C-10), 39.8 (-, C-2’), 39.6 (-, C-12), 38.0 (-, C-1), 
37.9 (+, C-8), 35.9 (-, C-2), 35.1 (-, C-2’’), 34.5 (-, C-6), 34.0 (-, C-7), 30.8 (-, C-16), 
25.5 (-, C-15), 22.9 (-, C-11), 19.4 (+, C-19), 18.9 (+, C-6’), 18.4 (+, C-6’’), 13.3 (+, 
C-18). 
 
LC-MS (ESI) (-c): m/z (%): 547.31 (100) [M – H]-; HR-MS C31H47O8: calc. 
547.3271, found 547.3269  
 
[α]D23  = - 56° [C 0.8, MeOH ] 
 
17-O-[{di-[3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl]-(1→3),(1→4)}-2,6-
dideoxy-α-L-glycopyranosyl]-testosterone (fraction-2) (74); 17-O-[{di-[3,4-di-
O-TES-2,6-dideoxy-α-L-galactopyranosyl]-(1→3),(1→4)}-2,6-dideoxy-β-L-
glycopyranosyl]-testosterone (fraction-1) (75) 
To an ice cooled solution of 30 (160 mg, 0.167 mmol) and testosterone (50 mg, 
0.167 mmol) in dry acetonitrile (10 ml) was added selectfluor™ (60 mg, 0.167 
mmol). After 15 min reaction mixture was treated with saturated NaHCO3 water 
solution and 30 ml of ethyl acetate was added. The phases were separated and 
the aqueous phase was extracted 3 times with ethyl acetate. The combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure. 
The residue was purified by column chromatography over silica gel (petroleum 
ether / ethyl acetate 10:1) to yield three fractions. 
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Yield:  1st fraction: 75 - 16 mg (0.0141 mmol, 8.4%), 
2nd fraction: 74 - 116 mg (0.102 mmol, 61%), 
3rd fraction: α/β mixture = 20 mg (0.0176 mmol, 10.5%).  
O
H
HH
OO
O
O
O
OTESTESO
O
OTES
TESO
 
1st fraction 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 5.13 (d, J = 3.0 
Hz, 1H, 1-H’’), 4.96 (d, J = 3.0 Hz, 1H, 1-H’’’), 4.38 (bd, J = 8.6 Hz, 1H, 1-H’), 3.90 
(m, 2H, 3-H’’, 3-H’’’), 3.83, 3.82 (2q, J = 6.1 Hz, 2H, 5-H’’, 5-H’’’), 3.61 (t, J = 8.6 
Hz, 1H, 17-H), 3.56 (bs, 2H, 4-H’’, 4-H’’’), 3.44 (ddd, J = 12.2, 9.1, 5.1 Hz, 1H, 3-
H’), 3.22 (dq, J = 9.1, 6.1 Hz, 1H, 5-H’), 3.17 (t, J = 9.1 Hz, 1H, 4-H’), 2.5 – 0.5 (m).  
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.6 (s, C-3), 171.4 (s, C-5), 
123.8 (d, C-4), 98.7, 98.6 (2d, C-1’’, C-1’’’), 98.5 (d, C-1’), 87.2 (d, C-17), 82.9 (d, 
C-4’), 81.2 (d, C-3’), 73.5, 73.48 (2d, C-4’’, C-4’’’), 70.7 (d, C-5’), 67.9, 67.6 (2d, C-
5’’, C-5’’’), 67.4, 67.3 (2d, C-3’’, C-3’’’), 54.0 (d, C-9), 50.6 (d, C-14), 42.4 (s, C-13), 
39.2 (t, C-2’), 38.6 (s, C-10), 36.6 (t, C-12), 35.7 (t, C-1), 35.5 (d, C-8), 34.0 (t, C-
2), 33.7, 33.6 (2t, C-2’’, C-2’’’), 32.8 (t, C-6), 31.6 (t, C-7), 27.6 (t, C-16), 23.3 (t, C-
15), 20.6 (t, C-11), 18.3 (q, C-19), 17.4 (q, C-6’), 17.3, 17.2 (2q, C-6’’, C-6’’’), 11.6 
(q, C-18), 7.0, 6.98, 6.8, 6.7, 5.2, 5.17, 4.8, 4.7 (4 x TES). 
 
[α]D23  = - 18.3° [C1, CHCl3 ] 
O
H
HH
OO
O
O
O
OTESTESO
O
OTES
TESO
 
2nd fraction   
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1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.71 (s, 1H, 4-H), 5.18 (d, J = 3.0 
Hz, 1H, 1-H’’), 4.99 (d, J = 3.0 Hz, 1H, 1-H’’’), 4.08 (d, J = 3.1 Hz, 1H, 1-H’), 3.90 
(m, 2H, 3-H’’, 3-H’’’), 3.84 (q, J = 6.2 Hz, 1H, 5-H’’), 3.81 (m, 1H, 3-H’), 3.78 (q, J = 
6.2 Hz, 1H, 5-H’’’), 3.68 (dq, J = 9.1, 6.2 Hz, 1H, 5-H’), 3.57 (bdd, J = 5.0, 2.1 Hz, 
2H, 4-H’’, 4-H’’’), 3.46 (t, J = 8.9 Hz, 1H, 17-H), 3.14 (t, J = 9.1 Hz, 1H, 4-H’), 2.5 – 
0.5 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.5 (s, C-3), 171.3 (s, C-5), 
123.8 (d, C-4), 100.5, 100.4 (2d, C-1’’, C-1’’’), 97.9 (d, C-1’), 87.2 (d, C-17), 82.9 
(d, C-4’), 79.0 (d, C-3’), 73.5, 73.4 (2d, C-4’’, C-4’’’), 67.9, 67.4 (3d, C-5’, C-5’’, C-
5’’’), 67.38, 67.0 (2d, C-3’’, C-3’’’), 53.9 (d, C-9), 50.2 (d, C-14), 42.8 (s, C-13), 38.6 
(s, C-10), 37.8 (t, C-2’), 37.1 (t, C-12), 35.7 (t, C-1), 35.4 (d, C-8), 34.0 (t, C-2), 
33.7, 33.6 (2t, C-2’’, C-2’’’), 32.8 (t, C-6), 31.5 (t, C-7), 28.5 (t, C-16), 23.3 (t, C-15), 
20.6 (t, C-11), 18.3 (q, C-19), 17.4 (q, C-6’), 17.3, 17.2 (2q, C-6’’, C-6’’’), 11.6 (q, 
C-18), 7.0, 6.98, 6.8, 6.7, 5.2, 5.17, 4.8, 4.7 (4 x TES). 
 
[α]D23  = - 38.7° [C1, CHCl3 ] 
 
17-O-[{di-[2,6-dideoxy-α-L-galactopyranosyl]-(1→3),(1→4)}-2,6-dideoxy-β-L-
glycopyranosyl]-testosterone (77) 
O
H
HH
OO
O
O
O
OHHO
O
HO
HO
 
Glycoconjugate 75 (16 mg, 0.014 mmol) was stirred with “TBAF mixture” (2ml) for 
3 days. The reaction mixture was concentrated under reduced pressure and 
purified by column chromatography over silica gel (ethyl acetate /MeOH 9:1, Rf- 
0.13). 
 
Yield: 9 mg (0.013 mmol, 95%). 
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1H-NMR (400 MHz, CD3OD, CD3OD = 3.31 ppm) δ: 5.71 (s, 1H, 4-H), 5.28 (d, J = 
3.7 Hz, 1H, 1-H’’), 5.04 (d, J = 3.3 Hz, 1H, 1-H’’’), 4.49 (bd, J = 8.2 Hz, 1H, 1-H’), 
4.0 – 3.85 (m, 4H, 5-H’’, 5-H’’’, 3-H’’, 3-H’’’), 3.67 (t, J = 8.4 Hz, 1H, 17-H), 3.61 (m, 
1H, 3-H’), 3.56 (bs, 2H, 4-H’’, 4-H’’’), 3.31 (dq, J = 8.6, 6.4 Hz, 1H, 5-H’), 3.15 (t, J 
= 8.6 Hz, 1H, 4-H’), 2.45 - 0.6 (m). 
 
13C-NMR (100 MHz, CD3OD, CD3OD = 50.2 ppm) δ: 202.3 (s, C-3), 175.2 (s, C-5), 
124.1 (d, C-4), 101.6, 100.7 (2d, C-1’’, C-1’’’), 99.8 (d, C-1’), 88.7 (d, C-17), 83.1 
(d, C-4’), 82.1 (d, C-3’), 72.2, 72.2 (2d, C-4’’, C-4’’’), 71.9.1 (d, C-5’), 68.3, 67.9 (2d, 
C-5’’, C-5’’’), 66.8, 66.7 (2d, C-3’’, C-3’’’), 55.5 (d, C-9), 51.9 (d, C-14), 43.6 (s, C-
13), 40.5 (s, C-10), 40.0 (t, C-2’), 37.9 (t, C-12), 36.8 (t, C-1), 36.7 (d, C-8), 34.7 (t, 
C-2), 33.9, 33.8 (2t, C-2’’, C-2’’’), 33.6 (t, C-6), 32.8 (t, C-7), 28.6 (t, C-16), 24.1 (t, 
C-15), 21.7 (t, C-11), 19.0 (q, C-19), 17.7 (q, C-6’), 17.2, 17.1 (2q, C-6’’, C-6’’’), 
12.1 (q, C-18). 
 
LC-MS (ESI) (-c): m/z (%): 677.40 (100) [M – H]-; HR-MS C37H57O11: calc. 
677.3901, found 677.3899  
 
[α]D23  = - 24.0° [C 0.5, MeOH ] 
 
17-O-[{di-[2,6-dideoxy-α-L-galactopyranosyl]-(1→3),(1→4)}-2,6-dideoxy-α-L-
glycopyranosyl]-testosterone (76) 
O
H
HH
OO
O
O
O
OHHO
O
HO
HO
 
Glycoconjugate 74 (63 mg, 0.055 mmol) was stirred with “TBAF mixture” (5ml) for 
3 days. The reaction mixture was concentrated under reduced pressure and crude 
product purified by column chromatography over silica gel (ethyl acetate /MeOH 
9:1, Rf- 0.13). 
 
Yield: 33 mg (0.049 mmol, 89%). 
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1H-NMR (400 MHz, CD3OD, CD3OD = 3.31 ppm) δ: 5.71 (s, 1H, 4-H), 5.27 (d, J = 
3.9 Hz, 1H, 1-H’’), 5.03 (d, J = 3.5 Hz, 1H, 1-H’’’), 4.85 (d, J = 3.1 Hz, 1H, 1-H’), 4.0 
– 3.85 (m, 5H, 5-H’’, 5-H’’’, 3-H’’, 3-H’’’, 3-H’), 3.70 (dq, J = 9.4, 6.2 Hz, 1H, 5-H’), 
3.58 – 3.50 (m, 3H, 17-H, 4-H’’, 4-H’’’), 3.17 (t, J = 9.4 Hz, 1H, 4-H’), 2.5 – 0.7 (m). 
 
13C-NMR (100 MHz, CD3OD, CD3OD = 50.2 ppm) δ: 203.4 (s, C-3), 176.2 (s, C-5), 
125.4 (d, C-4), 102.5, 102.0 (2d, C-1’’, C-1’’’), 100.2 (d, C-1’), 89.6 (d, C-17), 84.8 
(d, C-4’), 80.7 (d, C-3’), 73.4, 73.4 (2d, C-4’’, C-4’’’), 69.5, 67.4 (2d, C-5’’, C-5’’’), 
69.1 (d, C-5’), 68.0, 67.9 (2d, C-3’’, C-3’’’), 56.6 (d, C-9), 50.7 (d, C-14), 45.2 (s, C-
13), 41.2 (s, C-10), 40.0 (t, C-2’), 39.6 (t, C-12), 38.0 (t, C-1), 37.9 (d, C-8), 35.9 (t, 
C-2), 35.1, 35.0 (2t, C-2’’, C-2’’’), 34.8 (t, C-6), 34.0 (t, C-7), 30.8 (t, C-16), 25.5 (t, 
C-15), 22.9 (t, C-11), 20.0 (q, C-19), 18.9 (q, C-6’), 18.3, 18.3 (2q, C-6’’, C-6’’’), 
13.3 (q, C-18). 
 
LC-MS (ESI) (-c): m/z (%): 677.39 (100) [M – H]-; HR-MS C37H57O11: calc. 
677.3901, found 677.3876  
 
[α]D23  = -97.8° [C 0.5, MeOH ] 
 
17-O-(3-O-benzoyl-2,6-dideoxy-α-L-glucopyranosyl)-testosterone (78) 
O
H
HH
OO
OBz
HO
 
 To a solution of glycal 31 (35 mg, 0.1 mmol) and testosterone (28 mg, 0.1 mmol) 
in CH2Cl2 (5 ml) was added PPh3*HBr (8 mg). After 5 h the reaction was quenched 
with addition of Amberlite A-21. The mixture was filtrated, solids were washed with 
ethyl acetate and filtrate was evaporated under reduced pressure. The crude 
product was purified by column chromatography over silica gel (ethyl acetate / 
petroleum ether=1:2, Rf-0.61). 
 
Yield: 41 mg (0.065 mmol, 65%).  
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1H-NMR (400 MHz, CDCl3, CDCl3=7.26 ppm) δ: 8.05 (m, 2h, Ph), 7.5 (m, 3H, Ph), 
5.72 (s, 1H, 4-H), 5.35 (ddd, J = 11.4, 5.2, 9.3 Hz, 1H, 3-H’), 4.96 (d, J = 3.2 Hz, 
1H, 1-H’), 3.83 (dq, J = 9.3, 6.2 Hz, 1H, 5-H’), 3.54 (dd, J = 8.5,, 8.51 Hz, 1H, 17-
H), 3.40 (ddd, J = 9.3, 9.3, 4.1 Hz, 1H, 4-H’), 1.32 (d, J = 6.2 Hz, 3H, 6-H’), 2.5 – 
0.7 (m) 
  
13C-NMR (100 MHz, CDCl3, CDCl3=77 ppm) δ: 199.6 (C-3), 171.3 (C-5), 167.5 
(COPh), 133.3, 129.7, 128.4, (Ph), 123.8 (+, C-4), 97.5 (+, C-1’), 87.2 (+, C-17), 
75.9, 73.6, 68.1 (+, C-3’, C-4’, C-5’), 53.8 (+, C-9), 50.2 (+, C-14), 42.8 (C-13), 38.6 
(C-10), 37.2 (-, C-12), 35.7 (-, C-1), 35.6 (-, C-2’), 35.4 (+, C-8), 33.9 (-, C-2), 32.8 
(-, C-6), 31.5 (-, C-7), 28.4 (-, C-16), 23.3 (-, C-15), 20.6 (-, C-11), 17.7 (+, C-19), 
17.4 (+, C-6’), 11.7 (+, C-18). 
 
11.4.4. Experiments to the chapter 5.4. 
17-O-[(3-O-TES-4-O-(PS-DES)-2,6-dideoxy-α-L-galactopyranosyl)-(1→3)-(2,6-
dideoxy-α-L-glycopyranosyl)]-testosterone  (79) 
O
O
OTES
O
O
HO
O
H
HH
O
 
To a suspension of polymer-bound disaccharide 58 (200 mg, 0.116 mmol) in  a 
mixture of solvents (CH2Cl2/acetonitrile 1:1, 8 ml) were added testosterone (0.1 g, 
0.348 mmol) and selectfluor™ (61.6 mg, 1.5 eq). The suspension was shaken for 4 
h, then polymer was filtered off and washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 
ml) and dried in high vacuum for 4 h. Loading of afforded polymer-bound 
glycoconjugate 79 was determined after cleavage with ”TBAF mixture”. 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) GEL-NMR δ: 199.6 (C-3), 171.3 (C-
5), 123.7 (C-4), 98.9, 98.0 (C-1’, C-1’’), 86.9 (C-17), 79.0, 78.7 (C-4’, C-4’’), 72.7, 
72.6 (C-3’, C-3’’), 70.3, 67.6 (C-5’, C-5’’), 53.8 (C-9), 50.2 (C-14), 42.7 (C-13), 38.6 
(C-10), 38.4, 37.1 (C-2’, C-2’’), 36.9 (C-12), 35.6 (C-1), 35.4 (C-8), 33.8 (C-2), 32.7 
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(C-6), 32.4 (C-7), 28.4 (C-16), 23.2 (C-15), 20.5 (C-11), 18.1 (C-19), 17.8, 17.3 (C-
6’, C-6’’), 11.6 (C-18), 6.9, 5.7, 5.3 (TES). 
 
17-O-[(2,6-dideoxy-α-L-galactopyranosyl)-(1→3)-(2,6-dideoxy-α-L-
glycopyranosyl)]-testosterone (80) 
HO
O
OH
O
O
HO
O
H
HH
O
 
Yield: 11 mg (0.02 mmol, 17%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 5.13 (d, J = 3.7 
Hz, 1H, 1-H’), 4.86 (d, J = 3.4 Hz, 1H, 1-H’’), 4.02 – 3.93 (m, 2H, 3-H’’, 5-H’’), 3.84 
(ddd, J = 11.4, 9.2, 4.5 Hz, 1H, 3-H’), 3.72 (dq, J = 9.2, 6.0 Hz, 1H, 5-H’), 3.63 (bs, 
1H, 4-H’’), 3.49 (t, J = 8.4 Hz, 1H, 17-H), 3.17 (t, J = 9.2 Hz, 1H, 4-H’), 2.5 – 0.7 
(m). 
 
Phenyl {di-[2,6-dideoxy-α-L-galactopyranosyl]-(1→3),(1→4)}-2,6-dideoxy-1-
thio-α-L-glycopyranoside (82) 
HO
O
OH
O
O
O
O
OH
HO
SPh
 
To a suspension of polymer bound thioglycoside 58 (174 mg, 0.83 mmol) in 2.5 ml 
of CH2Cl2 was added 3,4-bis-O-TES-L-fucal 22 (90 mg, 2.5 mmol) and 1 mg of 
PPh3*HBr. The suspension was shaken for 6 h, polymer filtered off, washed with 
CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high vacuum for 4 h.  The 
polymer-bound trisaccharide 81 was weighted and loading was determined by 
weight difference  
 
Yield: 196 mg (0.063 mmol, 22 mg, 76%). 
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Polymer bound trisaccharide 81 was successfully cleaved with TBAF in THF to 
afford 19.5 mg of trisaccharide 82 (0.039 mmol, 63%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.43 (m, 2H, Ph), 7.24 (m, 3H, 
Ph), 5.52 (d, J = 5.0 Hz, 1H, 1-H), 5.18, 5.03 (d, d, J = 3.7 Hz, J = 3.45 Hz, 2H, 1-
H’, 1’’), 4.15 (dq, J = 9.3, 6.1 Hz, 1H, 5-H ), 3.84 (m, 5H), 3.56 (dd, J = 9.4, 1.6 Hz, 
2H, 4-H’,4-H’’), 3.20 (dd, J = 9.3, 8.8 Hz, 1H, 4-H), 2.43 (dd, J = 13.9, 4.5 Hz, 1H), 
2.05 (m, 3H), 1.55 (m, 2H), 1.24 (d, J = 6.1 Hz, 3H, CH3), 1.14 (d, J = 6.4 Hz, 3H, 
CH3’), 1.13 (d, J = 6.4 Hz, 3H, CH3’’) 
 
13C-NMR (100 MHz, CDCl3, CDCl3=77 ppm): 135.3, 131.1+, 128.9+, 126.9+ (Ph), 
100.8, 100.5 (2d, C-1’, C-1’’), 83.6 (d, C-1), 83.1 (d, C-4), 79.4 (d, C-3), 73.5, 73.4 
(2d, C-4’, C-4’’), 68.0 (2d, C-5, C-5’’), 67.7 (d, C-5’), 67.4, 67.3 (2d, C-3’, C-3’’), 
38.1 (t, C-2), 33.6 (2t, C-2’, C-2’’), 18.1 (q, C-6), 17.3, 17.2 (2q, C-6’, C-6’’). 
 
The obtained polymer 81 was involved in the following glycosidation reactions with 
testosterone (3-5 eq) and different thioglycoside activators:  
 
1. Selectfluor™ 2eq, CH2Cl2/CH3CN, RT. overnight (after treating the polymer 
83 with TBAF in THF glycoconjugate 84 was afforded in 15% yield). 
2.  PhI(OAc)2 (5 eq), Et4NI (5.5 eq) , CH2Cl2 , RT. overnight.  
3. NIS (1.6 eq), TMSOTf (cat.), CH2Cl2, -50oC – -20oC 3h, (at higher 
temperatures cleavage of polymer-bound trisaccharide was observed). 
In all reactions 17-Phenyl-S-testosterone was detected as a by-product. 
 
17-Ph-S-Testosterone 
1H-NMR (200 MHz, CDCl3, CDCl3=7.26 ppm) δ: 7.70 (m, 2H, Ph), 7.54 (m, 3H, 
Ph), 5.71(s, 1H, 4-H), 4.15 (dd, J = 8.3, 8.3 Hz, 0.5H, 17-H), 4.07 (dd, J = 9.0, 7.9 
Hz, 0.5H, 17-H), 2.5-0.75 (m). 
 
 
 
 
 141
17-O-(3-O-benzoyl-2,6-dideoxy-α-L-glucopyranosyl)-testosterone (See table 
6) (78) 
O
H
HH
OO
OBz
HO
 
To a suspension of polymer bound glycal 59 (147 mg, 0.07 mmol) in 2.5 ml of 
CH2Cl2 was added testosterone (60 mg, 3 eq, 0.21 mmol) and 1 mg of PPh3*HBr 
(cat.). The suspension was shaken for 6 h, then filtered off and washed with 
CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and dried in high vacuum for 4 h. The filtrated 
solution was evaporated under reduced pressure and the residue was purified by 
column chromatography over silica gel (petroleum ether / ethyl acetate 2:1, Rf- 
0.63) to yield 31mg (0.059 mmol, 85%) of crystalline product 78. After treating 
polymer with TBAF in THF the glycoside 53 was detected. NMR analysis see 
above. 
 
3-O-(3-O-benzoyl-2,6-dideoxy-α-L-glucopyranosyl)-digitoxigenin (85) 
O
O
OH
O
H
H
O
OBz
HO
H
 
To a suspension of polymer bound glycal 59 (73 mg, 0.033 mmol) in 1.5 ml of 
CH2Cl2 was added digitoxigenin (25 mg, 0.066 mmol) and 0.6 mg of PPh3*HBr 
(cat.). The suspension was shaken for 6 h, then resin filtered and washed with 
CH2Cl2 (5x2 ml), acetonitrile (5x2 ml) and dried in high vacuum for 4 h. The filtrate 
was evaporated and residue was purified by column chromatography over silica 
gel (petroleum ether / ethyl acetate 2:1, Rf- 0.45) to yield 15 mg (0.025 mmol, 75%) 
of crystalline product 85. After treating resin with TBAF in THF the compound 55 
was detected. 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.06 (m, 2H, Ph), 7.50 (m, 3H, 
Ph), 5.91 (dd, J = 1.5, 1.5 Hz, 1H, 22-H), 5.42 (ddd, J = 11.5, 9.3, 5.2 Hz, 1H, 3-
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H’), 5.02 (dd, J = 18.1, 1.6 Hz, 1H, 21-H), 5.01 (d, J = 2.7 Hz, 1H, 1-H’), 4.80 (dd, J 
= 18.1, 1.6 Hz, 1H, 21-H), 3.85 (dq, J = 9.3, 6.3 Hz, 1H, 5-H’), 3.40 (dd, J = 9.3, 9.3 
Hz, 1H, 4-H’), 2.71 (bs, 1H, OH), 2.28 (dd, J = 12.3, 5.2 Hz, 1H, 2-H’), 2.25 – 0.5 
(m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  174.6 (s, C-20), 174.5 (s, C-23), 
167.6 (s, COPh), 133.4, 129.8, 129.7, 128.4 (Ph), 117.7 (t, C-22), 94.8 (t, C-1’), 
85.6 (s, C-14), 76.7 (d, C-3’), 73.8 (d, C-4’), 73.4 (t, C-21), 71.5 (d, C-3), 68.1 (d, 
C-5’), 50.9 (d, C-17), 49.6 (s, C-13), 41.9 (d, C-8), 40.1 (s, C-12), 36.4 (d, C-5), 
35.9 (t, C-2’), 35.7 (d, C-9), 35.2 (s, C-10), 33.2 (t, C-4), 30.4 (t, C-15), 29.7 (t, C-
1), 29.6 (t), 26.9 (t, C-2), 26.61 (t, C-6), 26.60 (t, C-16), 23.7 (q, C-19), 21.4 (t, C-
7), 21.2 (t, C-11), 17.7 (q, C-6’), 15.8 (q, C-18). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY - 1.35 ppm: 5.38 (ddd, 1H, 
3-H’), 5.01 (d, 1H, 1-H’), 3.83 (dq, 1H, 5-H’), 3.40 (dd, 1H, 4-H’), 2.71 (bs, 1H, OH), 
2.28 (dd, 1H, 2-H’), 1.93 (ddd, 1H, 2-H’), 1.35 (d, 3H, 6-H’). 
 
Phenyl [3-O-benzoyl-2,6-dideoxy-α/β-L-glycopyranosyl]-(1→3)-2,6-dideoxy-1-
thio-α-L-glycopyranoside (86) 
O
O
HO SPh
O
OBz
HO
 
To a suspension of polymer bound glycal 59 (180 mg, 0.15 mmol) in mixture of 
solvents (3 ml, CH2Cl2/CH3CN - 1:1) was added thioglycoside 27 (108 mg, 0.45 
mmol), 1 mg of CSA (cat.) and 7 mg of LiBr. The suspension was shaken for 5 h, 
polymer filtered off and washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and 
dried in high vacuum for 4 h. The filtrate was evaporated and crude product 86 was 
purified by column chromatography over silica gel (petroleum ether / ethyl acetate 
3:1, Rf- 0.45). On the polymer no product was detected after treating with TBAF in 
THF for a 12h.  
 
Yield: 32mg (0.067 mmol, 45%) as a diastereomeric mixture. 
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1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.1 (m, 3H, Ph), 7.5 (m, 7H, Ph), 
5.62 (d, J = 5.4 Hz, 1H, 1-H), 5.35 (ddd, J = 11.7, 9.1, 5.2 Hz, 1H, 3-H’) 5.24 (d, J = 
2.9 Hz, 0.7H, 1-H’α), 4.76 (dd, J = 9.8, 2.0 Hz, 0.3H, 1-H’β), 4.23 (ddd,  J = 11.2, 
9.3, 6.1 Hz, 1H), 3.90 (m, 2H), 3.50 (m, 3H), 3.32 (ddd, J = 9.1, 9.1, 2.2 Hz, 0.7H), 
3.20 (dd, J = 9.0, 9.0 Hz, 0.3H), 2.8- 2.7 (m, 1.7H), 2.6- 2.2 (m, 3.7H), 1.37 (d, J = 
6.0 Hz, 3H, 6-H’), 1.35 (d, J = 6.1 Hz, 3H, 6-H) 
 
17-O-(3-O-pivaloyl-2,6-dideoxy-α-L-glucopyranosyl)-testosterone (87) 
O
H
HH
OO
OPiv
HO
 
To the polymer bound glycoside 60 in CH2Cl2 (2.5 ml) testosterone (53mg, 0.186 
mmol) and 1mg of PPh3*HBr was added. The suspension was shaken for 8h, 
polymer was filtered off, washed with CH2Cl2 (5x3 ml), acetonitrile (5x3 ml) and 
dried in high vacuum for 4 h. The filtrate was evaporated and residue was purified 
by column chromatography over silica gel (petroleum ether / ethyl acetate 2:1, Rf- 
0.47) to yield 24 mg (0.048, 77%) of product 87. After treating obtained polymer 
with TBAF in THF the compound 53 was detected. 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ:  5.76 (s, 1H, 4-H), 5.10 (ddd, J = 
11.5, 5.2, 9.2 Hz, 1H, 3-H’), 4.95 (d, J = 3.0 Hz, 1H, 1-H’), 3.55 (dd, J = 8.6, 8.6 Hz, 
1H, 17-H), 3.27 (ddd, J = 9.2, 8.9, 4.0 Hz, 1H, 4-H’), 1.24 (d, J = 6.2 Hz, 3H, 6-H’), 
2.7 – 0.7 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.6 (C-3), 171.3 (C-5), 175.5 
(COPiv), 123.8 (+, C-4), 97.5 (+, C-1’), 87.2 (+, C-17), 81.3 (+, C-3’), 73.6, 68.1 (+, 
C-4’, C-5’), 53.7 (+, C-9), 50.2 (+, C-14), 42.7 (C-13), 38.8 (s, C(CH3)3), 38.6 (C-
10), 37.2 (-, C-12), 35.7 (-, C-1), 35.6 (-, C-2’), 35.4 (+, C-8), 33.9 (-, C-2), 32.8 (-, 
C-6), 31.5 (-, C-7), 28.4 (-, C-16), 27.2 (+, C(CH3)3),  23.3 (-, C-15), 20.6 (-, C-11), 
17.7 (+, C-19), 17.4 (+, C-6’), 11.7 (+, C-18). 
 
 
 144
17-O-(3-O-benzoyl-2,6-dideoxy-α-L-galactopyranosyl)-testosterone (88) 
O
H
HH
OO
OBz
HO
 
To a suspension of polymer bound glycal 59 (167 mg, 0.35 mmol/g) in 2.5 ml 
CH2Cl2 was added testosterone (48 mg, 0.175 mmol)) and 1 mg of PPh3*HBr. The 
suspension was shaken for 6 h, polymer was filtered off, washed with CH2Cl2 (5x3 
ml), acetonitrile (5x3 ml) and dried in high vacuum for 4 h. The filtrate was 
evaporated and crude glycoconjugate 88 was purified by column chromatography 
over silica gel (petroleum ether / ethyl acetate 2:1). After treating resin with TBAF 
in THF the compound 53 was detected. 
 
Yield: 25 mg (0.048 mmol, 82%). 
 
 1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.05 (m, 2H, Ph), 7.5 (m, 3H, 
Ph), 5.68 (s, 1H, 4-H), 5.37 (1H, 3-H’), 4.85 (d, J = 2.8 Hz, 1H, 1-H’), 3.82 (bq, J = 
6.5 Hz, 1H, 5-H’), 3.48 (t, J = 8.5 Hz, 1H, 17-H), 3.60 (bs, 1H, 4-H’), 2.7 – 0.5 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.5 (C-3), 171.2 (C-5), 167.5 
(COPh), 133.3, 129.8, 128.5, (Ph), 123.8 (+, C-4), 99.3 (+, C-1’),87.1 (+, C-17), 
75.9 (+, C-3’), 73.6 (+, C-4’), 67.5 (C-5’), 53.8 (+, C-9), 50.1 (+, C-14), 42.7 (C-13), 
38.5 (C-10), 37.0 (-, C-12), 35.6 (-, C-1), 35.4 (+, C-8), 33.9 (-, C-2), 33.4 (-, C-2’), 
32.7 (-, C-6), 31.4 (-, C-7), 28.5 (-, C-16), 23.3 (-, C-15), 20.5 (-, C-11), 17.3 (+, C-
19), 18.0 (+, C-6’), 11.5 (+, C-18). 
 
Acetyl [3-O-TES-4-O-(PS-DES)-2,6-dideoxy-α-L-glucoopyranosyl]-(1→3)-2-
iodo-2,6-dideoxy-L-glyco/manno-pyranoside (93) 
O
O
OTES
O
OBz
O
OAc
I
 
 To a suspension of polymer bound glycal 59 (345 mg, 0.2 mmol) in 5 ml of CH2Cl2 
was added PhI(OAc)2 (644 mg, 2 mmol, 10 eq) and Et4N+I- (565mg, 2.2 mmol, 
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11eq). The suspension was shaken for 12 h, then filtered and washed with CH2Cl2 
(5x5 ml), methanol (5x5 ml) and polymer was dried in high vacuum for 4 h. The 
polymer-bound carbohydrate 93 was weighted and loading was determined by 
weight difference. 
 
Yield: 380 mg (0.188 mmol, 35 mg, 94%). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) GEL-NMR δ:  168.6 (PhCO), 165.1 
(CH3CO), 133.6, 129.6, 128.6 (Ph), 100.3 (C-1’) 95.0 (C-1, α) 93.9 (C-1, β), 78.9, 
73.3, 71.7, 70.6, 68.3, 67.1 (C-3, C-4, C-5, C-3’, C-4’, C-5’), 33.1 (C-2’), 29.1 (C-2) 
18.1, 17.3 (C-6, C-6’), 6.9, 5.3 (TES). 
 
Acetyl [2,6-dideoxy-α-L-glucoopyranosyl]-(1→3)-2-iodo-2,6-dideoxy-α-L-
mannopyranoside (94), Acetyl [2,6-dideoxy-α-L-glucoopyranosyl]-(1→3)-2-
iodo-2,6-dideoxy-β-L-glycopyranoside (95) 
HO
O
OH
O
OBz
O
OAc
I
HO
O
OH
O
OBz
O
OAc
I+
94 95  
150 mg Of the polymer 93 was treated with TBAF in THF for 12h. Polymer was 
filtered off and filtrate was evaporated under reduced pressure. Residue was 
purified by column chromatography over silica gel to afford compounds 94 and 95. 
 
Yield: 33 mg (0.06 mmol, 82%) 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.1 (m, 2H, Ph), 7.55 (m, 3H, Ph) 
6.34 (d, J = 1.7 Hz, 0.7H, 1-H), 5.89 (d, J = 9.2, 0.3H, 1-H, β), 5.59 (dd, J = 11.3, 
8.8 Hz 0.3H, 2-H), 5.21 (d, J = 2.2 Hz, 0.7H, 1-H’), 4.96 (d, J = 4.2 Hz, 0.3H, 1-H’) 
4.8 (dd, J = 8.4, 4.2 Hz, 0.7H), 4.60 (dd, J = 4.3, 1.8 Hz, 0.7H), 3.95 (m, 4H), 3.61 
(d, J = 2.7 Hz, 0.7H), 3.57 (d, J = 2.9 Hz, 0.3H) 2.3- 1.5 (m), 1.39, 1.26 (2x d, J = 
5.9, 6.6 Hz, 6H, 6-H’, 6-H). 
 
13C-NMR (100 MHz, CDCl3, CDCl3=77 ppm) δ: 167.8 (CO-Ph), 164.3 (CO-CH3), 
133.0, 129.0, 127.9 (Ph), 98.6, 94.1 (2+, C-1, C-1’), 78.1, 71.1, 70.1, 69.9, 65.8, 
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64.7 (6+, C-3, C-4, C-5, C-3’, C-4’, C-5’), 31.9 (-, C-2’), 27.8 (C-2), 17.3, 15.7 (2+, 
C-6, C-6’). 
 
Glycosidation of testosterone with polymer-bound disaccharide 93 
To a suspension of polymer bound glycoside 93 (120 mg, 0.072 mmol) in 2.5 ml of 
CH2Cl2 was added testosterone (62 mg, 0.216 mmol). The reaction mixture was 
cooled down to –70oC and 50 µl (3 eq) of TMSOTf was added. The resulted 
suspension was shaken for 4 h, then allowed to warm up to -30oC, reaction was 
quenched with some drops of triethly amine. The polymer was filtered off, washed 
with CH2Cl2 (5x2 ml), acetonitrile (5x2 ml) and dried in high vacuum for 4 h. The 
filtrate was evaporated and residue was purified by column chromatography over 
silica gel (ethyl acetate, Rf- 0.25). The only compound 53 was isolated and 
analysed by NMR spectroscopy. After treating resin with TBAF in THF no desired 
product was detected. 
 
11.5.1. Experiments to the chapter 6.1.1. 
17-O-[(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-(3-O-benzoyl-
2,6-dideoxy-α/β-L-glycopyranosyl)]-testosterone (96) 
O
H
HH
OO
OBz
OO
OTES
TESO
 
 To a solution of rhamnal 31 (20 mg, 0.085 mmol) and testosterone (25mg, 0.085 
mmol) in CH2Cl2 3 ml, was added solution of CSA (1mg, cat.) and LiBr (7 mg) in 
CH3CN (3 ml). The reaction was stirred for 4 h, then 3,4-bis-O-TES-L-fucal (35 mg, 
0.09 mmol) was added in a 2 ml of CH2Cl2. The resulted solution was allowed to 
stir another 6 h and the reaction was quenched with addition of Amberlite A-21. 
The polymer was filtered off and the filtrate was evaporated under reduced 
pressure. The crude product 96 was purified by column chromatography over silica 
gel (ethyl acetate / petroleum ether = 1:5) to afford three fractions: α-glycoside (40 
mg, 0.045 mmol, 53%), β-glycoside (10 mg, 0.011 mmol, 13%), and 8 mg of by-
product 24. 
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 α-glycoside: 
1H-NMR (400 MHz, CDCl3, CDCl3  =7.26 ppm) δ: 8.00 (m, 2H, Ph), 7.5 (m, 3H, Ph), 
5.72 (s, 1H, 4-H), 5.40 (ddd, J = 10.8, 9.4, 5.2 Hz, 1H, 3-H’), 5.15 (d, J = 3.3 Hz, 
1H, 1-H’), 4.89 (d, J = 3.1 Hz, 1H, 1-H’’), 3.8 – 3.9 (m, 3H), 3.4 – 3.6 (m, 3H), 2.5 – 
0.7 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.6 (C-3), 171.3 (C-5), 165.6 
(COPh), 133.1, 129.9, 129.5, 128.5 (Ph), 123.8 (+, C-4), 100.1 (+, C-1’’), 97.5 (+, 
C-1’), 87.2 (+, C-17), 81.5 (+, C-3’), 73.4, 73.0, 68.0, 67.2, 66.8 (+, C-4’, C-5’, C-3’’, 
C-4’’, C-5’’), 53.8 (+, C-9), 50.2 (+, C-14), 42.8 (C-13), 38.6 (C-10), 37.1 (-, C-12), 
35.8 (-, C-1), 35.7 (-, C-2’), 35.4 (+, C-8), 33.9 (-, C-2), 33.2 (-, C-2’’), 32.8 (-, C-6), 
31.5 (-, C-7), 28.5 (-, C-16), 23.3 (-, C-15), 20.5 (-, C-11), 18.1 (+, C-19), 17.4 (+, 
C-6’), 17.2 (+, C-6’’), 11.7 (+, C-18), 7.0, 6.7, 5.1, 4.6 (2 x TES). 
 
β-glycoside:  
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.00 (m, 2H, Ph), 7.5 (m, 3H, 
Ph), 5.72 (s, 1H, 4-H), 5.16 (d, J = 3.2 Hz, 1H, 1-H’’), 5.10 (ddd, J = 11.5, 5.0, 3.7 
Hz, 1H, 3-H’), 4.56 (dd, J = 9.8, 2.2 Hz, 1H, 1-H’), 3.4 – 3.9 (m, 5H), 2.5 – 0.4 (m). 
 
3-O-Benzoyl-4-O-TES-6-deoxy-L-rhamnal (101) 
To a solution of glycal 31 (1 g, 4.3 mmol), DMAP (300 mg, 0.2 eq, cat.) and 
imidazole (0.5 g, 1.3 eq) in 10 ml of DMF was added TESCl (0.79 ml, 4.7 mmol). 
The reaction mixture was stirred overnight. The crude product was purified by 
column chromatography over silica gel (petroleum ether / ethyl acetate 15:1).  
  
Yield: 1.4 g (4.0 mmol, 93%), colourless oil. 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.05 (m, 2H, Ph), 7.57 (m, 1H, 
Ph), 7.45 (m, 2H, Ph), 6.45 (dd, J = 6.0, 1.0 Hz, 1H, 1-H), 5.47 (ddd, J = 6.3, 2.5, 
1.2 Hz, 1H, 3-H), 4.83 (dd, J = 6.0, 2.5 Hz, 1H, 2-H), 4.00 (dq, J = 8.8, 6.2 Hz, 1H, 
5-H), 3.87 (dd, J = 8.8, 6.3 Hz, 1H, 4-H), 1.43 (d, J = 6.2 Hz, 3H, 6-H), 0.9 (t, J = 
7.8 Hz, 9H, TES), 0.56 (q, J = 7.8 Hz, 6H, TES). 
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13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 166.2 (CO-Ph), 146.0 (+, C-1), 
133.0, 129.6 128.4 (3+, Ph), 130.3 (q, Ph), 99.4 (+, C-2), 75.5, 73.7, 72.3 (3+, C-3, 
C-4, C-5), 17.4 (+, C-6), 6.4, 5.0 (+ -, TES). 
 
3-O-Benzoyl-4-O-TBS-6-deoxy-L-rhamnal (97) 
To a solution of glycal (jj-79) (1 g, 4.3 mmol), DMAP (300 mg, 0.2 eq, cat.) and 
imidazole (0.5 g, 1.3 eq) in 10 ml of DMF was added TESCl (0.79 ml, 4.7 mmol). 
The reaction mixture was stirred overnight. The crude product was purified by 
column chromatography over silica gel (petroleum ether / ethyl acetate 15:1).  
  
Yield: 1.44 g (4.1 mmol, 94%), colorless oil. 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.05 (m, 2H, Ph), 7.57 (m, 1H, 
Ph), 7.45 (m, 2H, Ph), 6.43 (dd, J = 6.0, 1.0 Hz, 1H, 1-H), 5.50 (ddd, J = 6.4, 2.5, 
1.3 Hz, 1H, 3-H), 4.80 (dd, J = 6.0, 2.5 Hz, 1H, 2-H), 3.97 (dq, J = 9.0, 6.3 Hz, 1H, 
5-H), 3.87 (dd, J = 9.0, 6.4 Hz, 1H, 4-H), 1.41 (d, J = 6.3 Hz, 3H, 6-H), 0.83 (s, 9H, 
TBS), 0.1, -0.2 (2s, 6H, TBS). 
 
13C-NMR (100 MHz, CDCl3, CDCl3=77 ppm) δ: 166.3 (CO-Ph), 146.1 (+, C-1), 
133.0, 129.6 128.4 (3+, Ph), 130.3 (s, Ph), 99.6 (+, C-2), 75.5, 73.7, 72.4 (3+, C-3, 
C-4, C-5), 25.7 (+, t-Bu), 18.0 (s, t-Bu), 17.8 (+, C-6), -4.1, -4.6 (2+ , Si(CH3)2). 
 
17-O-(3-O-benzoyl-2,6-dideoxy-α-L-glucopyranosyl)-testosterone (See 
scheme 16) (78) 
O
H
HH
OO
OBz
HO
 
To a solution of glycal 97 (30 mg, 0.086 mmol) and testosterone (23 mg, 0.080 
mmol) in CH2Cl2/acetonitrile (1:1, 3 ml) were added MS 4A (55 mg), LiBr (30 mg) 
and Dowex 50x8 (15 mg, cat., the TBS group also be proposed to cleave). After 24 
h reaction was quenched by addition of Amberlite A-21. The suspension was 
filtrated, solids were washed with ethyl acetate and the filtrate was evaporated 
under reduced pressure. The crude product 78 was purified by column 
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chromatography over silica gel (ethyl acetate / petroleum ether=1:2, Rf-0.61). 
Yield: 43 mg (0.070 mmol, 81%). NMR analyses see above. 
 
3-O-Pivaloyl-4-O-TES-6-deoxy-L-rhamnal (98) 
To a solution of glycal 32 (1 g, 4.7 mmol), DMAP (300 mg, 0.2 eq, cat.) and 
imidazole (0.5 g, 6.1 mmol) in 10 ml of DMF was added  triethylsilyl chloride (0.77 
g, 5.0 mmol). The reaction mixture was allowed to stir another 12h. The crude 
product solution in DMF directly was purified by column chromatography over silica 
gel (petroleum ether / ethyl acetate 15:1).  
 
Yield: 1.5 g (4.46 mmol, 95%), colourless oil. 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 6.36 (dd, J = 6.2, 0.9 Hz, 1H, 1-
H), 5.12 (dd, J = 5.4, 3.0 Hz, 1H, 3-H), 4.68 (dd, 6.2, 3.0 Hz, 1H, 2-H), 3.93 (dq, J = 
7.4, 6.5 Hz, 1H, 5-H), 3.74 (dd, J = 7.4, 5.4 Hz, 1H, 4-H), 1.35 (d, J = 6.5 Hz, 3H, 
6-H), 1.2 (s, 9H, Piv), 0.95 (t, 9H, TES), 0.6 (q, 6H, TES). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 178.2 (CO-Piv), 145.7 (+, C-1), 
98.9 (+, C-2), 75.2, 72.3, 72.0 (3x+, C-3, C-4, C-5), 38.8 (q, C(CH3)3), 27.2 (+, 
C(CH3)3), 17.2 (+, C-6), 6.8 (+, TES), 5.0 (-, TES). 
 
17-O-[(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-(3-O-pivaloyl-
2,6-dideoxy-α-L-glycopyranosyl)]-testosterone (100) 
O
H
HH
OO
OPiv
OO
OTES
TESO
 
 To a solution of rhamnal 98 (30 mg, 0.091 mmol) and testosterone (25mg, 0.091 
mmol) in CH3CN (3 ml) were added Dowex 50x8 (1 mg, cat.) and LiBr (5 mg). The 
reaction was shaken for 10 h, then 3,4-bis-O-TES-L-fucal (35 mg, 0.1 mmol) was 
added in a 2 ml of CH2Cl2. The resulted suspension was stirred another 5h, 
quenched with addition of Amberlite A-21, solids were filtered off and solvent was 
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evaporated under reduced pressure. The residue was purified by column 
chromatography (ethyl acetate / petroleum ether=1:5) to afford the glycoside 100.  
 
Yield: 48 mg (0.056 mmol, 62%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 5.16 (d, J = 3.3 
Hz, 1H, 1-H’) 5.12 (ddd, J = 11.7, 9.7, 4.9 Hz, 1H, 3-H’), 4.86 (d, J = 2.3 Hz, 1H, 1-
H’’), 4.0- 3.7 (m, 3H), 3.65- 3.35 (m, 3H), 2.5 – 0.7 (m). 
13C-NMR (100 MHz, CDCl3, CDCl3  =77 ppm) δ: 199.6 (C-3), 171.3 (C-5), 175.1 
(COPiv), 123.8 (+, C-4), 100.1 (+, C-1’’), 97.5 (+, C-1’), 87.2 (+, C-17), 81.5 (+, C-
3’), 73.4, 73.0, 68.0, 67.2, 66.8 (+, C-4’, C-5’, C-3’’, C-4’’, C-5’’), 53.8 (+, C-9), 50.2 
(+, C-14), 42.8 (C-13), 38.7 (q, C(CH3)3), 38.6 (C-10), 37.1 (-, C-12), 35.8 (-, C-1), 
35.7 (-, C-2’), 35.4 (+, C-8), 33.9 (-, C-2), 33.2 (-, C-2’’), 32.8 (-, C-6), 31.5 (-, C-7), 
28.5 (-, C-16), 27.0 (+, C(CH3)3), 23.3 (-, C-15), 20.5 (-, C-11), 18.1 (+, C-19), 17.4 
(+, C-6’), 17.2 (+, C-6’’), 11.7 (+, C-18), 7.0, 6.7, 5.1, 4.6 (2x TES). 
 
3-O-[(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-(3-O-benzoyl-
2,6-dideoxy-α-L-glycopyranosyl)]-digitoxigenin (103) 
O
OBz
OO
OTES
TESO
O
O
OH
O H
H
25
H
 
 To a solution of rhamnal 101 (25 mg, 0.072 mmol) and digitoxigenin (26mg, 0.070 
mmol) in 3 ml of CH2Cl2, were added polymer-bound PPh3*HBr (1mg, cat.) and 
LiBr (5 mg). The reaction was shaken for 4 h, and then 1 ml of CH3CN and 1 mg of 
Dowex 50x8 were added to initiate silyl ether cleavage. The resulted suspension 
was allowed to stir for 10h then 3,4-bis-O-TES-L-fucal (35 mg, 0.08 mmol) was 
added in 2 ml of CH2Cl2. Solution was stirred another 5h. The reaction was 
quenched by addition of Amberlite A-21, solids filtered off, washed with ethyl 
acetate and filtrate evaporated under reduced pressure. The crude product was 
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purified by column chromatography over silica gel (ethyl acetate / petroleum ether 
1:1). 
 
Yield: 30 mg (0.031 mmol, 45%). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.02 (m, 2H, Ph), 7.57 (m, 1H, 
Ph), 7.45 (m, 2H, Ph), 5.86 (s, 1H, 22-H), 5.45 (ddd, J = 11.3, 9.2, 5.1 Hz, 1H, 3-
H’), 5.26 (d, J = 3.5 Hz, 1H, 1-H’), 4.98 (dd, J = 18.1, 1.6 Hz, 1H, 21-H), 4.95 (d, J 
= 3.1 Hz, 1H, 1-H’’), 4.78 (dd, J = 18.1, 1.6 Hz, 1H, 21-H), 3.8 – 3.95 (m, 4H), 3.52 
(bs, 1H, 4-H’’), 3.45 (t, J = 9.2 Hz, 1H, 4-H’), 2.83 – 0.4 (m).  
 
13C-NMR (125 MHz, , CDCl3, CDCl3 = 77 ppm) δ:  179.6 (C-20), 178.4 (C-23), 
165.6 (s, COPh), 133.1, 129.5 128.5 (3+, Ph), 130.0 (s, Ph), 117.7 (+, C-22), 100.1 
(+, C-1’’), 94.6 (+, C-1’), 85.6 (C-14), 81.6 (+, C-3’), 73.4 (-, C-21), 73.2, 71.3, 68.1, 
67.2, 66.8 (5+, C-4’, C-5’, C-3’’, C-4’’, C-5’’), 50.9 (+, C-17), 49.6 (C-13), 41.9 (+, 
C-8), 40.0 (-, C-12), 36.3 (+, C-5), 36.1 (-, C-2’), 35.7 (+, C-9), 35.2 (C-10), 33.3 (-, 
C-2’), 33.2 (+), 30.4 (-), 29.5 (-), 26.9 (+), 26.87 (+), 26.6 (-), 23.7 (-), 21.4(s), 21.2 
(-), 18.4 (+, C-6’), 17.2 (+, C-6’’), 15.7 (+, C-18), 7.0, 6.7 (+, TES), 5.2, 4.7 (-, TES). 
 
17-O-(3-O-pivaloyl-2,6-dideoxy-α-L-glucopyranosyl)-testosterone (99) 
O
H
HH
OO
OPiv
HO
 
To a solution of glycoconjugate 100 (22 mg, 0.0255 mmol) in 2 ml mixture of 
solvents (CH2Cl2/Acetonitrile - 1:1) LiBr (5 mg) and Dowex 50x8 (2 mg, cat.) were 
added. The reaction mixture was allowed to stir for 4 h then the reaction was 
quenched by addition of Amberlite A-21. Solids were filtrated off and the filtrate 
was evaporated under reduced pressure. A crude product spectrum showed only 
glycoside 99 as a main product. No desired deprotection was observed. 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ:  5.76 (s, 1H, 4-H), 5.10 (ddd, J = 
11.5, 5.2, 9.2 Hz, 1H, 3-H’), 4.95 (d, J = 3.0 Hz, 1H, 1-H’), 3.55 (dd, J = 8.6, 8.6 Hz, 
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1H, 17-H), 3.27 (ddd, J = 9.2, 8.9, 4.0 Hz, 1H, 4-H’), 1.24 (d, J = 6.1 Hz, 3H, 6-H’), 
2.7 – 0.7 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.6 (C-3), 171.3 (C-5), 175.5 
(COPiv), 123.8 (+, C-4), 97.5 (+, C-1’), 87.2 (+, C-17), 81.3 (+, C-3’), 73.6, 68.1 (+, 
C-4’, C-5’), 53.7 (+, C-9), 50.2 (+, C-14), 42.7 (C-13), 38.8 (s, C(CH3)3), 38.6 (C-
10), 37.2 (-, C-12), 35.7 (-, C-1), 35.6 (-, C-2’), 35.4 (+, C-8), 33.9 (-, C-2), 32.8 (-, 
C-6), 31.5 (-, C-7), 28.4 (-, C-16), 27.2 (+, C(CH3)3),  23.3 (-, C-15), 20.6 (-, C-11), 
17.7 (+, C-19), 17.4 (+, C-6’), 11.7 (+, C-18). 
 
Attempts to deprotect glycoconjugate 96, with further glycosidation to afford 
trisaccharide. 
O
H
HH
OO
OBz
OO
OTES
TESO
O
H
HH
OO
OBz
HO
O
OTES
TESO
Dowex 50x8
PS-PPh2*HBr
96 78
DCM/acetonitrile
 
To a solution of 96 (29 mg, 0.033 mmol) in a 4 ml mixture of solvents 
(CH2Cl2/Acetonitrile = 1:1) LiBr (5 mg) and Dowex 50x8 (5 mg) were added. After 2 
h of stirring reaction was quenched by addition of Amberlite A-21. Solids were 
filtered off and the filtrate was evaporated under reduced pressure. The crude 
product was used in next step without further purification.  
To a solution of crude product from the previous step in CH2Cl2 (3 ml), was added 
polymer-bound PPh3HBr (1 mg, cat.), LiBr (5 mg) and 3,4-bis-O-TES-L-fucal (30 
mg, 0.086 mmol). The reaction was shaken for 4 h and then quenched by addition 
of Amberlite A-21. The solids were filtered off and the filtrate was evaporated under 
reduced pressure. Residue was purified by column chromatography over silica gel 
(ethyl acetate / petroleum ether=1:2, Rf-0.33) to afford a product 96 (16 mg, 0.018 
mmol, 55%). No desired trisaccharide was detected. 
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17-O-[(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-(3-O-TES-2,6-
dideoxy-α-L-galactopyranosyl)]-testosterone (104) 
O
TESO
O
O
TESO
TESO
O
H
HH
O
 
To a solution of fucal 46 (24 mg, 0.1 mmol) and testosterone (28mg, 0.1 mmol) in 3 
ml of CH2Cl2 were added polymer-bound PPh3*HBr (1mg, cat.) and LiBr (5 mg). 
The reaction mixture was shaken for 2 h, and then 3,4-bis-O-TES-L-fucal (40 mg, 
0.12 mmol) was added in 1 ml of CH2Cl2. The resulted solution was stirred another 
4 h, reaction quenched by addition of Amberlite A-21. The polymer was filtered off, 
washed with ethyl acetate and the filtrate was evaporated under reduced pressure. 
Residue was purified by column chromatography over silica gel (ethyl acetate / 
petroleum ether=1:4). 
 
Yield: 77.5 mg (0.087 mmol 87%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 5.09 (d, J = 2.8 
Hz, 1H, 1-H’), 4.89 (d, J = 2.9 Hz, 1H, 1-H’’), 4.30 (bq, J = 6.3 Hz, 1H, 5-H’’), 4.10 
(m, 2H, 3-H’, 3-H’’), 3.80 (bq, J = 6.8 Hz, 1H, 5-H’), 3.65 (bd, J = 2.4 Hz, 1H, 4-H’), 
3.55 (bs, 1H, 4-H’’), 3.45 (t, J = 8.2 Hz, 1H, 17-H), 2.5 – 0.5 (m).  
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.4 (C-3), 171.1 (C-5), 123.8 (+, 
C-4), 98.9 (+, C-1’’), 97.7 (+, C-1’), 87.5 (+, C-17), 74.9, 73.9, 67.8, 67.6, 67.3, 
66.9 (6+, C-3’, C-4’, C-5’, C-3’’, C-4’’, C-5’’), 53.9 (+, C-9), 50.1 (+, C-14), 42.8 (C-
13), 38.6 (C-10), 37.1 (-, C-12), 35.7 (-, C-1), 35.5 (-, C-2’), 35.4 (+, C-8), 34.3 (-, 
C-2’’), 33.9 (-, C-2), 32.9 (-, C-6), 31.5 (-, C-7), 28.6 (-, C-16), 26.9(-), 23.4 (-, C-
15), 20.6 (-, C-11), 17.9 (+, C-19), 17.5 (+, C-6’), 17.4 (+, C-6’’), 11.5 (+, C-18), 7.0, 
6.8, 6.7, 5.2, 5.1, 4.9, 4.8 (3 x TES). 
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3-O-[(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-(3-O-TES-2,6-
dideoxy-α-L-galactopyranosyl)]-digitoxigenin (105) 
O
TESO
O
O
TESO
TESO
O
O
OH
O
H
H
H
 
 To a solution of fucal 46 (24 mg, 0.1 mmol) and digitoxigenin (37mg, 0.1 mmol) in 
3 ml of CH2Cl2 were added polymer-bound PPh3*HBr (1mg, cat.) and LiBr (5 mg). 
The reaction mixture was shaken for 2 h, and then 3,4-bis-O-TES-L-fucal (40 mg, 
0.12 mmol) was added in 1 ml of CH2Cl2. The solution was stirred for another 4 h 
and then quenched by addition of Amberlite A-21. Solids were filtered off, washed 
with ethyl acetate and the filtrate was evaporated under reduced pressure. The 
residue was purified by column chromatography over silica gel (ethyl acetate / 
petroleum ether=1:2). 
 
Yield: 73 mg (0.075 mmol, 75%). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.86 (s, 1H, 22-H), 5.26 (d, J = 
2.7,  Hz, 1H, 1-H’), 4.98 (dd, J = 18.1, 1.5 Hz, 1H, 21-H), 4.95 (d, J = 2.7 Hz, 1H, 1-
H’’), 4.78 (dd, J = 18.1, 1.5 Hz, 1H, 21-H),4.32 (bq, J = 6.5 Hz, 1H, 5-H’’), 4.18 (dt, 
J = 11.8, 3.8 Hz, 1H, 3-H’’), 4.12 (ddd, J = 11.5, 3.8, 2.4 Hz, 1H, 3-H’), 3.86 (bs, 
1H, 14-H), 3.85 (bq, J = 6.5 Hz, 1H, 5-H’), 3.66 (bs, 1H, 4-H’), 3.55 (bs, 1H, 4-H’’), 
2.8 – 0.5 (m).  
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ:  174.5 (C-20), 174.4 (C-23), 117.7 
(+, C-22), 97.8 (+, C-1’’), 95.8 (+, C-1’), 85.6 (C-14), 75.1 (-, C-21), 73.9, 73.4, 
70.9, 67.8, 67.6, 67.3 (6+, C-3’, C-4’, C-5’, C-3’’, C-4’’, C-5’’), 50.9 (+, C-17), 49.6 
(C-13), 41.9 (+, C-8), 40.0 (-, C-12), 36.5 (+, C-5), 35.7 (+, C-9), 35.2 (C-10),  34.6 
(-, C-2’), 33.3 (-, C-2’), 32.9 (+), 30.4 (-), 29.9 (-), 26.9 (+), 26.87 (+), 26.8 (-), 26.6 
(-), 23.7 (-), 21.4(q), 21.2 (-), 17.9 (+, C-6’), 17.5 (+, C-6’’), 15.7 (+, C-18), 7.0, 6.8 
(2+, TES), 5.2, 4,7 (2-, TES). 
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7-O-[(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-(3-O-TES-2,6-
dideoxy-α-L-galactopyranosyl)]-3,4-di-O-acetyl-decarestrictine D (106) 
O
TESO
O
O
TESO
TESO
O
O
OAc
OAc
O
 
To a solution of fucal 46 (24 mg, 0.1 mmol) and decarestrictine 40 (30 mg, 0.1 
mmol) in CH2Cl2 were added polymer-bound PPh3*HBr (1 mg, cat.) and LiBr (5 
mg). The reaction mixture was shaken for 2 h, and then 3,4-bis-O-TES-L-fucal (40 
mg, 0.12 mmol) was added in 1 ml of CH2Cl2. The resulting solution was stirred for 
another 4 h and then quenched by addition of Amberlite A-21. Solids were filtered 
off, washed with ethyl acetate and the filtrate was evaporated under reduced 
pressure. The remaining residue was purified by column chromatography over 
silica gel (ethyl acetate / petroleum ether=1:2). 
 
Yield: 56 mg (0.062 mmol, 62%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.77 (ddd, J = 16.0, 8.5, 3.5, Hz, 
1H, 5-H), 5.60 (ddd, J = 16.0, 9.5, 1.5, Hz, 1H, 6-H), 5.33 (m, 1H, 4-H), 5.14 (ddd, 
J = 9.8, 6.6, 3.2 Hz, 1H, H-9), 5.06 (d, J = 3.0 Hz, 1H, 1-H’), 5.02 (ddd, J = 7.2, 5.0, 
2.5 Hz, 1H, 3-H), 4.83 (d, J = 3,1 Hz, 1H, 1-H’’), 4.30 (bq, J = 6.5 Hz, 1H, 5-H’’), 
4.15 – 4.0 (m, 3H), 3.75 (bq, J = 6.5 Hz, 1H, 5-H’), 3.63 (bd, J = 2.5 Hz, 1H, 4-H’), 
3.53 (bs, 1H, 4-H’’), 2.67 (dd, J = 14.0, 6.6 Hz, 1H, 8-H), 2.51 (dd, J = 14.0, 2.2 Hz, 
1H, 8-H), 2.17, 2.14 (2s, 6H, 2 x AcO), 2.1 – 1.4 (m, 6H, 2-H, 2-H’, 2-H’’), 1.26, 
1.23, 1.19 (3d, J = 6.6, 6.4, 6.4 Hz, 9H, 10-H, 6-H’, 6-H’’), 0.9 (m, 27H, 3 x TES), 
0.6 (m, 18H, 3 x TES). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.9, 169.5, 169.0 (2 x COCH3, 
C-1), 134.0 (+, C-6), 125.9 (+, C-5), 97.7 (+, C-1’’), 93.5 (+, C-1’), 74.5, 73.8, 71.9, 
71.8, 70.8, 68.3, 67.7, 67.5, 67.3, 66.8, (10+, C-3, C-4, C-7, C-9, C-3’’, C-4’’, C-5’’, 
C-3’, C-4’, C-5’), 40.9 (-, C-8), 33.8 (-, C-2’’), 33.5 (-, C-2), 32.9 (-, C-2’), 21.4 (+, C-
10), 21.0, 20.9 (2+, 2 x COCH3), 18.0 (+, C-6’), 17.3 (+, C-6’’), 7.0, 6.8, 5.2, 4.9, 
4.7 (3 x TES). 
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3-O-[(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-(3-O-TES-2,6-
dideoxy-α-L-galactopyranosyl)]-dehydro-epi-androsterone (107) 
O
TESO
O
O
TESO
TESO O
H
H H
O
 
To a solution of fucal 46 (24 mg, 0.1 mmol) and dehydroepiandrosteron (28mg, 0.1 
mmol) in CH2Cl2 5 ml, was added PPh3HBr-resin (1mg). The reaction was shaken 
for 2 h, and then 3,4-bis-O-TES-L-fucal (40 mg, 1,2 eq) was added in 1 ml of 
CH2Cl2. The solution was stirred for 5 h, quenched with A-21 and evaporated. After 
column chromatography (ethyl acetate / petroleum ether=1:3, Rf-0.62) the 
glycoconjugate 107 was obtained (71 mg, 84%). 
 
3-O-[(2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-(2,6-dideoxy-α-L-
galactopyranosyl)]-digitoxigenin (120) 
O
HO
O
O
HO
HO
O
O
OH
O
H
H
H
 
To a solution of fucal 46 (24 mg, 0.1 mmol) and digitoxigenin (37mg, 0.1 mmol) in 
CH2Cl2 5 ml, polymer-bound PPh3HBr (1mg, cat.) was added. The reaction was 
shaken for 2 h, and solution of allal 118 (35 mg, 0.1 mmol) in 1 ml of CH2Cl2 was 
added. The solution was stirred for another 24 h (reaction is very slow and not run 
to complete) and then quenched by addition of Amberlite A-21 (5 mg). The 
suspension was filtrated through a pad of celite and the solvent was evaporated 
under reduced pressure. The residue was dissolved in 10 ml of mixture (TBAF 
/AcOH/THF – 266 mg/0.151 ml/8.4 ml) and solution was allowed to stir overnight. 
The mixture was evaporated and crude product was purified by column 
chromatography over silica gel (ethyl acetate /MeOH = 10:1). 
 
Yield: 21 mg (0.033 mmol, 33%) 
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1H-NMR (500 MHz, CD3OD, = 3.35 ppm) δ: 5.92 (s, 1H, 22-H), 5.05 (dd, J = 18.4, 
1.6 Hz, 1H, 21-H), 4.97 (d, J = 2.7 Hz, 1H, 1-H’’), 4.93 (dd, J = 18.4, 1.6 Hz, 1H, 
21-H), 4.06 (dd, J = 5.2, 2.4 Hz, 1H, 3-H’), 3.95 (m, 2H, 5-H’’ 3-H’’), 3.90 (bs, 1H), 
3.86 (dq, J = 9.6, 6.2 Hz, 1H, 5-H’), 3.68 (bs, 1H, 4-H’’), 3.22 (dd, J = 9.6, 2.8 Hz, 
1H, 4-H’), 2.85 (bt, 1H, 3-H), 2.17 (m, 1H, 2-H’), 1.28 (d, J = 6.2 Hz, 3H, 6-H’), 1.19 
(d, J = 6.4 Hz, 3H, 6-H’’), 0.98 (s, 3H, 18-CH3), 0.91  (s, 3H, 19-CH3), 2.25 – 0.9 
(m). 
 
13C-NMR (125 MHz, CD3OD, = 49 ppm): 178.42 (s), 177.24(s), 117.78 (d, C-22), 
101.08 (d, C-1’), 97.32 (d, C-1’’), 86.43, 83.33 (d, C-4’’), 79.52, 79.26, 79.00, 75.34 
(t, C-21), 74.08 (d, C-4’), 73.25, 71.24 (d, C-5’), 69.05 (d, C-3’), 67.71 (d, C-3’’), 
66.24, 54.77, 52.15, 51.06, 42.72, 40.98, 38.97, 38.14, 36.84, 36.37, 35.76, 33.40, 
31.67, 30.91, 28.06, 27.89, 27.54, 24.34, 22.57, 22.37, 18.37, 17.08, 16.40 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 1845 Hz = 3.67: 4.97 (d, 1H, 1-
H’’), 3.94, 3.95 (m, 2H, 3-H’’, 5-H’’), 3.68 (bs, 1H, 4-H’’), 1.83 (ddd, 1H, 2-H’’), 1.74 
(dd, 1H, 2-H’’), 1.19 (d, 3H, 6-H’’). 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 1611 Hz = 3.22: 4.83 (bd, 1H, 1-
H’), 4.05 (bd, 1H, 3-H’), 3.85 (bq, 1H, 5-H’), 3.22 (dd, 1H, 4-H’), 2.17 (dd, 1H, 2-H’), 
1.80 (bdd, 1H, 2-H’), 1.26 (d, 3H, 6-H’).    
 
11.5.2. Experiments to the chapter 6.1.2. 
17-O-[(2,6-dideoxy-α-L-galactopyranosyl)-(1→4)-(2,6-dideoxy-α-L-
galactopyranosyl)]-testosterone (108) 
O
HO
O
O
HO
HO
O
H
HH
O
 
 67 mg (0.075 mmol) of glycoconjugate 104 was mixed with polymer-bound TBAT 
(200 mg) in CH3CN (10 ml). The reaction mixture was allowed to stir for 48 h, then 
the polymer was filtered off, washed with methanol and the filtrate was evaporated 
under reduced pressure. The crude product was purified by column 
chromatography over silica gel (ethyl acetate, Rf-0.14). 
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 Yield: 29 mg (0.052 mmol, 70%). 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) δ: 5.73 (s, 1H, 4-H), 4.96 (d, J = 4.6 Hz, 
1H, 1-H’’), 4.95 (d, J = 3.7 Hz, 1H 1-H’), 4.28 (bq, J = 6.5 Hz, 1H, 5-H’’), 4.04 (ddd, 
J = 11.8, 5.9, 3.0 Hz, 1H, 3-H’’), 3.98 (ddd, J = 11.8, 4.9, 2.0 Hz, 1H, 3-H’), 3.95 
(bq, J = 6.5 Hz, 1H, 5-H’), 3.62 (bd, J = 2.0 Hz, 1H, 4-H’), 3.59 (bd, J = 2.2 Hz, 1H, 
4-H’’), 3.54 (t, J = 8.5 Hz, 1H, 17-H), 1.26, 1.21 (2d, J = 6.5; 6.4 Hz, 2 x 3H, 6-H’, 
6-H’’), 2.5 – 0.7 (m).  
 
13C-NMR (125 MHz, CD3OD, = 49 ppm): 202.29 (s, C-3), 175.09 (s, C-5), 124.15 
(d, C-4), 101.45 (d, C-1’’), 99.87 (d, C-1’), 88.58 (d, C-17), 81.72 (d, C-4’), 72.32 
(d, C-4’’), 68.50 (d, C-5’’), 68.14 (d, C-5’), 66.72, 66.70 (2d, C-3’’, C-3’), 55.47 (d, 
C-9), 51.54 (d, C-14), 44.05 (s, C-13), 40.04 (s, C-10), 38.41 (t, C-12), 36.79 (t, C-
1), 36.75 (d, C-8), 34.71 (2t, C-2’, C-2), 33.88 (t, C-6), 33.30 (t, C-2’’), 32.83 (t, C-
7), 29.58 (t, C-16), 24.30 (t, C-15), 21.76 (t, C-11), 17.73 (q, C-19), 17.47, 17.10 
(2q, C-6’, C-6’’), 12.09 (q, C-18). 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 2140 Hz = 4.28: 4.96 (d, 1H, 1-
H’’), 4.27 (q, 1H, 5-H’’), 4.03 (dd, 1H, 3-H’’), 3.59 (bd, 1H, 4-H’’), 1.97 (ddd, 1H, 2-
Hax’’), 1.91 (dd, 1H, 2-Heq’’), 1.21 (d, 3H, 6-H’’). 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 1814 Hz = 3.63: 4.95 (bd, 1H, 1-
H’), 3.99 (bd, 1H, 3-H’), 3.97 (bq, 1H, 5-H’), 3.63 (dd, 1H, 4-H’), 1.84 (dd, 1H, 2-
Hax’), 1.79 (bdd, 1H, 2-Heq’), 1.20 (d, 3H, 6-H’).    
 
LC-MS (ESI) (-c): m/z (%): 547.33 (90) [M - H]-, 548.33 (25) [M]; HR-MS C31H47O8: 
calc. 547.3271, found 547.3278  
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17-O-[(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→3)-(2,6-dideoxy-α-
L-galactopyranosyl)-(1→4)-(2,6-dideoxy-α-L-galactopyranosyl)]-testosterone 
(109), 17-O-[{(3,4-di-O-TES-2,6-dideoxy-α-L-galactopyranosyl)-(1→3);(2,6-
dideoxy-α-L-galactopyranosyl)-(1→4)}-(2,6-dideoxy-α-L-galactopyranosyl)]-
testosterone (110) 
To a solution of fucal 22 (24 mg, 0.1 mmol) and glycoconjugate 108 (29 mg, 0.052 
mmol) in CH2Cl2 (5 ml) was added polymer-bound PPh3HBr (1mg). The reaction 
was allowed to stir for 24 h and quenched by addition of Amberlite A-21 (5 mg). 
The suspension filtrated through a pad of celite and solvent was evaporated under 
reduced pressure. After column chromatography over silica gel (ethyl acetate / 
petroleum ether = 1:4) the two products were isolated: trisaccharide 110 and 
trisaccharide 109  
O
OH
O
O
O
HO
O
H
HH
O
O
TESO
TESO
 
Yield: 109 25 mg (0.028 mmol, 28% from testosterone). 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.75 (s, 1H, 4-H), 5.09 (d, J = 2.5 
Hz, 1H’α), 4.96 (d, J = 2.2 Hz, 1H’’α), 4.91 (bs, 1H’’’α), 3.4-4.2 (m, 10H), 2.5 – 0.7 
(m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.94, 171.65, 124.27, 101.08, 
98.92, 96.37, 87.44, 83.92, 73.87, 70.31, 68.57, 67.79, 67.56, 66.71, 66.18, 54.32, 
50.64, 43.24, 39.06, 36.13, 35.89, 34.36, 33.20, 28.80, 27.32, 23.74, 21.02, 17.82, 
17.65, 17.46, 12.03, 7.43, 7.25, 5.63, 5.26. 
 
LC-MS (ESI) (-c): m/z (%): 677.39 (100) [M – H]-; HR-MS C37H57O11: calc. 
677.3901, found 677.3898  
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Yield: 110 18mg (0.023 mmol, 23%, from testosterone) 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.76 (s, 1H, 4-H), 5.12 (d, J = 2.7 
Hz, 1H, 1-H’), 4.97 (d, J = 2.3 Hz, 1H, 1-H’’), 4.90 (bs, 1H’’’α) 3.8-4.2 (m, 7H), 3.76 
(bs, 1H, 4-H’), 3.63 (bs, 2H, 4-H’’, 4-H’’’), 3.51 (dd, J = 8.4, 8.4 Hz, 1H, 17-H), 2.5 – 
0.7 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.94, 171.65, 124.52+, 97.8+, 
95.7+, 95.4+, 87.69+, 74.3+, 73.8+, 71.2+, 70.4+, 69.0+, 68.6+, 67.8+, 67.4+, 
65.9+, 54.55+, 50.87+, 37.78-, 36.38-, 36.13+, 34.61-, 33.96-, 33.45-, 32.16-, 31.3-
, 30.5-, 29.8-, 27.57-, 23.98-, 21.26-, 18.07+, 17.9+, 17.6+, 16.8+, 12.25+, 7.0+, 
6.82+, 6.81+, 5.3-, 4.9-, 4.8-. 
 
17-O-[(2,6-dideoxy-α-L-galactopyranosyl)-(1→3)-(2,6-dideoxy-α-L-
galactopyranosyl)-(1→4)-(2,6-dideoxy-α-L-galactopyranosyl)]-testosterone 
(111) 
O
OH
O
O
O
HO
O
H
HH
O
O
HO
HO
 
Trisaccharide 109 (25mg, 0.028 mmol) was dissolved in 5 ml of mixture (TBAF 
/AcOH/THF – 266 mg/0.151 ml/8.4 ml). The solution was stirred overnight, solvent 
was evaporated under reduced pressure and crude product was purified by column 
chromatography over silica gel (ethyl acetate/MeOH – 10/1). 
 
Yield: 19.3 mg (0.028 mmol, 99%, Rf- 0.45) 
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1H-NMR (500 MHz, CD3OD, = 3.35 ppm) δ: 5.72 (s, 1H, 4-H), 5.13 (d, J = 2.5 Hz, 
1H, 1-H’α), 4.98 (d, J = 2.2 Hz, 1H, 1-H’’α), 4.95 (bs, 1H, 1-H’’’α), 3.9-4.4 (m, 5H), 
3.76 (bs, 1H, 4-H’’), 3.63 (bs, 1H, 4-H’’’), 3.56 (bs, 1H, 4-H’), 3.55 (m, 1H, 17-H), 
2.4 – 0.7 (m). 
 
13C-NMR (125 MHz, CD3OD, = 49 ppm): 210.09, 202.30, 175.10, 124.15+, 
101.43+, 99.85+, 96.55+, 88.55+, 81.78+, 72.30+, 71.42+, 68.91+, 68.57+, 68.10+, 
67.86+, 66.85+, 66.75+, 55.45+, 51.52+, 44.04, 40.03, 38.39-, 36.78-, 36.74+, 
34.75-, 34.70-, 33.88-, 33.26-, 32.82-, 31.88-, 30.67-, 29.58-, 24.30-, 21.75-, 
17.73+, 17.52+, 17.19+, 17.14+, 17.10+, 12.09+ 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 2568 Hz = 5.13: 5.13 (d, 1-H’), 
4.00 (m. 3-H’, 5-H’), 3.56 (bs, 4-H’), 1.78-1.98 (2m, 2-H’), 1.25 (d, 6-H’). 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 2492 Hz = 4.98: 4.98 (d, 1-H’’), 
4.10 (m. 3-H’’, 5-H’’), 3.76 (bs, 4-H’’), 2.08 (ddd, 2-H’’), 1.94 (m, 2-H’’), 1.23 (d, 6-
H’). 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 2476 Hz = 4.95: 4.95 (d, 1-H’’’), 
3.96 (m. 3-H’’’, 5-H’’’), 3.63 (bs, 4-H’’’), 1.75-1.89 (m, 2-H’’’), 1.20 (d, 6-H’’’). 
 
Preparation of glycoconjugates 105, 113, 114 
To a solution of 3,4-Bis-O-TES-fucal (35 mg, 1 mmol) and digitoxigenin (37 mg, 1 
mmol) in CH2Cl2 (10 ml) polymer-bound PPH3*HBr (1 mg) was added. The mixture 
was shaken until no starting material was observed (t.l.c. ethyl acetate / petroleum 
ether – 1:3). The polymer-bound catalyst was removed by filtration and the solvent 
was evaporated. The residue was dissolved in methanol (10 ml) and polymer 
supported fluoride (Amberlite A-26+F-, 100mg) was added. The resulting mixture 
was stirred at 50oC for 20h. Polymer was removed by filtration and the solution 
was evaporated under reduced pressure. Yielded crude product mixture was 
involved in next step without purification (observed high ~50% glycoside-bond 
cleavage). The crude material was dissolved in 10 ml of CH2Cl2 and 3-O-TES-fucal 
46 (30 mg, 1.2 mmol) and polymer-bound PPH3*HBr (1 mg) were added. The 
mixture was shaken for 4 h, then 40 mg of 3,4-Bis-O-TES-fucal was added and the 
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mixture was shaken for another 5 h. The reaction was quenched by addition of 
Amberlite A-21 (10 mg). The suspension was filtered and the filtrate was 
evaporated under reduced pressure. 
Column chromatography over silica gel (ethyl acetate / petroleum ether - 1:3) 
yielded three main fractions: 1st fraction 105 (Rf-48, 28 mg, 28%), 2nd fraction 114 
(Rf-0.21, 9 mg, 7.3%), 3rd fraction 113 (Rf-0.09, 7 mg, 5.7%). 
O
O
OH
O
H
HO
TESO
O
O
TESO
TESO
H
 
1st fraction 105 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.86 (s, 1H, 22-H), 5.10 (d, J = 
2.3 Hz, 1H, 1-H’), 4.98 (dd, J = 18.1, 1.4 Hz, 1H, 21-H), 4.97 (d, J = 2.3 Hz, 1H, 1-
H’’), 4.79 (dd, J = 18.1, 1.4 Hz, 1H, 21-H), 4.2-3.75 (m, 5H), 3.71 (bs, 1H, 4-H’), 
3.60 (bs, 1H, 4-H’’), 2.25 – 0.0 (m).  
OTESO
TESO
O
O
OH
O
H
HO
O
HO
O
TESO
O
H
 
2nd fraction 114 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.89 (s, 1H, 22-H), 5.14 (bd, J = 
2.2 Hz, 1H, 1-H’), 5.05 (bd, J = 2.3 Hz, 1H, 1-H’’), 4.98 (dd, J = 18.1, 1.4 Hz, 1H, 
21-H), 4.89 (bd, J = 2.1 Hz, 1H, 1-H’’’), 4.78 (dd, J = 18.1, 1.4 Hz, 1H, 21-H), 4.4-
3.5 (m, 9H), 2.78 (m, 1H, 3-H), 2.25 – 0.0 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 174.4 (2s, C-20, C-23), 117.7 (d, 
C-22), 98.5 (d, C-1’’), 95.8 (d, C-1’’’), 94.2 (d, C-1’), 85.6 (s, C-14), 73.4 (t, C-21), 
73.8, 72.3, 71.2, 71.1, 67.7, 67.6, 66.6 (9d, C-3’, C-3’’, C-3’’’, C-4’, C-4’’, C-4’’’, C-
5’, C-5’’, C-5’’’), 66.6 (d, C-3), 50.9 (d, C-17), 49.6 (s, C-13), 41.9 (d, C-8), 40.1 (t, 
C-12), 36.6, 35.7 (2d, C-5, C-9), 35.2 (s, C-10), 33.2, 32.9 (2t, C-4, C-15), 32.8, 
30.5, 30.1 (3t, C-2’, C-2’’, C-2’’’), 29.7 (t, C-1), 26.9, 26.8, 26.7 (3t, C-2, C-6, C-16), 
23.8, (q, C-19), 21.4 (t, C-7), 21.2 (t, C-11), 17.9, 17.8, 16.6 (3q, C-6’, C-6’’, C-6’’’), 
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15.8 (q, C-18), 7.0, 6.83, 6.81, 6.7 (4q, 3 x Si(CH2CH3)3), 5.3, 5.2, 5.0, 4.9, 4.88 
(5t, 3 x Si(CH2CH3)3). 
 
LC-MS (ESI) (+c): m/z (%): 1129.68 (30) [M + Na]+; HR-MS C59H106O13Si3 +23Na: 
calc. 1129.6839, found 1129.6831  
O
O
OH
O
H
HO
O
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O
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HO
O
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3rd fraction 113 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.89 (s, 1H, 22-H), 5.11 (bd, J = 
2.2 Hz, 1H, 1-H’), 5.08 (bd, J = 2.2 Hz, 1H, 1-H’’), 4.98 (dd, J = 18.1, 1.4 Hz, 1H, 
21-H), 4.99 (bd, J = 2.1 Hz, 1H, 1-H’’’), 4.78 (dd, J = 18.1, 1.4 Hz, 1H, 21-H), 4.4-
3.5 (m, 9H), 2.80 (m, 1H, 3-H), 2.25 – 0.0 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 174.4 (s, C-20), 174.3 (s, C-23),  
117.7 (d, C-22), 97.9 (d, C-1’’), 95.6 (d, C-1’), 95.5 (d, C-1’’’), 85.6 (s, C-14), 73.4 
(C-21), 74.7, 73.9, 71.3, 70.4, 68.3, 68.2, 67.6, 67.5, 65.6 (9d, C-3’, C-3’’, C-3’’’, C-
4’, C-4’’, C-4’’’, C-5’, C-5’’, C-5’’’), 66.7 (d, C-3), 51.0 (d, C-17), 49.6 (s, C-13), 41.9 
(d, C-8), 40.1 (t, C-12), 36.5, 35.7 (2d, C-5, C-9), 35.2 (s, C-10), 33.2 (t, C-4, C-
15), 31.3, 30.5, 29.8 (3t, C-2’, C-2’’, C-2’’’), 29.7 (t, C-1), 26.9, 26.6 (3t, C-2, C-6, 
C-16), 23.8 (q, C-19), 21.4 (t, C-7), 21.2 (t, C-11), 17.9, 17.6, 16.8 (3q, C-6’, C-6’’, 
C-6’’’), 15.8 (q, C-18), 7.0, 6.82, 6.81 (3q, 3 x Si(CH2CH3)3), 5.3, 4.9, 4.8 (3t, 3 x 
Si(CH2CH3)3).  
 
LC-MS (ESI) (+c): m/z (%): 1129.65 (30) [M + Na]+; HR-MS C59H106O13Si3 +23Na: 
calc. 1129.6839, found 1129.6799  
 
 
 
 
 164
11.5.3. Experiments to the chapter 6.1.3. 
α-L-Erythro-hex-2-enopyranosylazide (120a), β-L-erythro-hex-2-
enopyranosylazide (120b), 3-azido-4-O-acetyl-1,5-anhydro-2,3,6-trideoxy-L-
ribo-hex-1-enit (121a), 3-azido-4-O-acetyl-1,5-anhydro-2,3,6-trideoxy-L-
arabino-hex-1-enit (121b) 
3,4-Di-O-acetyl-L-rhamnal 17 (1 g, 4.7 mmol) and solid NaN3 (0.79 g, 0.012 mol) 
were suspended in 10 ml of abs. acetonitrile and 1 g of powdered molecular sieves 
4A was added. After cooling down to –30o C BF3*Et2O (1.35 ml) was added 
dropwise within 30 min. The suspension was stirred at the same temperature for 
another 1h, then sodium bicarbonate (1 g) was added to the reaction mixture to 
neutralize the Lewis acid. The mixture was allowed to warm up with stirring within 
30 min to RT. The resulted slurry was filtered, washed with ethyl acetate and the 
solvent was evaporated.  The raw material was dissolved in ethyl acetate and 
washed with brine. The organic phase was separated and the solvent evaporated 
under reduced pressure. The crude product mixture was purified by column 
chromatography (ethyl acetate / petroleum ether 1:10) yielding colourless oil - 
mixture of Fierier product and glycal type product.  
 
Yield: 0.9 g (4.6 mmol, 98%). 
OAcO
N-NN O
N-
N
N
+
121a 121b
+
+
 
121ab (Glycal) 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 6.53 (d, J = 6.0 Hz, 1H, 1-H), 
4.87 (dd, J = 5.2, 5.2 Hz, 1H, 4-H), 4.3-3.9 (m, 2H, 3-H, 5-H), 2.19 (s, 3H, Ac), 1.34 
(d, J = 6.4 Hz, 3H, 6-H). 
O
O
AcO
NNN
N
N
N
+
120a 120b
-
+
+
-
 
120ab (Ferier product) 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.95 (bd, J = 10.1, 1H, 2-H), 5.77 
(ddd, J = 10.1, 1.9, 3.0 Hz, 1H, 3-H), 5.50 (bs, 1H, 1-H), 5.09 (ddd, J = 9.0, 3.0, 1.9 
Hz, 1H, 4-H), 3.98 (dq, J = 9.0, 6.3 Hz, 1H, 5-H), 1.29 (d, J = 6.3 Hz, 3H, 6-H). 
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Preparation of allylglycosides 122, 123, 126 
O
AcO
N3
O
O
AcO
N3
O
O
AcO
N3
O
O
AcO O
6%
42%
7.8%
O
AcO
N3
O +122
123
124 15% 125 15%
126
Fr-1
Fr-2
Fr-3
Fr-4
 
Polymer-bound PPh3*HBr (500 mg) was added to a solution of azidoglycal mixture 
121ab (1.0 g, 5 mmol) and allyl alcohol 1.7 ml (25 mmol, 5 eq) in 10 ml of dry 
CH2Cl2. The suspension was stirred at ambient temperature for 48 h. The reaction 
was quenched by addition of Amberlite A-21 (500 mg) and filtered through a pad of 
Celite. The solvent was removed under reduced pressure and the residue was 
purified by column chromatography (ethyl acetate / petroleum ether 1:10) to obtain 
four fractions. 
 
Yield: 1st fraction: 122 (77 mg, 0.302 mmol 6 %), 
          2nd fraction: 123 (100 mg, 0.47 mmol 7.8%),  
          3rd fraction: mixture containing 124 and 125 - 1:1 
          4th fraction: 126 (530 mg, 2.08 mmol 42 %), 
 
1st fraction 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ:  5.88 (dddd, J = 17.2, 10.0, 6.0, 
5.2 Hz, 1H, –CH=CH2), 5.28 (dq, J = 17.2, 1.5 Hz, 1H, –CH=CHH’), 5.18 (dq, J = 
10.0, 1.3 Hz, 1H, –CH=CHH’), 4.87 (d, J = 3.1 Hz, 1H, 1-H), 4.64 (dd, J = 9.7, 9.7 
Hz, 1H, 4-H), 4.11 (ddt, J = 12.7, 5.2, 1.49 Hz, 1H, -O-CHH’-CH=), 3.93 (ddt, J = 
12.7, 6.0, 1.3 Hz, 1H, -O-CHH’-CH=), 3.87 (ddd, J = 12.3, 9.7, 5.0 Hz, 1H, 3-H), 
3.78 (dq, J = 9.7, 6.2 Hz, 1H, 5-H), 2.15 (ddd, J = 13.0, 5.0, 0.9 Hz, 1H, 2-H), 2.10 
(s, 3H, AcO), 1.72 (ddd, J = 13.0, 12.3, 3.5 Hz, 1H, 2-H), 1.13 (d, J = 6.2 Hz, 3H, 6-
H) 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.93 (s, C=O), 133.77 (d, -
CH=CH2), 117.28 (t, –CH=CH2), 95.41 (d, C-1), 75.47 (d, C-4)), 67.84 (t, –CH2-
CH=), 65.97 (d, C-5), 57.63 (d, C-3), 35.11 (t, C-2), 20.76 (q, COCH3), 17.34 (q, C-
6). 
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2nd fraction 
1H-NMR (400 MHz, CDCl3, CDCl3  =7.26 ppm) δ:  5.90 (dddd, J = 17.2, 10.4, 6.1, 
5.1 Hz, 1H, –CH=CH2), 5.82 (d, J = 10.2 Hz, 1H, 2-H), 5.77 (ddd, J = 10.2, 2.3, 1.5 
Hz, 1H, 3-H),  5.27 (dq, J = 17.2, 1.4 Hz, 1H, –CH=CHH’), 5.16 (ddt, J = 10.4, 1.4, 
1.3 Hz, 1H, –CH=CHH’), 5.02 (dq, J = 9.2, 1.5 Hz, 1H, 4-H), 4.97 (s, 1H, 1-H), 4.22 
(ddt, J = 12.8, 5.1, 1.4 Hz, 1H, -O-CHH’-CH=), 4.03 (ddt, J = 12.8, 6.1, 1.2 Hz, 1H, 
-O-CHH’-CH=), 3.95 (dq, J = 9.2, 6.3 Hz, 1H, 5-H), 2.05 (s, 3H, AcO), 1.19 (d, J = 
6.3 Hz, 3H, 6-H) 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 170.36 (s, C=O), 134.36 (d, -
CH=CH2), 129.66, 127.69 (2d, C-2, C-3), 117.12 (t, –CH=CH2), 93.50 (d, C-1), 
70.82 (d, C-4), 68.97 (t, –CH2-CH=), 64.76 (d, C-5), 20.94 (q, COCH3), 17.83 (q, C-
6). 
 
4th fraction 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.80 (dddd, J = 17.2, 10.5, 5.8, 
4.7 Hz, 1H, –CH=CH2), 5.22 (dddd, J = 17.2, 1.7, 1.6, 1.6 Hz, 1H, –CH=CHH’), 
5.06 (dddd, J = 10.4, 1.5, 1.5, 1.4 Hz, 1H, –CH=CHH’), 4.71 (dd, J = 4.2, 1.2 Hz, 
1H, 1-H), 4.53 (dd, J = 9.5, 3.7 Hz, 1H, 4-H), 4.13 (bq, J = 9.5, 6.4 Hz, 1H, 5-H), 
4.08 (m, 1H, -O-CH2-CH=), 4.01 (bddd, J = 3.7, 3.7, 3.7 Hz, 1H, 3-H), 3.86 (dddd, 
J = 13.3, 5.9, 1.3, 1.3 Hz, 1H -O-CH2-CH=), 2.02 (ddd, J = 14.8, 3.2, 1.2 Hz, 1H, 2-
Hax), 2.00 (s, 3H, AcO), 1.94 (ddd, J = 14.8, 4.1, 3.7 Hz, 1H, 2-Heq), 1.06 (d, J = 6.4 
Hz, 3H, 6-H) 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.64 (s, C=O), 133.80 (d, -
CH=CH2), 116.47 (t, –CH=CH2), 94.18 (d, C-1), 73.56 (d, C-4), 67.77 (t, –CH2-
CH=), 61.61 (d, C-5), 55.31 (d, C-3), 32.40 (t, C-2), 20.31 (q, COCH3), 16.90 (q, C-
6). 
 
Allyl-3-azido-2,3,6-trideoxy-α-L-allopyranoside (126a) 
O
HO
N3
O
 
The reaction was carried out according to the protocol TP8 except for the following 
details: starting material 126 (430 mg, 1.68 mmol). 
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 Yield: 358 mg (1.67 mmol, >99%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.89 (dddd, J = 17.2, 10.5, 5.7, 
4.8 Hz, 1H, –CH=CH2), 5.31 (dq, J = 17.2, 1.5 Hz, 1H, –CH=CHH’), 5.15 (dq, J = 
10.5, 1.5 Hz, 1H, –CH=CHH’), 4.80 (d, J = 4.0 Hz, 1H, 1-H), 4.17 (ddt, J = 13.4, 
4.8, 1.5 Hz, 1H, -O-CHH’-CH=), 4.03 (ddd, J = 3.7, 3.4, 3.7 Hz, 1H, 3-H), 3.93 (ddt, 
J = 13.4, 5.7, 1.4 Hz, 1H, -O-CHH’-CH=), 3.87 (dq, J = 9.3, 6.3 Hz, 1H, 5-H), 3.30 
(ddd, J = 9.4, 9.3, 3.7 Hz, 1H, 4-H), 2.23 (d, J = 9.4 Hz, 1H, OH), 2.21 (ddd, J = 
14.9, 3.4, 1.2 Hz, 1H. 2-Hax), 2.02 (dt, J = 14.9, 4.0, Hz, 1H, 2-Heq), 1.23 (d, J = 
6.3, Hz, 3H, 6-H) 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  134.11 (d, -CH=CH2), 116.34 (t, –
CH=CH2), 94.27 (d, C-1), 72.05 (d, C-4), 67.90 (t, –CH2-CH=), 64.50 (d, C-5), 
58.06 (d, C-3), 32.12 (t, C-2), 17.36 (q, C-6). 
 
Preparation of disaccharides 127 and 128 
O
O
N3
O
O
AcO
N3
O
O
N3
O
O
AcO
N3
127 (15%)
128 (5%)  
Polymer-bound PPh3*HBr (20 mg) was added to a solution of azidoglycal mixture 
121ab (335 mg, 1.7 mmol, 1.1 eq) and allylglycoside 126a (350 mg, 1.65 mmol) in 
10 ml of CH2Cl2. The suspension was stirred for 48 h at RT. The reaction mixture 
was quenched by addition of Amberlite A-21 (20 mg), filtered through a pad of 
Celite and concentrated under reduced pressure. The products were finally 
separated by flash column chromatography over silica gel (ethyl acetate / 
petroleum ether 1:10). The four fractions were isolated: 
1st fraction: adduct mixture 121a,b (183 mg, 0.92 mmol, 55%) 
2nd fraction: 127 (100 mg, 0.24 mmol, 15%), 
3rd fraction: mixture fraction (30 mg). 
4th fraction: 128 (30 mg, 0.073 mmol, 5%). 
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2nd fraction 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.87 (dddd, J = 17.0, 10.2, 5.9, 
5.0 Hz, 1H, –CH=CH2), 5.28 (dq, J = 17.0, 1.5 Hz, 1H, –CH=CHH’), 5.13 (dq, J = 
10.2, 1.4 Hz, 1H, –CH=CHH’), 4.76 (dd, J = 9.2, 1.5 Hz, 1H, 1-H’), 4.73 (d, J = 4.2 
Hz, 1H, 1-H), 4.60 (dd, J = 9.7, 3.3 Hz, 1H, 4-H’), 4.13 (m, 3H), 4.05 (dq, J = 9.5, 
6.2 Hz, 1H), 3.93 (m, 2H), 3.37 (dd, J = 9.4, 3.5 Hz, 1H, 4-H), 2.09 (s, 3H, AcO), 
2.00 (m, 2H), 1.93 (ddd, J = 14.9, 4.3, 4.3 Hz, 1H), 1.82 (ddd, J = 13.9, 9.4, 3.3 Hz, 
1H), 1.18 (d, J = 6.0 Hz, 3H), 1.17 (d, J = 6.2 Hz, 3H) 
  
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.82 (s, COCH3), 134.13 (d, -
CH=CH2), 116.88 (t, –CH=CH2), 99.06 (d, C-1’), 94.29 (d, C-1), 81.38 (d, C-4), 
74.18 (d, C-4’), 67.87 (t, –CH2-CH=), 67.65 (d, C-5’), 62.26 (d, c-5), 2 x 58.01 (2d, 
C-3, C-3’), 35.71 (t, C-2’), 33.33 (t, C-2), 20.46 (q, COCH3), 17.72, 17.34 (2q, C-6, 
C-6’). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2949Hz = 5.90ppm: 5.89 
(ddd, 1H, –CH=CH2), 5.31 (dd, 1H, –CH=CHH’), 5.16 (d, 1H, –CH=CHH’), 4.15 
(dd, 1H, -O-CHH’-CH=), 3.96 (dd, 1H, -O-CHH’-CH=). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2316Hz = 4.63ppm: 4.79 
(dd, 1H, 1-H’), 4.63 (dd, 1H, 4-H’), 4.18 (ddd, 1H, 3-H’), 3.93 (dq, 1H, 5-H’), 2.05 
(dd, 1H, 2-H’ax), 1.86 (dd, 1H, 2-H’eq), 1.20 (dd, 3H, 6-H’). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2380Hz = 4.76ppm: 4.76 
(d, 1H, 1-H), 4.15 (ddd, 1H, 3-H), 4.08 (dq, 1H, 5-H), 3.40 (dd, 1H, 4-H), 2.05 (dd, 
1H, 2-Hax), 1.95 (ddd, 1H, 2-Heq), 1.19 (d, 3H, 6-H). 
 
4th fraction 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.91 (dddd, J = 17.0, 10.5, 5.8, 
5.1 Hz, 1H, –CH=CH2), 5.32 (dq, J = 17.0, 1.5 Hz, 1H, –CH=CHH’), 5.17 (dq, J = 
10.5, 1.4 Hz, 1H, –CH=CHH’), 5.07 (d, J = 3.4 Hz, 1H, 1-H’), 4.81 (d, J = 3.4 Hz, 
1H, 1-H), 4.66 (dd, J = 9.7, 9.6 Hz, 1H, 4-H’), 4.19 (m, 2H), 4.10 (ddd, J = 4.0, 3.6, 
3.6 Hz, 1H, 3-H), 3.97 (dd, J = 13.1, 6.0 Hz, -O-CHH’-CH=), 3.81 (dq, J = 9.7, 6.3 
Hz, 1H, 5-H’), 3.47 (bdd, J = 9.0, 3.6 Hz, 1H, 4-H), 2.23 (dd, J = 13.3, 5.0 Hz, 1H, 
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2-H’ax), 2.18 (ddd, J = 14.8, 1.3, 3.6 Hz, 1H, 2-Hax), 2.12 (s, 3H, AcO), 1.97 (ddd, J 
= 14.8, 4.2, 4.0 Hz, 1H, 2-Heq), 1.77 (ddd, J = 13.3, 12.8, 3.4 Hz, 1H, 2-H’eq), 1.27 
(d, J = 6.4 Hz, 3H, 6-H), 1.15 (d, J = 6.3 Hz, 3H, 6-H’). 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.94 (s, COCH3), 134.06 (d, -
CH=CH2), 116.88 (t, –CH=CH2), 94.48 (d, C-1), 92.35 (d, C-1’), 75.22 (d, C-4’), 
68.11 (t, –CH2-CH=), 66.75 (d, C-5’), 62.94 (d, C-5), 57.43 (d, C-3’), 53.45 (d, C-3), 
34.72 (t, C-2’), 32.31 (t, C-2), 20.79 (q, COCH3), 18.14 (q, C-6), 17.30 (q, C-6’). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2969Hz = 5.93ppm: 5.93 
(dd, 1H, –CH=CH2), 5.35 (dq, 1H, –CH=CHH’), 5.20 (d, 1H, –CH=CHH’), 4.22 (dd, 
1H, -O-CHH’-CH=), 4.00 (dd, 1H, -O-CHH’-CH=). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2348Hz = 4.69ppm: 5.10 
(d, 1H, 1-H’), 4.69 (dd, 1H, 4-H’), 3.86 (ddd, 1H, 3-H’), 3.48 (dq, 1H, 5-H’), 2.25 
(ddd, 1H, 2-H’ax), 1.80 (ddd, 1H, 2-H’eq), 1.18 (d, 3H, 6-H’) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 1753Hz = 3.51ppm: 4.84 
(d, 1H, 1-H), 4.18 (dq, 1H, 5-H), 4.13 (ddd, 1H, 3-H), 3.51 (dd, 1H, 4-H), 2.21 (ddd, 
1H, 2-Hax), 2.00 (ddd, 1H, 2-Heq), 1.29 (d, 3H, 6-H). 
 
Testosteryl-3-azido-2,3,6-trideoxy-α-L-allopyranoside (129), testosteryl-3-
azido-2,3,6-trideoxy-α-L-allopyranoside (130) 
O
H
HH
O
OHO
N3
 
To a stirred mixture of testosterone 73 mg (0.25 mmol) and azidoglycal mixture 
121ab 50 mg (0.25 mmol) in dry CH2Cl2 (5 ml) polymer-bound PPh3*HBr (2 mg) 
was added. The stirring was continued for 24 h, followed by quenching with 
Amberlite A-21 (10 mg). The mixture was filtered through a pad of Celite and the 
solvent was removed under reduced pressure. The products were finally separated 
by flash column chromatography over silica gel (ethyl acetate / petroleum ether 
3:1) to afford the glycoconjugate 4-O-Ac-129 (16 mg, 0.033 mmol, 13.2%), 
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glycoconjugate 4-O-Ac-130 (15 mg, 0.031 mmol, 12.4%) and a mixture of both 
diastereomers (26 mg, 0.054 mmol, 21.6%).  
The both products were separately deacetylated using the protocol TP8. 
  
Yield: 129 (11.2 mg, 0.0253 mmol, 82%). 
 
 1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 4.83 (d, J = 3.8 
Hz, 1H, 1-H’), 4.57 (dd, J = 9.6, 3.4 Hz, 1H, 4-H’), 4.22 (dq, J = 9.6, 6.2 Hz, 1H, 5-
H’), 4.15 (ddd, J = 3.4, 3.4, 3.4 Hz, 1H, 3-H’), 3.45 (dd, J = 8.5, 8.5 Hz, 1H, 17-H), 
2.5 – 0.7 (m). 
  
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.50 (s, C-3), 171.21 (s, C-5), 
170.12 (s, C=O), 123.84 (d, C-4), 96.27 (d, C-1’), 88.36 (d, C-17), 73.55 (d, C-4’), 
61.98 (d, C-5’), 55.01 (d, C-3), 53.92 (d, C-9), 50.08 (d, C-14), 42.98 (s, C-13), 
38.64 (s, C-10), 37.05 (t, C-12), 35.72 (t, C-1), 35.42 (d, C-8), 33.93 (t, C-2), 32.77 
(t, C-6), 32.29 (t, C-2’), 31.52 (t, C-7), 28.62 (t, C-16), 23.43 (t, C-15), 20.84 (q, 
COCH3), 20.58 (t, C-11), 17.39 (q, C-19), 17.15 (q, C-6’), 11.65 (q, C-18). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY = 2433Hz- 4.86ppm: 4.86 
(d, 1H, 1-H’), 4.59 (dd, 1H, 4-H’), 4.25 (dq, 1H, 5-H’), 4.18 (ddd, 1H, 3-H’), 2.22 
(dd, 1H, 2-H’ax), 2.05 (dd, 1H, 2-H’eq), 1.16 (d, 3H, 6-H’) 
 
Yield: 130 (11.6 mg, 0.0262 mmol, 80%),  
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.71 (s, 1H, 4-H), 4.66 (dd, J = 
9.2, 2.3 Hz, 1H, 1-H’), 4.65 (dd, J = 9.3, 3.5 Hz, 1H, 4-H’), 4.16 (ddd, J = 3.5, 3.5, 
3.5 Hz, 1H, 3-H’), 3.89 (dq, J = 9.3, 6.2 Hz, 1H, 5-H’, 3.64 (dd, J = 8.4, 8.4 Hz, 1H, 
17-H), 2.26 (ddd, J = 14.3, 4.0, 2.3 Hz, 1H), 1.68 (ddd, J = 14.3, 13.9, 4.8 Hz, 1H), 
1.20 (d, J = 6.2 Hz, 3H, 6-H’), 2.5 – 0.7 (m). 
  
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.55 (s, C-3) , 171.21 (s, C-5), 
170.13 (s, C=O), 123.82 (d, C-4), 96.42 (d, C-1’), 87.23 (d, C-17), 74.37 (d, C-4’), 
67.96 (d, C-5’), 58.04 (d, C-3’), 53.95 (d, C-9), 50.62 (d, C-14), 42.40 (s, C-13), 
38.64 (s, C-10), 37.00 (t, C-12), 36.56 (t, C-2’), 35.72 (t, C-1), 35.48 (d, C-8), 33.95 
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(t, C-2), 32.79 (t, C-6), 31.56 (t, C-7), 27.52 (t, C-16), 23.15 (t, C-15), 20.65 (q, 
COCH3), 20.57 (t, C-11), 17.90 (q, C-6’), 17.39 (q, C-19), 11.63 (q, C-18). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY = 2096 Hz - 4.19ppm: 4.68 
(dd, 1H, 1-H’), 4.67 (dd, 1H, 4-H’), 4.19 (ddd, 1H, 3-H’), 3.92 (dq, 1H, 5-H’), 2.01 
(ddd, 1H, 2-H’ax), 1.83 (ddd, 1H, 2-H’eq), 1.23 (d, 3H, 6-H’) 
 
Glycosidation of testosteryl-3-azido-2,3,6-trideoxy-α-L-allopyranoside (131) 
O
H
HH
O
OO
N3
O
TESOOTES  
To a stirred solution of 129 11.2 mg (0.0253 mmol) and glycal 22 (10 mg, 1.05 eq) 
in dry CH2Cl2 (5 ml) polymer-bound PPh3HBr (0.5 mg) was added. The stirring was 
continued for 24 h, followed by addition of Amberlite A-21 (5 mg). The mixture was 
filtered through a pad of Celite and concentrated under reduced pressure. The 
residue was purified by column chromatography. 
  
Yield: 16.1 mg (0.02 mmol 80 %). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 5.09 (d, J = 3.1 
Hz,1H, 1-H‘’), 4.80 (d, J = 3.8 Hz, 1H, 1-H’), 4.12 (m, 2H, 3-H’, 5-H’), 3.96 (ddd, J = 
11.6, 2.4, 4.1 Hz, 1H, 3-H‘’), 3.74 (q, J = 6.3 Hz, 1H, 5-H‘’), 3.59 (s, 1H, 4-H'’), 3.45 
(dd, J = 8.5, 8.5 Hz, 1H, 17-H), 3.37 (dd, J = 9.0, 3.2 Hz, 1H, 4-H’), 2.5 – 0.7 (m). 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.47 (s, C-3), 171.23 (s, C-5), 
123.84 (d, C-4), 96.50 (d, C-1’), 93.41 (d, C-1’’), 88.20 (d, C-17), 74.19 (d, C-4’), 
73.40 (d, C-4’’), 68.27 (d, C-5’’), 67.50 (d, C-3’’), 63.18 (d, C-3’), 53.98 (d, C-9), 
52.94 (d, C-5’), 50.19 (d, C-14), 42.97 (s, C-13), 38.67 (s, C-10), 37.11 (t, C-12), 
35.75 (t, C-1), 35.46 (d, C-8), 33.95 (t, C-2), 32.80 (t, C-6), 32.32 (t, C-2’), 32.27 (t, 
C-2’’), 31.57 (t, C-7), 28.70 (t, C-16), 23.44 (t, C-15), 20.61 (t, C-11), 17.77 (q, C-
19), 17.41 (q, C-6’), 17.26 (q, C-6’’), 11.67 (q, C-18), 7.00, 6.80, 5.23, 4.81 (2t, 2q, 
2 x TES). 
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 1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2558Hz = 5.12ppm: 5.11 
(d, 1H, 1-H’’), 3.98 (ddd, 1H, 3-H’’), 3.77 (q, 1H, 5-H’’), 3.62 (s, 1H, 4-H’’), 2.11 
(ddd, 1H, 2-H’’ax), 1.67 (dd, 1H, 2-H’’eq), 1.19 (d, 3H, 6-H’’) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2415Hz = 4.83ppm: 4.83 
(d, 1H, 1-H’) 4.13 (m, 2H, 3-H’, 5-H’), 3.39 (dd, 1H, 4-H’), 2.20 (dd, 1H, 2-H’ax), 
1.94 (ddd, 1H, 2-H’eq), 1.21 (d, 3H, 6-H’). 
 
Glycosidation of testosteryl-3-azido-2,3,6-trideoxy-β-L-allopyranoside (132) 
O
H
HH
OOO
N3
O
TESOOTES  
To a stirred solution of 130 11.6 mg (0.026 mmol) and glycal 22 (10 mg, 1.05 eq) in 
dry CH2Cl2 (5 ml) polymer-bound PPh3HBr (0.5 mg) was added. The stirring was 
continued for 24 h, followed by addition of Amberlite A-21 (5 mg). The mixture was 
filtered through a pad of Celite and concentrated under reduced pressure. The 
residue was purified by column chromatography. 
 
Yield: 14.6 mg (0.0182 mmol, 70%). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (s, 1H, 4-H), 5.08 (d, J = 3.1 
Hz, 1H, 1-H‘’), 4.65 (dd, J = 9.0, 1.5 Hz, 1H, 1-H’), 4.17 (ddd, J = 3.2, 3.2, 3.2 Hz, 
1H, 3-H’), 3.95 (ddd, J = 11.7, 4.1, 2.4 Hz, 1H, 3-H‘’), 3.85 (dq, J = 8.9, 6.2 Hz, 1H, 
5-H’), 3.79 (bq, J = 6.3 Hz, 1H, 5-H‘’), 3.64 (dd, J = 8.3, 8.3 Hz, 1H, 17-H), 3.60 
(bs, 1H, 4-H‘’), 3.53 (dd, J = 8.9, 3.2 Hz, 1H, 4-H’), 1.25 (d, J = 6.2 Hz, 3H, 6-H’), 
1.16 (d, J = 6.3 Hz, 3H, 6-H‘’), 2.5 – 0.7 (m). 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.50 (s, C-3), 171.26 (s, C-5), 
123.83 (d, C-4), 96.58 (d, C-1’), 94.33 (d, C-1’’), 87.14 (d, C-17), 75.44 (d, C-4’), 
73.36 (d, C-4’’), 69.02 (d, C-5’), 68.41 (d, C-5’’), 67.43 (d, C-3’’), 55.80 (d, C-3’), 
53.99 (d, C-9), 50.64 (d, C-14), 42.40 (s, C-13), 38.66 (s, C-10), 36.61 (t, C-12), 
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35.74 (t, C-1), 35.72 (t, C-2’), 35.51 (d, C-8), 33.96 (t, C-2), 32.81 (t, C-6), 31.95 (t, 
C-2’’), 31.59 (t, C-7), 27.52 (t, C-16), 23.17 (t, C-15), 20.60 (t, C-11), 18.53 (q, C-
6’), 17.41 (q, C-19), 17.22 (q, C-6’’), 11.63 (q, C-18), 6.99, 6.77, 5.21, 4.79 (2t, 2q, 
2 x TES). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2557Hz = 5.11ppm: 5.11 
(d, 1H, 1-H’’), 3.98 (ddd, 1H, 3-H’’), 3.81 (q, 1H, 5-H’’), 3.62 (bs, 1H, 4-H’’), 2.12 
(ddd, 1H, 2-H’’ax), 1.69 (dd, 1H, 2-H’’eq), 1.18 (d, 3H, 6-H’’) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2340Hz = 4.68ppm: 4.68 
(d, 1H, 1-H’), 4.19 (ddd, 1H, 3-H’), 3.87 (q, 1H, 5-H’), 3.56 (dd, 1H, 4-H’), 1.98 
(ddd, 1H, 2-H’ax), 1.69 (ddd, 1H, 2-H’eq), 1.27 (d, 3H, 6-H’) 
 
Preparation of aminoglycoconjugate 133 
O
H
HH
O
OO
NH2
O
HOOH  
A solution of TBAF (1M, 0.06 ml, 3 eq) in THF was added to a solution of 
glycoconjugate 131 (16.1 mg, 0.02 mmol) in THF (1 ml). After the solution was 
stirred for 4 h, polymer bound PPH3 (20 mg, 1.1 mmol/g) was added. The 
suspension was stirred at room temperature for 24 h and the polymer was filtered 
off. The resulting solution was evaporated under reduced pressure and the residue 
was purified by column chromatography (ethyl acetate / EtOH 6:1). The product 
was converted to an acetic acid salt to improve the stability.  
 
Yield: 10 mg (0.0183 mmol, 91%).  
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) δ: 5.75 (s, 1H, H-4), 5.10 (d, J = 3.3 Hz, 
1H, 1-H’’), 4.92 (d, J = 2.8 Hz, 1H, 1-H’), 3.98 (m, 3H), 3.61 (bd, J = 2.6 Hz, 1H, 4-
H’’), 3.59 (t, J = 8.5 Hz, 1H, 17-H), 3.52 (dd, J = 7.1, 3.8 Hz, 1H, 3-H’), 3.46 (dd, J 
= 9.4, 3.8 Hz, 1H, 4-H’), 2.6 – 0-7 (m). 
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13C-NMR (125 MHz, CD3OD, = 49 ppm) δ: 202.27 (s, C-3), 174.98 (s, C-5), 124.18 
(d, C-4), 99.07 (d, C-1’), 95.36 (d, C-1’’), 89.70 (d, C-17), 76.33 (d, C-4’), 72.13 (d, 
C-4’’), 68.51 , 66.83 (2d, C-3’’, C-5’’), 63.38 (d, C-5’), 55.42 (d, C-9), 51.35 (d, C-
14), 45.62 (d, C-3’’), 44.04 (s, C-13), 40.02 (s, C-10), 38.29 (t, C-12), 36.79 (t, C-
1), 36.74 (d, C-8), 34.70 (t, C-2), 34.22 (t, C-2’), 33.86 (t, C-6), 32.97 (t, C-2’’), 
32.80 (t, C-7), 29.78 (t, C-16), 24.34 (t, C-15), 23.00 (q, CH3COO-), 21.73 (t, C-11), 
18.62 (q, C-19), 17.72, 17.10 (2q, C-6’, C-6’’), 12.24 (q, C-18). 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 2542Hz = 5.08ppm: 5.08 (d, 1H, 
1-H’’), 3.95 (m, 2H, 3-H’, 5-H’’), 3.59 (d, 1H, 4-H’’), 1.98 (ddd, 1H, 2-H’’ax), 1.84 (dd, 
1H, 2-H’’eq), 1.24 (d, 3H, 6-H’’). 
 
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 2456Hz = 4.91ppm: 4.91 (d, 1H, 
1-H’), 3.98 (dq, 1H, 5-H’), 3.50 (ddd, 1H, 3-H’), 3.44 (dd, 1H, 4-H’), 2.08 (dd, 1H, 2-
H’ax), 1.97 (ddd, 1H, 2-H’eq), 1.25 (d, 3H, 6-H’). 
 
LC-MS (ESI) (-c): m/z (%): 546.34 (60) [M – H]-; HR-MS C31H48NO7: calc. 
546.3431, found 546.3431  
 
Preparation of aminoglycoconjugates 134 
O
H
HH
OOO
NH2
O
HOOH  
The reaction was carried out according to the experiment 133: starting material 
132 14.6 mg (0.0182 mmol) 
 
Yield: 7.1 mg (0.013 mmol, 71%) 
 
1H-NMR (500 MHz, CD3OD, CD3OD, = 3.35 ppm) δ: 5.75 (s, 1H, 4-H), 5.07 (d, J = 
3.4 Hz, 1H, 1-H’’), 4.93 (dd, J = 7.1, 2.6 Hz, 1H, 1-H’), 3.97 (m, 3H), 3.77 (t, J = 
8.1, 8.1 Hz, 1H, H-17), 3.73 (bq, J = 6.2 Hz, 1H, 5-H’’), 3.61 (bs, 1H, 4-H’’), 3.53 
(dd, J = 7.0, 3.6 Hz, 1H, 4-H’), 2.5-0.7 (m). 
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13C-NMR (125 MHz, CD3OD, = 49 ppm) δ: 202.32 (s, C-3), 175.11 (s, C-5), 124.14 
(d, C-4), 97.66 (d, C-1’’), 97.01 (d, C-1’), 87.31 (d, C-17), 77.14 (d, C-4’), 72.13 (d, 
C-4’’), 70.66 (d, C-3’), 68.49 (d, C-3’’), 66.83 (d, C-5’’), 55.51 (d, C-9), 51.87 (d, C-
14), 45.48 (d, C-5’), 43.65 (s, C-13), 40.04 (s, C-10), 38.12 (t, C-12), 36.80 (t, C-1), 
36.75 (d, C-8), 35.00 (t, C-2’) 34.70 (t, C-2), 33.88 (t, C-6), 33.05 (t, C-7), 32.86 (t, 
C-2’’), 28.28 (t, C-16), 24.24 (t, C-15), 22.68 (t, C-11), 21.72 (q, CH3COO-), 19.82 
(q, C-6’), 17.72 (q, C-19), 17.09 (q, C-6’’), 12.15 (q, C-18). 
  
1H-NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 2531Hz = 5.06ppm: 5.06 (d, 1-
H’), 3.94 (m, 2H, 3-H’, 5-H’), 3.59 (bd, 1H, 4-H’), 1.96 (ddd, 1H, 2-H’ax), 1.86 (dd, 
1H, 2-H’eq), 1.23 (d, 3H, 6-H’) 
 
1H -NMR (500 MHz, CD3OD, = 3.35 ppm) TOCSY 2458Hz = 4.91ppm: 4.91 (dd, 
1H, 1-H’’), 3.99 (dd, 1H, 3-H’’), 3.73 (q, 1H, 5-H’’), 3.52 (dd, 1H, 4-H’’), 2.04 (ddd, 
1H, 2-H’’ax), 1.80 (ddd, 1H, 2-H’’eq), 1.32 (d, 3H, 6-H’’) 
 
11.5.4. Experiments to the chapter 6.1.4. 
17-O-(1-THP)-testosterone (135) 
The reaction was carried out according to the protocol TP6 except the following 
details: testosterone (10 mg, 0.0347 mmol).  
 
Yield: 12.5 mg (0.0337 mmol, 97%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.75 (s, 1H, 4-H), 4.65 (bd, J=3.7 
Hz, 1H), 3.91 (ddd, J=10.9, 7.9, 2.9 Hz, 1H), 3.67 (ddd, J=8.1, 8.5, 4.7 Hz, 1H, 17-
H), 3.5 (m, 1H), 2.5 – 0.7 (m). 
 
7-O-(1-THP)-3,4-di-O-acetyl-decarestrictine D (136) 
The reaction was carried out according to the protocol TP6:  
 
Yield: 12.6 mg (0.0328 mmol, 99%). 
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1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.87 (ddd, J = 16.0, 9.4, 1.1 Hz, 
0.5H), 5.80 (dd, J = 16.0, 3.3 Hz, 0.5H), 5.71 (dd, J = 16.0, 3.5 Hz, 0.5H), 5.63 
(ddd, J = 16.0, 9.4, 1.3 Hz, 0.5H), 5.32 (dddd, J = 16.2, 5.0, 3.3, 1.25 Hz, 1H), 5.13 
(dddd, J = 21.7, 10.9, 6.3, 1.8 Hz, 1H), 5.03 (m, 1H), 4.61 (dd, J = 4.3, 2.9 Hz, 
0.5H), 4.52 (dd, J = 4.5, 2.9 Hz, 0.5H), 4.24 (ddd, J = 10.4, 9.7, 3.5 Hz, 0.5H), 4.12 
(ddd, J = 10.5, 9.6, 3.2 Hz, 0.5H), 3.80 (m, 1H), 3.43 (m, 1H), 2.66 (ddd, J = 14.2, 
14.2, 7.2 Hz, 1H), 2.55 (ddd, J = 14.2, 11.6, 2.6 Hz, 1H), 2.14, 2.12, 2.11 (3s, 6H), 
1.4-2.0 (m, 8H), 1.22, (d, J = 6.3 Hz, 3H) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.88, 169.50, 169.41, 169.11, 
169.10, 136.12+, 134.66+, 125.74+, 122.90+, 98.90, 97.20+, 95.21+, 94.64, 
76.96+,  74.88+, 72.18+, 71.99+, 70.88+,68.38+, 68.27+, 62.86-, 62.71-, 41.11-, 
40.08-, 33.87-, 33.43-, 30.77-, 30.71-, 30.68, 25.43-, 25.39-, 25.23-, 21.45+, 
21.40+, 20.97+, 20.90+, 20.87+, 19.82-, 19.76-, 19.74-. 
 
3-O-(1-THP)-digitoxigenin (137) 
The reaction was carried out according to the protocol TP6: digitoxigenin (10 mg, 
0.0267 mmol) 
 
Yield: 12.2 mg (0.0265 mmol, 99%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.88 (s, 1H), 5.01 (ddd, J = 18.1, 
1.6, 1.25 Hz, 1H), 4.82 (dd, J = 18.1, 1.6 Hz, 1H), 4.63 (m, 1H), 3.98 (bs, 1H), 3.90 
(m, 1H), 3.50 (m, 1H), 2.80 (m, 1H), 2.4-0.7 (m).  
  
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 174.54 (s, C-20), 174.47 (s, C-23), 
117.64 (d, C-22), 96.94+, 96.75+, 94.63+, 85.59, 73.41-, 71.09+, 70.79+, 62.90-, 
62.87-, 62.81-, 50.94+, 50.92+, 49.58, 49.57, 41.88+, 40.05-, 36.49+, 36.36+, 
35.70+, 35.66+, 35.19, 33.18-, 33.15-, 32.23-, 31.40-, 30.67-, 30.39-, 30.05-, 
29.88-, 26.87-, 26.85-, 26.78-, 26.67-, 26.56-, 25.57-, 25.55-, 25.43-, 24.14-, 
23.68+, 21.42-, 21.32-, 21.16-, 20.07-, 20.01-, 19.72-, 15.74+ 
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(3R)-3-OTHP-pent-4-enic acid ethyl ester (139) 
O
THPO O
 
The reaction was carried out according to the protocol TP6: alcohol 138 (20 mg, 
0.139 mg) 
 
Yield: 31.2 mg (0.137 mmol, 99%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.91 (ddd, J = 17.2, 10.5, 6.5 Hz, 
0.34H, 4-H), 5.66 (ddd, J = 17.2, 10.2, 7.7 Hz, 0.66H, 4-H), 5.29 (dd, J = 17.1, 1.5 
Hz, 0.66H, 5-H), 5.25 (d, J = 17.2, 1.2 Hz, 0.34H, 5-H), 5.21, (dd, J = 10.2, 1.5 Hz, 
0.66H, 5-H’), 5.11 (ddd, J = 10.5, 1.5, 1.2 Hz, 0.34H, 5-H’), 4.73 (dd, J = 4.1, 3.0 
Hz, 0.34H, H-a), 4.69 (dd, J = 3.1, 3.1 Hz, 0.66H, H-a), 4.55 (ddd, J = 7.9, 7.7, 5.7 
Hz, 0.66H, 3-H), 4.50 (ddd, J = 8.0, 6.5, 5.6 Hz, 0.34H, 3-H), 4.14, 4.12 (2q, J = 7.3 
Hz, 2H, CH2-CH3), 3.84, 3.48 (2m, 2H, H-e), 2.64 (dd, J = 14.9, 8.1 Hz, 0.66H, 2-
H), 2.61 (dd, J = 14.9, 8.0 Hz, 0.34H, 2-H), 2.48 (dd, J = 14.7, 5.7 Hz, 0.66H, 2-H), 
2.47 (dd, J = 15.1, 5.5 Hz, 0.34H, 2-H), 1.4-1.8 (m, 6H, H-b, H-c, H-d), 1.25, 1.23 
(2d, J = 7.3 Hz, 3H, CH2-CH3). 
  
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 170.92 (s, C=O), 170.79 (s, C=O), 
138.34 (d, -CH=CH2), 136.75 (d, -CH=CH2), 118.37 (t, –CH=CH2), 115.53 (t, –
CH=CH2), 98.68 (d, C-a), 94.56 (d, C-a), 74.94 (d, C-3), 72.80 (d, C-3), 61.59 (t, 
CH2-CH3), 60.40 (t, CH2-CH3), 41.23 (t, C-2), 40.58 (t, C-2), 30.70-, 30.40-, 25.46-, 
25.33-, 19.52-, 18.93-, 14.19 (q, CH3) 
 
(3R)-3-Hydroxy-pent-4-enic acid ethyl ester (138) 
O
OH O
 
The reaction was carried out according to the protocol TP7: protected alcohol 139 
(31.2 mg, 0.137 mmol) 
 
Yield: 19.59 mg (0.136 mmol, 99%)  
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.87 (ddd, J = 17.1, 10.5, 545 Hz, 
1H, 4-H), 5.31 (ddd, J = 17.1, 1.4, 1.4 Hz, 1H, 5-H), 5.14 (ddd, J = 10.5, 1.4, 1.4 
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Hz, 1H, 5-H), 4.53 (ddd, J = 8.7, 4.6, 2.8 Hz, 1H, 3-H), 4.16 (q, J = 7.1 Hz, 2H, 
CH2), 3.02 (bs, 1H, OH), 2.57 (dd, J = 16.1, 4.6 Hz, 1H, 2-H), 2.50 (dd, J = 16.1, 
8.7 Hz, 1H, 2-H), 1.26 (t, J = 7.1 Hz, 3H, CH3) 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 172.22 (s, C=O), 138.78 (d, C-4), 
115.35 (t, C-5), 68.90 (d, C-3), 60.75 (t, CH2-CH3), 41.13 (t, C-2), 14.13 (q, CH3). 
 
Deprotection of 3-O-THP-digitoxigenine (25) 
The reaction was carried out according to the protocol TP7: protected alcohol 137 
(12.2 mg, 0.0265 mmol) 
 
Yield: 9.8 mg (0.0262 mmol, 99%)  
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.86 (ddd, J = 1.7, 1.7, 0.6 Hz, 
1H), 4.98 (ddd, J = 18.1, 1.7, 0.5 Hz, 1H), 4.80 (dd, J = 18.1, 1.7 Hz, 1H), 4.12 
(bdd, J = 2.6, 2.6 Hz, 1H), 2.77 (dd, J = 9.1, 5.5 Hz, 1H), 2.4 - 0.7 (m). 
 
 13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 174.46 (s, C-20), 174.45 (s, C-
23), 117.68 (d, C-22), 85.57 (s, C-14), 73.41 (t, C-21), 66.79 (d, C-3), 50.91 (d, C-
17), 49.58 (s, C-13), 41.82 (d, C-8), 40.02 (t, C-12), 35.95, 35.47 (2d, C-5, C-9), 
35.38 (s, C-10), 33.31, 33.14 (2t , C-4, C-15), 29.61 (t, C-1), 27.89, 26.86, 26.44 
(3t, C-2, C-6, C-16), 23.69 (q, C-19), 21.33 (t, C-7), 21.14 (t, C-11), 15.75 (q, C-
18). 
 
Deprotection of 7-O-THP-3,4-di-O-acetyl-decarestrictine D (40) 
The reaction was carried out according to the protocol TP7: protected alcohol 136 
(12.6 mg, 0.0328 mmol).  
 
Yield: 9.75 mg (0.0325 mmol, 99%)  
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.72 (dd, J = 16.0, 7.9 Hz, 1H, 6-
H), 5.66 (dd, J = 16.0, 2.6 Hz, 1H, 5-H), 5.22, 5.00 (2ddd, J = 5.2, 2.6, 2.6 Hz, J = 
10.0, 5.2, 2.6 Hz, 2H, 4-H, 3-H), 5.08 (m, 1H, 9-H), 4.12 (ddd, J = 10.6, 7.9, 3.4 Hz, 
1H, 7-H), 2.68 (bs, 1H, OH7), 2.61, 2.52 (2ddd, J = 14.3, 10.0, 2.6 Hz, J = 14.3, 
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2.6, 2.6 Hz, 2H, 2-H), 2.08, 2.07(2s, 6H, 2 x CH3CO), 1.83-1.73 (m, 2H, 8-H), 1.18 
(d, J = 6.2 Hz, 3H, 10-H). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.86, 169.44, 169.21, 136.88+, 
123.86+, 72.45+, 72.28+, 70.92+, 68.06+, 42.46-, 33.81-, 21.36+, 20.96+, 20.87+ 
 
11.6.1. Experiments to the chapter 6.2.1. 
Benzyl 2´,6´-dideoxy-3´,4´-di-O-triethylsilyl-α/β-L-arabino-hexopyranoside 
(141) 
O
OTES
O
TESO
 
 To a shaken suspension of thioglycoside 140 (40 mg, 0.085 mmol), molecular 
sieves 4A (100 mg) and benzyl alcohol (20 mg, 0.17 mmol) in CH2Cl2 (5 ml) 
polymer-bound Iodo-bis-trifluoroacetat (1 eq, 2.5 mmol/g) was added. The reaction 
was gently shaken for 1h at rt. Amberlite A-21 (40 mg) was added and the 
suspension was filtered and concentrated under reduced pressure. Removal of 
thio impurities was achieved as described in protocol TP1 (see above). The crude 
product was purified by column chromatography over silica gel (ethyl acetate / 
petroleum ether=1:10, Rf-0.30) to yield an inseparable mixture of α,β-isomers. 
 
Yield: 32 mg (0.068 mmol, 85%, α/β - 8:1). 
 
1H-NMR (200 MHz, CDCl3, CDCl3=7.26 ppm) δ: 7.37 (m, 5H, Ph), 4.90 (d, J = 3.2 
Hz, 1H, 1-H), 4.59 (2d, J = 47.2, 12.1 Hz, 2H, CH2Ph), 4.01 (ddd, J = 11.3, 8.4, 5.0 
Hz, 1H, 3-H), 3.71 (dq, J = 8.9, 6.3 Hz, 1H, 5-H), 3.22 (dd, J = 8.9, 8.4 Hz, 1H, 4-
H), 2.16 (ddd, J = 13.0, 5.0, 1.2 Hz, 1H, 2-Hax), 1.70 (ddd, J = 13.0, 11.3, 3.2 Hz, 
1H, 2-Heq), 1.28 (d, J = 6.3 Hz, 3H, 6-H’). 
 
n-Heptyl 2’,6’-dideoxy-3’,4’-di-O-triethylsilyl-α/β-L-arabino-hexopyranoside 
(142) 
O
OTES
O
TESO
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To a solution of thioglycoside 140 (47 mg, 0.1 mmol), n-heptanol (15 mg, 0.14 
mmol) in CH2Cl2 were added molecular sieves 4Ǻ (100 mg) and polymer-bound 
Iodo-bis-trifluoroacetate (40 mg, with 2.5 mmol x g-1). The crude product was 
purified by flash column chromatography (ethyl acetate / petroleum ether 1:15; Rf= 
0.36) to yield an inseparable mixture of α,β-isomers. 
 
Yield: 29 mg (0.061 mmol, 62%, α/β 1.2:1, Rf-0.36) 
 
1H-NMR (200 MHz, CDCl3, CDCl3=7.26 ppm) δ: 4.78 (d, J = 2.6 Hz, 0.55H, 1-Hα), 
4.45 (dd, J = 9.6, 1.8 Hz, 0.45H, 1-Hβ), 3.91 (m, 1H, 3-H), 3.63 (m, 2H), 3.22 (m, 
2H), 2.11 (ddd, J = 13.0, 5.0, 1.2 Hz, 1H, 2-H), 1.65 (m,  3H), 1.30 (m, 13H), 1.00 
(m, 18H, TES-CH3), 0.70 (m, 12H, TES-CH2). 
 
3,4-Di-O-TES-rhamnal (143) 
Yield: 7.1 mg (0.02 mmol, 20%, Rf-0.4) 
 
1H-NMR (400 MHz, CDCl3, CDCl3=7.26 ppm) δ: 6.27 (d, J = 6.1, 1.0 Hz, 1H, 1-H), 
4.66 (dd, J = 6.1, 2.9 Hz, 1H, 2-H), 4.13 (ddd, J = 5.5, 1.0, 2.9 Hz, 1H, 3-H), 3.86 
(dq,  J = 6.7, 7.5 Hz, 1H, 5-H), 3.53 (dd, J = 7.5, 5.5 Hz, 1H, 4-H), 1.32 (d, J = 6.7 
Hz, 3H, 6-H), 0.95 (m, 18H, TES), 0.65 (m, 12H, TES). 
 
13C-NMR (100 MHz, CDCl3, CDCl3=77 ppm) δ: 143.0 (+, C-1), 102.8 (+, C-2), 75.1, 
74.7, 69.3 (3+, C-4, C-5, C-3), 17.2 (+, C-6), 6.4, 5.0 (+ -, TES). 
 
Benzyl 2’,6’-dideoxy-3’,4’-di-O-triethylsilyl-α/β-L-arabino-hexopyranoside 
(141) 
O
OTES
O
TESO
 
A solution of thioglycoside 140 (23 mg, 49 µmol) and benzyl alcohol (10 mg, 0.1 
mmol) was shaken in THF/CH3CN (1:2; 5 ml) at –50oC. Polymer-bound Iodo-bis-
trifluoroacetate (20 mg, 2.5 mmol/g) was added and shaking was continued for 1 h 
at –50°C. Amberlite A-21 (20 mg) was added and the suspension was filtered 
through a pad of Al2O3. The filtrate was concentrated under reduced pressure. 
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Removal of thio impurities was achieved as described in protocol TP1 (see above). 
The crude product was purified by flash column chromatography (ethyl acetate / 
petroleum ether= 1:10; Rf-0.30) to yield an inseparable mixture of α,β-isomers.  
 
Yield: 21 mg (93%, 45.6 µmol, α/β - 4:1). 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.37 (m, 5H, Ph), 4.90 (d, J = 3.2 
Hz, 0.8H, 1-Hα), 4.59 (2d, J = 47.2, 12.1 Hz, 2H, CH2Ph), 4.26 (dd, J = 5.8, 1.8 Hz, 
0.2H, 1-Hβ), 4.01 (ddd, J = 11.3, 8.5, 5.0 Hz, 0.8H, 3-Hα), 3.71 (dq +m, J = 8.9, 6.3 
Hz, 1H+0.2H, 5-H+3-Hβ), 3.22 (dd, J = 8.9, 8.5 Hz, 1H, 4-H), 2.16 (ddd, J = 13.1, 
5.0, 1.2 Hz, 1H, 2-H), 1.70 (ddd, J = 13.1, 11.3, 3.2 Hz, 1H, 2-H), 1.28 (d, J = 6.3 
Hz, 3H, 6-H’), 0.95 (m, 18H, TES), 0.65 (m, 12H, TES). 
 
Testosteryl 2´,6´-dideoxy-3´,4´-di-O-triethylsilyl-α/β-L-arabino-
hexopyranoside (149) 
O
OTES
TESO
O
H
HH
O
 
To a shaken solution of thioglycoside 140 (40 mg, 85 µmol) and testosterone (25 
mg, 87 µmol) in THF/CH3CN (1:2; 5 ml) polymer-bound Iodo-bis-trifluoroacetate 
(37 mg, 2.5 mmol x g-1) was added at –50°C and shaking was continued for 3 h at 
that temperature. Amberlite A-21 (40 mg) was added and after 30 min the 
suspension was filtered and concentrated under reduced pressure. Removal of 
thio impurities was achieved as described in protocol TP1 (see above). The crude 
product was purified by column chromatography (ethyl acetate / petroleum ether= 
1:3) to yield two fractions. 
  
Yield: 1st fraction: 149α 25 mg (0.039 mmol, 46%, Rf - 0.6). 
 
1H-NMR (200 MHz, CDCl3, CDCl3=7.26 ppm) δ: 5.76 (s, 1H, 4-H), 4.84 (d, J = 2.7 
Hz, 1H, 1-H’α), 3.95 (ddd, J = 11.0, 8.7, 4.7 Hz, 1H, 3-H’), 3.67 (dq, J = 8.7, 6.4 
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Hz, 1H, 5-H’), 3.47 (dd, J = 8.4, 8.4 Hz, 1H, 17-H), 3.16 (dd, J = 8.7, 8.7 Hz, 1H, 4-
H’), 2.5 – 0.7 (m). 
 
Yield: 2nd fraction: 149β 21 mg (0.032 mmol, 37%, Rf - 0.53). 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.76 (s, 1H, 4-H), 4.40 (dd, J = 
9.3, 1.8 Hz, 1H, 1-H’β), 4.00 (ddd, J = 11.2, 8.5, 4.7 Hz, 1H, 3-H’), 3.87 (dq, J = 
8.6, 6.3 Hz, 1H, 5-H’), 3.62 (dd, J = 8.4, 8.4 Hz, 1H, 17-H), 3.20 (dd, J = 8.6, 8.5 
Hz, 1H, 4-H’),  2.5 – 0.7 (m). 
 
1-O-(2´,6´-deoxy-3´,4´di-O-triethylsilyl-α/β-D-arabino-hexopyranosyl) (2:3, 4:5-
di-O-isopropyliden)-α-D-fructo-hexopyranoside (145) 
O
O
O
OOOO
OTES
TESO
 
To a solution of thioglycoside 140 (40 mg, 85 µmol) and diacetonfructopyranose 
(22.3 mg, 85 µmol) in THF/CH3CN (2:3, 5 ml) polymer-bound Iodo-bis-
trifluoroacetate (37 mg, 2.5 mmol x g-1) was added at –50oC and shaken was 
continued for 3 h at that temperature. Amberlite A-21 (40 mg) was added and after 
30 min the suspension was filtered and concentrated under reduced pressure. 
Removal of thio impurities was achieved as described in protocol TP1 (see above). 
The crude product was purified by column chromatography (ethyl acetate / 
petroleum ether 1:6; Rf= 0.52) to yield an inseparable mixture of α,β-isomers. As a 
byproduct 2,6-dideoxy-3,4-di-O-triethylsilyl-α/β-L-arabino-hexopyranose 146 was 
formed (Rf= 0.3). 
 
Yield: 25 mg (0.040 mmol, 47%, α/β – 1.36:1).  
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 4.88 (d, J = 3.0 Hz, 0.56H, 1-Hα), 
4.63 (ddd, J = 7.7, 7.7, 2.5 Hz, 1H), 4.51 (dd, J = 9.6, 1.8 Hz, 0.42H, 1-Hβ), 4.33, 
4.43 (2d, J = 2.5 Hz, 1H), 4.25 (bd, J = 7.9 Hz, 1H), 4.05 (d, 0.44H), 3.85-4.00 (m, 
2H), 3.73 (m, 1.6H), 3.60 (m, 1H), 3.50 (d, 1H), 3.18 (m, 1.6H), 2.17 (ddd, 1H), 1.3-
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1.6 (8s, 12H, 4xCH3), 1.27, 1.23 (2d, J = 5.7, 6.2 Hz, 3H, 6-H), ), 0.95 (m, 18H, 
TES), 0.65 (m, 12H, TES). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 108.98, 108.92, 108.50, 108.37, 
102.53, 102.42, 99.26+, 97.40+, 78.88+, 78.55+, 72.98+, 72.51+ 71.06+, 71.03+, 
70.75+, 70.37+, 70.29+, 70.08+, 69.81+, 68.78+, 67.32-, 61.01-, 60.99-, 40.29-, 
39.00-, 26.91-, 26.55+, 26.53+, 25.94+, 25.87+, 25.42+, 25.17+, 24.13+, 23.99+, 
18.30+, 18.19+, 7.04+, 6.92+, 6.93+, 5.38-, 5.37-, 5.30- 
 
Dehydro-epi-androsteronyl 2´,6´-dideoxy-3´,4´-di-O-triethylsilyl-α/β-L-arabino-
hexopyranoside (147) 
O
OTES
TESO
O
H
H H
O
 
To a shaken solution of thioglycoside 140 (55 mg, 0.117 mmol) and dehydro-epi-
androsteron (33 mg, 0.117 mmol) in THF/CH3CN (1:2; 5 ml) polymer-bound Iodo-
bis-trifluoroacetate (47 mg, 2.5 mmol x g-1) was added at –50°C and shaking was 
continued for 3 h at that temperature. Amberlite A-21 (50 mg) was added and after 
30 min the suspension was filtered through a pad of celite and concentrated under 
reduced pressure. Removal of thio impurities was achieved as described in 
protocol TP1 (see above). The crude product was purified by column 
chromatography (ethyl acetate / petroleum ether 1:8; Rf= 0.53) to yield an 
inseparable mixture of α,β-isomers. 
 
Yield: 46 mg (0.071 mmol, 54%, Rf-0.53, α/β – 1:1.25). 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.38 (dd, J = 14.3, 5.3 Hz, 1H, 
steroid), 4.94 (d, J = 2.8 Hz, 0.43H, 1-Hα), 4.57 (dd, J = 9.7, 1.8 Hz, 0.55H, 1-Hβ), 
3.92 (ddd, J = 11.2, 8.1, 4.9 Hz, 0.43H, 3-H), 3.55-3.75 (m, 1.6H), 3.4 (m, 0.43H), 
3.15-3.25 (m, 1.55H), 2.5 – 0.7 (m). 
 
 13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 221.15, 221.13, 141.20, 120.91, 
120.69, 97.29, 95.26, 79.11, 78.50, 77.64, 76.09, 73.16, 72.38, 70.58, 68.48, 
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51.78, 51.76, 50.28, 47.53, 41.16, 40.20, 39.77, 38.62, 37.32, 37.09, 36.90, 36.84, 
35.83, 35.82, 31.50, 31.49, 31.44, 30.80, 29.45, 28.08, 26.89, 21.86, 20.34, 20.33, 
19.43, 19.36, 18.44, 18.35, 13.53, 7.05, 7.01, 6.96, 5.35, 5.34, 5.33 
 
3,4-Di-O-triethylsilyl-2,6-dideoxy-L-arabino-hexopyranoside (146) 
To a shaken solution of sugar 140 (40 mg, 0.085 mmol) and diacetonglucose (21 
mg, 0.085mmol) in a mixture of solvents (THF/CH3CN -1:2, 5 ml) at –50oC polymer 
bound Iodo-bis-trifluoroacetat (37 mg, 2.5 mmol/g) was added. The reaction was 
shaken for 2-3 h at the same temperature, then quenched with addition of 
Amberlite A-21(40 mg), shaken another 30 min, filtrated through a pad of celite and 
solvent was evaporated under reduced pressure. The crude product was purified 
by column chromatography over silica gel (ethyl acetate / petroleum ether=1:6). No 
expected product was detected. As a main product 2,6-dideoxy-3,4-di-O-
triethylsilyl-α/β-L-arabino-hexopyranose 146 was formed (Rf= 0.3). 
 
Yield: 27 mg (0.072 mmol, 85%, Rf-0.3). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.27 (ddd, J = 3.2, 3.0, 1.8 Hz, 
0.57H, 1-Hα), 4.82 (ddd, J = 9.2, 6.5, 2.2 Hz, 0.42H, 1-Hβ), 3.98 (ddd, J = 10.9, 
8.1, 4.8 Hz, 0.57H, 3-H), 3.87 (dq, J = 8.6, 6.3 Hz, 0.57H, 5-H), 3.64 (ddd, J = 11.1, 
8.1, 4.9 Hz, 0.44H, 3-H’), 3.31 (dq, J = 8.5, 6.3 Hz, 0.41H, 5-H’), 3.18 (dd, J = 8.5, 
8.1 Hz, 1H, 4-H, 4-H’), 3.17 (bd, J = 8.0 Hz, 0.45H, OHβ), 2.54 (dd, J = 3.2, 2.5 Hz, 
0.54H, OHα), 2.25 (ddd, J = 12.5, 4.9, 1.8 Hz, 0.42H, 2-H), 2.10 (ddd, J = 13.0, 
4.9, 1.7 Hz, 0.58H, 2-H’), 1.67 (dddd, J = 13.0, 11.1, 2.2, 3.5 Hz, 0.5H, 2-H’), 1.56 
(ddd, J = 12.5, 11.3, 9.5 Hz, 0.5H, 2-H), 1.31 (d, J = 6.3 Hz, 1.3H, 6-H), 1.25 (d, J 
= 6.3 Hz, 1.8H, 6-H’), 0.95 (m, 18H, TES), 0.65 (m, 12H, TES). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 93.60, 91.79 (C1), 78.75, 78.09 
(C4), 72.72, 72.71 (C3, C5), 70.06 (C3), 69.04 (C5), 41.76, 39.12 (C2), 18.52, 18. 
43 (C6), 7.02, 6.93 (+), 5.30 (-). 
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11.6.2. Experiments to the chapter 6.2.3. 
Testosteryl 2´,6´-dideoxy-3´,4´-di-O-acetyl-α/β-L-arabino-hexopyranoside 
(150) 
O
AcO
AcO
O
H
HH
O
 
The two reactions were carried out according to the protocol TP1 except the 
following details: 
First reaction: thioglycoside 18 (32 mg, 0.1 mmol), testosterone (28 mg, 0.1 mmol), 
selectfluor™ (35.4 mg, 0.1 mmol). 
Second reaction: thioglycoside 19 (32 mg, 0.1 mmol), testosterone (28 mg, 0.1 
mmol), selectfluor™ (35.4 mg, 0.1 mmol). 
Both reactions gave the same yield and α/β ratio of diastereomers.  
 
Yield: 49 mg (0.097 mmol, 97%, α/β - 2:1). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.71 (s, 1H, 4-H), 5.27 (ddd, J 
= 11.5, 9.6, 5.3 Hz, 0.66H, 3-H’α), 4.94 (ddd, J = 11.7, 9.4, 5.2 Hz, 0.33H, 3-H’β), 
4.92 (d, J = 3.0 Hz, 0.66H, 1-H’α), 4.75 (dd, J = 9.4, 9.4 Hz, 0.33H, 4-H’β), 4.71 
(dd, J = 9.6, 9.6 Hz, 0.66H, 4-H’α), 4.51 (dd, J = 9.6, 1.8 Hz, 0.33H, 1-H’β), 3.89 
(dq, J = 9.6, 6.2 Hz, 0.66H, 5-H’α), 3.66 (t, J = 8.4 Hz, 0.33H, 17-Hβ), 3.51 (t, J = 
8.5 Hz, 0.66H, 17-Hα), 3.42 (dq, J = 9.4, 6.1 Hz, 0.33H, 5-H’β), 2.5-0.7 (m) 
 
13C-NMR α-anomer (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 199.3 (s, C-3), 170.9, 
170.2 (2s, COCH3), 123.8 (d, C-4), 97.3 (d, C-1’), 87.2 (d, C-17), 74.9, 69.1, 65.6 
(3d, C-3’, 4’, 5’), 53.8 (d, C-9), 50.2 (d, C-14), 42.8 (s, C-13), 38.6 (s, C-10), 37.1(t, 
C-12), 35.6 (t, C-1), 35.5 (t, C-2’), 35.4 (d, C-8), 33.8 (t, C-2), 32.7 (t, C-6), 31.4 (t, 
C-7), 28.3 (t, C-16), 23.2 (t, C-15), 20.7, 20.5 (2q, 2COCH3), 17.4 (q, C-19), 17.3 
(q, C-6’), 11.6 (q, C-18) 
 
13C-NMR β-anomer (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 199.3 (s, C-3), 171.1, 
170.3 (2s, COCH3), 123.8 (d, C-4), 98.1 (d, C-1’), 87.3 (d, C-17), 74.1, 70.9, 69.8 
(3d, C-3’, 4’, 5’), 53.9 (d, C-9), 50.6 (d, C-14), 42.4 (s, C-13), 38.6 (s, C-10), 36.8(t, 
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C-12), 36.5 (t, C-2’), 35.6 (t, C-1), 35.4 (d, C-8), 33.9 (t, C-2), 32.7 (t, C-6), 31.5 (t, 
C-7), 27.4 (t, C-16), 23.1 (t, C-15), 20.9, 20.8 (2q, 2COCH3), 17.6 (q, C-19), 17.3 
(q, C-6’), 11.5 (q, C-18) 
 
1H-NMR α-anomer (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 2641 Hz = 5.28 ppm: δ 
= 5.28 (ddd, 3-H’), 4.92 (d, 1-H’), 4.71 (dd, 4-H’), 3.89 (dq, 5-H’), 2.22 (dd, 2-H’ax), 
1.76 (ddd, 2-H’eq), 1.15 (d, 6-H’) 
 
1H-NMR β-anomer (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 2254 Hz = 4.51 ppm: δ 
= 4.94 (ddd, 3-H’), 4.75 (dd, 4-H’), 4.50 (dd, 1-H’), 3.42 (dq, 5-H’), 2.27 (ddd, 2-
H’ax), 1.70 (ddd, 2-H’eq), 1.21 (d, 6-H’) 
 
Testosteryl 2´-deoxy-3´,4´,6´-tri-O-acetyl-α/β-D-arabino-hexopyranoside (151) 
O
OAc
AcO
AcO
O
H
HH
O
 
The reaction was carried out according to the protocol TP1: 
 
Yield: 55 mg (0.098 mmol, 98%, α/β - 2:1) 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ:  5.69 (s, 1H, 4-H), 5.27 (ddd, J = 
11.5, 9.5, 5.3 Hz, 0.68H, 3-H’α), 5.26 (m, 1H), 4.94 (m, 2H, 0.32H, 0.68H, 1H, 3-
H’β, 1-H’α, 4-H’βα), 4.57 (dd, J = 9.6, 1.6 Hz, 0.32H, 1-H’β), 4.28 (m, 1.6H), 4.2-
3.95 (m, 2.6H), 3.60 (m, 1.3H), 2.5 – 0.7 (m). 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 199.25, 199.23, 170.87, 170.82, 
170.59, 170.56, 170.25, 170.12, 169.78, 169.64, 123.84+, 99.93+, 95.01+, 89.07+, 
84.37+, 71.86+, 70.76+, 69.50, 69.22, 69.08, 67.72, 62.62, 62.39, 53.92, 53.82, 
50.47, 50.20, 42.79, 42.30, 38.56, 38.55, 37.26, 36.95, 36.34, 35.66, 35.34, 35.29, 
33.85, 32.66, 31.43, 28.82, 26.82, 26.71, 23.28, 23.25, 20.89, 20.81, 20.71, 20.67, 
20.64, 20.63, 20.52, 20.50, 17.35, 17.32, 11.61 
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1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 1096 Hz = 2.19 α: 5.30 
(ddd, 1H, 3-H), 4.97 (dd, 1H, 4-H), 4.95 (d, 1H, 1-H), 4.27 (dd, 1H, 6-H), 4.04 (dd, 
1H, 6-H’), 3.99 (ddd, 1H, 5-H), 2.19 (dd, 1H, 2-H), 1.82 (ddd, 1H, 2-H’) 
  
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2302 Hz = 4.60 β: 4.98 
(ddd, 1H, 3-H), 4.95 (dd, 1H, 4-H), 4.60 (dd, 1H, 1-H), 4.26 (dd, 1H, 6-H), 4.09 (dd, 
1H, 6-H’), 3.56 (ddd, 1H, 5-H), 2.32 (ddd, 1H, 2-H), 1.73 (ddd, 1H, 2-H’). 
 
LC-MS (ESI) (+c): m/z (%): 583.29 (100) [M + Na]+; HR-MS C31H44O9 +23Na: calc. 
583.2883, found 583.2888. 
 
Dehydro-epi-androsteryl 2´-deoxy-3´,4´,6´-tri-O-acetyl-α/β-D-arabino-
hexopyranoside (152) 
O
OAc
AcO
AcO O
H
H H
O
 
The reaction was carried out according to the protocol TP1: 
 
Yield: 55 mg (0.098 mmol, 98%, α/β - 2:1) 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.38 (dd+m, J = 14.3, 5.3 Hz, 
1H+0.32H, 6-H + 3-H’α), 5.12 (d, J = 3.1 Hz, 0.6H, 1-H’α), 5.00 (m, 1.32H, 4-H’, 3-
H’β), 4.70 (dd, J = 9.8, 1.6 Hz, 0.32H, 1-H’β), 4.4-4.0 (m, 2.7H, 6-H’, 5-H’α), 3.5 
(m, 0.33H, 5-H’β), 2.5 – 0.7 (m) 
  
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 220.98, 220.95, 170.71, 170.20, 
169.91, 140.91, 140.71, 97.84+, 95.04+, 81.81+, 78.71+, 70.77+, 69.65+, 69.15+, 
67.87+, 64.35+, 62.53-, 51.73+, 50.23+, 47.49, 42.69, 39.93-, 38.79-, 37.14-, 
36.97-, 36.82-, 36.65-, 36.54-, 35.79-, 35.50-, 31.90+, 31.45+, 31.40-, 30.77-, 
30.47-, 29.64-, 29.43-, 27.68-, 25.31+, 23.39+, 21.83-, 20.94+, 20.73+, 20.70+, 
20.30-, 19.33+, 13.50+, 10.91+ 
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1H-NMR (500 MHz, CDCl3, CDCl3=7.26 ppm) TOCSY: 2567 Hz = 5.13 α: 5.37 
(ddd, 1H, 3-H), 5.13 (d, 1H, 1-H) 4.97 (dd, 1H, 4-H), 4.28 (dd, 1H, 6-H), 4.07 (dd, 
1H, 6-H’), 4.06 (ddd, 1H, 5-H), 2.20 (dd, 1H, 2-H), 1.82 (ddd, 1H, 2-H’) 
  
1H-NMR (500 MHz, CDCl3, CDCl3=7.26 ppm) TOCSY: 2302 Hz = 4.60 β: 5.05 
(ddd, 1H, 3-H), 4.97 (dd, 1H, 4-H), 4.70 (dd, 1H, 1-H), 4.30 (dd, 1H, 6-H), 4.09 (dd, 
1H, 6-H’), 3.60 (ddd, 1H, 5-H), 2.30 (ddd, 1H, 2-H), 1.77 (ddd, 1H, 2-H’). 
 
1-O-(2´-deoxy-3´,4´,6´-tri-O-acetyl-α/β-D-arabino-hexopyranosyl) (2:3, 4:5-di-
O-isopropyliden)-α-D-fructo-hexopyranoside (153)  
O
OAc
AcO
AcO
O
O
O
OOO
 
The reaction was carried out according to the protocol TP1: 
 
Yield: 50 mg (0.094 mmol, 94%, α/β - 2:1) 
 
α-anomer 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.30 (ddd, J = 11.5, 9.6, 5.1 Hz, 
1H 3-H’), 5.01 (dd, J = 9.6, 9.6 Hz, 1H, 4-H’), 4.99 ( d, J = 3.1 Hz, 1H, 1-H’), 4.62 
(dd, J = 7.9, 2.6 Hz, 1H, 3-H), 4.40 (d, J = 2.6 Hz, 1H, 2-H), 4.29 (dd, J = 12.2, 4.6 
Hz, 1H, 6-H’), 4.24 (dd, J = 7.9, 1.5 Hz, 1H, 4-H), 4.05 (m, 2H, 6-H’, 5-H’), 3.93 
(dd, J = 12.9, 1.5 Hz, 1H, 5-H),  3.82 (d, J = 10.3 Hz, 1H, 6-H), 3.73 (d, J = 12.9 
Hz, 1H, 5-H), 3.45 (d, J = 10.3 Hz, 1H, 6-H), 2.30 (dd, J = 12.8, 5.1 Hz, 1H, 2-H’), 
2.08, 2.03, 1.99 (3s, 9H, 3xAc), 1.83 (ddd, J = 12.8, 11.5, 3.1 Hz, 1H, 2-H’), 1.55, 
1.50, 1.46, 1.34 (4s, 12H, 4xCH3) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 170.73, 170.11, 169.87, 109.04, 
108.82, 101.96, 96.88, 71.02, 70.19, 69.87, 69.06, 69.00, 68.20, 68.15, 62.17, 
61.12, 34.82, 26.55, 25.91, 25.49, 24.05, 20.91, 20.76, 20.71 
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1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 1880 Hz= 3.76 fructose: 
4.64 (dd, 1H, 3-H), 4.43 (d, 1H, 2-H), 4.26 (dd, 1H, 4-H), 3.95 (dd, 1H, 5-H), 3.75 
(d, 1H, 5-H). 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 1738 Hz= 3.48 fructose: 
3.85 (d, 1H, 6-H), 3.47 (d, 1H, 6-H). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 1164 Hz= 2.33 glucose: 
5.32 (ddd, 1H, 3-H), 5.04 (dd, 1H, 4-H), 5.02 (d, 1H, 1-H), 4.31 (dd, 1H, 6-H), 4.08 
(m, 2H, 6-H, 5-H), 2.32 (dd, 1H, 2-H), 1.85 (ddd, 1H, 2-H). 
 
LC-MS (ESI) (+c): m/z (%): 555.16 (100) [M + Na]+; HR-MS C24H36O13 +23Na: calc. 
555.2054, found 555.2066.  
  
[α]25D = + 44.5o (c = 1 in CHCl3). 
 
β-anomer 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.00 (m, 1H, 3-H’), 4.96 (dd, J = 
9.3, 9.3 Hz, 1H, 4-H’), 4.70 (dd, J = 9.5, 1.6 Hz, 1H, 1-H’), 4.59 (dd, J = 8.0, 2.6 Hz, 
1H, 3-H), 4.38 (d, J = 2.6 Hz, 1H, 2-H), 4.26 (dd, J = 12.4, 5.1 Hz, 1H, 6-H’), 4.23 
(dd, J = 8.3, 8.0 Hz, 1H, 4-H), 4.27 (m, 1H, 6-H’), 4.12-3.90 (m, 2H, 5-H, 6-H’), 
3.72 (m, 2H, 5-H, 6-H), 3.59 (ddd, J = 9.3, 5.0, 2.3 Hz, 1H, 5-H’), 2.36 (ddd, J = 
12.2, 4.7, 1.6 Hz, 1H, 2-H’), 2.07, 2.03, 2.02 (3s, 9H, 3xAc), 1.74 (ddd, J = 11.6, 
12.2, 9.5 Hz, 1H, 2-H’), 1.54, 1.45, 1.38, 1.33 (4s, 12H, 4xCH3) 
  
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 170.72, 170.23, 169.78, 109.01, 
108.62, 102.27, 99.97, 72.01, 70.92, 70.59, 70.10, 69.99, 69.57, 69.18, 62.55, 
61.14, 35.87, 26.58, 25.85, 25.50, 23.97, 20.89, 20.74, 20.70 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2365 Hz= 4.73 glucose: 
5.04 (ddd, 1H, 3-H), 4.99 (dd, 1H, 4-H), 4.73 (dd, 1H, 1-H), 4.28 (dd, 1H, 6-H), 4.12 
(dd, 1H, 6-H), 3.62 (ddd, 1H, 5-H), 2.38 (ddd, 1H, 2-H), 1.77 (ddd, 1H, 2-H) 
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1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2310 Hz= 4.62 fructose: 
4.61 (dd, 1H, 3-H), 4.41 (d, 1H, 2-H), 4.24 (dd, 1H, 4-H), 3.93 (dd, 1H, 5-H), 3.76 
(d, 1H, 5-H) 
  
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 1738 Hz= 3.48 fructose: 
3.85 (d, 1H, 6-H), 3.47 (d, 1H, 6-H). 
 
LC-MS (ESI) (+c): m/z (%): 555.17 (100) [M + Na]+; HR-MS C24H36O13 +23Na: calc. 
555.2054, found 555.2054.  
 
[α]25D = - 5.2o (c = 0.5 in CHCl3).   
 
3-O-(2´-deoxy-3´,4´,6´-tri-O-acetyl-α/β-D-arabino-hexopyranosyl) (1:2, 5:6-di-
O-isopropyliden)-α-D-gluco-hexofuranoside (154) 
O
OAc
OAc
OAc
O
O
O
O
O
O
 
The reaction was carried out according to the protocol TP1. 
 
Yield: 42 mg (0.079 mmol, 79%, α/β - 4:1) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.97 (d, J = 3.7 Hz, 0.2H, 1-H), 
5.88 (d, J = 3.5 Hz, 0.8H, 1-H), 5.26 (ddd, J = 11.7, 9.6, 5.4 Hz, 1H, 3-H’), 5.23 (d, 
J = 2.4 Hz, 0.8H, 1-H’α), 4.99 (dd, J = 9.6, 1.5 Hz, 0.2H, 1-H’β), 4.95 (dd, J = 9.6, 
9.6 Hz, 1H, 4-H’), 4.56 (d, J = 3.7 Hz, 0.2H, 2-H), 4.55 (d, J = 3.5 Hz, 0.8H, 2-H), 
4.32 (dd, J = 6.8, 3.8 Hz, 0.2H), 4.27 (dd, J = 12.0, 5.6 Hz, 1H), 4.23 (d, J = 2.7 Hz, 
0.8H), 4.21 (d, J = 4.1 Hz, 0.2H), 4.11 (m, 2.6H), 4.05 (m, 2.2H), 3.96 (dd, J = 8.1, 
4.8 Hz, 0.8H), 3.7 (m, 0.6H), 2.25 (dd, J = 13.0, 5.4 Hz, 1H, 2-H’), 2.08, 2.07, 2.03, 
2.01, 2.00, 1.99 (6s, 9H, 3xAc), 1.82 (ddd, J = 13.0, 11.7, 3.7 Hz, 1H, 2-H’) 1.48, 
1.41, 1.38, 1.34, 1.31, 1.30, 1.29 (5s, 12H, 4xCH3) 
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13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) α’α-diastereomer δ: 170.66, 170.10, 
169.81, 111.97, 109.22, 105.29, 98.07, 84.00, 81.33, 80.71, 72.40, 69.57, 68.63, 
67.78, 62.60, 34.64, 26.86, 26.82, 26.31, 25.31, 20.88, 20.66 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) β’α -diastereomer δ: 170.69, 170.10, 
169.86, 112.21, 106.35, 100.94, 96.68, 84.04, 81.33, 79.15, 75.02, 71.11, 69.27, 
69.07, 67.84, 67.28, 62.16, 34.81, 29.65, 27.16, 27.16, 26.88, 26.54, 23.97, 23.95, 
20.93, 20.72 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 926 Hz= 1.85 pyranose 
α’α + βα: 5.29 (ddd, 1H, 3-H), 5.26 (s, 0.8H, 1-Hα), 5.00 (dd, 0.2H, 1-Hβ), 4.98 
(dd, 1H, 4-H), 4.29 (dd, 1H, 6-H), 4.14 (dd, 1H, 6-H), 4.04 (ddd, 1H, 5-H), 2.27 (dd, 
1H, 2-H), 1.85 (ddd, 1H, 2-H) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2957 Hz= 5.91 furanose 
α’α: 5.91 (d, J = 3.47 Hz, 1-H), 4.57 (d, J = 5.99 Hz, 2-H), 4.25 (d,), 4.15 (dd,), 4.06 
(dd, 6-H), 3.99 (dd, 6-H) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 3000 Hz= 6.00 furanose 
β’α : 6.00 (d, 1-H), 4.59 (d, 2-H), 4.34 (dd,), 4.23 (d,), 3.72 (bdd, 6-H) 
 
Digitoxigenyl 2-deoxy-3,4,6-tri-O-acetyl-α/β-D-arabino-pyranoside (155) 
O
OAc
AcO
AcO
O
O
OH
O
H
H
H
 
The reaction was carried out according to the protocol TP1. 
 
Yield: 64 mg (0.099 mmol, 99%, α/β - 4:1) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.86 (s, 1H, 22-H), 5.35 (ddd, J 
= 11.5, 9.5, 5.3 Hz, 0.8H, 3-H’), 5.03 (d, J = 3.0 Hz, 0.8H, 1-H’), 4.97 (bdd, J = 8.0, 
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8.44 Hz, 1.0H+0.2H, 4-H’, 3-H’), 4.97 (d, J = 18.0 Hz, 1H, 21-H), 4.79 (d, J = 18.0 
Hz, 1H, 21-H), 4.61 (dd, J = 9.6, 1.5 Hz, 0.2H, 1-H’), 4.28 (dd, J = 12.4, 4.6 Hz, 1H, 
6-H’), 4.11 (bdd, J = 14.2, 7.0 Hz, 1.2H, 6-H’), 4.00 (m, 1.8H), 3.91 (bs, 0.8H), 2.75 
(m, 1H, 3-H), 2.27 (ddd, J = 12.7, 3.0, 1.5 Hz, 0.2H, 2-H’), 2.4 – 0.7 (m).  
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) α-anomer δ: 174.40, 170.68, 170.32, 
169.88, 117.68, 94.61, 85.51, 73.38, 71.65, 69.75, 69.21, 67.93, 62.46, 60.34, 
50.90, 49.57, 41.83, 39.99, 36.53, 35.68, 35.53, 35.21, 33.13, 31.88, 29.97, 26.85, 
26.51, 23.77, 23.65, 21.27, 21.14, 20.97, 20.73, 20.71, 15.73, 14.16 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) β-anomer δ: 174.43, 171.08, 170.37, 
169.72, 117.68, 97.45, 85.52, 73.60, 71.90, 70.95, 69.29, 67.93, 62.67, 60.34, 
50.90, 49.57, 41.83, 40.02, 36.69, 36.29. 35.75, 35.15, 33.10, 30.04, 29.91, 26.88, 
26.55, 26.47, 23.60, 21.35, 21.14, 20.99, 20.76, 15.73, 14.16 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2535 Hz= 5.07, α-anomer: 
5.38 (ddd, 1H, 3-H), 5.07 (d, 1H, 1-H), 5.00 (dd, 1H, 4-H), 4.31 (dd, 1H, 6-H), 4.04 
(dd, 1H, 6-H), 4.01 (ddd, 1H, 5-H), 2.20 (ddd, 1H, 2-H), 1.87 (ddd, 1H, 2-H) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2321 Hz= 4.61, β-anomer: 
5.03 (ddd, 1H, 3-H), 4.99 (dd, 1H, 4-H), 4.64 (dd, 1H, 1-H), 4.28 (dd, 1H, 6-H), 4.11 
(dd, 1H, 6-H), 3.59 (ddd, 1H, 5-H), 2.30 (dd, 1H, 2-H), 1.79 (ddd, 1H, 2-H). 
 
LC-MS (ESI) (+c): m/z (%): 669.32 (100) [M + Na]+; HR-MS C35H50O11 +23Na: calc. 
669.3251, found 669.3248.  
 
Ethyl 4-O-(2´-deoxy-3´,4´,6´-tri-O-acetyl-α/β-D-arabino-hexopyranosyl) 2,3-
dideoxy-6-pivaloyl-α-threo-D-hexopyranoside (156) 
O
OAc
AcO
AcO
O
O
O
PivO
 
The reaction was carried out according to the protocol TP1. 
 
Yield: 51 mg (0.096 mmol, 96%, α/β - 2: 1) 
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1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.22 (ddd, J = 11.5, 9.4, 5.2 Hz, 
0.7H, 3-H’α), 5.17 (d, J = 3.0 Hz, 0.7H, 1-H’α), 5.00 (dd, J = 9.6, 9.8 Hz, 0.7H, 4-
H’α), 4.99 (ddd, J = 11.2, 9.3, 5.1 Hz, 0.3H, 3-H’β), 4.94 (dd, J = 9.3, 9.3 Hz, 0.3H, 
4-H’β), 4.77 (d, J = 2.2 Hz, 0.7H, 1-Hα), 4.76 (d, J = 2.8 Hz, 0.3H, 1-Hβ), 4.59 (dd, 
J = 9.6, 2.5 Hz, 0.3H, 1-H’β), 4.39 (dd, J = 11.5, 2.2 Hz, 0.7H, 6-Hα), 4.30 (dd, J = 
12.2, 4.6 Hz, 0.7H, 6-Hα), 4.26 (m, 0.6H, 6-Hβ), 4.17 (dd, J = 11.5, 6.7 Hz, 0.7H, 
6-H’α), 4.14 (dd, J = 11.6, 5.9 Hz, 0.3H, 6-H’β), 4.10 (dd, J = 12.0, 2.6 Hz, 0.3H, 6-
H’β), 4.03 (dd, J = 12.2, 2.2 Hz, 0.7H, 6-H’α), 3.92 (ddd, J = 10.0, 4.5, 2.2 Hz, 0.7 
H, 5-Hα), 3.89 (ddd, J = 9.4, 6.8, 2.2 Hz, 0.7H, 5-H’α), 3.83 (ddd. J = 9.7, 6.0, 1.9 
Hz, 0.3H, 5-Hβ), 3.74 (dq, J = 9.7, 7.1 Hz, 0.7H, H-Et-CH2α), 3.70 (dq, J = 9.7, 7.1 
Hz, 0.3H, H-Et-CH2β), 3.6-3.48 (m, 1.3H, 5-H’α, 4-Hα, 4-Hβ), 3.45 (dq, J = 9.7, 7.1 
Hz, 0.7H, H-Et-CH2α), 3.43 (dq, J = 9.7, 7.1 Hz, 0.3H, H-Et-CH2β), 2.28 (ddd, J = 
12.8, 4.8, 2.0 Hz, 0.3H, 2-H’β), 2.20 (ddd, J = 12.9, 5.2, 1.3 Hz, 0.7H, 2-H’α), 2.09, 
2.04, 2.00 (3s, 6H, 3 x Ac α), 2.06, 2.02, 2.01 (3s, 3H, 3 x Ac β), 1.22 (s, 6H, Piv 
α), 1.22 (m, 3H, Et), 1.21 (s, 3H, Piv β). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 178.19, 170.63, 170.17, 170.08, 
169.86, 169.73, 100.27+, 95.71+, 95.54+, 92.40+, 75.67+, 71.94+, 70.40+, 69.74+, 
69.69+, 69.39+, 69.19+, 69.08+, 69.04+, 68.70+, 63.72-, 62.54-, 38.81-, 35.14-, 
29.66-, 28.64-, 27.24+, 22.59-, 20.93+, 20.83+, 20.70+, 20.68+, 15.00+ 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2209 Hz= 4.42, α’α-
diastereomer: 4.80 (d, 1H, 1-H), 4.41 (d, 1H, 6-H), 4.20 (dd, 1H, 6-H), 3.92 (ddd, 
1H, 5-H), 3.57 (ddd, 1H, 4-H), 2.1-1.6 (m, 4H, 3-H, 2-H). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 1928 Hz= 3.86, β’α-
diastereomer:  4.78 (d, 1-H), 4.30 (dd, 1H, 6-H), 4.17 (dd, 1H, 6-H), 3.86 (ddd, 1H, 
5-H), 3.52 (ddd, 1H, 4-H), 2.1-1.6 (m, 4H, 3-H, 2-H). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2310 Hz= 4.62, β’α-
diastereomer: 5.01 (ddd, 1H, 3-H’), 4.96 (dd, 1H, 4-H’), 4.62 (dd, 1H, 1-H’), 4.28 
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(dd, 1H, 6-H’); 4.12 (dd, 1H, 6-H’), 3.60 (ddd, 1H, 5-H’), 2.31 (ddd, 1H, 2-H’), 1.76 
(ddd, 1H, 2-H’). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2601 Hz= 5.20, α’α-
diastereomer:  5.25 (ddd, 1H, 3-H’), 5.20 (d, 1H, 1-H’), 5.03 (dd, 1H, 4-H’), 4.33 
(dd, 1H, 6-H’); 4.06 (dd, 1H, 6-H’), 3.94 (ddd, 1H, 5-H’), 2.23 (ddd, 1H, 2-H’), 1.87 
(ddd, 1H, 2-H’). 
 
LC-MS (ESI) (+c): m/z (%): 555.19 (100) [M + Na]+; HR-MS C25H40O12 +23Na: calc. 
555.2417, found 555.2402.  
 
7-O-(2´-Deoxy-3´,4´,6´-tri-O-acetyl-α/β-D-arabino-pyranosyl)-3,4-di-O-acetyl-
decarestrictine (157) 
O
OAc
AcO
AcO
O
O
OAc
OAc
O
 
The reaction was carried out according to the protocol TP1. 
 
Yield: 56 mg (0.098 mmol, 98%, α/β - 2:1) 
 
1st fraction: 157β 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.81 (dd, J = 16.0, 3.6 Hz, 1H, 
5-H), 5.63 (ddd, J = 16.0, 9.6, 1.1 Hz, 1H, 6-H), 5.34 (ddd, J = 4.8, 3.6, 0.91 Hz, 
1H, 4-H), 5.16 (ddq, J = 17.6, 6.3, 1.6 Hz, 1H, 9-H), 5.04 (ddd, J = 7.3, 4.8, 2.5 
Hz,1H, 3-H), 4.95 (m, 2H, 3-H’, 4-H’), 4.50 (dd, J = 9.6, 1.8 Hz, 1H, 1-H’β), 4.33 
(ddd, J = 10.8, 9.6, 4.0 Hz, 1H, 7-H), 4.28 (dd, J = 12.2, 4.9 Hz, 1H, 6-H’), 4.07 (dd, 
J = 12.1, 2.2 Hz, 1H, 6-H’), 3.51 (ddd, J = 9.4, 5.0, 2.3 Hz, 1H, 5-H’), 2.69 (dd, J = 
14.1, 7.3 Hz, 1H, 2-H), 2.54 (dd, J = 14.1, 2.5 Hz, 1H, 2-H), 2.23 (ddd, J = 12.3, 
4.0, 1.6 Hz, 1H, 8-H), 2.19, 2.13, 2.10 (3s, 9H, 3 x CH3CO’), 2.02, 2.01 (2s, 6H, 2 x 
CH3CO), 1.95 (bd, J = 12.3 Hz, 1H, 8-H), 1.65 – 1.90 (m, 2H, 2 x 2-H’), 1.21 (d, J = 
6.3 Hz, 3H, 10-H).     
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13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 170.6, 170.3, 169.8, 169.4, 
169.1, 133.8, 127.0, 95.3, 72.0, 72.0, 70.9, 70.8, 69.1, 68.1, 62.5, 40.8, 36.1, 33.5, 
21.3, 21.0, 20.9, 20.8, 20.7. 
 
LC-MS (ESI) (+c): m/z (%): 595.17 (100) [M + Na]+; HR-MS C27H38O13 +23Na: calc. 
595.2003, found 595.2003.  
 
[α]25D = - 3.7o (c = 0.5 in CHCl3). 
 
2nd fraction 157α 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.79 (dd, J = 16.6, 9.0 Hz, 1H, 
6-H), 5.72 (dd, J = 16.6, 3.1, 1H, 5-H), 5.32 (dd, J = 5.2, 3.1, 0.9 Hz, 1H, 4-H), 5.27 
(ddd, J = 11.3, 10.0, 5.3 Hz, 1H, 3-H’), 5.01 (ddq, J = 11.1, 6.4, 1.7 Hz, 1H, 9-H), 
5.04 (ddd, J = 7.2, 5.2, 2.8 Hz,1H, 3-H), 5.00 (d, J = 2.7 Hz, 1H, 1-H’α),  4.98 (t, J 
= 10.0 Hz, 1H, 4-H’), 4.27 (dd, J = 12.3, 3.7 Hz, 1H, 6-H’), 4.07 (ddd, J = 10.6, 9.0, 
3.5 Hz, 1H, 7-H), 3.92 (dd, J = 12.3, 2.2 Hz, 1H, 6-H’),  3.87 (ddd, J = 10.0, 3.7, 2.3 
Hz, 1H, 5-H’), 2.67 (dd, J = 14.1, 7.2 Hz, 1H, 2-H), 2.56 (dd, J = 14.1, 2.8 Hz, 1H, 
2-H), 2.16 (m, 1H, 8-H), 2.17, 2.11, 2.09 (3s, 9H, 3 x CH3CO’), 2.02, 2.00 (2s, 6H, 
2 x CH3CO), 1.89 (ddd, J = 14.0, 3.3, 1.7 Hz, 1H, 8-H), 1.80 (bt, J = 11.3 Hz, 2H, 2 
x 2-H’), 1.22 (d, J = 6.4 Hz, 3H, 10-H).     
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 170.6, 170.3, 169.8, 169.79, 
169.4, 169.0, 135.1, 124.0, 95.6, 72.1, 70.7, 69.2, 69.0, 68.1, 67.9, 62.0, 40.1, 
35.1, 33.7, 21.4, 21.0, 20.9, 20.87, 20.71, 20.70. 
 
LC-MS (ESI) (+c): m/z (%): 595.17 (100) [M + Na]+; HR-MS C27H38O13 +23Na: calc. 
595.2003, found 595.2007. 
 
[α]25D = + 105.5o (c = 1 in CHCl3). 
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Allyl 4-O-(2´-deoxy-3´,4´,6´-tri-O-acetyl-α/β-D-arabino-pyranosyl)-3-azido-
2,3,6-trideoxy-α-L-arabino-pyranoside (158) 
O
OAc
AcO
AcO
O
O
N3
O
 
The reaction was carried out according to the protocol TP1. 
 
Yield: 39 mg (0.08 mmol, 80%, α/β - 2:1) 
 
anomeric mixture 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.92 (ddd, J = 22.4, 10.5, 6.0 Hz, 
1H, CH=CH2), 5.35-5.20 (m, 3H, 3-H, CH=CH2), 5.1 (bs, 1H), 5.07 (dd, J = 9.4, 9.4 
Hz, 1H, 4-H), 4.91 (d, J = 2.8 Hz, 0.9H, 1-Hα), 4.4 (m, 1.8H), 4.1 (m, 2.6H), 3.95 
(dd, J = 12.8, 6.1 Hz, 1H), 3.75 (m, 2H), 3.14 (dd, J = 9.4, 9.4 Hz, 1H, 4-H’), 2.28 
(dd, J = 12.9, 5.0 Hz, 2H), 2.11, 2.07, 2.04 (3s, 9H, 3Ac), 2.06 (m, 2H), 1.84 (dddd, 
J = 20.8, 11.9, 11.9, 3.4 Hz, 2H), 1.25 (d, J = 6.3 Hz, 3H, 6-H’). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 170.82, 170.26, 169.92, 133.74+, 
117.50-, 98.36+, 95.22+, 81.83+, 68.95+, 68.69+, 67.86-, 67.25+, 62.22-, 58.17+, 
35.19-, 35.01-, 29.67-, 20.97+, 20.75+, 18.04+ 
 
α’α-diastereomer 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.91 (ddd, J = 16.8, 11.1, 5.5, 
5.4 Hz, 1H, -CH=CH2), 5.30 (dq, J = 17.0, 1.5 Hz, 1H, -CH=CHH’), 5.29 (ddd, J = 
11.6, 9.6, 5.1 Hz, 1H, 3-H’), 5.21 (dq, J = 10.4, 1.1 Hz, 1H, -CH=CHH’), 5.08 (d, J 
= 3.0 Hz, 1H, 1-H’), 5.04 (t, J = 9.6 Hz, 1H, 4-H’), 4.89 (d, J = 2.8 Hz, 1H, 1-H), 
4.39 (m, 2H, 5-H’, 6-H’), 4.12 (dd, J = 13.0, 5.3 Hz, 1H, O-CHH’-CH=), 4.10 (m, 
1H, 6-H’), 3.94 (dd, J = 12.8, 6.1 Hz, 1H, O-CHH’-CH=), 3.74 (dq, J = 9.4, 6.2 Hz, 
1H, 5-H), 3.73 (m, 1H, 3-H), 3.13 (t, J = 9.4 Hz, 1H, 4-H), 2.26 (bd, J = 12.9 Hz, 
2H, 2-Hax, 2-Hax’), 2.09, 2.05, 2.02 (3s, 9H, 3 x CH3CO), 1.85 (dt, J = 12.6, 3.4 Hz, 
1H, 2-Heq’), 1.80 (dt, J = 12.6, 3.45 Hz, 1H, 2-Heq), 1.23 (d, J = 6.2 Hz, 3H, 6-H). 
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13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 170.8, 170.2, 169.9 (3s, 3 x 
CH3CO), 133.8 (d, -CH=CH2), 117.5 (t, -CH=CH2), 98.4 (d, C-1’), 95.3 (d, C-1), 
81.9 (d, C-4), 69.1 (d, C-4’), 69.0 (d, C-3’), 68.7 (d, C-5’), 67.9 (t, O-CH2-CH=), 
67.3 (d, C-5), 62.3 (t, C-6’), 58.2 (d, C-3), 35.2, 35.1 (2t, C-2, C-2’), 20.9 (q, 
CH3CO), 20.7 (q, 2 x CH3CO), 18.1 (q, C-6).  
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2461 Hz = 4.92: 4.92 (d, 
1H, 1-H), 3.75 (m, 2H, 3-H, 5-H), 3.15 (dd, 1H, 4-H), 2.29 (ddd, 1H, 2-Hax), 1.82 
(ddd, 1H, 2-Heq), 1.26 (d, 3H, 6-H). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2205 Hz = 4.41: 5.31 (ddd, 
1H, 3-H’), 5.10 (d, 1H, 1-H’), 5.07 (t, 1H, 4-H’), 4.42 (dd, 1H, 5-H’), 4.40 (dd, 1H, 6-
H’), 4.12 (dd, 1H, 6-H’), 2.29 (dd, 1H, 2-Hax’), 1.88 (dd, 1H, 2-Heq’). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2622 Hz = 5.24: 5.94 (ddd, 
1H, -CH=CH2), 5.33 (dq, 1H, -CH=CHH’), 5.24 (dq, 1H, -CH=CHH’), 4.15 (ddd, 1H, 
O-CHH’-CH=), 3.97 (dd, 1H, O-CHH’-CH=). 
 
LC-MS (ESI) (+c): m/z (%): 595.17 (100) [M + Na]+; HR-MS C27H38O13 +23Na: calc. 
595.2003, found 595.2003.  
 
4-O-(3’,4’,6´-Tri-O-acetyl-2’-deoxy-α/β-D-arabino-hexopyranosyl)-1,5-anhydro-
3-O-benzoyl-2,6-dideoxy-L-arabino-hex-1-enit (159) 
O
OAc
AcO
AcO
O
OBz
O
 
The reaction was carried out according to the protocol TP1. 
 
Yield: 38 mg (0.075 mmol, 75%, α/β - 2:1). 
 
anomeric mixture 
 1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 8.05 (d, 2H, Ph), 7.5 (m, 3H, 
Ph), 6.51 (dd, J = 6.0, 1.0 Hz, 1H, 1-H’), 5.59 (dd, J = 4.6, 3.7 Hz, 1H, 3-H’), 5.32 
(ddd, J = 11.5, 9.6, 5.1 Hz, 1H, 3-H), 5.23 (d, J = 2.6 Hz, 0.7H, 1-Hα), 5.02 (dd, J = 
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9.6, 9.6 Hz, 1H, 4-H), 4.91 (dd, J = 5.9, 3.5 Hz, 1H, 2-H’), 4.3-3.8 (m, 5H), 2.32 
(ddd, J = 12.8, 5.1, 0.9 Hz, 1H, 2-H), 2.04, 2.02, 2.01 (3s, 9H, 3Ac), 1.88, (ddd, J = 
12.8, 11.5, 3.54 Hz, 1H, 2-H), 1.46 (d, J = 6.6 Hz, 3H, 6-H). 
 
α-anomer 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 8.01 (d, J = 7.3 Hz, 2H, Ph-o), 
7.57 (t, J = 7.3 Hz, 1H, Ph-p), 7.44 (t, J = 7.3 Hz, 2H, Ph-m), 6.47 (d, J = 6.0 Hz, 
1H, 1-H), 5.55 (dd, J = 4.8, 3.7 Hz, 1H, 3-H), 5.28 (ddd, J = 11.8, 9.6, 5.0 Hz, 1H, 
3-H’), 5.19 (d, J = 2.8 Hz, 1H, 1-H’), 4.98 (t, J = 9.6, 1H, 4-H’), 4.87 (dd, J = 6.0, 
3.7 Hz, 1H, 2-H), 4.20 (dq, J = 6.5, 6.5 Hz, 1H, 5-H), 4.06 (m, 2H, 5-H’, 6-H’), 3.90 
(dd, J = 6.5, 4.8 Hz, 1H, 4-H), 3.82 (dd, J = 12.0, 1.3 Hz, 1H, 6-H’), 2.27 (dd, J = 
12.5, 5.0 Hz, 1H, 2-Hax’), 1.99, 1.98, 1.97 (3s, 9H, 3 x CH3CO), 1.84 (ddd, J = 12.5, 
11.8, 2.8 Hz, 1H, 2-Heq’), 1.42 (d, J = 6.5 Hz, 3H, 6-H). 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 170.6, 170.1, 169.8 (3s, 3 x 
CH3CO), 166.0 (s, PhCO), 146.1 (d, C-1), 133.2 (d, Ph–p), 130.0 (s, P1-H), 129.6 
(d, Ph-o), 128.5 (d, Ph-m), 98.3 (d, C-2), 97.1 (d, C-1’), 77.0 (d, C-4), 72.3 (d, C-5), 
69.3 (d, C-3), 68.9, 68.8, 68.6 (3d, C-3’, C-4’, C-5’), 61.8 (t, C-6’), 35.1 (t, C-2’), 
20.9, 20.64, 20.60 (3q, 3 x CH3CO), 16.8 (q, C-6). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 3250 Hz= 6.50: 6.50 (d, 
1H, 1-H), 5.58 (m, 1H, 3-H), 4.89 (dd, 1H, 2-H), 4.22 (dq, 1H, 5-H), 3.92 (dd, 1H, 4-
H), 1.46 (d, 3H, 6-H). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2608 Hz= 5.21: 5.30 (ddd, 
1H, 3-H’), 5.21 (d, 1H, 1-H’), 5.01 (t, 1H, 4-H’), 4.10 (d, 1H, 6-H’), 4.07 (dd, 1H, 5-
H’), 3.85 (d, 1H, 6-H’), 2.30 (ddd, 1H, 2-Hax’), 1.86 (dt, 1H, 2-Heq’). 
 
LC-MS (ESI) (+c): m/z (%): 529.17 (100) [M + Na]+; HR-MS C25H30O11 +23Na: calc. 
529.1686, found 529.1669. 
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Testosteryl [2´,6´-dideoxy-3´,4´-di-O-triethylsilyl]-α/β-L-arabino-
hexopyranoside (160) 
O
OTES
TESO
O
H
HH
O
 
The reaction was carried out according to the protocol TP2. 
 
Yield: 30 mg (0.046 mmol, 93%, α/β - 2:1) 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.76 (s, 1H, 4-H), 4.83 (d, J = 2.6 
Hz, 0.7H, 1-H’, α), 4.44 (dd, J = 9.7, 1.8 Hz, 0.3H, 1-H’, β), 3.96 (ddd, J = 11.3, 8.6, 
4.8 Hz, 0.7H, 3-H’), 3.73 (ddq, J = 9.0, 6.1 , 5.9 Hz, 1H, 5-H’), 3.51 (dd, J = 9.0, 8.6 
Hz, 1H, 4-H’), 3.12 (dd, J = 8.5, 8.5 Hz, 1H, 17-H), 1.32 (d, J = 6.1 Hz, 3H, 6-H’), 
2.5 – 0.7 (m).  
 
Testosteryl [2´,6´-dideoxy-3´,4´-di-O-(tert-butyldimethylsilyl)]-α/β-L-arabino-
hexopyranoside (161) 
O
OTBS
TBSO
O
H
HH
O
 
 The reaction was carried out according to the protocol TP2. 
 
Yield: 32 mg (0.049 mmol, 99%, α/β - 2:1) 
 
1st fraction: 161β 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.72 (s, 1H, 4-H), 4.38 (dd, J = 
9.7, 1.6 Hz, 1H 1-H’), 3.63 (t, J = 8.5 Hz, 1H, 17-H), 3.60 (m, 1H, 5-H’), 3.15 (m, 
2H, 3-H’, 4-H’), 2.5 – 0.7 (m). 
 
 200
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 199.5, 171.3, 123.8, 98.4, 87.2, 
77.9, 73.3, 72.6, 54.0, 50.7, 42.4, 41.3, 38.7, 36.6, 35.7, 35.5, 34.0, 32.8, 31.6, 
27.7, 26.9, 26.3, 26.1, 23.2, 20.6, 18.8, 18.3, 18.1, 17.4, 11.7, -2.7, -3.0, -3.8, -4.0 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2204 Hz= 4.41: 4.41 (d, 
1H, 1-H’), 3.62 (ddd, 1H, 5-H’), 3.18 (m, 2H, 3-H’, 4-H’), 2.07 (ddd, 1H, 2-Hax’), 
1.61 (dd, 1H, 2-Heq’), 1.27 (d, 3H, 6-H’). 
 
LC-MS (ESI) (+c): m/z (%): 669.43 (100) [M + Na]+; HR-MS C37H66O5Si2 +23Na: 
calc. 669.4347, found 669.4354. 
 
[α]25D = + 64.6o (c = 1 in CHCl3).   
  
2nd fraction: 161α  
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.72 (s, 1H, 4-H), 4.79 (d, J = 
2.0 Hz, 1H 1-H’), 3.93 (ddd, J = 11.0, 8.7, 4.3 Hz, 1H, 3-H’), 3.63 (dq, J = 8.7, 6.4 
Hz, 1H, 5-H’), 3.44 (t, J = 8.5 Hz, 1H, 17-H), 3.12 (t, J = 8.7 Hz, 1H, 4-H’), 2.5 – 0.7 
(m). 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 199.4, 171.2, 123.9, 98.2, 87.6, 
78.5, 70.8, 69.3, 53.9, 50.2, 42.8, 39.9, 38.7, 37.1, 35.7, 35.5, 33.9, 32.8, 31.5, 
28.6, 26.9, 26.3, 26.1, 23.4, 20.6, 18.6, 18.4, 18.1, 17.4, 11.6, -2.8, -3.0, -4.1, -4.4 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2412 Hz= 4.82: 4.82 (d, 
1H, 1-H’), 3.95 (ddd, 1H 3-H’), 3.65 (dq, 1H, 5-H’), 3.15 (t, 1H, 4-H’), 2.07 (ddd, 1H, 
2-Hax’), 1.61 (dd, 1H, 2-Heq’), 1.27 (d, 3H, 6-H’). 
 
LC-MS (ESI) (+c): m/z (%): 647.45 (100) [M + Na]+; HR-MS C37H67O5Si2: calc. 
647.4527, found 647.4545. 
 
[α]25D = + 3.7o (c = 1 in CHCl3). 
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1-O-(2´,6´-deoxy-3´,4´di-O-(tert-butyldimethylsilyl)-α/β-D-arabino-
hexopyranosyl) (2:3, 4:5-di-O-isopropyliden)-α-D-fructo-hexopyranoside 
(162) 
O
OTBS
TBSO O
O
O
OOO
 
The reaction was carried out according to the protocol TP2. 
 
Yield: 19 mg (0.03 mmol, 60%, α/β - 1.8:1). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 4.89 (d, J = 2.7 Hz, 0.6H, 1-H’α), 
4.67 (dd, J = 7.9, 2.6 Hz, 1H), 4.47 (d, J = 2.5 Hz, 1H), 4.33 (dd, J = 9.0, 2.3 Hz, 
0.4H, 1-H’β), 4.28 (bd, J = 8.0 Hz, 1H), 4.1-3.5 (m, 5H), 3.20 (dd, J = 8.5, 8.5 Hz, 
1H, 4-H’), 2.16 (ddd, J = 13.0, 4.9, 1.1 Hz, 1H), 1.64, 1.58, 1.51, 1.47 (4s, 12H, 4 x 
CH3), 1.24 (d, J = 6.1 Hz, 1H, 6-H’), 0.95 (m, 18H), 0.1 (m, 12H). 
 
Digitoxigenyl [2,6-dideoxy-3,4-di-O-(tert-butyldimethylsilyl)]-α/β-L-arabino-
pyranoside (163) 
O
TBSO
TBSO
O
O
OH
O
H
H
H
 
 The reaction was carried out according to the protocol TP2. 
 
Yield: 35 mg (0.048 mmol, 95%, α/β - 3:1). 
 
1st fraction: 163β 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.86 (s, 1H, 22-H), 4.98 (dd, J 
= 18.0, 1.5 Hz, 1H, 21-H), 4.80 (dd, J = 18.0, 1.5 Hz, 1H, 21-H), 4.46 (dd, J = 9.6, 
1.8 Hz, 1H, 1-H’), 3.99 (bs, 1H), 3.62 (ddd, J = 11.5, 4.7, 7.1 Hz, 1H, 3-H’), 3.17 
(m, 1H, 4-H’), 3.16 (dq, J = 8.2, 6.8 Hz, 1H, 5-H’), 2.75 (m, 1H, 3-H), 2.2 – 0.0 (m).  
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13C-NMR (125 MHz, CDCl , CDCl = 77 ppm): δ = 174.41, 174.40, 117.7, 97.3, 
85.6, 77.9, 73.4, 73.4, 72.9, 72.6, 51.0, 49.6, 41.9, 41.5, 40.1, 36.2, 35.7, 35.2, 
33.2, 32.0, 30.0, 26.9, 26.88, 26.4, 26.3, 26.1, 24.6, 23.6, 21.3, 21.2, 18.8, 18.3, 
18.1, 15.8, 14.2, -2.7, -3.0, -3.9, -4.0 
3 3 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2246 Hz= 4.49: 4.49 (d, 
1H, 1-H’), 3.64 (ddd, 1H, 3-H’), 3.20 (t, 1H, 4-H’), 3.19 (dq, 1H, 5-H’), 2.06 (ddd, 
1H, 2-Hax’), 1.65 (dd, 1H, 2-Heq’), 1.27 (d, 3H, 6-H’). 
 
LC-MS (ESI) (+c): m/z (%): 755.46 (30) [M + Na]+, 796.48 (100) [M + CH3CN + 
Na]+; HR-MS C41H72O7Si2 + Na: calc. 755.4714, found 755.4700. 
 
[α]25D = + 25.2o (c = 1 in CHCl3). 
 
2nd fraction: 163α 
1H-NMR (500 MHz, CDCl , CDCl3 = 7.26 ppm): δ = 5.87 (s, 1H, 22-H), 4.98 (d, J = 
18.0 Hz, 1H, 21-H), 4.86 (d, J = 1.9 Hz, 1H, 1-H’), 4.80 (dd, J = 18.0, 1.5 Hz, 1H, 
21-H), 3.99 (ddd, J = 11.2, 8.5, 4.1 Hz, 1H, 3-H’), 3.88 (bs, 1H), 3.63 (dq, J = 8.5, 
6.3 Hz, 1H, 5-H’), 3.14 (t, J = 8.5 Hz, 1H, 4-H’), 2.75 (m, 1H, 3-H), 2.2 – 0.0 (m).  
3
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 174.5, 174.4, 117.7, 94.5, 85.6, 
78.6, 73.4, 70.8, 70.4, 69.3, 50.9, 49.6, 41.9, 40.14, 40.1, 36.4, 35.7, 35.2, 33.2, 
30.4, 29.5, 26.9, 26.88, 26.74, 26.7, 26.3, 26.2, 23.8, 21.5, 21.2, 18.7, 18.5, 18.1, 
15.8, -2.8, -2.9, -4.1, -4.4  
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2446 Hz= 4.89: 4.89 (d, 
1H, 1-H’), 4.01 (ddd, 1H, 3-H’), 3.66 (dq, 1H, 5-H’), 3.16 (t, 1H, 4-H’), 2.04 (ddd, 
1H, 2-Hax’), 1.67 (dd, 1H, 2-Heq’), 1.22 (d, 3H, 6-H’). 
 
LC-MS (ESI) (+c): m/z (%): 796.48 (100) [M + CH3CN + Na]+; HR-MS 
C43H75O7NSi2 + Na: calc. 796.4980, found 796.4982. 
 
[α]25D = - 29.6o (c = 1 in CHCl3). 
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Dehydro-epi-androsteryl [2´,6´-dideoxy-3´,4´-di-O-(tert-butyldimethyl silyl)]-
α/β-L-arabino-hexopyranoside (164) 
O
OTBS
TBSO
O
H
H H
O
 
The reaction was carried out according to the protocol TP2. 
 
Yield: 29 mg (0.045 mmol, 90%, α/β - 3:1). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.36 (ddd, J = 13.1, 13.1, 5.0 Hz, 
1H, 6-H), 4.94 (d, J = 2.7 Hz, 0.75H, 1-H’α), 4.58 (dd, J = 9.6, 1.6 Hz, 0.25H, 1-
H’β), 3.94 (ddd, J = 10.9, 7.9, 4.5 Hz, 0.75H, 3-H’α), 3.7-3.5 (m, 2H), 3.4 (m, 0.7H), 
3.2-3.1 (m, dd J = 8.2, 8.2 Hz, 1.8H), 2.7 – 0.0 (m). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 221.12, 221.10, 141.18, 141.17, 
130.71+, 128.97+, 127.11+, 120.88+, 120.67+, 97.15+, 95.43+, 78.47+, 76.44+, 
73.21+, 72.60+, 70.78+, 68.94+, 64.38+, 51.75+, 50.27+, 47.52, 39.91-, 38.76-, 
37.30-, 36.89-, 36.84, 35.82-, 31.49+, 31.48-, 30.80-, 29.53-, 26.29+, 26.25+, 
26.11+, 25.33+, 21.86-, 20.32-, 19.42+, 18.62+, 18.28+, 18.27+, 18.08, 18.03, 
13.51+, -2.82+, -3.09+, -4.01+, -4.29+ 
 
Ethyl 4-O-[2´,6´-dideoxy-3´,4´-di-O-(tert-butyldimethylsilyl)-α/β-L-arabino-
hexopyranosyl]-2,3-dideoxy-6-pivaloyl-α-D-threo-hexopyranoside (165)  
O
OTBS
TBSO
O
O
O
PivO
 
The reaction was carried out according to the protocol TP2. 
 
Yield: 19 mg (0.031 mmol, 60%, α/β - 5:1) 
 
1st fraction: 165β 
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1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 4.77 (d, J = 2.7 Hz, 1H, 1-H), 
4.51 (dd, J = 9.6, 1.8 Hz, 1H, 1-H’), 4.47 (dd, J = 11.9, 1.6 Hz, 1H, 6-H), 4.10 (dd, J 
= 11.9, 7.5 Hz, 1H, 6-H), 3.82 (ddd, J = 9.4, 7.5, 1.6 Hz, 1H, 5-H), 3.73 (dq, J = 
9.6, 7.0 Hz, 1H, O-CHH’-CH3), 3.62 (m, 2H, 3-H’, 4-H), 3.44 (dq, J = 9.6, 7.0 Hz, 
1H, O-CHH’-CH3), 3.13 (m, 2H, 4-H’, 5-H’),  2.03 (ddd, J = 12.5, 4.9, 2.0 Hz, 1H, 2-
H’ax), 1.92 (m, 1H, 3-H), 1.80 (m, 2H, 3-H, 2-H), 1.69 (m, 1H, 2-H), 1.55 (m, 1H, 2-
H’eq), 1.21 (m, 15H, 6-H’, COC(CH3)3, O-CH2-CH3), 0.90, 0.89 (2s, 18H, 2 x Si-t-
Bu), 0.10, 0.09, 0.08 (3s, 12H, 2 x Si(CH3)2). 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 178.3 (s, CO), 95.6, 95.4 (2d, C-
1’, C-1), 77.9 (d, C-4’), 73.2 (d, C-3’), 72.7 (d, C-5’), 70.6 (d, C-4), 70.0 (d, C-5), 
64.5 (t, C-6), 62.1 (t, OCH2CH3), 41.3 (t, C-2’), 38.8 (s, COC(CH3)3), 28.9 (t, C-2), 
27.3 (q, COC(CH3)3), 26.3, 26.1 (2q, 2 x SiC(CH3)3), 23.7 (t, C-3), 18.7, 18.1 (2q, 2 
x SiC(CH3)3), 18.3 (q, C-6’), 15.0 (q, O-CH2-CH3), -2.8, -3.0, -3.9, -4.1 (4q, 2 x 
Si(CH3)2C(CH3)3). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2400Hz= 4.80: 4.80 (d, 
1H, 1-H), 4.50 (dd, 1H, 6-H), 4.13 (dd, 1H, 6-H), 3.85 (ddd, 1H, 5-H), 3.66 (ddd, 
1H, 4-H), 1.94 (m, 1H, 3-H), 1.83 (m, 2H, 3-H, 2-H), 1.72 (m, 1H, 2-H). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2273 Hz= 4.55: 4.55 (d, 
1H, 1-H’), 3.63 (ddd, 1H, 3-H’), 3.16 (m, 2H, 5-H’, 4-H’), 2.06 (dd, 1H, 2-H’ax), 1.58 
(ddd, 1H, 2-H’eq), 1.26 (q, 3H, 6-H’).       
 
LC-MS (ESI) (+c): m/z (%): 641.41 (100) [M + Na]+; HR-MS C31H62O8Si2 + Na: 
calc. 641.3881, found 641.3894. 
 
[α]25D = + 22.7o (c = 1 in CHCl3). 
 
2nd fraction: 165α 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 4.81 (d, J = 2.8 Hz, 1H, 1-H’), 
4.76 (d, J = 2.8 Hz, 1H, 1-H), 4.21 (dd, J = 11.7, 1.7 Hz, 1H, 6-H), 4.17 (dd, J = 
11.7, 5.2 Hz, 1H 6-H), 3.90 (ddd, J = 11.0, 9.0, 4.5 Hz, 1H, 3-H’), 3.79 (ddd, J = 
10.0, 5.2, 2.0 Hz, 1H, 5-H), 3.73 (dq, J = 9.0, 6.6 Hz, 1H, 5-H’), 3.70 (dq, J = 9.0, 
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6.8 Hz, 1H, O-CHH’-CH3), 3.45 (dq, J = 9.0, 6.8 Hz, 1H, O-CHH’-CH3), 3.42 (dd, J 
= 10.0, 4.4 Hz, 1H, 4-H), 3.13 (t, J = 9.0 Hz, 1H, 4-H’), 2.01 (m, 2H, 2-H’ax, 3-H), 
1.92 (ddt, J = 12.9, 4.4 Hz, 1H, 3-H), 1.79 (bd, J = 14.0 Hz, 1H, 2-H), 1.70 (ddt, J = 
14.0, 12.9, 4.0 Hz, 1H, 2-H), 1.60 (ddd, J = 13.4, 11.0, 3.6 Hz, 1H, 2-H’eq), 1.23 (t, 
J = 6.8 Hz, 3H, O-CH2-CH3), 1.21 (s, 9H, COC(CH3)3), 1.18 (d, J = 6.6 Hz, 3H, 6-
H’), 0.90, 0.89 (2s, 18H, 2 x Si-t-Bu), 0.10, 0.09, 0.07 (3s, 12H, 2 x Si(CH3)2). 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 178.2 (s, CO), 99.4 (d, C-1’), 
96.0 (d, C-1), 78.4 (d, C-4’), 74.9 (d, C-4), 70.6 (d, C-3’), 70.0 (d, C-5), 69.3 (d, C-
5’), 63.8 (t, C-6), 62.4 (t, OCH2CH3), 39.8 (t, C-2’), 38.8 (s, COC(CH3)3), 29.2 (t, C-
2), 27.2 (q, COC(CH3)3), 26.9 (t, C-3), 26.2, 26.1 (2q, 2 x SiC(CH3)3), 18.5, 18.1 
(2q, 2 x SiC(CH3)3), 18.3 (q, C-6’), 15.1 (q, O-CH2-CH3), -2.8, -3.1, -4.0, -4.4 (4q, 2 
x Si(CH3)2C(CH3)3). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 631 Hz= 1.26: 3.75 (dq, 
1H, O-CHH’-CH3), 3.48 (dq, 1H, O-CHH’-CH3), 1.26 (t, 3H, OCH2CH3).  
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 2397 Hz= 4.79: 4.79 (d, 
1H, 1-H), 4.24 (dd, 1H, 6-H), 4.20 (dd, 1H, 6-H), 3.82 (ddd, 1H, 5-H), 3.45 (ddd, 
1H, 4-H), 2.04 (ddd, 1H, 3-H), 1.94 (dq, 1H, 3-H), 1.81 (d, 1H, 2-H), 1.74 (ddd, 1H, 
2-H). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY: 1580 Hz= 3.16: 4.83 (dd, 
1H, 1-H’), 3.92 (ddd, 1H, 3-H’), 3.72 (dq, 1H, 5-H’), 3.16 (t, 1H, 4-H’), 2.03 (dd, 1H, 
2-H’ax), 1.63 (ddd, 1H, 2-H’eq), 1.20 (q, 3H, 6-H’).       
 
LC-MS (ESI) (+c): m/z (%): 641.36 (100) [M + Na]+; HR-MS C31H62O8Si2 + Na: 
calc. 641.3881, found 641.3904. 
 
[α]25D = + 19.6o (c = 1 in CHCl3). 
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3-O-[2´,6´-dideoxy-3´,4´-di-O-(tert-butyldimethylsilyl)-α/β-L-arabino-
hexopyranosyl]-(1:2,5:6-di-O-isopropylidene)-α-D-gluco-hexofuranosid (166) 
O
OTBS
OTBS
O
O
O
O
O
O
 
The reaction was carried out according to the protocol TP2. 
 
Yield: 17 mg (0.0275 mmol, 55%, α/β - 2:1) 
 
diastereomeric mixture 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.91 (d, J = 3.5 Hz, 1H, 1-H), 
4.99 (d, J = 3.3 Hz, 0.7H, 1-H’α), 4.82 (dd, J =  9.8, 1.7 Hz, 0.33H, 1-H’β), 4.53 (d, 
J = 3.7 Hz, 0.7H), 4.4-3.8 (m, 4H), 3.6 (m, 0.6H), 3.18 (dd, J = 8.6, 8.6 Hz, 1H, 4-
H’), 2.1 (m, 1H), 1.54, 1.44, 1.39, 1.34 (4s, 12H, 4 x CH3), 1.22 (d, J = 6.2 Hz, 3H, 
6-H’), 0.93 (m, 18H, 2 x t-BuSiMe2), 0.11 (m, 12H, 2 x t-BuSiMe2 ). 
 
 
 
Cyclohexyl α/β-L-rhamnoside (169) 
A suspension of phenylthio 3,4-di-O-benzyl-2,6-dideoxy-α-L-arabino-
hexopyranoside 167 (42 mg, 0.1 mmol) and powdered molecular sieves 4A (50 
mg) in acetonitrile (5 ml) was cooled to 0°C and treated with selectfluor (0.105 
mmol). The reaction mixture was shaken for 20 minutes (t.l.c: ethyl acetate / 
petroleum ether 1:15) after which time the reaction was terminated by addition of 
dry Amberlite A-21 (10 mg). The resulting suspension was filtered through a pad of 
Al2O3 and washed with ethyl acetate (2x 1 ml). The solvent was evaporated in 
vacuo and the residue was dissolved in isopropanol (5 ml). To this solution 
polymer-supported borohydride (200 mg) was added. The suspension was shaken 
overnight and the polymer was removed by filtration which was followed by 
washing with isopropanol (1 ml).  A second portion of polymer-supported 
borohydride (200 mg) was added to the filtrate in order to remove final traces of 
diphenyl disulfide. The suspension was shaken for additional 12 h, filtered and the 
solvent was removed under reduced pressure. The resulting material 168 was 
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subjected to hydrogenation conditions by dissolving it in methanol (20 ml) in the 
presence of Pd/C (10 mol%) over hydrogen atmosphere (20 bar) to yield fully 
debenzylated disaccharide 169 within 2h as an inseparable mixture of isomers.  
 
Yield: 21.4 mg, 93 µmol; 93% (α/β= 2:1, inseparable mixture of isomers);  
 
1-O-Cyclohexyl-3,4-bis-O-benzyl-α/β-L-rhamnoside (168) 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 7.31 (m, 10H, 2 x Ph), 5.02 (d, 
J = 3.0 Hz, 0.6H, 1-Hα), 4.96 (d, J = 10.9 Hz, 1H, Ph-CHH), 4.67 (s, 2H, Ph-CH2), 
4.66 (d, J = 10.9 Hz, 1H, Ph-CHH), 4.56 (dd, J = 9.8, 1.9 Hz, 0.4H, 1-Hβ), 4.00 
(ddd, J = 11.3, 9.3, 5.0 Hz, 0.6H, 3-Hα), 3.83 (dq, J = 9.3, 6.2 Hz, 0.6H, 5-Hα), 
3.64 (m, 0.4H, 3-Hβ), 3.52 (m, 1H, Cy1), 3.33 (dq, J = 9.0, 6.1 Hz, 0.4H, 5-Hβ), 
3.16 (t, J = 9.0 Hz, 0.4H, 4-Hβ), 3.14 (t, J = 9.3 Hz, 0.6H, 4-Hα), 2.31 (ddd, J = 
12.3, 5.0, 1.8 Hz, 0.4H, 2-Haxβ), 2.26 (ddd, J = 12.7, 5.0, 1.2 Hz, 0.6H, 2-Haxα), 2.0 
- 1.28 (m 14H), 1.33 (d, J = 6.1 Hz, 6-Hβ), 1.29 (d, J = 6.2 Hz, 6-Hα). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm): δ = 128.37, 128.33, 128.32, 128.08, 
128.02, 127.65, 127.60, 127.57, 127.44 (2 x Ph), 97.28 (C-1β), 94.73 (C-1α), 84.55 
(C-4α), 83.67 (C-4β), 79.45, 77.60, 75.22, 74.17, 71.71, 71.23, 67.15 (C-3α, C-3β, 
C-5α, C-5β, 2 x Bn-CH2, C-cy1), 37.53, (C-2β), 36.31 (C-2α), 33.63, 33.41, 31.90, 
31.45, 29.66, 25.69, 25.61, 24.25, 24.10, 23.97 (Cy2,3,4,5,6), 18.22 (C-6β), 18.11 (C-
6α). 
 
1-O-Cyclohexyl-α/β-L-rhamnoside (169) 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 4.99 (d, J = 3.2 Hz, 0.6H, 1-
Hα), 4.61 (dd, J = 9.6, 1.8 Hz, 0.4H, 1-Hβ), 3.92 (ddd, J = 11.6, 9.0, 5.0 Hz, 0.6H, 
3-Hα), 3.70 (dq, J = 9.1, 6.2 Hz, 0.6H, 5-Hα), 3.65 – 3.43 (m, 1.4H), 3.25 (dq, J = 
9.1, 6.1 Hz, 0.4H, 5-Hβ), 3.13 (bs, 2H, 2 x OH), 3.07 (bt, J = 9.0 Hz, 1H, 4-H), 2.14 
(ddd, J = 12.4, 5.0, 1.8 Hz, 0.4H, 2-Haxβ), 2.7 (ddd, J = 12.7, 5.0, 1.1 Hz, 0.6H, 2-
Haxα), 2.0 - 1.15 (m 14H), 1.32 (d, J = 6.1 Hz, 6-Hβ), 1.26 (d, J = 6.2 Hz, 6-Hα). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm): δ =  97.31 (C-1β), 94.95 (C-1α), 
78.20 (C-4α), 77.56 (C-4β), 74.50, 71.90, 71.55, 69.30, 67.52 (C-3α, C-3β, C-5α, 
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C-5β, C-cy1), 39.64, (C-2β), 38.32 (C-2α), 33.57, 33.48, 31.87, 31.51, 25.66, 
25.59, 24.26, 24.28, 23.98 (Cy2,3,4,5,6), 17.75 (C-6β), 17.68 (C-6α). 
 
11.7. Experiments to the chapter 7. 
4-O-(3’,4’-Di-O-acetyl-2’,6’-dideoxy-α-L-arabino-hexopyranosyl)-3-O-benzoyl-
2,6-dideoxy-L-arabino-hex-1-enit (170) 
O
AcO
AcO
OO
BzO
 
The reaction was carried out according to the protocol TP1 except for the following 
details: thioglycoside 18 was used. 
 
Yield: 43.4 mg (0.097 mmol, 97%). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 8.01 (d, J = 7.1 Hz, 2H, Ph-o), 
7.57 (dd, J = 7.1, 7.1 Hz, 1H, Ph-p), 7.45 (dd, J = 7.1, 7.1 Hz, 2H, Ph-m), 6.45 (d, J 
= 6.1 Hz, 1H, 1-H), 5.51 (bdd, J = 4.1, 3.5 Hz, 1H, 3-H), 5.25 (d, J = 3.7 Hz, 1H, 1-
H’), 5.23 (ddd, J = 11.5, 9.6, 5.2 Hz, 1H, 3-H’), 4.87 (dd, J = 6.1, 3.5 Hz, 1H, 2-H), 
4.71 (dd, J = 9.6, 9.6 Hz, 1H, 4-H’), 4.18 (dq, J = 6.7, 6.5 Hz, 1H, 5-H), 3.94 (dq, J 
= 9.6, 6.3 Hz, 1H, 5-H’), 3.93 (m, 1H, 4-H), 2.15 (dd, J = 13.0, 5.2 Hz, 1H, 2-H’ax), 
2.04, 1.96 (2s, 6H, 2CH3CO), 1.75 (ddd, J = 13.0, 11.5, 3.7 Hz, 1H, 2-H’eq), 1.46 
(d, J = 6.5 Hz, 3H, 6-H), 1.18 (d, J = 6.3 Hz, 3H, 6-H’);  
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 170.1 (s, CH3CO), 170.11 (s, 
CH3CO), 165.9 (s, PhCO), 146.0 (d, C-1), 133.2 (d, Ph-o), 129.9 (s, Ph-1), 129.6 
(d, Ph-o), 128.5 (d, Ph-m), 98.5 (d, C-2), 96.4 (d, C-1’), 75.4 (d, C-4), 74.7 (d, C-
4’), 73.3 (d, C-5), 70.8 (d, C-3), 68.6 (d, C-3’), 66.5 (d, C-5’), 35.4 (t, C-2’), 20.9, 
20.8 (2q, 2 x CH3CO), 17.4 (q, C-6’), 17.3 (q, C-6).  
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 3442 Hz = 6.48 ppm: δ = 6.48 (d, 
1-H), 5.54 (ddd, 3-H), 4.90 (dd, 2-H), 4.20 (dq, 5-H), 3.96 (dd, 4-H), 1.49 (d, 6-H);  
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1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 1094 Hz = 2.19 ppm: δ = 5.28 (d, 
1-H’), 5.25 (ddd, 3-H’), 4.73 (dd, 4-H’), 3.97 (dq, 5-H’), 2.19 (dd, 2-H’ax), 1.78 (ddd, 
2-H’eq), 1.21 (d, 6-H’) 
 
4-O-(3’,4’-Di-O-acetyl-2’,6’-dideoxy-α-L-arabino-hexopyranosyl)-3-O-pivaloyl-
2,6-dideoxy-L-arabino-hex-1-enit (171) 
O
AcO
AcO
OO
PivO
 
The reaction was carried out according to the protocol TP1 except for the following 
details: thioglycoside 19 (65 mg, 0.2 mmol), glycal 32 (43 mg, 0.2 mmol), 
selectfluor (71 mg, 0.2 mmol). 
 
Yield: 83 mg (0.194 mmol, 97%). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 6.43 (dd, J = 6.1, 1.2 Hz, 1H, 1-
H), 5.21 (bdd, J = 3.1, 5.8 Hz, 1H, 3-H), 5.23 (d, J = 3.7 Hz, 1H, 1-H’), 5.23 (ddd, J 
= 11.6, 9.7, 5.2 Hz, 1H, 3-H’), 4.71 (dd, J = 6.1, 3.1 Hz, 1H, 2-H), 4.70 (dd, J = 9.7, 
9.7 Hz, 1H, 4-H’), 4.15 (bdq, J = 6.6, 6.6 Hz, 1H, 5-H), 3.95 (dq, J = 9.7, 6.5 Hz, 
1H, 5-H’), 3.74 (dd, J = 7.0, 5.8 Hz, 1H, 4-H), 2.19 (dd, J = 13.0, 5.2 Hz, 1H, 2-
H’ax), 2.04, 1.96 (2s, 6H, 2CH3CO), 1.75 (ddd, J = 13.0, 11.6, 3.7 Hz, 1H, 2-H’eq), 
1.40 (d, J = 6.6 Hz, 3H, 6-H), 1.20 (s, 9H, (CH3)3C), 1.19 (d, J = 6.4 Hz, 3H, 6-H’); 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ =178.0 s, 170.1 s, 170.1 s, 146.0 
d, 98.5 d, 96.5 d, 75.7 d, 74.7 d, 73.2 d, 70.2 d, 68.7 d, 66.4 d, 38.7 s, 35.4 t, 27.0 
q 20.9 q, 20.8 q, 17.3 q, 17.2 q;  
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 3210 Hz = 6.42 ppm: δ = 6.42 (d, 
1-H), 5.22 (ddd, 3-H), 4.72 (dd, 2-H), 4.11 (dq, 5-H), 3.75 (dd, 4-H), 1.40 (d, 6-H);  
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 1094 Hz = 2.19 ppm: δ = 5.22 (d, 
1-H’), 5.25 (ddd, 3-H’), 4.73 (dd, 4-H’), 3.95 (dq, 5-H’), 2.19 (dd, 2-H’ax), 1.75 (ddd, 
2-H’eq), 1.21 (d, 6-H’) 
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4-O-( 3’-O-(3’’,4’’-Di-O-acetyl-2’’,6’’-dideoxy-β-L-arabino-hexopyranosyl)-2’,6’-
dideoxy-α-L-arabino-hexopyranosyl)-3-O-pivaloyl-2,6-dideoxy-L-arabino-hex-
1-enit (173β); 4-O-(3’-O-(3’’,4’’-Di-O-acetyl-2’’,6’’-dideoxy-α-L-arabino-
hexopyranosyl)-2’,6’-dideoxy-α-L-arabino-hexopyranosyl)-3-O-pivaloyl-2,6-
dideoxy-L-arabino-hex-1-enit (173α) 
O
O
HO
OO
PivO
O
AcO
AcO
 
The reaction was carried out according to the protocol TP1 except for the following 
details: thioglycoside 18 (52 mg, 0.16 mmol), deprotected disaccharide 171 (55 
mg, 0.16 mmol), selectfluor (55 mg, 0.16 mmol). Column chromatography 
(CH2Cl2/Acetone 12:1). The two fractions were isolated. 
1st fraction: 173β 5.5 mg (0.0099 mmol, 6.2%). 
2nd fraction:173α 24 mg (0.043 mmol, 27%) 
 
1st fraction 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 6.40 (d, J = 5.8 Hz, 1H, 1-H), 
5.19 (dd, J = 4.0, 3.9 Hz, 1H, 3-H), 5.13 (d, J = 3.3 Hz, 1H, 1-H’), 4.95 (ddd, J = 
11.8, 9.4, 5.2 Hz, 1H, 3-H’’), 4.75 (dd, J = 9.4, 9.4 Hz, 1H, 4-H’’), 4.72 (dd, J = 5.8, 
3.2 Hz, 1H, 2-H), 4.63 (dd, J = 9.6, 1.6 Hz, 1H, 1-H’’), 4.10 (dq, J = 6.6, 6.4 Hz, 1H, 
5-H), 3.8-3.9 (m, 2H, 3-H’, 4-H), 3.69 (dq, J = 9.2, 6.2 Hz, 1H, 5-H’), 3.57 (dq, J = 
9.4, 6.1 Hz, 1H, 5-H’’), 3.11 (dd, J = 9.2, 9.2 Hz, 1H, 4-H’), 2.33 (ddd, J = 12.6, 5.2, 
1.6 Hz, 1H, 2-H’’ax), 2.04, 2.02 (2s, 6H, 2CH3CO), 2.00 (m, 1H, 2-H’ax), 1.7-1.8 (m, 
2H, 2-H’eq, 2-H’’eq), 1.39 (d, J = 6.6 Hz, 3H, 6-H), 1.30 (d, J = 6.2 Hz, 3H, 6-H’), 
1.25 (d, J = 6.1 Hz, 3H, 6-H’’), 1.19 (s, 9H, Piv) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ =  177.9 (s, COPiv), 170.2, 169.9 
(2s, COAc), 145.7 (d, C-1), 99.4 (d, C-1’’), 98.4 (d, C-2), 97.2 (d, C-1’), 80.3 (d, C-
4), 75.6 (d, C-3’), 75.4 (d, C-4’), 73.6 (d, C-4’’), 73.4 (d, C-5), 70.4 (d, C-3’’), 70.3 
(d, C-5’’), 69.6 (d, C-3), 68.6 (d, C-5’), 38.8 (s, C(CH3)3), 36.6, 36.5 (2t, C-2’, 2’’), 
27.0 (q, C(CH3)3), 20.9, 20.8 (2q, 2COCH3), 17.7 (q, C-6), 17.5 (q, C-6’), 17.2 (C-
6’’) 
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1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 2613 Hz = 5.22 ppm: δ = 6.43 (d, 
1-H), 5.22 (dd, 3-H), 4.75 (dd, 2-H), 4.13 (dq, 5-H), 3.77 (dd, 4-H), 1.42 (d, 6-H) 
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 2581 Hz = 5.16 ppm: δ =: 5.16 (d, 
1-H’), 3.76 (ddd, 3-H’), 3.72 (dq, 5-H’), 3.14 (dd, 4-H’), 2.04 (dd, 2-H’ax), 1.76 (ddd, 
2-H’eq), 1.32 (d, 6-H’) 
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 2330 Hz = 4.66 ppm: δ = 4.98 
(ddd, 3-H’’), 4.78 (dd, 4-H’’), 4.66 (dd, 1-H’’), 3.60 (dq, 5-H’’), 2.36 (ddd, 2-H’’ax), 
1.76 (ddd, 2-H’’eq), 1.28 (d, 6-H’’) 
 
2nd fraction   
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 6.38 (d, J = 5.7 Hz, 1H, H-1), 
5.22 (m, 2H, 3-H, 3-H’’), 5.11 (bs, 2H, 1-H’, 1-H’’), 4.73 (dd, J = 9.7, 9.7 Hz, 1H, 4-
H’’), 4.69 (dd, J = 5.7, 3.2 Hz, 1H, 2-H), 4.07 (dq, J = 6.8, 6.6 Hz, 1H, 5-H), 3.86 
(dq, J = 9.7, 6.1 Hz, 1H, 5-H’’), 3.8-3.7 (m, 3H, 3-H’, 4-H, 5-H’), 3.20 (ddd, J = 9.1, 
9.1, 2.7 Hz, 1H, 4-H’), 2.43 (d, J = 3.0 Hz, 1H, OH), 2.25 (dd, J = 12.5, 5.2 Hz, 1H, 
2-H’’ax), 2.18 (dd, J = 12.7, 4.7 Hz, 1H, 2-H’ax), 2.05, 2.00 (2s, 6H, 2CH3CO), 1.78 
(ddd, J = 12.7, 12.0, 3.6 Hz, 1H, 2-H’’eq), 1.70 (ddd, J = 12.7, 11.7, 3.7 Hz, 1H, 2-
H’eq), 1.37 (d, J = 6.6 Hz, 3H, 6-H), 1.28 (d, J = 6.1 Hz, 3H, 6-H’), 1.18 (s, 9H, 
Piv),1.14 (d, J = 6.1 Hz, 3H, 6-H’’) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ =  177.9 (s, COPiv), 170.4, 170.1 
(2s, COAc), 145.7 (d, C-1), 98.6, 98.57 (2d, C-1’, 2), 97.1 (d, C-1’’), 77.8 (d, C-3’), 
75.9 (d, C-4’), 75.5 (d, C-5’), 74.6 (d, C-4’’), 73.4 (d, C-5), 70.3 (d, C-3), 69.0 (d, C-
3’’), 68.3 (d, C-4), 66.1 (d, C-5’’), 38.7 (s, C(CH3)3), 37.1 (t, C-2’), 35.6 (t, C-2’’), 
27.0 (q, C(CH3)3), 20.9, 20.8 (2q, 2COCH3), 17.7 (q, C-6’), 17.4, 17.3 (2q, C-6, 6’’) 
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 3250 Hz = 6.41 ppm: δ = 6.41 (d, 
1-H), 5.23 (dd, 3-H), 4.72 (dd, 2-H), 4.10 (dq, 5-H), 3.76 (dd, 4-H), 1.40 (d, 6-H) 
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 1612 Hz = 3.22 ppm: δ = 5.13 (d, 
1-H’), 3.81 (ddd, 3-H’), 3.77 (dq, 5-H’), 3.22 (dd, 4-H’), 2.46 (s, OH), 2.21 (dd, 2-
H’ax), 1.73 (ddd, 2-H’eq), 1.30 (d, 6-H’) 
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 1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 1140 Hz = 2.28 ppm: δ = 5.24 
(ddd, 3-H’’), 5.13 (d, 1-H’’), 4.75 (dd, 4-H’’), 3.88 (dq, 5-H’’), 2.28 (ddd, 2-H’’ax), 
1.80 (ddd, 2-H’’eq), 1.17 (d, 6-H’’) 
  
17-O [4-O-(3’,4’-Di-O-acetyl-2’,6’-dideoxy-α-L-arabino-hexopyranosyl)-3-O-
benzoyl-2,6-dideoxy-β-L-arabino-hexopyranosyl]-testosterone (172β); 17-O 
(4-O-(3’,4’-Di-O-acetyl-2’,6’-dideoxy-α-L-arabino-hexopyranosyl)-3-O-benzoyl-
2,6-dideoxy-α-L-arabino-hexopyranosyl)-testosteron (172α)  
O
H
HH
O
O
AcO
AcO
OO
BzO
 
To a mixture of testosterone (28 mg, 0.1 mmol) and disaccharide 170 (44 mg, 0.1 
mmol) in dry acetonitrile (5 ml) Dowex 50w2 (2 mg) was added. Stirring was 
continued for 24 h followed by quenching with amberlite A-21 (10 mg). The mixture 
was filtered through a pad of Celite and the solvent was removed under reduced 
pressure. The isomers were finally separated by flash column chromatography 
(ethyl acetate/petroleum ether 1:5). 
1st fraction: 173β 10.3 mg (0.014 mmol, 14%),  
2nd fraction: 173α 33.9 mg (0.046 mmol, 46%). 
 
1st fraction 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 7.99 (d, J = 7.5 Hz, 2H, Ph-o), 
7.58 (dd, J = 7.5, 7.5 Hz, 1H, Ph-p), 7.45 (dd, J = 7.5, 7.5 Hz, 2H, Ph-m), 5.72 (s, 
1H, 4-H), 5.23 (d, J = 3.3 Hz, 1H, 1-H’’), 5.15 (m, 2H, 3-H’, 3’’), 4.65 (dd, J = 9.6, 
9.5 Hz, 1H, 4-H’’), 4.56 (dd, J = 9.5, 1.7 Hz, 1H, 1-H’), 3.93 (dq, J = 9.6, 6.2 Hz, 
1H, 5-H’’), 3.69 (t, J = 8.3 Hz, 1H, 17-H), 3.59 (dd, J = 9.0, 9.0 Hz, 1H, 4-H’), 3.44 
(dq, J = 9.0, 6.08 Hz, 1H, 5-H’), 2.5-0.7 (m) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ =  199.5 (s, C-3), 171.3 (s, C-5), 
170.1, 170.0 (2s, COCH3), 165.4 (s, COPh), 133.3 (s, Ph), 129.7 (d, Ph-p), 129.5 
(d, Ph-o), 128.6 (d, Ph-m), 123.8 (d, C-4), 98.1 (d, C-1’), 97.7 (d, C-1’’), 87.21 (d, 
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C-17), 79.6 (d, C-4’), 75.0 (d, C-3’), 74.7 (d, C-4’’), 70.5 (d, C-5’), 68.5(d, C-3’’), 
66.4 (d, C-5’’), 54.0 (d, C-9), 50.6 (d, C-14), 42.4 (s, C-13), 38.7 (s, C-10), 37.1 (t, 
C-12), 36.6 (t, C-2’), 35.7 (t, C-1), 35.5 (t, C-2’’), 35.3 (d, C-8), 34.0 (t, C-2), 32.8 (t, 
C-6), 31.6 (t, C-7), 27.5 (t, C-16), 23.2 (t, C-15), 20.9, 20.8 (2q, 2COCH3), 20.6 (t, 
C-11), 18.6 (q, C-6’), 17.4 (q, C-19), 17.3 (q, C-6’’), 11.6 (q, C-18) 
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 2298 Hz = 4.59 ppm: δ = 5.18 
(ddd, 3-H’), 4.59 (dd, 1-H’), 3.62 (dd, 4-H’), 3.47 (dq, 5-H’), 2.44 (ddd, 2-H’ax), 1.73 
(ddd, 2-H’eq), 1.41 (d, 6-H’) 
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 2344 Hz = 4.69 ppm: δ = 5.26 (d, 
1-H’’), 5.18 (ddd, 3-H’’), 4.68 (dd, 4-H’’), 3.96 (dq, 5-H’’), 1.99 (ddd, 2-H’’ax), 1.64 
(ddd, 2-H’’eq), 1.19 (d, 6-H’’) 
 
2nd fraction 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 8.00 (d, J = 7.5 Hz, 2H, Ph-o), 
7.58 (dd, J = 7.5, 7.5 Hz, 1H, Ph-p), 7.45 (dd, J = 7.5, 7.5 Hz, 2H, Ph-m), 5.73 (s, 
1H, 4-H), 5.47 (ddd, J = 11.2, 9.1, 5.1 Hz, 1H, 3-H’), 5.24 (d, J = 3.1 Hz, 1H, 1-H’’), 
5.19 (ddd, J = 11.4, 9.2, 5.1 Hz, 1H, 3-H’’), 4.91 (d, J = 2.7 Hz, 1H, 1-H’), 4.66 (dd, 
J = 9.5, 9.2 Hz, 1H, 4-H’’), 3.96 (dq, J = 9.5, 6.2 Hz, 1H, 5-H’’), 3.91 (dq, J = 9.3, 
6.2 Hz, 1H, 5-H’), 3.55 (dd, J = 9.3, 9.1 Hz, 1H, 4-H’), 3.52 (t, J = 8.5, 8.5 Hz, 1H, 
17-H), 2.5 – 0.7 (m) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 199.5 (s, C-3), 171.3 (s, C-5), 
170.1, 170.0 (2s, 2COCH3), 165.4(s, COPh), 133.2 (s, Ph), 129.9 (d, Ph-p), 129.5 
(d, Ph-o), 128.6 (d, Ph-m), 123.8 (d, C-4), 97.8 (d, C-1’’), 97.4 (d, C-1’), 87.5 (d, C-
17), 80.6 (d, C-4’), 74.8 (d, C-4’’), 73.4 (d, C-3’), 68.5 (d, C-3’’), 66.4 (d, C-5’’), 66.4 
(d, C-5’), 53.9 (d, C-9), 50.3 (d, C-14), 42.9 (s, C-13), 38.7 (s, C-10), 37.2 (t, C-12), 
35.7 (t, C-1), 35.7 (t, C-2’’), 35.5 (t, C-2’), 35.4 (d, C-8), 33.9 (t, C-2), 32.8 (t, C-6 ), 
31.6 (t, C-7), 28.5 (t, C-16), 23.4 (t, C-15), 20.9, 20.8 (2q, COCH3), 20.6 (t, C-11), 
18.4 (q, C-6’), 17.4 (q, C-19), 17.3 (q, C-6’’), 11.7 (q, C-18) 
 
 214
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 2472 Hz = 4.94 ppm: δ = 5.50 
(ddd, 3-H’), 4.94 (d, 1-H’), 3.94 (dq, 5-H’), 3.57 (dd, 4-H’), 2.42 (ddd, 2-H’ax), 1.78 
(ddd, 2-H’eq), 1.35 (d, 6-H’) 
 
1H-NMR (500 MHz, CDCl3 = 7.26 ppm) TOCSY - 2343 Hz = 4.68 ppm: δ = 5.27 (d, 
1-H’’), 5.21 (ddd, 3-H’’), 4.68 (dd, 4-H’’), 3.98 (dq, 5-H’’), 2.01 (dd, 2-H’’ax), 1.65 
(ddd, 2-H’’eq), 1.19 (d, 6-H’’) 
 
11.8.1. Experiments to the chapter 9.4. 
Allyl-3,4-di-O-acetyl-2,6-dideohy-α-L-glucopyranoside (179) 
OMeAcO
AcO
O
OMeAcO
AcO
O +
31.6% 41%178 179  
To a stirred solution of 3,4-di-O-acetyl-L-rhamnal (5 g, 23 mmol) and allyl alcohol 
(2 g, 34.5 mmol, 1.5 eq) in dry CH2Cl2 (50 ml) polymer-bound PPh3*HBr (20 mg) 
was added. The reaction mixture was stirred at room temperature for 24 h, filtered 
through a pad of Celite and concentrated under reduced pressure. The products 
were finally separated by flash column chromatography over silica gel (ethyl 
acetate / petroleum ether 1:6). 
 
Yield:  α-anomer (2.6g, 9.56 mmol, 41%), 
β-anomer (2.0 g, 7.35 mmol 31.6%),  
Ferrier product mixture (1.0 g, 4.72 mmol, 18.7%). 
 
α-anomer 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.89 (dddd, J = 17.0, 10.7, 5.8, 
5.3 Hz, 1H, –CH=CH2), 5.30 (ddd, J = 11.7, 9.7, 5.3 Hz, 1H, 3-H), 5.29 (dq, J = 
17.0, 1.5 Hz, 1H, –CH=CHH’), 5.18 (dq, J = 10.7, 1.3 Hz, 1H, –CH=CHH’), 4.90 (d, 
J = 3.1 Hz, 1H, 1-H), 4.73 (t, J = 9.7 Hz, 1H, 4-H), 4.13 (ddt, J = 12.9, 5.3, 1.5 Hz, 
1H, -O-CHH’-CH=), 3.94 (ddt, J = 12.9, 5.8, 1.3, Hz, 1H, -O-CHH’-CH=), 3.86 (dq, 
J = 9.7, 6.2 Hz, 1H, 5-H), 2.24 (ddd, J = 12.8, 5.3, 1.19 Hz, 1H, 2-Hax), 2.04, 1.99 
(2s, 6H, 2 x AcO), 1.79 (ddd, J = 12.8, 11.7, 3.1 Hz, 1H, 2-Heq), 1.17 (d, J = 6.2 Hz, 
3H, 6-H). 
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13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ:  170.51 (2s, 2 x COCH3), 134.27 
(d, -CH=CH2), 117.46 (t, –CH=CH2), 96.21 (d, C-1), 75.20, 69.40, 66.00 (3d, C-4, 
C-3, C-5), 68.21 (t, –CH2-CH=), 35.58 (t, C-2), 21.30, 21.12 (2q, 2 x COCH3), 
17.82 (q, C-6).  
 
LC-MS (ESI) (+c): m/z (%): 336.15 (100) [M + CH3CN + Na]+; HRMS (ESI) for 
C15H23NO6 +23Na: calc: 336.1423, found: 336.1431. 
 
[α]26D = - 156.3o (c = 1, CHCl3). 
 
Allyl-3-O-(tret-butyldimethylsilyl)-2,6-dideohy-α-L-glucopyranoside (180) 
OMeHO
TBSO
O
 
The reaction was carried out according to the protocol TP8: starting material 179.  
Yield: 1.90 g (10.0 mmol, >98%). The crude product was used for the next step 
without further purification. 
To a stirred solution of 2-deoxy-α-allyl-L-rhamnoside (1.90 g, 0.01 mol), imidazole 
(1.0 g, 0.015 mol, 1.5 eq) and DMAP (cat.) in DMF (15 ml) was slowly added 
TBSCl (1.55g, 0.01 mol, 1 eq) at 0oC. The solution was stirred at 0oC for 4 h and 
then at room temperature for additional 12 h. The pure product 180 was isolated 
after purification by flash column chromatography as colorless oil. 
 
Yield: 2.68 g (8.86 mmol, 89 %). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.90 (dddd, J = 17.1, 10.5, 4.9, 
5.8 Hz, 1H, –CH=CH2), 5.27 (dq, J = 17.1, 1.6 Hz, 1H, –CH=CHH’), 5.16 (dq, J = 
10.5, 1.5 Hz, 1H, –CH=CHH’), 4.85 (d, J = 3.4 Hz, 1H, 1-H), 4.12 (ddt, J = 13.2, 
4.9, 1.5 Hz, 1H, -O-CHH’-CH=), 3.93 (m, 2H, -O-CHH’-CH=, 3-H), 3.68 (dq, J = 
9.1, 6.2 Hz, 1H, 5-H), 3.10 (dt, J = 9.1, 2.0 Hz, 1H, 4-H), 2.23 (d, J = 2.0 Hz, 1H, 
OH), 2.02 (ddd, J = 12.9, 5.1, 1.1 Hz, 1H, 2-Hax), 1.68 (ddd, J = 12.9, 11.3, 3.4 Hz, 
1H, 2-Heq), 1.28 (d, J = 6.2 Hz, 3H, 6-H), 0.89 (s, 9H, t-Bu-Si), 0.11, 0.09 (2s, 6H, 
Si(CH3)2). 
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13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 134.40 (d, -CH=CH2), 116.58 (t, –
CH=CH2), 96.61 (d, C-1), 78.02, 70.56, 67.46, (3d, C-3, C-4, C-5), 67.55 (t, –CH2-
CH=), 38.63 (t, C-2), 25.76 (q, Si-C(CH3)3), 17.98 (s, Si-C(CH3)3), 17.84 (q, C-6), -
4.20, -4.64 (2q, Si(CH3)2). 
 
Allyl-3-O-(tret-butyldimethylsilyl)-4-O-acetyl-2,6-dideohy-α-L-
glucopyranoside (182) 
OMeAcO
TBSO
O
 
The sugar 180 (2.58 g, 8.5 mmol) was dissolved in pyridine (10 ml) and Ac2O (1.02 
ml, 11.05 mmol, 1.3 eq) was added. The reaction mixture was stirred overnight. 
The solvent was evaporated under reduced pressure and the residue was 
extracted with ethyl acetate, washed with water, dried over MgSO4 and again 
concentrated under reduced pressure. 
 
Yield: 2.9 g (8.4 mmol, 99%) 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.90 (dddd, J = 17.2, 10.5, 5.8, 
5.0 Hz, 1H, –CH=CH2), 5.27 (dq, J = 17.2, 1.6 Hz, 1H, –CH=CHH’), 5.18 (dq, J = 
10.5, 1.4 Hz, 1H, –CH=CHH’), 4.86 (d, J = 3.3 Hz, 1H, 1-H), 4.63 (t, J = 9.5 Hz, 
1H, 4-H), 4.11(ddt, J = 13.1, 5.0, 1.5 Hz, 1H, -O-CHH’-CH=), 4.05 (ddd, J = 11.3, 
9.5, 5.3 Hz, 1H, 3-H), 3.92 (ddt, J = 13.1, 5.8, 1.3, Hz, 1H, -O-CHH’-CH=), 3.73 
(dq, J = 9.5, 6.2 Hz, 1H, 5-H), 2.06 (s, 3H, AcO), 2.06 (ddd, J = 13.1, 5.3, 1.1 Hz, 
1H, 2-Hax), 1.75 (ddd, J = 13.1, 11.3, 3.3 Hz, 1H, 2-Heq), 1.13 (d, J = 6.2 Hz, 3H, 6-
H), 0.84 (s, 9H, t-BuSi), 0.04, 0.03 (2s, 6H, Me2Si). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 170.33 (s, COCH3), 134.61 (d, -
CH=CH2), 117.06 (t, –CH=CH2), 96.74 (d, C-1), 68.03 (t, –CH2-CH=), 78.12, 67.80, 
66.29 (3d, C-3, C-4, C-5), 39.42 (t, C-2), 25.88 (q, Si-C(CH3)3), 21.46 (q, COCH3), 
18.12 (s, Si-C(CH3)3 , 17.91 (q, C-6), -4.18, -4.58 (2q, Si(CH3)2). 
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Dimerization of allyl glycoside 182 and catalytic hydrogenation (183) 
OMeAcO
TBSO
O
OMeAcO
TBSO
O
 
The reaction was carried out according to the protocol TP3 except for the following 
details: starting material 182 (100 mg, 0.29 mmol) in dry benzene (3 ml), Column 
chromatography (ethyl acetate / petroleum ether 1:10) 
Yield: 69 mg (0.104 mmol, 72%); recovery of starting material 20 mg (0.058 mmol, 
20%). Obtained olefin was directly involved in catalytic hydrogenation. 
 
The reaction was carried out according to the protocol TP4 except for the following 
details: olefin (69 mg, 0.104 mmol) in the solvent mixture (5 ml). 
 
Yield: 70 mg (0.103 mmol, 99%).  
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ:  4.79 (d, J = 2.7 Hz, 1H, 1-H), 
4.61 (dd, J = 9.1, 9.5 Hz, 1H, 4-H), 4.00 (ddd, J = 10.8, 9.1, 5.2 Hz, 1H, 3-H), 3.69 
(dq, J = 9.5, 6.3 Hz, 1H, 5-H), 3.60 (m, 1H, –O-CHH’-CH2-), 3.36 (m, 1H, –O-CHH’-
CH2-), 2.05 (s, 3H, AcO), 2.01 (dd, J = 13.3, 5.2 Hz, 1H, 2-Hax), 1.72 (ddd, J = 
13.3, 10.8, 3.5 Hz, 1H, 2-Heq), 1.62 (m, 2H, –O-CH2-CH2-), 1.12 (d, J = 6.3 Hz, 3H, 
6-H), 0.83 (s, 9H, t-Bu), 0.03, 0.02 (2s, 6H, 2xMe) 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 169.92 (s, COCH3), 97.12 (d, 1-H), 
77.79 (d, 4-H), 67.53, 65.87 (2d, C-3, C-5), 67.05 (t, –O-CH2-CH2-), 39.23 (t, C-2), 
26.36 (t, –O-CH2-CH2-), 25.54 (q, SiC(CH3)3), 21.12 (q, COCH3), 17.79 (s, 
SiC(CH3)3), 17.63 (q, C-6), -4.50, -4.90 (2q, Si(CH3)2). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2410Hz = 4.82ppm: 4.81 
(d, 1H, 1-H), 4.63 (dd, 1H, 4-H), 4.03 (ddd, 1H, 3-H), 3.72 (dq, 1H, 5-H), 2.04 (dd, 
1H, 2-H), 1.74 (ddd, 1H, 2-H), 1.14 (d, 3H, 6-H) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 1697Hz = 3.39ppm: 3.63 
(bd, –O-CHH’-CH2-), 3.39 (ddd, 1H, –O-CHH’-CH2-), 1.65 (ddd, 2H, –O-CH2-CH2-). 
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Dimerization of allyl glycoside 179 and catalytic hydrogenation (185) 
OMeAcO
AcO
O
OMeAcO
AcO
O
 
The reaction was carried out according to the protocol TP3: starting material 179 (4 
g, 15 mmol) in dry benzene (30 ml), Column chromatography (ethyl acetate / 
petroleum ether 1:7). Yield: 3.1 g (6.0 mmol, 80%). 
The product was involved in catalytic hydrogenation according to the protocol TP4: 
starting material 3.1 g (6.0 mmol) in the mixture of solvents (50 ml). 
 
Yield: 3.1 g (5.97 mmol, >99%).  
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.25 (ddd, J = 11.6, 9.5, 5.4 Hz, 
1H, 3-H), 4.84 (d, J = 2.8 Hz, 1H, 1-H), 4.72 (dd, J = 9.7, 9.5 Hz, 1H, 4-H), 3.83 
(dq, J = 9.7, 6.4 Hz, 1H, 5-H), 3.63 (m, 1H, –O-CHH’-CH2-), 3.35 (m, 1H, –O-CHH’-
CH2-), 2.20 (ddd, J = 12.7, 5.4, 0.9 Hz, 1H, 2-Hax), 2.04, 1.99 (2s, 6H, 2 x AcO), 
1.77 (ddd, J = 12.7, 11.6, 3.7 Hz, 1H, 2-Heq), 1.64 (m, 2H, –O-CH2-CH2-), 1.16 (d, J 
= 6.4 Hz, 3H, 6-H) 
 
Deacetylation of homodimer 185 and preparation of tetrol (188) 
OMeHO
HO
O
OMeHO
HO
O
 
The reaction was carried out according to the protocol TP8: acylated alcohol 185 
3.1 g (5.97 mmol). The crude product was used for the next step without further 
purification. 
 
Yield: 2.08 g (5.95 mmol, >99%) 
 
1H-NMR (200 MHz, CD3OD, = 3.35 ppm) δ: 4.80 (d, J = 3.0 Hz, 1H, 1-H), 3.77 
(ddd, J = 11.7, 9.1, 5.1 Hz, 1H, 3-H), 3.66 (m, 1H, –O-CHH’-CH2-), 3.58 (dq, J = 
9.3, 6.2 Hz, 1H, 5-H), 3.44 (m, 1H, –O-CHH’-CH2-), 2.93 (dd, J = 9.3, 9.1 Hz, 1H, 
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4-H), 2.05 (ddd, J = 12.9, 5.1, 0.9 Hz, 1H, 2-Hax), 1.70 (m, 2H, –O-CHH’-CH2-), 1.6 
(ddd, J = 12.9, 11.7, 3.0 Hz, 1H, 2-Heq), 1.24 (d, J = 6.2 Hz, 3H, 6-H) 
 
Silylation of homodimeric tetrol (184) 
OMeHO
TBSO
O
OMeHO
TBSO
O
 
To an ice cooled stirred solution of tetrol 188 (383 mg, 1.1 mmol), imidazole (223 
mg, 3.3 mmol, 3.0 eq) and DMAP (cat.) in DMF (10 ml) TBSCl (330 mg, 2.2 mmol, 
2 eq) was slowly added. The solution was stirred at 0oC for 4 h and then allowed to 
warm up to RT. After additional 12h the reaction was terminated by addition of n-
hexane (10 ml). The DMF phase was extracted with n-hexane (2x 5 ml) and the 
combined hexane phases were concentrated under reduced pressure. The crude 
material was subjected to gel filtration (petroleum ether / ethyl acetate 10:1) after 
which it could be directly employed for the next step.  
 
Yield: 507 mg (0.875 mmol, 84%). 
  
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 4.79 (d, J = 3.3 Hz, 1H, 1-H), 
3.90 (ddd, J = 11.3, 9.0, 4.9 Hz, 1H, 3-H), 3.65 (dq, J = 9.3, 6.3 Hz, 1H, 5-H), 3.60 
(m, 1H, –O-CHH’-CH2-), 3.35 (m, 1H, –O-CHH’-CH2-), 3.09 (ddd, J = 9.0, 9.0, 2.0 
Hz, 1H, 4-H), 2.24 (d, J = 2.0 Hz, 1H, OH), 1.99 (dd, J = 12.7, 4.9 Hz, 1H, 2-Hax), 
1.66 (ddd, J = 12.7, 11.3, 3.3 Hz, 1H, 2-Heq), 1.28 (d, J = 6.3 Hz, 3H, 6-H), 0.89 (s, 
9H, t-Bu), 0.11, 0.09 (2s, 6H, Me2Si). 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 97.34 (d, C-1), 78.04, 70.64, 67.37 
(3d, C-3, C-4, C-5), 66.90 (t, –O-CH2-CH2-), 38.76 (t, C-2), 26.40 (t, –O-CH2-CH2-), 
25.77 (q, Si-C(CH3)3), 17.99 (s, Si-C(CH3)3), 17.89 (q, C-6), -4.18, -4.61 (2q, 
Si(CH3)2). 
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O-Allylation of diol 184 (186) 
OMeHO
TBSO
O
OMeO
TBSO
O
 
The reaction was carried out according to the protocol TP5: starting material 184 
(50 mg, 0.086 mmol) in DMSO (0.5 ml), allylbromid   208 mg (1.72 mmol, 20 eq), 
LiN(SiMe3)2 100 mg (0.6 mmol) in THF (0.5 ml). Column chromatography (ethyl 
acetate / petroleum ether 1:10). 
 
Yield: 13.3 mg (0.021 mmol, 25%), 
isolated starting material 16 mg (0.027 mmol, 32%) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.94 (dddd, J = 17.0, 10.5, 5.8, 
5.8 Hz, 1H, –CH=CH2), 5.24 (dd, J = 17.0, 1.5 Hz, 1H, –CH=CHH’), 5.14 (d, J = 
10.5 Hz, 1H, –CH=CHH’), 4.78, 4.75 (2d, J = 3.0 Hz, 2H, 1-H, 1-H’), 4.34 (dd, J = 
12.0, 5.4 Hz, 1H, -O-CHH’-CH=), 4.08 (dd, J = 12.0, 6.0 Hz, 1H, -O-CHH’-CH=), 
3.99 (ddd, J = 10.9, 9.0, 5.0 Hz, 1H, 3-H’), 3.90 (ddd, J = 11.1, 8.8, 4.9 Hz, 1H, 3-
H), 3.62 (m, 4H, 5-H, 5-H’, –O-CH2-CH2-), 3.34 (m, 2H, –O-CH2-CH2-), 3.09 (ddd, J 
= 9.2, 8.8, 2.0 Hz, 1H, 4-H), 2.83 (dd, J = 9.0, 9.0 Hz, 1H, 4-H’), 2.22 (d, J = 2.0 
Hz, 1H, OH), 1.99 (ddd, J = 13.0, 4.0, 3.7 Hz, 2H, 2-Hax, 2-Hax’), 1.61 (m, 6H, 2 x –
O-CH2-CH2-, 2-Heq, 2-H’eq), 1.28 (d, J = 6.1 Hz, 3H, 6-H), 1.26 (d, J = 6.1 Hz, 3H, 
6-H’), 0.89 (s, 18H, 2 x t-BuSi), 0.11, 0.10, 0.09, 0.08 (4s, 12H, 2 x Me2Si). 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 135.14 (d, -CH=CH2), 116.81 (t, –
CH=CH2), 97.31 (d, C-1), 97.14 (d, C-1’), 85.36 (d, C-4’), 78.05 (d, C-4), 74.31 (t, –
CH2-CH=), 70.65 (d, C-3), 70.18 (d, C-3’), 67.35, 67.20 (2d, C-5, C-5’), 66.90, 
66.82 (2t, 2 x –O-CH2-CH2-), 39.56, 38.76 (2t, C-2, C-2’), 26.40, 26.39 (2t, 2 x –O-
CH2-CH2-), 25.84, 25.78 (2q, 2 x SiC(CH3)3), 18.13, 17.99 (2s, SiC(CH3)3), 17.95, 
17.89 (2q, C-6, C-6’), -4.17, -4.55, -4.57, -4.61 (4q, 2 x SiMe2). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2186Hz = 4.37ppm: 5.95 
(ddd, 1H, –CH=CH2), 5.27 (dd, 1H, –CH=CHH’), 5.17 (d, 1H, –CH=CHH’), 4.37 
(ddd, 1H, -O-CHH’-CH=), 4.11 (ddd, 1H, -O-CHH’-CH=) 
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1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 1561Hz = 3.12ppm: 4.81 
(d, 1H, 1-H), 3.92 (ddd, 1H, 3-H), 3.67 (dq, 1H, 5-H), 3.12 (ddd, 1H, 4-H), 2.25 (d, 
1H, OH), 2.02 (dd, 1H, 2-Hax), 1.68 (ddd, 1H, 2-Heq), 1.31 (d, 3H, 6-H).  
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 1428Hz = 2.68ppm: 4.78 
(d, 1H, 1-H’), 4.03 (ddd, 1H, 3-H’), 3.66 (dq, 1H, 5-H’), 2.85 (dd, 1H, 4-H’), 2.01 
(dd, , 1H, 2-H’ax), 1.67 (ddd, 1H, 2-H’eq), 1.28 (d, 3H, 6-H’) 
 
Pivaloylation of homodimeric tetrol (189) 
OMeHO
PivO
O
OMeHO
PivO
O
 
The sugar 188 (0.3 g, 0.856 mmol) was dissolved in pyridine (10 ml) and PivCl 
(0.21 ml, 1.72 mmol, 2.2 eq) was added. The reaction mixture was stirred 
overnight. The solvent was evaporated under reduced pressure and the residue 
was extracted with ethyl acetate, washed with water, dried over MgSO4 and again 
concentrated  under reduced pressure. 
 
Yield: 377 mg  (0.727 mmol, 85%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.13 (ddd, J = 11.6, 9.2, 5.2 Hz, 
1H, 3-H), 4.89 (d, J = 3.0 Hz, 1H, 1-H), 3.71 (dq, J = 9.2, 6.2 Hz, 1H, 5-H), 3.70 (m, 
1H, –O-CHH’-CH2-), 3.35 (m, 1H, –O-CHH’-CH2-), 3.22 (dd, J = 9.2, 9.2 Hz, 1H, 4-
H), 2.87 (bs, 1H, OH), 2.12 (ddd, J = 12.6, 5.2, 1.0 Hz, 1H, 2-Hax), 1.74 (ddd, J = 
12.6, 11.6, 3.0 Hz, 1H, 2-Heq), 1.65 (m, 2H, –O-CH2-CH2-), 1.31 (d, J = 6.2 Hz, 3H, 
6-H), 1.19 (s, 9H, PivO) 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 179.90 (s, COC(CH3)3), 96.62 (d, 
C-1), 76.00, 72.47, 68.26 (3d, C-3, C-4, C-5), 66.60 (t, –O-CH2-CH2-), 38.84 (s, 
COC(CH3)3), 35.29 (t, C-2), 27.06 (q, COC(CH3)3), 26.28 (t, –O-CH2-CH2-), 17.74 
(q, C-6). 
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O-Allylation of diol 189 (190, 192) 
The reaction was carried out according to the protocol TP5: starting material 189 
(50 mg, 0.096 mmol), allylbromide 232 mg (1.92 mmol), LiN(SiMe3)2 112 mg (0.67 
mmol). Column chromatography (ethyl acetate / petroleum ether 1:10). Three 
fractions were isolated. 
OMeO
PivO
O
OMeO
PivO
O
 
Yield: 190 20 mg (0.034 mmol, 35%) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.86 (dddd, J = 17.1, 11.0, 5.9, 
5.2 Hz, 1H, –CH=CH2), 5.23 (dd, J = 17.1, 1.5 Hz, 1H, –CH=CHH’), 5.17 (ddd, J = 
11.1, 9.1, 5.1 Hz, 1H, 3-H), 5.13 (dd, J = 11.0, 1.2 Hz, 1H, –CH=CHH’), 4.78 (d, J 
= 2.7 Hz, 1H, 1-H), 4.18 (dd, J = 12.1, 5.2 Hz, 1H, -O-CHH’-CH=), 4.08 (dd, J = 
12.3, 5.9 Hz, 1H, -O-CHH’-CH=), 3.74 (dq, J = 9.2, 6.2 Hz, 1H, 5-H), 3.60 (ddd, J = 
9.2, 6.2, 5.9 Hz, 1H, –O-CHH’-CH2-), 3.32 (ddd, J = 9.2, 5.9, 5.2 Hz, 1H, –O-CHH’-
CH2-), 3.06 (dd, J = 9.2, 9.1 Hz, 1H, 4-H), 2.21 (ddd, J = 12.6, 5.2, 0.9 Hz, 1H, 2-
H), 1.61 (m, 3H, 2-H, –O-CH2-CH2-), 1.29 (d, J = 6.2 Hz, 3H, 6-H), 1.19 (s, 9H, 
COC(CH3)3) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 177.39 (s, C=O), 134.72 (d, -
CH=CH2), 116.76 (t, –CH=CH2), 96.70 (d, C-1), 82.27 (d, C-4), 73.44 (t, –CH2-
CH=), 71.62 (d, C-3), 66.92 (t, –O-CH2-CH2-), 66.90 (d, C-5), 38.61 (s, 
COC(CH3)3), 35.37 (t, C-2), 27.11 (q, COC(CH3)3), 26.30 (t, –O-CH2-CH2-), 18.19 
(q, C-6). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2057Hz = 4.11ppm: 5.88 
(dddd, 1H, –CH=CH2), 5.27 (dd, 1H, –CH=CHH’), 5.15 (d, 1H, –CH=CHH’), 4.20 
(dd, 1H, -O-CHH’-CH=), 4.11 (dd, 1H, -O-CHH’-CH=) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2404Hz = 4.81ppm: 5.19 
(ddd, 1H, 3-H), 4.81 (d, 1H, 1-H), 3.77 (dq, 1H, 5-H), 3.09 (dd, 1H, 4-H), 2.23 (ddd, 
1H, 2-H), 1.62 (ddd, 1H, 2-H), 1.31 (d, 3H, 6-H) 
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1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 1675Hz = 3.35ppm: 3.63 
(d, 1H, –O-CHH’-CH2-), 3.35 (ddd, 1H, –O-CHH’-CH2-), 1.64 (ddd, 2H, –O-CH2-
CH2-) 
 
OMeO
PivO
O
OMePivO
O
O
 
Yield: 192 8.6 mg (0.014 mmol, 15%). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.84 (bdddd, J = 17.4, 10.3, 5.4, 
5.2 Hz, 2H, 2 x  –CH=CH2), 5.23 (ddd, J = 17.4, 9.4, 1.5 Hz, 2H, 2 x  –CH=CHH’), 
5.21 (m, 1H, 3-H’), 5.14 (d, J = 10,3 Hz, 1H, –CH=CHH’), 5.11 (dd, J = 10.3, 1.3 
Hz, 1H, –CH=CHH’), 4.85 (d, J = 3.0 Hz, 1H, 1-H’), 4.79 (d, J = 3.1 Hz, 1H, 1-H), 
4.70 (dd, J = 9.4, 9.4 Hz, 1H, 4-H), 4.20 (dd, J = 12.2, 5.3 Hz, 1H, -O-CHH’-CH=), 
4.10 (dd, J = 12.2, 5.9 Hz, 1H, -O-CHH’-CH=), 4.07 (dd, J = 12.8, 5.4 Hz, 1H, -O-
CHH’-CH=), 3.93 (dd, J = 12.8, 5.3 Hz, 1H, -O-CHH’-CH=), 3.76 (m, 3H), 3.62 (m, 
2H), 3.35 (m, 2H), 3.08 (dd, J = 9.2, 9.2 Hz, 1H, 4-H’), 2.24 (ddd, J = 12.6, 6.6, 5.6 
Hz, 2H, 2-H, 2-H’), 1.62 (m, 6H), 1.30 (d, J = 6.3 Hz, 3H, 6-H’), 1.22, 1.20 (2s, 18H, 
2 x PivO), 1.13 (d, J = 6.2 Hz, 3H, 6-H) 
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm) δ: 177.52, 177.48 (2s, 2 x 
COC(CH3)3), 134.90, 134.64 (2d, 2 x -CH=CH2), 116.94, 116.34 (2t, 2 x –
CH=CH2), 97.27 (d, C-1), 96.78 (d, C-1’), 82.26 (d, C-4’), 75.83 (d, C-4), 74.36 (d, 
C-5’), 73.64, 70.45 (2t, 2 x –CH2-CH=), 71.71 (d, C-3’), 67.25 (d, C-3), 67.00 (t, 2 x 
–O-CH2-CH2-), 66.01 (d, C-5), 38.79, 38.65 ( 2s, 2 x COC(CH3)3), 35.68, 35.38 (2t, 
C-2, C-2’), 27.16, 27.13 (2q, COC(CH3)3), 26.41, 26.37 (2t, 2 x –O-CH2-CH2-), 
18.22 (q, C-6’), 17.54 (q, C-6). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2115Hz = 4.23ppm: 5.90 
(dddd, 1H, –CH=CH2’), 5.26 (dd, 1H, –CH=CHH’), 5.18 (d, 1H, –CH=CHH’), 4.22 
(dd, 1H, -O-CHH’-CH=’), 4.13 (dd, 1H, -O-CHH’-CH=’) 
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1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 1981Hz = 3.96ppm: 5.86 
(dddd, 1H, –CH=CH2), 5.25 (dd, 1H, –CH=CHH’), 5.14 (d, 1H, –CH=CHH’), 4.10 
(dd, 1H, -O-CHH’-CH=), 3.96 (dd, 1H, -O-CHH’-CH=) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 1554Hz = 3.11ppm: 5.21 
(ddd, 1H, 3-H’),  4.82 (d, 1-H’), 3.79 (dq, 1H, 5-H’), 3.11 (dd, 1H, 4-H’), 2.26 (dd, 
1H, 2-H’), 1.63 (ddd, 1H, 2-H’), 1.32 (d, 3H, 6-H’) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2365Hz = 4.73ppm: 4.88 
(d, 1H, 1-H), 4.73 (dd, 1H, 4-H), 3.79 (ddd, 1H, 3-H), 3.77 (dq, 1H, 5-H), 2.27 (dd, 
1H, 2-H), 1.71 (ddd, 1H, 2-H), 1.16 (d, 3H, 6-H) 
 
Silylation of homodimeric tetrol (193) 
OMeHO
TBDPS
O
OMeHO
TBDPSO
O
 
To a solution of tetrol 188 (393 mg, 1.13 mmol), imidazole (223 mg, 3.3 mmol), 
DMAP (cat.) in DMF (10 ml) was slowly added TBDPSCl (565 mg, 2.26 mmol) at 
0°C. The solution was stirred at 0°C for 4h and then temperature was raised to rt. 
After additional 12h the reaction was terminated by addition of n-hexane (10 ml). 
The DMF phase was extracted with n-hexane (2x 5 ml) and the combined hexane 
phases were concentrated under reduced pressure. The crude material was 
subjected to gel filtration (petroleum ether / ethyl acetate 10:1) after which it could 
directly be employed for the next step.  
 
Yield: 857 mg (1.034 mmol, 94%). 
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.68 (m, 4H, Ph), 7.38 (m, 6H, 
Ph), 4.63 (d, J = 3.0 Hz, 1H, 1-H), 4.01 (ddd, J = 11.2, 9.0, 5.1 Hz, 1H, 3-H), 3.50 
(dq, J = 9.1, 6.2 Hz, 1H, 5-H), 3.44 (m, 1H, –O-CHH’-CH2-), 3.23 (ddd, J = 9.1, 9.0, 
2.5 Hz, 1H, 4-H), 3.15 (m, 1H, –O-CHH’-CH2-), 2.14 (d, J = 2.5 Hz, 1H, OH), 1.84 
(ddd, J = 12.6, 5.1, 0.9 Hz, 1H, 2-Hax), 1.67 (ddd, J = 12.6, 11.2, 3.0 Hz, 1H, 2-
Heq), 1.33 (m, 2H, –O-CH2-CH2-), 1.25 (d, J = 6.2 Hz, 3H, 6-H), 1.08 (s, 9H, t-Bu) 
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O-Allylation of diol 193 (194) 
OMeO
TBDPSO
O
OMeO
TBDPSO
O
 
The reaction was carried out according to the protocol TP5: starting material 193 
4.6 g (5.5 mmol), allylbromide 9.4 ml (0.11 mmol), LiN(SiMe3)2 6.45 g (0.0385 mol), 
moderate cooling required (ice bath). Column chromatography (ethyl acetate / 
petroleum ether 1:10). 
 
Yield: 2.4 g (2.64 mmol, 48%),  
mixfraction 100 mg (~2%),  
isolated monoallylated product 195 2.39 g (2.75 mmol, 50%). 
 
1H-NMR (400 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 7.76 (dd, J = 7.9, 1.5 Hz, 2H, Ar), 
7.71 (dd, J = 7.9, 1.5 Hz, 2H, Ar), 7.36 (m, 6H, Ar), 5.97 (dddd, J = 17.2, 10.3, 5.7, 
5.7 Hz, 1H, –CH=CH2), 5.28 (dd, J = 17.2, 1.6 Hz, 1H, –CH=CHH’), 5.20 (dd, J = 
10.3, 1.7 Hz, 1H, –CH=CHH’), 4.52 (bs, 1H, 1-H), 4.50 (dd, J = 11.9, 5.7 Hz, 1H, -
O-CHH’-CH=), 4.25 (ddd, J = 10.1, 8.9, 5.9 Hz, 1H, 3-H), 4.18 (dd, J = 11.9, 5.7 
Hz, 1H, -O-CHH’-CH=), 3.60 (dq, J = 9.1, 6.2 Hz, 1H, 5-H), 3.39 (m, 1H, –O-CHH’-
CH2-), 3.05 (m, 1H, –O-CHH’-CH2-), 3.02 (dd, J = 9.1, 8.9 Hz, 1H, 4-H), 1.54 (m, 
2H, 2-H), 1.28 (d, J = 6.2 Hz, 3H, 6-H), 1.27 (m, 2H, –O-CH2-CH2-), 1.10 (s, 9H, t-
Bu) 
 
13C-NMR (100 MHz, CDCl3, CDCl3 = 77 ppm) δ: 135.92 (d, Ar), 135.85 (d, Ar), 
135.10 (d, -CH=CH2), 134.94 (s, Ar), 133.80 (s, Ar), 129.55, 129.47, 127.49 (3d, 3 
x Ar), 116.78 (t, –CH=CH2), 96.95 (d, C-1), 85.68 (d, C-4), 74.27 (t, –CH2-CH=), 
71.15 (d, C-3), 67.21 (d, C-5), 66.49 (t, –O-CH2-CH2-), 38.95 (t, C-2), 27.05 (q, 
SiC(CH3)3), 26.01 (t, –O-CH2-CH2-), 19.17 (s, SiC(CH3)3), 18.19 (q, C-6). 
 
Desilylation of homodimer 194 (196) 
OMeO
HO
O
OMeO
HO
O
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A solution of tetra-n-butyl ammonium fluoride (1M, 1.65 mmol, 1.65 ml, 3 eq) in 
THF was added to a solution of homodimer (0.5 g, 0.55 mmol) in THF (10 ml). The 
solution was stirred overnight, the solvent was removed under reduced pressure 
and the crude material was purified by column chromatography (petroleum ether / 
ethyl acetate 1:3) to give the corresponding diol. 
 
Yield: 200 mg (0.465 mmol, 85 %) colorless, amorphous powder. 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ: 5.97 (dddd, J = 17.2, 10.3, 5.7, 
5.7 Hz, 1H, –CH=CH2), 5.32 (dq, J = 17.2, 1.6 Hz, 1H, –CH=CHH’), 5.22 (dq, J = 
10.3, 1.4 Hz, 1H, –CH=CHH’), 4.83 (d, J = 3.3 Hz, 1H, 1-H), 4.25 (dq, J = 5.7, 1.3 
Hz, 2H, -O-CH2-CH=), 4.00 (dddd, J = 11.7, 9.0, 5.1, 3.1 Hz, 1H, 3-H), 3.66 (dq, J 
= 9.2, 6.2 Hz, 1H, 5-H), 3.63 (dt, J = 9.4, 6.4, Hz, 1H, –O-CHH’-CH2-), 3.36 (dt, J = 
9.4, 6.4 Hz, 1H, –O-CHH’-CH2-), 2.87 (dd, J = 9.2, 9.0 Hz, 1H, 4-H), 2.34 (d, J = 
3.1 Hz, 1H, OH), 2.13 (ddd, J = 12.9, 5.1, 1.1 Hz, 1H, 2-Hax), 1.69 (ddd, J = 12.9, 
11.7, 3.3 Hz, 1H, 2-Heq), 1,63 (ddd J = 6.4, 6.4, 6.4 Hz, 2H, –O-CH2-CH2-), 1.30 (d, 
J = 6.2 Hz, 3H, 6-H).  
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm)δ: 134.87 (d, -CH=CH2), 117.24 (t, –
CH=CH2), 97.11 (d, C-1), 86.37 (d, C-4), 73.97 (t, –CH2-CH=), 68.73 (d, C-3), 
66.96 (d, C-5), 66.86 (t, –O-CH2-CH2-), 37.69 (t, C-2)), 26.41 (t, –O-CH2-CH2-), 
18.16 (q, C-6). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2134Hz = 4.25ppm: 5.97 
(dddd, 1H, –CH=CH2), 5.32 (dq, 1H, –CH=CHH’), 5.22 (dq, 1H, –CH=CHH’), 4.24 
(dd, 2H, -O-CH2-CH=). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 2414Hz = 4.83ppm: 4.83 
(d, 1H, 1-H), 4.01 (dddd, 1H, 3-H), 3.67 (dq, 1H, 5-H), 2.88 (dd, 1H, 4-H), 2.34 (d, 
1H, OH), 2.13 (ddd, 1H, 2-Hax), 1.69 (ddd, 1H, 2-Heq), 1.30 (d, 3H, 6-H) 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) TOCSY 1680Hz = 3.36ppm: 3.63 
(dt, 1H, –O-CHH’-CH2-), 3.36 (ddd, 1H, –O-CHH’-CH2-), 1.63 (dq, 2H, –O-CH2-
CH2-).  
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11.8.2. Experiments to the chapter 9.5.1. 
Trifluorosulfonation of allylated homodimeric diol 196 (197) 
OMeO
TfO
O
OMeO
TfO
O
 
To a solution of sugar 196 (100 mg, 0.232 mmol) in dry CH2Cl2 (20 ml) with 
pyridine as a base (100µl) at – 15oC Tf2O (138 mg, 0.49 mmol) in dry CH2Cl2 (5 ml) 
was added. The reaction mixture was stirred for 2h, diluted with water and 
extracted with petrol ether (2 x 40 ml). The organic extracts were combined, 
washed with water, dried over an MgSO4 and the solvent was evaporated under 
reduced pressure. The crude product was dissolved in a small amount of CH2Cl2 
and filtered through a small column of silica gel. 
 
Yield: 125 mg (0.22 mmol, 96%). very unstable colourless film.  
 
1H-NMR (200 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 5.93 (ddt, J = 17.2, 10.3, 5.5 
Hz, 2H, 2 x -CH=), 5.41 (ddd, J = 12.3, 9.2, 5.3 Hz, 2H, 2 x 3-H), 5.27 (dq, J = 
17.2, 1.5 Hz, 2 x H, -CH=CHH’), 5.11 (dq, J = 10.3, 1.5 Hz, 2H, 2 x  -CH=CHH’), 
4.51 (d, J = 3.1 Hz, 2H, 2 x 1-H), 4.18 (ddt, J = 12.1, 5.5, 1.2 Hz, 2H, 2 x =CH-
CHH’-O-), 3.91 (ddt, J = 12.1, 5.5, 1.0 Hz, 2H, 2 x =CH-CHH’-O-), 3.77 (dq, J = 
9.2, 6.2 Hz, 2H, 2 x 5-H), 3.38 (m, 2H, 2 x –O-CHH’-CH2-), 3.05 (m, 2H, 2 x –O-
CHH’-CH2-), 2.90 (t, J = 9.2 Hz, 2H, 2 x 4-H), 2.29 (ddd, J = 12.3, 5.3, 0.9 Hz, 2H, 
2 x 2-Hax), 1.63 (dt, J = 12.3, 3.1 Hz, 2H, 2 x 2-Heq), 1.38 (m, 4H, 2 x –O-CH2-CH2-
), 1.29 (d, J = 6.2 Hz, 6H, 2 x 6-H). 
 
Nucleophilic substitution of trifluorsulfonate ester with azide in the 
homodimer 197 (198) 
OMeO
N3
O
OMeO
N3
O
 
The solution of sugar 197 (200 mg, 0.465 mmol) in benzene (1 ml) was treated 
with n-BuN+ N3- (300 mg, 1.06 mmol, 2.3 eq). The reaction mixture was heated at 
70oC for 15 min, diluted with water and extracted with ethyl acetate (3 x 30 ml). 
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The organic extracts were combined, dried over an MgSO4 and solvent was 
evaporated under reduced pressure. The crude product was purified by column 
chromatography over silica gel (ethyl acetate / petroleum ether 1:12). 
 
Yield: 80 mg (0.167 mmol, 36%).   
  
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 5.78 (ddt, J = 17.2, 10.4, 5.4 Hz, 
2H, 2 x –CH=CH2), 5.18 (dq, J = 17.2, 1.6 Hz, 2H, 2 x –CH=CHH’), 5.01 (bdd, J = 
10.4, 1.3 Hz, 2H, 2 x –CH=CHH’), 4.53 (d, J = 4.1 Hz, 2H, 2 x 1-H), 4.25 (dq, J = 
9.1, 6.2 Hz, 2H, 2 x 5-H), 3.85 (dd, J = 12.7, 5.4 Hz, 2H, 2 x -O-CHH’-CH=), 3.70 
(m, 2H, 2 x –O-CHH’-CH2-), 3.60 (dd, J = 12.7, 5.4 Hz, 2H, 2 x -O-CHH’-CH=), 
3.41 (dt, J = 3.8, 3.4 Hz, 2H, 2 x 3-H), 3.26 (m, 2H, 2 x –O-CHH’-CH2-), 2.82 (dd, J 
= 9.1, 3.8 Hz, 2H, 2 x 4-H), 1.85 (ddd, J = 14.5, 3.4, 0.9 Hz, 2H, 2 x 2-Hax), 1.76 
(m, 4H, 2 x –O-CH2-CH2-), 1.33 (dt, J = 14.5, 4.1 Hz, 2H, 2 x 2-Heq), 1.31 (d, J = 
6.2 Hz, 6H, 2 x 6-H).  
 
13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ =  135.1 (d, 2 x  -CH=CH2), 
116.7 (t, 2 x –CH=CH2), 95.6 (d, 2 x C-1), 80.1 (d, 2 x C-4), 69.9 (t, 2 x –CH2-
CH=), 67.4 (t, 2 x –O-CH2-CH2-), 63.4 (d, 2 x C-5), 54.8 (d, 2 x C-3), 33.0 (t, 2 x C-
2), 26.9 (t, 2 x –O-CH2-CH2-), 18.2 (q, 2 x C-6).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 2324 Hz = 4.65 ppm: δ = 4.65 (d, 2H, 2 x 1-H), 
4.37 (dq, 2H, 2 x 5-H), 3.53 (dt, 2H, 2 x 3-H), 2.94 (dd, 2H, 2 x 4-H), 1.96 (ddd, 2H, 
2 x 2-Hax), 1.44 (dt, 2H, 2 x 2-Heq), 1.41 (d, 6H, 2 x 6-H).     
 
LC-MS (ESI) (+c): m/z (%): 453.26 (100) [M – N2]+, 487.26 (92) [M + Li]+, 503.24 
(88) [M + Na]+; HR-MS C22H36N6O6 +23Na: calc. 503.2594, found 503.2593  
 
Reduction of homodimeric azide 198 and trifluoroacetation the obtained 
amine (200) 
OMeO
TFAHN O
OMeO
TFAHN O
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A solution of azide 198 (80 mg, 0.167 mmol) in THF (5 ml) is added to a solution of 
LiAlH4 (25 mg, 0.658 mmol) in THF (10 ml). The reaction mixture was stirred 45 
min. at RT, then NaF (500 mg) was added followed by addition of a water/THF 
mixture (1 ml water, 4 ml THF). The resulted suspension was stirred for additional 
1 h, filtered and the solvent was evaporated under reduced pressure. The crude 
amine 199 was directly acetylated without further purifications. 
To a solution of crude amine 199 in CH2Cl2 (25 ml) was added dry triethly amine 
(50 mg, 0.5 mmol, 3 eq) at 0oC followed by addition of trifluoroacetic anhydride 
(105 mg, 0.5 mmol). The mixture was allowed to stir at RT for 30 min, whereupon 
t.l.c (ethyl acetate / petroleum ether 1:5) showed that acetylation was complete. 
The mixture was concentrated under reduced pressure to afford a crude product 
which was purified by column chromatography over silica gel (ethyl acetate / 
petroleum ether 1:7). 
 
Yield: 62 mg (0.1 mmol, 60% in two steps). 
 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 8.00 (d, J = 8.5 Hz, 2H, 2 x NH), 
5.97 (dddd, J = 17.2, 10.4, 6.0, 5.3 Hz, 2H, 2 x –CH=CH2), 5.34 (dq, J = 17.2, 1.5 
Hz, 2H, 2 x –CH=CHH’), 5.15 (bdd, J = 10.4, 1.1 Hz, 2H, 2 x –CH=CHH’), 4.50 (m, 
2H, 2 x 3-H), 4.48 (d, J = 3.0 Hz, 2H, 2 x 1-H), 4.38 (dd, J = 12.5, 5.3 Hz, 2H, 2 x -
O-CHH’-CH=), 3.85 (dd, J = 12.5, 6.0 Hz, 2H, 2 x -O-CHH’-CH=), 3.84 (dq, J = 9.5, 
6.2 Hz, 2H, 2 x 5-H), 3.56 (m, 2H, 2 x –O-CHH’-CH2-), 3.06 (m, 2H, 2 x –O-CHH’-
CH2-), 2.89 (dd, J = 9.5, 3.9 Hz, 2H, 2 x 4-H), 1.3 – 1.6 (m, 8H, 2 x 2-Hax, 2 x 2-Heq, 
2 x –O-CH2-CH2-), 1.41 (d, J = 6.2 Hz, 6H, 2 x 6-H). 
 
 13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 135.1 (d, 2 x -CH=CH2), 117.1 
(t, 2 x –CH=CH2), 96.8 (d, 2 x C-1), 78.1 (d, 2 x C-4), 70.5 (t, 2 x –CH2-CH=), 67.4 
(t, 2 x –O-CH2-CH2-), 63.5 (d, 2 x C-5), 43.7 (d, 2 x C-3), 32.7 (t, 2 x C-2), 26.6 (t, 2 
x –O-CH2-CH2-), 18.3 (q, 2 x C-6).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 2551 Hz = 4.50 ppm: δ = 8.00 (d, 2H, 2 x NH), 
4.50 (ddd, 2H, 2 x 3-H), 4.48 (d, 2H, 2 x 1-H), 3.84 (dq, 2H, 2 x 5-H), 2.89 (dd, 2H, 
2 x 4-H), 1.53 (ddd, 2H, 2 x 2-Hax), 1.41 (d, 6H, 2 x 6-H), 1.38 (dt, 2H, 2 x 2-Heq). 
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 1H-NMR (500 MHz, C6D6) TOCSY - 2192 Hz = 4.38 ppm: δ = 5.98 (dddd, 2H, 2 x 
–CH=CH2), 5.34 dq, 2H, 2 x –CH=CHH’), 5.15 (bdd, 2H, 2 x –CH=CHH’), 4.38 (dd, 
2H, 2 x -O-CHH’-CH=), 3.85 (dd, 2H, 2 x -O-CHH’-CH=). 
 
 1H-NMR (500 MHz, C6D6) TOCSY - 1783 Hz = 3.57 ppm: δ = 3.57 (m, 2H, 2 x –O-
CHH’-CH2-), 3.06 (m, 2H, 2 x –O-CHH’-CH2-), 1.48 (m, 4H, 2 x –O-CH2-CH2-).  
 
11.8.3. Experiments to the chapter 9.5.2. 
Preparation of diketone 201 
OMeO
O
O
OMeO
O
O
 
To a solution of the diol 196 (51 mg, 0.118 mmol) in dry CH2Cl2 (10 ml) was added 
the Dess-Martin periodinane (111 mg, 0.261 mmol). The mixture was stirred at RT 
for 3h, after which t.l.c. (ethyl acetate / petroleum ether 1:3) revealed that oxidation 
was completed. Remaining oxidant was removed by washing with aqueous 
Na2S2O3-solution. The organic phase was dried (MgSO4) and concentrated under 
reduced pressure. The crude product was purified by column chromatography 
(silica gel; ethyl acetate / petroleum ether 1:5). 
 
Yield: 50 mg (0.117 mmol, 99%). 
  
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 5.98 (dddd, J = 17.12 10.6, 6.0, 
5.0 Hz, 2H, 2 x –CH=CH2), 5.31 (dq, J = 17.2, 1.6 Hz, 2H, 2 x –CH=CHH’), 5.13 
(dq, J = 10.6, 1.3 Hz, 2H, 2 x –CH=CHH’), 4.79 (d, J = 4.3 Hz, 2H, 2 x 1-H), 4.56 
(bddt, J = 12.7, 5.0, 1.3 Hz, 2H, 2 x -O-CHH’-CH=), 4.17 (dq, J = 9.6, 6.2 Hz, 2H, 2 
x 5-H), 3.99 (bdd, J = 12.7, 6.0 Hz, 2H, 2 x -O-CHH’-CH=),  3.46 (dt, J = 9.6, 6.3 
Hz, 2H, 2 x –O-CHH’-CH2-), 3.43 (bd, J = 9.6 Hz, 2H, 2 x 4-H), 3.10 (dt, J = 9.6, 
5.7 Hz, 2H, 2 x –O-CHH’-CH2-), 2.50 (bd, J = 14.1 Hz, 2H, 2 x 2-Hax), 2.27 (dd, J = 
14.1, 4.3 Hz, 2H, 2 x 2-Heq), 1.52 (d, J = 6.2 Hz, 6H, 2 x 6-H), 1.43 (bq, J = 5.7 Hz, 
4H, 2 x –O-CH2-CH2-).  
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13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 202.2 (s, 2 x C-3), 135.2 (d, 2 
x -CH=CH2), 116.8 (t, 2 x –CH=CH2), 98.6 (d, 2 x C-1), 85.0 (d, 2 x C-4), 72.4 (t, 2 
x –CH2-CH=), 69.4 (d, 2 x C-5), 67.2 (t, 2 x –O-CH2-CH2-), 46.9 (t, 2 x C-2), 26.4 (t, 
2 x –O-CH2-CH2-), 19.1 (q, 2 x C-6). ).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 759 Hz = 1.52 ppm: δ = 4.79 (d, 2H, 2 x 1-H), 
4.18 (dq, 2H, 2 x 5-H), 3.43 (d, 2H, 2 x 4-H), 2.50 (d, 2H, 2 x 2-Hax), 2.26 (dd, 2H, 2 
x 2-Heq), 1.52 (d, 6H, 2 x 6-H). ). 
 
 1H-NMR (500 MHz, C6D6) TOCSY - 1549 Hz = 3.10 ppm: δ = 3.46 (dt, 2H, 2 x  –
O-CHH’-CH2-), 3.09 (dt, 2H, 2 x –O-CHH’-CH2-), 1.43 (bq, 4H, 2 x –O-CH2-CH2-).  
 
Preparation of homodimeric oxime 202 
OMeO
N
O
OMeO
N
O
HO
HO
 
To a solution of hydroxylamine hydrochloride (7 mg, 0.1 mmol), NaOAc (25 mg, 
0.3 mmol) and molecular sieves 4-Å (50 mg) in methanol (1.5 ml) the ketone 201 
(10 mg, 0.0233 mmol) was added. The suspension was stirred for 1h, then the 
solvent was evaporated under reduced pressure and the crude product was 
purified by column chromatography over silica gel (ethyl acetate / petroleum ether 
1:4). 
 
Yield: 10.2 mg (0.0224 mmol, 96%). 
 
1H-NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm): δ = 8.57 (bs, 2H, 2 x =N-OH), 5.92 
(dddd, J = 17.2, 10.4, 6.4, 5.2 Hz, 2H, 2 x –CH=CH2), 5.28 (dq, J = 17.2, 1.5 Hz, 
2H, 2 x –CH=CHH’), 5.19 (dq, J = 10.4, 1.3 Hz, 2H, 2 x –CH=CHH’), 4.88 (dd, J = 
4.1, 2.3 Hz, 2H, 2 x 1-H), 4.33 (bdd, J = 12.5, 5.2 Hz, 2H, 2 x -O-CHH’-CH=), 3.99 
(dd, J = 12.5, 6.4 Hz, 2H, 2 x -O-CHH’-CH=), 3.91 (dq, J = 8.3, 6.3 Hz, 2H, 2 x 5-
H), 3.63 (m, 2H, 2 x –O-CHH’-CH2-), 3.59 (d, J = 8.3 Hz, 2H, 2 x 4-H), 3.34 (m, 2H, 
2 x –O-CHH’-CH2-), 3.30 (dd, J = 14.3, 2.3 Hz, 2H, 2 x 2-Hax), 2.31 (dd, J = 14.3, 
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4.1 Hz, 2H, 2 x 2-Heq), 1.61 (m, 4H, 2 x –O-CH2-CH2-), 1.31 (d, J = 6.3 Hz, 6H, 2 x 
6-H).  
 
13C-NMR (125 MHz, CDCl3, CDCl3 = 77 ppm): δ = 153.5 (s, 2 x C-3), 134.5 (d, 2 x -
CH=CH2), 117.6 (t, 2 x –CH=CH2), 96.4 (d, 2 x C-1), 79.3 (d, 2 x C-4), 71.8 (t, 2 x –
CH2-CH=), 69.2 (d, 2 x C-5), 66.5 (t, 2 x –O-CH2-CH2-), 29.9 (t, 2 x C-2), 26.4 (t, 2 
x –O-CH2-CH2-), 18.2 (q, 2 x C-6). ). 
 
 LC-MS (ESI) (+c): m/z (%): 457.25 (40) [M + H]+, 479.23 (100) [M + Na]+; HR-MS 
C22H37N2O8: calc. 457.2550, found 457.2550  
 
Reductive amination of homodimeric ketone 201 (203) 
OMeO
BnHN O
OMeO
BnHN O
 
Ketone 201 (10 mg, 0.0233 mmol), benzylamine (25 mg, 0.233 mmol) and 
NaBH3CN (4 mg, 0.064 mmol) were stirred in methanol (2 ml) for 4h until t.l.c. 
(ethyl acetate /MeOH 10:1) showed that the reaction was complete. The solvent 
was evaporated under reduced pressure and the crude product was purified by 
column chromatography over RP-18 silica gel (MeOH, Rf = 0.5). 
 
Yield: 12.7 mg (0.021 mmol, 90%). 
 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 7.57 (m, 4H, 2 x Ph), 7.2-7.4 (m, 
6H, 2 x Ph),  5.94 (ddt, J = 17.2, 10.5, 5.1 Hz, 2H, 2 x –CH=CH2), 5.33 (dq, J = 
17.2, 1.7 Hz, 2H, 2 x –CH=CHH’), 5.13 (dq, J = 10.5, 1.6 Hz, 2H, 2 x –CH=CHH’), 
4.77 (dd, J = 4.1, 1.9 Hz, 2H, 2 x 1-H), 4.37 (dq, J = 8.6, 6.3 Hz, 2H, 2 x 5-H), 4.06 
(d, J = 13.3 Hz, 2H, 2 x Ph-CHH’-),  4.01 (ddt, J = 12.8, 5.1, 1.6 Hz, 2H, 2 x -O-
CHH’-CH=), 3.88 (d, J = 13.3 Hz, 2H, 2 x Ph-CHH’-), 3.79 (ddt, J = 12.8, 5.1, 1.5 
Hz, 2H, 2 x -O-CHH’-CH=), 3.75 (m, 2H, 2 x –O-CHH’-CH2-), 3.30 (m, 2H, 2 x –O-
CHH’-CH2-), 3.13 (dd, J = 8.6, 3.7 Hz, 2H, 2 x 4-H), 3.07 (dt, J = 4.1, 3.7 Hz, 2H, 2 
x 3-H), 2.13 (ddd, J = 14.0, 4.3, 1.9 Hz, 2H, 2 x 2-Hax), 1.61 (dt, J = 14.0, 4.1 Hz, 
2H, 2 x 2-Heq), 1.5 – 1.8 (m, 4H, 2 x –O-CH2-CH2-), 1.52 (d, J = 6.3 Hz, 6H, 2 x 6-
H). 
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  13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 142.1 (s, 2 x Ph), 135.8 (d, 2 
x -CH=CH2), 128.5, 127.1, 126.9 (3d, 6 x Ph), 116.0 (t, 2 x –CH=CH2), 97.4 (d, 2 x 
C-1), 81.2 (d, 2 x C-4), 69.5 (t, 2 x –CH2-CH=), 67.3 (t, 2 x –O-CH2-CH2-), 64.1 (d, 
2 x C-5), 52.0 (t, 2 x Ph-CH2-), 50.7 (d, 2 x C-3), 32.7 (t, 2 x C-2), 27.0 (t, 2 x –O-
CH2-CH2-), 18.7 (q, 2 x C-6).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 2387 Hz = 4.77 ppm: δ = 4.77 (dd, 2H, 2 x 1-
H), 4.38 (dq, 2H, 2 x 5-H), 3.13 (dd, 2H, 2 x 4-H), 3.07 (dt, 2H, 2 x 3-H), 2.13 (ddd, 
2H, 2 x 2-Hax), 1.61 (dt, 2H, 2 x 2-Heq), 1.52 (d, 6H, 2 x 6-H).  
 
LC-MS (ESI) (+c): m/z (%): 609.39 (100) [M]+, 610.39 (30) [M + H]+, 611.40 (30) [M 
+ 2H]+; HR-MS C36H53N2O6: calc. 609.3925, found 609.3917 
 
Reductive amination of homodimeric ketone 201 using ammonium 
acetate(204) 
Ketone 201 (10 mg, 0.0233 mmol), ammonium acetate (18 mg, 0.233 mmol) and 
NaBH3CN (2 mg, 0.032 mmol) were stirred in methanol (5 ml) for 24h followed by 
the addition of a second portion of NaBH3CN (2 mg, 0.032 mmol). The reaction 
mixture was allowed to stir another 24h. To the yielded reaction mixture 
triethylamine (23 mg, 0.233 mmol) and CF3COOEt (100 mg, 0.7 mmol) were 
added and the mixture was allowed to stir overnight. The solvent was evaporated 
under reduced pressure. Prior to column chromatography the crude product was 
separated from trifluoracatamide by sublimation in high vacuum (0.01 mbar, 60oC) 
then the residue was purified by column chromatography over silica gel (ethyl 
acetate / petroleum ether 1:5) to yield two fractions: 
1st fraction: 204 (6 mg, 0.0097 mmol, 41%),  
2nd fraction: 205 (1.3 mg, 0.0021 mmol, 9%). 
OMeO
O
OMeO
O
TFAHN
TFAHN
 
1st fraction 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 8.00 (d, J = 8.5 Hz, 2H, 2 x NH), 
5.97 (dddd, J = 17.2, 10.4, 6.0, 5.3 Hz, 2H, 2 x –CH=CH2), 5.34 (dq, J = 17.2, 1.5 
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Hz, 2H, 2 x –CH=CHH’), 5.15 (bdd, J = 10.4, 1.1 Hz, 2H, 2 x –CH=CHH’), 4.50 (m, 
2H, 2 x 3-H), 4.48 (d, J = 3.0 Hz, 2H, 2 x 1-H), 4.38 (dd, J = 12.5, 5.3 Hz, 2H, 2 x -
O-CHH’-CH=), 3.85 (dd, J = 12.5, 6.0 Hz, 2H, 2 x -O-CHH’-CH=), 3.84 (dq, J = 9.5, 
6.2 Hz, 2H, 2 x 5-H), 3.56 (m, 2H, 2 x –O-CHH’-CH2-), 3.06 (m, 2H, 2 x –O-CHH’-
CH2-), 2.89 (dd, J = 9.5, 3.9 Hz, 2H, 2 x 4-H), 1.3 – 1.6 (m, 8H, 2 x 2-Hax, 2 x 2-Heq, 
2 x –O-CH2-CH2-), 1.41 (d, J = 6.2 Hz, 6H, 2 x 6-H). 
 
 13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 135.1 (d, 2 x -CH=CH2), 117.1 
(t, 2 x –CH=CH2), 96.8 (d, 2 x C-1), 78.1 (d, 2 x C-4), 70.5 (t, 2 x –CH2-CH=), 67.4 
(t, 2 x –O-CH2-CH2-), 63.5 (d, 2 x C-5), 43.7 (d, 2 x C-3), 32.7 (t, 2 x C-2), 26.6 (t, 2 
x –O-CH2-CH2-), 18.3 (q, 2 x C-6).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 2551 Hz = 4.50 ppm: δ = 8.00 (d, 2H, 2 x NH), 
4.50 (ddd, 2H, 2 x 3-H), 4.48 (d, 2H, 2 x 1-H), 3.84 (dq, 2H, 2 x 5-H), 2.89 (dd, 2H, 
2 x 4-H), 1.53 (ddd, 2H, 2 x 2-Hax), 1.41 (d, 6H, 2 x 6-H), 1.38 (dt, 2H, 2 x 2-Heq). 
 
 1H-NMR (500 MHz, C6D6) TOCSY - 2192 Hz = 4.38 ppm: δ = 5.98 (dddd, 2H, 2 x 
–CH=CH2), 5.34 dq, 2H, 2 x –CH=CHH’), 5.15 (bdd, 2H, 2 x –CH=CHH’), 4.38 (dd, 
2H, 2 x -O-CHH’-CH=), 3.85 (dd, 2H, 2 x -O-CHH’-CH=). 
 
 1H-NMR (500 MHz, C6D6) TOCSY - 1783 Hz = 3.57 ppm: δ = 3.57 (m, 2H, 2 x –O-
CHH’-CH2-), 3.06 (m, 2H, 2 x –O-CHH’-CH2-), 1.48 (m, 4H, 2 x –O-CH2-CH2-).  
OMeO
O
OMeO
O
TFAHN
TFAHN  
2nd fraction 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 8.08 (d, J = 8.1 Hz, 1H, NH1), 
6.05 (dd, J = 8.1 Hz, 1H, NH2), 5.99 (dddd, J = 17.2, 10.4, 6.4, 5.2 Hz, 1H, –
CH=CH22), 5.82 (dddd, J = 17.1, 10.5, 5.3, 5.2 Hz, 1H, –CH=CH21), 5.35 (dq, J = 
17.2, 1.5 Hz, 1H, –CH=CHH’2), 5.26 (dq, J = 17.1, 1.6 Hz, 1H, –CH=CHH’1), 5.12 
(dq, J = 10.4, 1.5 Hz, 1H, –CH=CHH’2), 5.11 (dq, J = 10.5, 1.5 Hz, 1H, –
CH=CHH’1), 4.65 (d, J = 3.1 Hz, 1H, 1-H2), 4.51 (d, J = 3.3 Hz, 1H, 1-H1), 4.44 (m, 
1H, 3-H1), 4.37 (dd, J = 12.3, 5.2 Hz, 1H, -O-CHH’-CH=1), 4.32 (m, 1H, 3-H2), 4.01 
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(dd, J = 12.6, 5.2 Hz, 1H, -O-CHH’-CH=2), 3.91 (dq, J = 9.2, 6.3 Hz, 1H, 5-H2), 3.8 
– 3.9 (m, 3H, -O-CHH’-CH=1, -O-CHH’-CH=2, 5-H1), 3.60, 3.22, 3.08 (3m, 4H, 2 x –
O-CH2-CH2-), 2.91 (t, J = 9.2 Hz, 1H, 4-H2), 2.89 (dd, J = 9.5, 3.6 Hz, 1H, 4-H1), 
1.96 (dd, J = 12.5, 4.6 Hz, 1H, 2-Hax2), 1.68 (dd, J = 12.5, 3.1 Hz, 1H, 2-Heq2), 1.55 
(m, 5H, 2-Hax1, 2 x –O-CH2-CH2-), 1.41 (d, J = 6.2 Hz, 3H, 6-H1), 1.39 (d, J = 6.3 
Hz, 3H, 6-H2), 1.38 (m, 1H, 2-Heq1). 
 
13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ =156.7, 156.5 (2s, 2 x COCF3), 
135.3, 135.0 (2d, -CH=CH21, -CH=CH22), 117.3, 117.2 (2t, –CH=CH21, –CH=CH22), 
96.99 (d, C-11), 96.51 (d, C-12), 82.15 (d, C-42), 78.29 (d, C-41), 73.43 (t, –CH2-
CH=2), 70.61 (t, –CH2-CH=1), 68.23 (d, C-52), 67.82, 67.09 (2t, 2 x –O-CH2-CH2-), 
63.64 (d, C-51), 49.79 (d, C-32), 43.90 (d, C-31), 35.37 (t, C-22), 32.88 (t, C-21), 
27.11, 26.58 (2t, 2 x –O-CH2-CH2-), 18.64, 18.51 (2q, C-61, C-62). 
 
Reductive amination and introduction of 15N label (206) 
Bisketone 201 (350 mg, 0.821 mmol), 15N-ammonium acetate (700 mg, 9.0 mmol) 
and NaBH3CN (105 mg, 1.64 mmol) were stirred in methanol (100 ml) for 24h 
followed by the addition of a second portion NaBH3CN (105 mg, 1.64 mmol). The 
reaction mixture was allowed to stir for another 24h after which triethylamine (1.5 
ml, 10 mmol) and CF3COOEt (3.6 ml, 30 mmol) were added and stirring was 
continued overnight. The solvent was evaporated under reduced pressure. Prior to 
column chromatography the crude product was separated from trifluoroacetamide 
by sublimation in high vacuum (0.01 mbar, 60 oC). The remaining residue was 
purified by column chromatography over silica gel (ethyl acetate / petroleum ether 
1:5) to yield three fractions:  
1st fraction: 206 (177 mg, 0.284 mmol, 35%). 
2nd fraction: 207 (20 mg, 0.032 mmol, 3.9%) 
3rd fraction: 208 (20 mg, 0.046 mmol, 5.6%). 
OMeO
O
OMeO
O
TFAH15N
TFAH15N
 
1st fraction 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 7.89 (dd, J = 92.1, 9.1 Hz, 2H, 2 x 
NH), 5.86 (dddd, J = 17.2, 10.4, 6.4, 5.1 Hz, 2H, 2 x –CH=CH2), 5.22 (dq, J = 17.2, 
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1.5 Hz, 2H, 2 x –CH=CHH’), 5.03 (bdd, J = 10.4, 1.3 Hz, 2H, 2 x –CH=CHH’), 4.38 
(m, 2H, 2 x 3-H), 4.37 (d, J = 3.1 Hz, 2H, 2 x 1-H), 4.27 (dd, J = 12.4, 5.1 Hz, 2H, 2 
x -O-CHH’-CH=), 3.85 (m, 4H, 2 x -O-CHH’-CH=, 2 x 5-H), 3.44 (m, 2H, 2 x –O-
CHH’-CH2-), 2.95 (m, 2H, 2 x –O-CHH’-CH2-), 2.77 (ddd, J = 9.6, 3.8, 3.8 Hz, 2H, 2 
x 4-H), 1.2 – 1.5 (m, 8H, 2 x 2-Hax, 2 x 2-Heq, 2 x –O-CH2-CH2-), 1.30 (d, J = 6.2 
Hz, 6H, 2 x 6-H). 
 
 13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 157.10, 156.95, 156.81, 
156.67, 156.53, 156.38, 156.24 (s, 2 x COCF3), 135.13 (d, 2 x -CH=CH2), 117.1 (t, 
2 x –CH=CH2), 96.82 (d, 2 x C-1), 78.1 (d, 2 x C-4), 70.5 (t, 2 x –CH2-CH=), 67.4 
(t, 2 x –O-CH2-CH2-), 63.5 (d, 2 x C-5), 43.75, 43.68 (d, 2 x C-3), 32.7 (t, 2 x C-2), 
26.6 (t, 2 x –O-CH2-CH2-), 18.3 (q, 2 x C-6).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 2241 Hz = 4.48 ppm: δ = 8.00 (dd, 2H, 2 x 
NH), 4.50 (ddd, 2H, 2 x 3-H), 4.48 (d, 2H, 2 x 1-H), 3.84 (dq, 2H, 2 x 5-H), 2.89 
(ddd, 2H, 2 x 4-H), 1.53 (ddd, 2H, 2 x 2-Hax), 1.42 (d, 6H, 2 x 6-H), 1.38 (dt, 2H, 2 x 
2-Heq). 
 
1H-NMR (500 MHz, C6D6) TOCSY - 2193 Hz = 4.39 ppm: δ = 5.98 (dddd, 2H, 2 x –
CH=CH2), 5.34 dq, 2H, 2 x –CH=CHH’), 5.15 (bdd, 2H, 2 x –CH=CHH’), 4.39 (dd, 
2H, 2 x -O-CHH’-CH=), 3.85 (dd, 2H, 2 x -O-CHH’-CH=). 
 
1H-NMR (500 MHz, C6D6) TOCSY - 1782 Hz = 3.56 ppm: δ = 3.56 (m, 2H, 2 x –O-
CHH’-CH2-), 3.06 (m, 2H, 2 x –O-CHH’-CH2-), 1.48 (m, 4H, 2 x –O-CH2-CH2-).  
OMeO
O
OMeO
O
TFAH15N
TFAH15N  
2nd fraction 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 8.08 (dd, J = 92.2, 9.1 Hz, 1H, 
15NH1), 6.00 (dd, J = 90.9, 8.1 Hz, 1H, 15NH2), 5.97 (dddd, J = 17.2, 10.5, 6.4, 5.1 
Hz, 1H, –CH=CH22), 5.83 (dddd, J = 17.2, 10.6, 5.4, 5.3 Hz, 1H, –CH=CH21), 5.33 
(dq, J = 17.2, 1.5 Hz, 1H, –CH=CHH’2), 5.26 (dq, J = 17.2, 1.6 Hz, 1H, –
CH=CHH’1), 5.15 (dq, J = 10.5, 1.6 Hz, 1H, –CH=CHH’2), 5.11 (dq, J = 10.6, 1.4 
 237
Hz, 1H, –CH=CHH’1), 4.65 (d, J = 2.7 Hz, 1H, 1-H2), 4.51 (d, J = 3.0 Hz, 1H, 1-H1), 
4.50 (m, 1H, 3-H1), 4.38 (dd, J = 12.3, 5.3 Hz, 1H, -O-CHH’-CH=1), 4.32 (m, 1H, 3-
H2), 4.01 (dd, J = 12.6, 5.1 Hz, 1H, -O-CHH’-CH=2), 3.91 (dq, J = 9.0, 6.2 Hz, 1H, 
5-H2), 3.8 – 3.9 (m, 3H, -O-CHH’-CH=1, -O-CHH’-CH=2, 5-H1), 3.60, 3.22, 3.08 
(3m, 4H, 2 x –O-CH2-CH2-), 2.95 (t, J = 9.9 Hz, 1H, 4-H2), 2.88 (ddd, J = 9.5, 3.6, 
3.6 Hz, 1H, 4-H1), 1.97 (dd, J = 12.8, 4.5 Hz, 1H, 2-Hax2), 1.68 (dt, J = 12.8, 3.6 Hz, 
1H, 2-Heq2), 1.55 (m, 5H, 2-Hax1, 2 x –O-CH2-CH2-), 1.39 (d, J = 6.2 Hz, 3H, 6-H1), 
1.38 (d, J = 6.2 Hz, 3H, 6-H2), 1.38 (m, 1H, 2-Heq1). 
 
13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ =156.7, 156.5 (2s, 2 x COCF3), 
135.3, 135.0 (2d, -CH=CH21, -CH=CH22), 117.3, 117.2 (2t, –CH=CH21, –CH=CH22), 
97.00, 96.98 (2d, C-11), 96.53, 96.51 (2d, C-12), 82.17, 82.14 (2d, C-42), 78.29 (d, 
C-41), 73.43 (t, –CH2-CH=2), 70.61 (t, –CH2-CH=1), 68.24, 68.22 (2d, C-52), 67.82, 
67.09 (2t, 2 x –O-CH2-CH2-), 63.64 (d, C-51), 49.84, 49.74 (2d, C-32), 43.95, 43.85 
(2d, C-31), 35.37 (t, C-22), 32.88 (t, C-21), 27.11, 26.58 (2t, 2 x –O-CH2-CH2-), 
18.64, 18.51 (2q, C-61, C-62).  
 
LC-MS (ESI) (+c): m/z (%): 645.15 (100) [M + Na]+. 
O
O
O
Me
O
O Me
O
H15N
CN
 
3rd fraction 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 6.29 (dddd, J = 17.2, 10.4, 6.2, 
5.3 Hz, 1H, –CH=CH22), 5.94 (ddt, J = 17.2, 10.5, 5.2 Hz, 1H, –CH=CH21), 5.47 
(dq, J = 17.2, 1.7 Hz, 1H, –CH=CHH’2), 5.35 (dq, J = 17.2, 1.7 Hz, 1H, –
CH=CHH’1), 5.22 (dq, J = 10.4, 2.0 Hz, 1H, –CH=CHH’2), 5.16 (dq, J = 10.5, 1.6 
Hz, 1H, –CH=CHH’1), 4.76 (d, J = 3.5 Hz, 1H, 1-H1), 4.70 (dd, J = 81.5, 9.2 Hz, 1H, 
15NH), 4.70 (ddt, J = 12.3, 5.3, 1.3 Hz, 1H, -O-CHH’-CH=2), 4.49 (ddt, J = 12.7, 5.2, 
1.4 Hz, 1H, -O-CHH’-CH=1), 4.42 (bd, J = 3.6 Hz, 1H, 1-H2), 4.33 (dq, J = 9.6, 6.3 
Hz, 1H, 5-H2), 4.30 (dq, J = 9.5, 6.3 Hz, 1H, 5-H1), 4.05 (m, 2H, -O-CHH’-CH=1, -O-
CHH’-CH=2), 3.91 (m, 1H, 3-H1), 3.72 (ddd, J = 9.5, 8.4, 1.7 Hz, 1H, –O-CHH’-
CH2-2), 3.53 (ddd, J = 9.6, 7.6, 3.2 Hz, 1H, –O-CHH’-CH2-1), 3.22 (dd, J = 9.6, 1.3 
Hz, 1H, 4-H2), 3.17 (m, –O-CHH’-CH2-1), 3.09 (ddd, J = 9.5, 7.0, 2.13 Hz, 1H, –O-
 238
CHH’-CH2-2), 3.01 (ddd, J = 9.5, 4.0, 4.0 Hz, 1H 4-H1), 2.48 (bd, J = 13.6 Hz, 1H, 
2-Hax2), 2.46 (dd, J = 14.0, 2.8 Hz, 1H, 2-Hax1), 1.94 (ddd, J = 13.6, 5.7, 4.0 Hz, 1H, 
2-Heq2), 1.78 (ddt, J = 14.0, 3.5, 3.7 Hz, 1H, 2-Heq1), 1.65 (m, 1H, –O-CH2-CHH’-2), 
1.54 (d, J = 6.3 Hz, 3H, 6-H1), 1 52 (m, 2H, –O-CH2-CH2-1), 1.45 (m, 1H, –O-CH2-
CHH’-2), 1.34 (d, J = 6.3 Hz, 3H, 6-H2).   
 
13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 136.6 (d, -CH=CH22), 135.1 (d, 
-CH=CH21), 122.3 (s, C≡N),116.6 (t, –CH=CH22), 116.5 (t, –CH=CH21), 98.4 (d, C-
11), 96.2 (d, C-12), 87.1 (d, C-42), 82.0, 81.9 (2d, C-41), 74.7 (t, –CH2-CH=1), 71.5 
(t, –CH2-CH=2), 68.7 (t, –O-CH2-CH2-2), 68.5 (t, –O-CH2-CH2-1), 64.0, 63.9 (2d, C-
51, C-52), 57.6, 57.5 (s, C-32), 49.4, 49.3 (2d, C-31), 41.5, 41.4 (2t, C-22), 36.4 (t, C-
21), 29.1 (t, –O-CH2-CH2-2), 28.7 (t, –O-CH2-CH2-1), 18.7 (q, C-61), 17.9 (q, C-62).  
 
LC-MS (ESI) (+c): m/z (%): 438.26 (100) [M + H]+. 
 
11.8.4. Experiments to the chapter 9.6.2. 
Macrocyclization of bisallylated homodimer 204 (211, 212) 
The reaction was carried out according to the protocol TP3 except for the following 
details: olefin 204 (55 mg, 0.089 mmol), benzol (50 ml), Grubbs 1 catalyst (20 
mol%), reaction time 7 days, RT. After column chromatography over silica gel, 
three fractions were isolated:  
1st fraction: tetracyclus 211 (23 mg, 0.0194 mmol, 44%), 
2nd fraction: hexacyclus 212 (3.6 mg, 0.002 mmol, 4.5 %), 
and starting material 204 16.5 mg (0.0267 mmol, 30%).  
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1st fraction 
LC-MS (ESI) (+c): m/z (%): 1202.86 (60) [M + H2O]+, 1207.81 (100) [M + Na]+  
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2nd fraction 
LC-MS (ESI) (+c): m/z (%): 1794.53 (70) [M + H2O]+, 1799.51 (100) [M + Na]+. 
 
Catalytic hydrogenation of macrocyclus 211 (213) 
O
O
O
O
Me
NHTFA
TFAHN
O
Me
O
O
O
O
O
Me NHTFA
O
Me
O
TFAHN
 
The reaction was carried out according to the protocol TP4 except for the following 
details: tetracyclus 211 (23 mg, 0.0194 mmol), solvent ethyl acetate, reaction time 
12h. 
 
Yield: 23 mg (0.0193 mmol, > 99%). 
  
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 7.94 (d, J = 9.1 Hz, 4H, 4 x NH), 
4.52 (bdd, J = 9.1, 3.8 Hz, 4H, 4 x 3-H), 4.48 (d, J = 2.6 Hz, 4H, 4 x 1-H), 3.93 (m, 
4H, 4 x –O-CHH’-CH2-tail), 3.74 (dq, J = 9.7, 6.0 Hz, 4H, 4 x 5-H), 3.63 (m, 4H, 4 x 
–O-CHH’-CH2-head), 3.20 (m, 4H, 4 x –O-CHH’-CH2-tail), 3.07 (m, 4H, 4 x –O-CHH’-
CH2-head), 2.78 (dd, J = 9.7, 3.8 Hz, 4H, 4 x 4-H), 1.78 (m, 8H, 4 x –O-CH2-CH2-tail), 
1.4 - 1.6 (m, 16H, 4 x 2-H, 4 x –O-CH2-CH2-head), 1.40 (d, J = 6.0 Hz, 12H, 4 x 6-
H). 
 
 13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 156.6 (q, J = 35.9 Hz, 4 x 
COCF3), 117.1 (q, J = 288.7 Hz, 4 x COCF3), 96.9 (d, 4 x C-1), 79.3 (d, 4 x C-4), 
70.2 (t, 4 x –O-CH2-CH2-tail), 67.5 (t, 4 x –O-CH2-CH2-head), 63.8 (d, 4 x C-5), 44.2 
(d, 4 x C-3), 32.9 (t, 4 x C-2), 27.7 (t, 4 x –O-CH2-CH2-tail), 27.2 (t, 4 x –O-CH2-CH2-
head), 18.4 (q, 4 x C-6). 
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  1H-NMR (500 MHz, C6D6) TOCSY - 3971 Hz = 7.94 ppm: δ = 7.94 (d, 4H, 4 x NH), 
4.52 (dd, 4H, 4 x 3-H), 4.48 (d, 4H, 4 x 1-H), 3.74 (dq, 4H, 4 x 5-H), 2.78 (dd, 4H, 4 
x 4-H), 1.53 (dd, 4H, 4 x 2-Hax), 1.43 (dd, 4H, 4 x 2-Heq), 1.40 (d, 12H, 4 x 6-H). 
 
 1H-NMR (500 MHz, C6D6) TOCSY - 1969 Hz = 3.94 ppm: δ = 3.93 (m, 4H, 4 x –O-
CHH’-CH2-tail), 3.20 (m, 4H, 4 x –O-CHH’-CH2-tail), 1.78 (m, 8H, 4 x –O-CH2-CH2-
tail).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 1817 Hz = 3.63 ppm: δ = 3.63 (m, 4H, 4 x –O-
CHH’-CH2-head), 3.06 (m, 4H, 4 x –O-CHH’-CH2-head), 1.55 (m, 8H, 4 x –O-CH2-
CH2-head).    
 
Catalytic hydrogenation of macrocyclus 212 (214) 
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The reaction was carried out according to the protocol TP4 except for the following 
details: hexacyclus 212 (27 mg, 0.0152 mmol), solvent ethyl acetate, reaction time 
12h. 
 
Yield: 27 mg (0.01519 mmol, > 99%). 
 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 7.99 (d, J = 9.0 Hz, 6H, 6 x NH), 
4.57 (bdd, J = 9.0, 3.7 Hz, 6H, 6 x 3-H), 4.51 (d, J = 2.3 Hz, 6H, 6 x 1-H), 4.00 (m, 
6H, 6 x –O-CHH’-CH2-tail), 3.82 (dq, J = 9.5, 6.2 Hz, 6H, 6 x 5-H), 3.60 (m, 6H, 6 x 
–O-CHH’-CH2-head), 3.29 (m, 6H, 6 x –O-CHH’-CH2-tail), 3.08 (m, 6H, 6 x –O-CHH’-
CH2-head), 2.87 (dd, J = 9.5, 3.7 Hz, 6H, 6 x 4-H), 1.80 (m, 12H, 6 x –O-CH2-CH2-
tail), 1.4 - 1.6 (m, 24H, 6 x 2-H, 6 x –O-CH2-CH2-head), 1.45 (d, J = 6.2 Hz, 18H, 6 x 
6-H). 
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13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 156.6 (q, J = 35.9 Hz, 6 x 
COCF3), 117.1 (q, J = 288.8 Hz, 6 x COCF3), 96.9 (d, 6 x C-1), 79.3 (d, 6 x C-4), 
69.7 (t, 6 x –O-CH2-CH2-tail), 67.4 (t, 6 x –O-CH2-CH2-head), 63.7 (d, 6 x C-5), 44.0 
(d, 6 x C-3), 32.8 (t, 6 x C-2), 26.9 (t, 6 x –O-CH2-CH2-tail), 26.8 (t, 6 x –O-CH2-CH2-
head), 18.3 (q, 6 x C-6).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 1438 Hz = 2.87 ppm: δ = 7.99 (d, 6H, 6 x NH), 
4.57 (dd, 6H, 6 x 3-H), 4.51 (d, 6H, 6 x 1-H), 3.82 (dq, 6H, 6 x 5-H), 2.87 (dd, 6H, 6 
x 4-H), 1.58 (dd, 6H, 6 x 2-Hax), 1.50 (dd, 6H, 6 x 2-Heq), 1.45 (d, 18H, 6 x 6-H). 
 
1H-NMR (500 MHz, C6D6) TOCSY - 1999 Hz = 4.00 ppm: δ = 4.00 (m, 6H, 6 x –O-
CHH’-CH2-tail), 3.30 (m, 6H, 6 x –O-CHH’-CH2-tail), 1.80 (m, 12H, 6 x –O-CH2-CH2-
tail).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 1543 Hz = 3.09 ppm: δ = 3.60 (m, 6H, 6 x –O-
CHH’-CH2-head), 3.09 (m, 6H, 6 x –O-CHH’-CH2-head), 1.52 (m, 12H, 6 x –O-CH2-
CH2-head). 
 
 LC-MS (ESI) (+c): m/z (%): 1807.50 (100) [M + Na]+. 
 
Preparation of macrocycle 215 by N-deprotection 
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The hydrogenated product 213 (21 mg, 0.0177 mmol) was dissolved in 12 ml 
THF/1.0M aqueous NaOH (1:3) and methanol (5 ml) was added to homogenise 
the solution. This mixture was allowed to stir at RT for 20 h, at which time t.l.c. 
(CH3CN/25% aqueous NH3 10:1, Rf – 0.5, t.l.c. should be exposed to aq. 
ammonia vapor prior to use) indicated that the detrifluoroacetylation was 
complete. The mixture was extracted with CH2Cl2 (3 x 50 ml). The organic 
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phase was dried over a Na2SO4 and evaporated under reduced pressure. Amin 
215 was lyophilised from benzol to yield a very hygroscopic gray-green powder. 
 
Yield: 13.5 mg (0.0168 mmol, 95%). 
 
1H-NMR (500 MHz, Py, Py = 8.71 ppm): δ = 4.83 (d, J = 3.5 Hz, 4H, 4 x 1-H), 4.06 
(dq, J = 9.3, 6.2 Hz, 4H, 4 x 5-H), 3.77 (m, 4H, 4 x –O-CHH’-CH2-tail), 3.69 (m, 4H, 
4 x –O-CHH’-CH2-head), 3.50 (bs, 4H, 4 x 3-H), 3.39 (m, 4H, 4 x –O-CHH’-CH2-head), 
3.34 (m, 4H, 4 x –O-CHH’-CH2-tail), 3.02 (dd, J = 9.3, 3.5 Hz, 4H, 4 x 4-H), 2.23 (bd, 
J = 14.13 Hz, 4H, 4 x 2-Hax), 1.89 (dt, J = 14.00, 4.35 Hz, 4H, 4 x 2-Heq), 1.6 – 1.8 
(m, 16H, 4 x –O-CH2-CH2-tail, 4 x –O-CH2-CH2-head), 1.40 (d, J = 6.2 Hz, 12H, 4 x 6-
H).  
 
13C-NMR (125 MHz, Py, Py = 149.5 ppm): δ = 97.5 (d, 4 x C-1), 81.9 (d, 4 x C-4), 
69.2 (t, 4 x –O-CH2-CH2-head), 67.7 (t, 4 x –O-CH2-CH2-tail), 62.1 (d, 4 x C-5), 45.8 
(d, 4 x C-3), 34.6 (t, 4 x C-2), 27.6 (t, 4 x –O-CH2-CH2-head), 27.3 (t, 4 x –O-CH2-
CH2-tail), 18.6 (q, 4 x C-6).  
 
1H-NMR (500 MHz, Py) TOCSY - 2417 Hz = 4.83 ppm: δ = 4.83 (d, 4H, 4 x 1-H), 
4.06 (dq, 4H, 4 x 5-H), 3.50 (bs, 4H, 4 x 3-H), 3.02 (dd, 4H, 4 x 4-H), 2.24 (bd, 4H, 
4 x 2-Hax), 1.89 (dt, 4H, 4 x 2-Heq), 1.40 (d, 12H, 4 x 6-H).  
 
1H-NMR (500 MHz, Py) TOCSY - 1886 Hz = 3.77 ppm: δ = 3.77 (m, 4H, 4 x –O-
CHH’-CH2-tail), 3.33 (m, 4H, 4 x –O-CHH’-CH2-tail), 1.70 (m, 8H, 4 x –O-CH2-CH2-
tail).  
 
1H-NMR (500 MHz, Py) TOCSY - 1846 Hz = 3.69 ppm: δ = 3.69 (m, 4H, 4 x –O-
CHH’-CH2-head), 3.39 (m, 4H, 4 x –O-CHH’-CH2-head), 1.74 (m, 8H, 4 x –O-CH2-
CH2-head).  
 
LC-MS (ESI) (+c): m/z (%): 403.29 (100) [M + 2H]2+, 805.56 (80) [M + H]+, 827.56 
(30) [M + Na]+; HR-MS C40H77N4O12: calc. 805.5538, found 805.5519.  
 
[α]25D = - 127.7o (c = 1 in CHCl3).  
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 Preparation of macrocycle 216 by N-deprotection 
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The hydrogenated product 214 (27 mg, 0.0152 mmol) was dissolved in 12 ml 
THF/1.0M aqueous NaOH (1:3) and methanol (5 ml) was added to homogenise a 
solution. This mixture was allowed to stir at RT for 20 h, at which time t.l.c. 
(CH3CN/25% aqueous NH3 10:1, Rf – 0.5, t.l.c. should be exposed to aq. ammonia 
vapor prior to use) indicated that the detrifluoroacetylation was complete. The 
mixture was extracted with CH2Cl2 (3 x 50 ml). The organic phase was dried over a 
Na2SO4 and evaporated under reduced pressure. Amin 216 was lyophilised from 
benzol to yield a very hygroscopic gray-green powder. 
 
Yield: 18 mg (0.0151 mmol, 99%). 
 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 4.65 (d, J = 3.1 Hz, 6H, 6 x 1-H), 
4.01 (dq, J = 9.5, 6.1 Hz, 6H, 6 x 5-H), 3.62 (m, 6H, 6 x –O-CHH’-CH2-tail), 3.45 (m, 
6H, 6 x –O-CHH’-CH2-head), 3.33 (bs, 6H, 6 x 3-H), 3.13 (m, 12H, 6 x –O-CHH’-
CH2-head, 6 x –O-CHH’-CH2-tail), 2.81 (dd, J = 9.5, 3.2 Hz, 6H, 6 x 4-H), 2.16 (bd, J 
= 14.4 Hz, 6H, 6 x 2-Hax), 1.35 – 1.7 (m, 30H, 6 x –O-CH2-CH2-tail, 6 x –O-CH2-
CH2-head, 6 x 2-Heq), 1.42 (d, J = 6.1 Hz, 18H, 6 x 6-H).  
 
13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 97.76 (d, 6 x C-1), 82.3 (d, 6 x 
C-4), 69.0 (t, 6 x –O-CH2-CH2-head), 67.7 (t, 4 x –O-CH2-CH2-tail), 62.3 (d, 4 x C-5), 
45.9 (d, 4 x C-3), 34.7 (t, 4 x C-2), 27.6 (t, 4 x –O-CH2-CH2-head), 27.3 (t, 4 x –O-
CH2-CH2-tail), 18.7 (q, 4 x C-6).  
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1H-NMR (500 MHz, C6D6) TOCSY - 2384 Hz = 4.77 ppm: δ = 4.77 (d, 6H, 6 x 1-H), 
4.12 (dq, 6H, 6 x 5-H), 3.45 (bs, 6H, 6 x 3-H), 2.92 (dd, 6H, 6 x 4-H), 2.27 (bd, 6H, 
6 x 2-Hax), 1.78 (dt, 6H, 6 x 2-Heq), 1.54 (d, 18H, 6 x 6-H).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 1871 Hz = 3.74 ppm: δ = 3.74 (m, 6H, 6 x –O-
CHH’-CH2-tail), 3.26 (m, 6H, 6 x –O-CHH’-CH2-tail), 1.66 (m, 12H, 6 x –O-CH2-CH2-
tail).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 1787 Hz = 3.57 ppm: δ = 3.57 (m, 6H, 6 x –O-
CHH’-CH2-head), 3.25 (m, 6H, 6 x –O-CHH’-CH2-head), 1.71 (m, 12H, 6 x –O-CH2-
CH2-head).  
 
LC-MS (ESI) (+c): m/z (%): 604.41 (10) [M + 2H]2+, 1207.80 (30) [M + H]+; HR-MS 
C60H115N6O18: calc. 1207.8268, found 1207.8284.  
 
[α]25D = - 112.3o (c = 1 in CHCl3).  
 
Macrocyclization of 15N-labelled bisallylated homodimer 215 and catalytic 
hydrogenation of macrocycle 218 and 219  
The reaction was carried out according to the protocol TP3 except for the following 
details: olefin 215 (150 mg, 0.24 mmol), CH2Cl2 (150 ml), Grubbs 1 catalyst (20 
mol %), reaction time 7 days, RT. The products were hydrogenated without further 
purification. 
Yield: tetracyclus 218 (65 mg, 0.0543 mmol, 45%).  
Yield: hexacyclus 219 (7 mg, 0.004 mmol, 5%). 
The reaction was carried out according to the protocol TP4 except for the following 
details: tetracyclus 218 (130 mg, 0.1086 mmol), solvent ethyl acetate, reaction time 
12h. 
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Yield: 130 mg (0.1086 mmol, >99%). 
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1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 7.84 (dd, J = 91.6,  9.2 Hz, 4H, 4 
x NH), 4.40 (bdd, J = 8.6, 3.8 Hz, 4H, 4 x 3-H), 4.35 (bs, 4H, 4 x 1-H), 3.82 (m, 4H, 
4 x –O-CHH’-CH2-tail), 3.63 (dq, J = 9.3, 6.0 Hz, 4H, 4 x 5-H), 3.51 (m, 4H, 4 x –O-
CHH’-CH2-head), 3.08 (m, 4H, 4 x –O-CHH’-CH2-tail), 2.94 (m, 4H, 4 x –O-CHH’-CH2-
head), 2.66 (ddd, J = 9.3, 3.8, 3.8 Hz, 4H, 4 x 4-H), 1.66 (m, 8H, 4 x –O-CH2-CH2-
tail), 1.2 - 1.6 (m, 16H, 4 x 2-H, 4 x –O-CH2-CH2-head), 1.28 (d, J = 6.0 Hz, 12H, 4 x 
6-H). 
 
15N-NMR (50 MHz, C6D6, CH3NO2 = 0 ppm): δ = -266.56 (d, J = 91.6 Hz, 4 x NH). 
 
13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 156.67 (q, J = 35.9 Hz, 4 x 
COCF3), 117.2 (q, J = 288.7 Hz, 4 x COCF3), 96.9 (d, 4 x C-1), 79.25 (d, 4 x C-4), 
70.2 (t, 4 x –O-CH2-CH2-tail), 67.5 (t, 4 x –O-CH2-CH2-head), 63.8 (d, 4 x C-5), 44.2, 
44.1 (2d, 4 x C-3), 32.9 (t, 4 x C-2), 27.7 (t, 4 x –O-CH2-CH2-tail), 27.2 (t, 4 x –O-
CH2-CH2-head), 18.4 (q, 4 x C-6). 
 
 1H-NMR (500 MHz, C6D6) TOCSY - 2257 Hz = 4.51 ppm: δ = 7.95 (dd, 4H, 4 x 
NH), 4.52 (dd, 4H, 4 x 3-H), 4.47 (d, 4H, 4 x 1-H), 3.74 (dq, 4H, 4 x 5-H), 2.78 (dd, 
4H, 4 x 4-H), 1.53 (dd, 4H, 4 x 2-Hax), 1.42 (dd, 4H, 4 x 2-Heq), 1.40 (d, 12H, 4 x 6-
H). 
 
LC-MS (ESI) (+c): m/z (%): 1215.45 (100) [M + Na]+; HR-MS C48H7215N4O16 +Na: 
calc. 1215.4531, found 1215.4532.  
 
[α]25D = - 115.6o (c = 1 in CHCl3). 
 
The reaction was carried out according to the protocol TP4 except for the following 
details: hexacyclus 219 (11 mg, 0.0062 mmol), solvent ethyl acetate, reaction time 
12h. 
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Yield: 11mg (0.0062 mmol, >99%) 
 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 7.90 (dd, J = 92.4,  9.2 Hz, 6H, 6 
x NH), 4.57 (bdd, J = 8.3, 3.5 Hz, 6H, 6 x 3-H), 4.38 (d, J = 2.4 Hz, 6H, 6 x 1-H), 
3.90 (m, 6H, 6 x –O-CHH’-CH2-tail), 3.71 (dq, J = 9.5, 6.2 Hz, 6H, 6 x 5-H), 3.48 (m, 
6H, 6 x –O-CHH’-CH2-head), 3.17 (m, 6H, 6 x –O-CHH’-CH2-tail), 2.95 (m, 6H, 6 x –
O-CHH’-CH2-head), 2.75 (ddd, J = 9.5, 3.8, 3.5 Hz, 6H, 6 x 4-H), 1.74, 1.65 (2m, 
12H, 6 x –O-CH2-CH2-tail), 1.2 - 1.5 (m, 24H, 6 x 2-H, 6 x –O-CH2-CH2-head), 1.34 
(d, J = 6.2 Hz, 18H, 6 x 6-H). 
 
15N-NMR (50 MHz, C6D6, CH3NO2 = 0 ppm): δ = -266.36 (d, J = 92.4 Hz, 6 x NH). 
 
13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 156.5 (q, J = 35.9 Hz, 6 x 
COCF3), 117.2 (q, J = 288.8 Hz, 6 x COCF3), 96.8 (d, 6 x C-1), 79.2 (d, 6 x C-4), 
69.7 (t, 6 x –O-CH2-CH2-tail), 67.3 (t, 6 x –O-CH2-CH2-head), 63.6 (d, 6 x C-5), 43.9, 
43.8 (2d, 6 x C-3), 32.7 (t, 6 x C-2), 26.9 (t, 6 x –O-CH2-CH2-tail), 26.8 (t, 6 x –O-
CH2-CH2-head), 18.3 (q, 6 x C-6).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 2286 Hz = 4.57 ppm: δ = 8.02 (dd, 6H, 6 x 
NH), 4.57 (dd, 6H, 6 x 3-H), 4.50 (d, 6H, 6 x 1-H), 3.82 (dq, 6H, 6 x 5-H), 2.86 
(ddd, 6H, 6 x 4-H), 1.56 (dd, 6H, 6 x 2-Hax), 1.50 (m, 6H, 6 x 2-Heq), 1.46 (d, 18H, 6 
x 6-H). 
 
LC-MS (ESI) (+c): m/z (%): 1811.18 (100) [M + Na]+. 
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Preparation of macrocycle 220 by N-deprotection 
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The hydrogenated tetracyclus (130 mg, 0.109 mmol) was dissolved in THF/1.0M 
aqueous NaOH (1:3, 72 ml) and methanol (20 ml) was added in order to obtain a 
clear solution. This mixture was allowed to stir at RT for 20 h, at which time t.l.c. 
(CH3CN/25% aqueous NH3 10:1, Rf – 0.5, t.l.c. should be exposed to aq. ammonia 
vapor prior to use) indicated that the deprotection step was completed. The mixture 
was extracted with CH2Cl2 (3 x 50 ml), the organic phase was dried over a Na2SO4 
and evaporated under reduced pressure. Amine 220 was lyophilized from benzene 
to yield macrocycle as a hygroscopic gray crystalline powder. 
 
Yield: 88 mg (0.109 mmol, >99%). 
 
1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 4.63 (d, J = 3.4 Hz, 4H, 4 x 1-H), 
3.98 (dq, J = 9.3, 6.1 Hz, 4H, 4 x 5-H), 3.62 (m, 4H, 4 x –O-CHH’-CH2-tail), 3.39 (m, 
4H, 4 x –O-CHH’-CH2-head), 3.25 (bs, 4H, 4 x 3-H), 3.08 (m, 8H, 4 x –O-CHH’-CH2-
head, 4 x –O-CHH’-CH2-tail), 2.77 (dd, J = 9.3, 3.0 Hz, 4H, 4 x 4-H), 2.10 (bd, J = 
14.1 Hz, 4H, 4 x 2-Hax), 1.64 (dt, J = 14.1, 4.7 Hz, 4H, 4 x 2-Heq), 1.54 (m, 16H, 4 x 
–O-CH2-CH2-tail, 4 x –O-CH2-CH2-head), 1.41 (d, J = 6.1 Hz, 12H, 4 x 6-H). 
 
15N-NMR (50 MHz, C6D6, CH3NO2 = 0 ppm): δ = - 360.81 (s, 4 x NH). 
  
13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 97.8 (d, 4 x C-1), 82.7 (d, 4 x 
C-4), 68.9 (t, 4 x –O-CH2-CH2-head), 67.7 (t, 4 x –O-CH2-CH2-tail), 62.1 (d, 4 x C-5), 
45.9 (d, 4 x C-3), 34.9 (t, 4 x C-2), 27.8 (t, 4 x –O-CH2-CH2-head), 27.5 (t, 4 x –O-
CH2-CH2-tail), 18.7 (q, 4 x C-6).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 2374 Hz = 4.75 ppm: δ = 4.75 (d, 4H, 4 x 1-H), 
4.09 (dq, 4H, 4 x 5-H), 3.36 (bs, 4H, 4 x 3-H), 2.88 (dd, 4H, 4 x 4-H), 2.22 (bd, 4H, 
4 x 2-Hax), 1.75 (dt, 4H, 4 x 2-Heq), 1.51 (d, 12H, 4 x 6-H).  
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1H-NMR (500 MHz, C6D6) TOCSY - 1864 Hz = 3.73 ppm: δ = 3.73 (m, 4H, 4 x –O-
CHH’-CH2-tail), 3.21 (m, 4H, 4 x –O-CHH’-CH2-tail), 1.65 (m, 8H, 4 x –O-CH2-CH2-
tail).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 1752 Hz = 3.50 ppm: δ = 3.50 (m, 4H, 4 x –O-
CHH’-CH2-head), 3.19 (m, 4H, 4 x –O-CHH’-CH2-head), 1.67 (m, 8H, 4 x –O-CH2-
CH2-head).  
 
LC-MS (ESI) (+c): m/z (%): 809.54 (90) [M + H]+, 831.49 (100) [M + Na]+; HR-MS 
C40H7715N4O12: calc. 809.5419, found 809.5403.  
 
[α]25D = - 139.9o (c = 1 in CHCl3).  
 
Preparation of macrocycle 221 by N-deprotection 
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The hydrogenated hexacyclus (11 mg, 6.2 µmol) was dissolved in 10 ml THF/1.0M 
aqueous NaOH (1:3) and methanol (5 ml) was added in order to obtain a clear 
solution. This mixture was allowed to stir at RT for 20 h, at which time t.l.c. 
(CH3CN/25% aqueous NH3 10:1, Rf – 0.5, t.l.c. should be exposed to aq. ammonia 
vapor prior to use) indicated that the deprotection was completed. The mixture was 
extracted with CH2Cl2 (3 x 10 ml), organic phase was dried over Na2SO4 and 
evaporated under reduced pressure. Amine 221 was lyophilized from benzene to 
yield macrocycle as a hygroscopic gray crystalline powder. 
 
Yield: 7.4 mg (0.0061 mmol, 99%). 
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1H-NMR (500 MHz, C6D6, C6D6 = 7.16 ppm): δ = 4.65 (d, J = 3.7 Hz, 6H, 6 x 1-H), 
4.01 (dq, J = 9.4, 6.2 Hz, 6H, 6 x 5-H), 3.61 (m, 6H, 6 x –O-CHH’-CH2-tail), 3.40 (m, 
6H, 6 x –O-CHH’-CH2-head), 3.27 (bs, 6H, 6 x 3-H), 3.12 (m, 12H, 6 x –O-CHH’-
CH2-head, 6 x –O-CHH’-CH2-tail), 2.79 (dd, J = 9.4, 3.1 Hz, 6H, 6 x 4-H), 2.12 (bd, J 
= 14.0 Hz, 6H, 6 x 2-Hax), 1.2 – 1.8 (m, 30H, 6 x –O-CH2-CH2-tail, 6 x –O-CH2-CH2-
head, 6 x 2-Heq), 1.43 (d, J = 6.2 Hz, 18H, 6 x 6-H).  
 
15N-NMR (50 MHz, C6D6, CH3NO2 = 0 ppm): δ = - 360.77 (s, 6 x NH). 
 
13C-NMR (125 MHz, C6D6, C6D6 = 128.06 ppm): δ = 97.86 (d, 6 x C-1), 82.67 (d, 6 
x C-4), 68.80 (t, 6 x –O-CH2-CH2-head), 67.67 (t, 4 x –O-CH2-CH2-tail), 62.15 (d, 4 x 
C-5), 45.93, 45.91 (d, 4 x C-3), 34.97 (t, 4 x C-2), 27.60 (t, 4 x –O-CH2-CH2-head), 
27.31 (t, 4 x –O-CH2-CH2-tail), 18.74 (q, 4 x C-6).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 2384 Hz = 4.77 ppm: δ = 4.77 (d, 6H, 6 x 1-H), 
4.12 (dq, 6H, 6 x 5-H), 3.38 (bs, 6H, 6 x 3-H), 2.91 (dd, 6H, 6 x 4-H), 2.24 (bd, 6H, 
6 x 2-Hax), 1.77 (dt, 6H, 6 x 2-Heq), 1.55 (d, 18H, 6 x 6-H).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 1864 Hz = 3.73 ppm: δ = 3.73 (m, 6H, 6 x –O-
CHH’-CH2-tail), 3.25 (m, 6H, 6 x –O-CHH’-CH2-tail), 1.65 (m, 12H, 6 x –O-CH2-CH2-
tail).  
 
1H-NMR (500 MHz, C6D6) TOCSY - 1758 Hz = 3.51 ppm: δ = 3.51 (m, 6H, 6 x –O-
CHH’-CH2-head), 3.22 (m, 6H, 6 x –O-CHH’-CH2-head), 1.68 (m, 12H, 6 x –O-CH2-
CH2-head).  
 
LC-MS (ESI) (+c): m/z (%): 607.90 (10) [M + 2H]2+, 1213.80(30) [M + H]+; HR-MS 
C60H11515N6O18: calc. 1213.8090, found 1213.8068.  
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